-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FwOR3JLuztqhHQS7syiBirmO7gy5HlrPJ8jwzNskZLu3Iw/MYMfoCc4YeaG2u44B
 L5Sto+WeXNLYkXLMtLgL9A==

<SEC-DOCUMENT>0001213809-06-000056.txt : 20061221
<SEC-HEADER>0001213809-06-000056.hdr.sgml : 20061221
<ACCEPTANCE-DATETIME>20061221113329
ACCESSION NUMBER:		0001213809-06-000056
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20061221
DATE AS OF CHANGE:		20061221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-139542
		FILM NUMBER:		061292015

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>forms_3121806.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. FORM S-3 12.18.06
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Form S-3 12.18.06
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="COLOR: black" align="left" noshade size="3" width="100%">
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>As
      filed with the Securities and Exchange Commission on December 21,
      2006</strong></font></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Registration
      No. 333-_________</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>FORM
      S-3</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>REGISTRATION
      STATEMENT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNDER</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>THE
      SECURITIES ACT OF 1933</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>DYADIC
      INTERNATIONAL, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Delaware</strong></font></div>
            </td>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>45-0486747</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or Other Jurisdiction</font></div>
            </td>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(I.R.S.
                Employer</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
                Incorporation or Organization)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification
                No.)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">&#160;</td>
            <td colspan="2" valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Mark
                A. Emalfarb</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">&#160;</td>
            <td colspan="2" valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Chief
                Executive Officer and President</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>140
                Intracoastal Pointe Drive, Suite 404</strong></font></div>
            </td>
            <td colspan="2" valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
                International, Inc.</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Jupiter,
                Florida 33477</strong></font></div>
            </td>
            <td colspan="2" valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>140
                Intracoastal Pointe Drive, Suite 404</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(561)
                743-8333</strong></font></div>
            </td>
            <td colspan="2" valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Jupiter,
                Florida 33477</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">&#160;</td>
            <td colspan="2" valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(561)
                743-8333</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address,
                Including Zip Code, and Telephone Number, Including Area Code, of
                Registrant's Principal Executive Offices)</font></div>
            </td>
            <td colspan="2" valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Name,
                Address, Including Zip Code, and Telephone Number, Including Area
                Code, of
                Agent for Service)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="40%">&#160;</td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Andrew
                E. Balog, Esq.</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Greenberg
                Traurig, P.A.</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1221
                Brickell Avenue</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Miami,
                Florida 33131</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Telephone
                No.: (305) 579-0500</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Facsimile
                No.: (305) 579-0717</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Approximate
      date of commencement of proposed sale to the public:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      soon
      as practicable after this Registration Statement becomes effective.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      the
      only securities being registered on this Form are being offered pursuant to
      dividend or interest reinvestment plans, please check the following
      box.&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      any of
      the securities being registered on this Form are to be offered on a delayed
      or
      continuous basis pursuant to Rule 415 under the Securities Act of 1933 (the
      "Securities Act"), other than securities offered only in connection with
      dividend or interest reinvestment plans, check the following
      box.&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">x</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      this
      Form is filed to register additional securities for an offering pursuant to
      Rule
      462(b) under the Securities Act, please check the following box and list the
      Securities Act registration statement number of the earlier effective
      registration statement for the same offering. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      this
      Form is a post-effective amendment filed pursuant to Rule 462(c) under the
      Securities Act, check the following box and list the Securities Act registration
      statement number of the earlier effective registration statement for the same
      offering. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      this
      Form is a registration statement pursuant to General Instruction I.D. or a
      post-effective amendment thereto that shall become effective upon filing with
      the Commission pursuant to Rule 462(e) under the Securities Act, please check
      the following box. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      this
      Form is a post-effective amendment to a registration statement filed pursuant
      to
      General Instruction I.D. filed to register additional securities or additional
      classes of securities pursuant to Rule 413(b) under the Securities Act, please
      check the following box. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">___________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CALCULATION
      OF REGISTRATION FEE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Title
                of Each Class</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
                Securities to be Registered</strong></font></div>
            </td>
            <td valign="bottom" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount
                to be Registered (1)</strong></font></div>
            </td>
            <td valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Proposed
                Maximum Offering Price </strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Per
                Share (2)</strong></font></div>
            </td>
            <td valign="bottom" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Proposed
                Maximum Aggregate Offering </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Price
                (2)</strong></font></div>
            </td>
            <td valign="bottom" width="16%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount
                of Registration Fee </strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="30%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                Stock, par value $0.001</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5,581,484</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="top" width="15%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$6.79</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="bottom" width="15%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$37,898,276</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="bottom" width="16%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$4,056</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                common stock being registered consists of : (i) 2,136,752 shares
                of common
                stock issued to an investor in a private placement completed on November
                8, 2006; (ii) 2,787,000 shares of common stock issued to investors
                in a
                private placement completed on December 1, 2006 and (iii) 657,732
                shares
                of common stock issuable upon exercise of warrants issued to the
                investors
                and the placement agent in the private placement completed on December
                1,
                2006. Pursuant to Rule 416 of the Securities Act, such shares of
                common
                stock shall include an indeterminable number of shares of common
                stock
                that may be issued in the event of a stock split, stock dividend,
                anti-dilution adjustment or similar transaction involving the common
                stock. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Estimated
                solely for the purpose of calculating the registration fee pursuant
                to
                Rule 457(c) of the Securities Act based on the average of the high
                and low
                sales prices for the common stock on December 15, 2006, as reported
                by the
                American Stock Exchange.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      Registrant hereby amends this Registration Statement on such date or dates
      as
      may be necessary to delay its effective date until the Registrant shall file
      a
      further amendment which specifically states that this Registration Statement
      shall thereafter become effective in accordance with Section 8(a) of the
      Securities Act of 1933 or until the Registration Statement shall become
      effective on such date as the Commission, acting pursuant to said Section 8(a),
      may determine.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SUBJECT
      TO COMPLETION, DATED DECEMBER 21, 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="8%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 5.65pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                information in this prospectus is not complete and may be changed.
                The
                selling stockholders named in this prospectus may not sell these
                securities until the registration statement filed with the Securities
                and
                Exchange Commission is effective. This prospectus is not an offer
                to sell
                these securities, and it is not soliciting an offer to buy these
                securities in any jurisdiction where the offer or sale is not
                permitted.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><u>PROSPECTUS</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      International, Inc.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5,581,484
      Shares of</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Common
      Stock</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      5,581,484 shares of our common stock offered by this prospectus include (i)
      2,136,752 shares of common stock issued to a selling stockholder identified
      in
      this prospectus in a private placement completed on November 8, 2006; (ii)
      2,787,000 shares of common stock issued to selling stockholders identified
      in
      this prospectus in a private placement completed on December 1, 2006; and (iii)
      657,732 shares of common stock issuable upon the exercise of warrants issued
      to
      the selling stockholders in the private placement completed on December 1,
      2006.
      For further information regarding these private placements, please see &#8220;Summary
      Description of our Business&#8212;Recent Developments&#8221; on page 4 of this
      prospectus.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      not selling any shares of our common stock under this prospectus and will not
      receive any of the proceeds from the resale of the shares by the selling
      stockholders. However, we will receive the exercise price of the warrants when
      and if they are exercised to the extent so exercised for cash. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      common stock trades on the American Stock Exchange under the symbol "DIL."
      On
      December 15, 2006, the last reported sale price of our common stock as reported
      on the American Stock Exchange was $6.67 per share.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders, or their pledgees, donees, transferees or other
      successors-in-interest, may offer the shares from time to time through public
      or
      private transactions, on or off the American Stock Exchange, at prevailing
      market prices or at privately negotiated prices. They may make sales directly
      to
      purchasers or to or through agents, broker-dealers or underwriters.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>_______________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investing
      in our common stock involves a high degree of risk. You should consider
      carefully the risk factors beginning on page </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      this prospectus for a discussion of these risks.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>_______________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Neither
      the Securities and Exchange Commission nor any state securities commission
      has
      approved or disapproved of these securities or passed upon the accuracy or
      adequacy of this prospectus. Any representation to the contrary is a criminal
      offense.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      date of this prospectus is _______, 2007.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>2</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="TOC">TABL</a>E
      OF CONTENTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><a href="#_Toc153253205"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u><br>&#160;</u></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="left">
        <table border="0" bordercolor="#000000" cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="right" valign="top" width="75%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="top" width="5%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Page</strong></font></div>
              </td>
            </tr>
            <tr>
              <td align="right" valign="top" width="75%">&#160;</td>
              <td align="right" valign="top" width="5%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#SUM">Summary
                  Description of Our Business</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#RISK">Risk
                  Factors</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#DISC">Disclosure
                  Regarding Forward-Looking
                  Statements</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#USE">Use
                  of Proceeds</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#SELL">Selling
                  Stockholders</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#PLAN">Plan
                  of Distribution</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#LEGAL">Legal
                  Matters</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#EXP">Experts</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#WHERE">Where
                  You Can Find More Information</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="75%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#INCORP">Incorporation
                  of Certain Documents by
                  Reference</a></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
              <td valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>3</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="SUM">SUM</a>MARY
      DESCRIPTION OF OUR BUSINESS </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      summary highlights selected information and does not contain all the information
      that is important to you. You should carefully read this prospectus and the
      documents we have referred you to in &#8220;Incorporation of Certain Documents by
      Reference&#8221; on page&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      information about us and our financial statements. As used herein, and except
      as
      the context may otherwise require, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or
&#8220;Dyadic&#8221; mean, collectively, Dyadic International, Inc. and all of its
      consolidated subsidiaries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Our
      Business</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are a
      global biotechnology company based in Jupiter, Florida, with operations in
      the
      United States of America, Hong Kong and mainland China, Poland and The
      Netherlands. We are engaged in research and development, the collaborative
      licensing of our patented and other proprietary technologies to develop and
      manufacture biological products and the manufacture and sale of industrial
      enzymes and other proteins for the industrial, biorefinery and pharmaceutical
      industries, including:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                textile, pulp &amp; paper, animal feed, alcohol, starch, and food and
                beverage industries, where we currently sell more than 45 liquid
                and dry
                enzyme products to more than 200 industrial customers in approximately
                50
                countries, which we refer to as our Enzyme Business;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">enzymes
                and related biotechnological processes for&#160;use in converting various
                agricultural products (e.g. corn), agricultural residue products
                (e.g.
                dried distillers grains (DDG&#8217;s), wheat straw, and sugar cane
                bagasse)&#160;and forestry industry residues (e.g. wood pulp and chips)
                into fermentable sugars, which can then be used in the production
                of
                traditional and cellulosic ethanol, as well as other products currently
                derived from petroleum, such as plastics and polymers, which we
                collectively refer to as &#8220;Biorefinery Products&#8221;;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">human
                therapeutic protein candidates, with focus on antibodies, for use
                by
                pharmaceutical and biotechnology companies in pre-clinical and clinical
                drug development applications and commercialization following drug
                approval, which we refer to as our BioSciences Business.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      developed and use a number of proprietary fungal strains to produce enzymes
      and
      other biomaterials, but the one on which we have principally focused is a
      patented system for protein production, or protein expression, which we call
      the
      C1 Expression System. This System is based on our patented </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chrysosporium
      lucknowense</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      fungus,
      known as C1, as its host production organism. A host production organism is
      an
      organism which has been genetically altered to express genes to produce targeted
      protein products. We discovered the C1 microorganism in the mid-1990's and
      initially developed it, without the application of molecular biology, to produce
      neutral cellulases for our textile manufacturing customers. By 1998, we began
      to
      apply molecular genetics and other proprietary biotechnology tools to C1 to
      create a technology, which we refer to as the C1 Host Technology. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      were
      organized under the name CCP Worldwide, Inc., as a Delaware corporation on
      September 23, 2002. On October 29, 2004, we completed the merger of our newly
      created and wholly owned subsidiary, CCP Acquisition Corp., a Florida
      corporation, with and into a Florida corporation formerly known as Dyadic
      International, Inc., which was the surviving corporation of the merger and
      became our wholly owned subsidiary. Following the merger, our new subsidiary
      changed its name to Dyadic International (USA), Inc. (&#8220;Dyadic-Florida&#8221;) from
      Dyadic International, Inc., and our name was changed to Dyadic International,
      Inc. from CCP Worldwide, Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      connection with the merger, we disposed of our then sole operating subsidiary,
      Custom Craft Packaging, Inc., which was engaged in the packaging business,
      in a
      sale of all of the shares of that subsidiary to its founder; all of the then
      officers and directors of the Company resigned from their positions and were
      replaced with Dyadic-Florida's officers and directors; and Dyadic-Florida became
      our sole operating subsidiary. For accounting purposes, the merger was accounted
      for in a manner identical to a reverse acquisition of the Company by
      Dyadic-Florida, except that no goodwill or other intangible assets have been
      recorded. Accordingly, Dyadic-Florida was deemed to be the accounting acquirer
      of the Company because the former stockholders of Dyadic-Florida became the
      owners of a majority of the Company&#8217;s issued and outstanding shares of common
      stock after the merger, inclusive of shares of common stock issued in the
      initial closing of the private placement of the Company&#8217;s securities on the same
      date as the merger. For reporting purposes, the transaction is equivalent to
      the
      issuance of stock by Dyadic-Florida for the net monetary assets of the Company,
      which after the transactions effected on October 29, 2004 were nil, accompanied
      by a recapitalization. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      executive offices are located at 140 Intracoastal Pointe Drive, Suite 404,
      Jupiter, Florida 33477, and our telephone number is (561) 743-8333. The address
      of our website is www.Dyadic-Group.com. The contents of our website are not
      part
      of this prospectus, and our Internet address is included in this prospectus
      as
      an inactive textual reference only.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>4</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Recent
      Developments</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      October 26, 2006, we entered into a securities purchase agreement (the &#8220;ABRD
      Securities Purchase Agreement&#8221;) with Abengoa Bioenergy R&amp;D, Inc. (&#8220; ABRD&#8221;),
      a subsidiary of Abengoa Bioenergy Corporation. Also on October 26, 2006,
      Dyadic-Florida entered into a non-exclusive research and development agreement
      with ABRD pertaining to the conduct of a research and development (&#8220;R&amp;D&#8221;)
      program to be completed over a period of approximately three years, under which
      Dyadic-Florida will seek to apply its proprietary technologies to the
      development of cost-effective enzyme mixtures and related processing and
      manufacturing technologies for commercial application in ABRD&#8217;s bioethanol
      (cellulosic ethanol) production process (the &#8220;R&amp;D Agreement&#8221;). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the ABRD Securities Purchase Agreement, ABRD invested $10 million
      in
      us, for which it was issued 2,136,752 shares of our common stock at $4.68 per
      share (the closing share price on October 25, 2006, as reported on the American
      Stock Exchange (&#8220;AMEX&#8221;)). We completed this private sale on November 8, 2006.
      Under certain circumstances, as described below, we may have to issue additional
      securities of the Company to ABRD.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      use the proceeds from this private sale to fund the performance of our R&amp;D
      obligations under the R&amp;D Agreement over a period of approximately three
      years, as described below, under which we will seek to apply our proprietary
      technologies to the development of one or more enzyme mixtures and related
      processing and manufacturing technologies customized to ABRD&#8217;s proprietary
      biomass substrates. The R&amp;D Agreement contemplates that we will perform both
      (i) research of general application to the cellulosic ethanol field furthering
      our extensive research and development and large-scale manufacturing
      technologies for producing large volumes of low cost cellulases, xylanases
      and
      other hemicellulases and (ii) research of specific applications for the
      achievement of the goals of the ABRD R&amp;D Program to develop an economically
      viable commercial process for the production of large volumes of effective,
      low
      cost enzyme mixtures for the proprietary biomass substrates of specific interest
      to ABRD. In general, we are granted exclusive ownership of all intellectual
      property we develop in connection with our performance obligation under the
      R&amp;D Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the R&amp;D Agreement, if we successfully develop one or more enzyme
      mixtures and related processing and manufacturing&#160;technologies for ABRD and
      ABRD&#160;exercises an option to&#160;license on a non-exclusive basis such
      technologies, we will be entitled to receive license fees, technology transfer
      fees and royalties on ethanol production by ABRD affiliates, which will be
      recognized as earned. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      under the ABRD Securities Purchase Agreement, we have agreed to use the $10
      million to fund our performance of certain foundational and applications
      research in the cellulosic ethanol field and to spend not less than $10.0
      million (the &#8220;R&amp;D Spending Obligation&#8221;) over the course of the &#8220;R&amp;D
      Spend Measurement Period&#8221; (the period commencing on October 26, 2006 and ending
      three years following Steering Committee approval of the initial Statement
      of
      Work for calendar year 2007), during which we are to perform research (the
      amount so expended by Dyadic being referred to as the &#8220;Applicable R&amp;D
      Spend&#8221;). If we breach our R&amp;D Spending Obligation, in addition to certain
      royalty-free, non-exclusive licensing rights which would be granted to ABRD,
      we
      are obligated, at ABRD&#8217;s election, to either (x) issue additional shares of our
      common stock or (y) remit to ABRD a cash sum, in either instance having a dollar
      value equal to the amount by which $10.0 million exceeds the dollar value of
      the
      Applicable R&amp;D Spend, and if shares are used, they are valued at the greater
      of (x) $4.68 per share or (y) the closing selling price of the shares on the
      AMEX on the last trading day in the R&amp;D Spend Measurement Period.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      within
      180 days following November 8, 2006 (the closing date of the transactions
      contemplated by the ABRD Securities Purchase Agreement and the R&amp;D
      Agreement), we have completed a specified type of transaction involving the
      sale
      of our common stock (or convertible securities other than warrants or options)
      at a price lower than $4.68 per share, ABRD is entitled to have additional
      shares issued to them so that its investment is at the same price. If within
      180
      days following November 8, 2006 we have not completed a specified type of
      transaction involving the sale of our common stock totaling at least $20 million
      in gross proceeds, then ABRD is entitled to receive three-year warrants to
      purchase up to 427,351 shares of our common stock at an exercise price of $5.85
      per share. If within 180 days following November 8, 2006 we have completed
      a
      specified type of transaction involving the sale of our common stock or
      convertible securities (other than warrants) totaling at least $20 million
      in
      gross proceeds in which, in addition to our issuance of common stock, we issue
      warrants, then ABRD is entitled to receive, in lieu of the three-year warrants,
      warrants having terms and conditions identical to the terms and conditions
      of
      the warrants issued in such specified transaction and for which ABRD would
      receive pro rata warrant coverage.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares issued to ABRD on November 8, 2006 were not registered under the
      Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or any state
      securities laws. Pursuant to the ABRD Securities Purchase Agreement, we agreed
      to file a registration statement with the Securities and Exchange Commission
      (&#8220;SEC&#8221;) covering the resale of the shares issued on November 8, 2006, as well as
      additional shares, if any, issuable after November 8, 2006. We agreed to file
      the registration statement of which this prospectus is a part with the SEC
      by
      December 23, 2006 and cause it to become effective with the SEC within 210
      days
      following November 8, 2006. We are required to keep the registration statement
      of which this prospectus is a part effective until the earlier of the date
      on
      which the shares have been sold or can be sold publicly under Rule 144(k) of
      the
      Securities Act. </font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>5</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      may
      suspend the use of the registration statement of which this prospectus is a
      part
      for a 20-day trading period for as many as two times in any 12-month period.
      In
      certain events, including in the event the registration statement of which
      this
      prospectus is a part does not become effective timely or ceases to be effective
      during the registration period due to certain events, we have agreed to pay
      to
      ABRD cash, as liquidated damages, on such event and on each monthly anniversary
      of such event, an amount equal to 1% of (x) the number of shares held by ABRD
      at
      time of such event multiplied by (y) the purchase price paid by ABRD for such
      shares then held, provided that the total amount of all of these payments is
      not
      permitted to exceed 10% of the aggregate purchase price paid by ABRD.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      ABRD Securities Purchase Agreement, ABRD has agreed for a period of one year
      following November 8, 2006 to maintain exclusive beneficial ownership of, as
      well as an exclusive pecuniary interest in, all of the shares and other
      securities, if any, issuable to it pursuant to the ABRD Securities Purchase
      Agreement. Furthermore, ABRD has agreed for a period of two years following
      November 8, 2006 to refrain from directly or indirectly increasing its
      beneficial ownership, or pecuniary interest, to more than 15% of our
      shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      foregoing description of the ABRD Securities Purchase Agreement and the R&amp;D
      Agreement is qualified in its entirety by reference to our Current Report on
      Form 8-K dated October 26, 2006, as filed with the SEC on November 1,
      2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      November 17, 2006, we entered into a securities purchase agreement (the
&#8220;Securities Purchase Agreement&#8221;) with certain investors to purchase in a private
      placement 2,787,000 shares of our common stock at a price of $4.68 per share
      and
      warrants to purchase up to 557,400 shares of our common stock at an exercise
      price of $6.33 per share for gross proceeds of $13,043,160. We completed this
      private placement on December 1, 2006. Cowen and Company, LLC acted as the
      exclusive placement agent for the private placement for which we issued to
      it
      warrants to purchase up to 83,610 shares of our common stock at $5.24 per share
      and warrants to purchase up to 16,722 shares of our common stock at $6.33 per
      share. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      warrants issued to the investors become exercisable on May 31, 2007, expire
      three years thereafter, contain price adjustment and economic anti-dilution
      features, as well as anti-dilution protection from stock splits and similar
      events, contain limited cashless exercise procedures and are callable by us
      under certain circumstances. The warrants issued to the placement agent are
      substantially identical to the warrants issued to the investors, except that
      (i)
      the warrant for 83,610 shares has an exercise price of $5.24 per share rather
      than $6.33 per share and (ii) they have a five-year term rather than a
      three-year term and (iii) they provide for unqualified cashless exercise
      procedures rather than limited cashless exercise procedures. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      use the resulting net proceeds of approximately $12,300,000 to continue
      development of our C1 Host Technology for applications in the markets targeted
      by our businesses, with the goal of strengthening our product pipeline and
      accelerating the commercial launch of new products in pulp and paper, animal
      feed and other areas, and expanding R&amp;D infrastructure as well as sales and
      marketing efforts. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      securities issuable to the investors at the closing of the private placement
      were not be registered under the Securities Act or any state securities laws.
      Pursuant to the Securities Purchase Agreement, we have agreed to file a
      registration statement with the SEC covering the resale of the shares issued
      to
      the investors at closing and the shares of common stock underlying the warrants
      issued to the investors at closing. We agreed to file the registration statement
      of which this prospectus is a part with the SEC within 45 days following
      December 1, 2006 and cause it to become effective with the SEC within 135 days
      following December 1, 2006. We are required to keep the registration statement
      of which this prospectus is a part effective until the earlier of the date
      on
      which the shares have been sold or can be sold publicly under Rule 144(k) of
      the
      Securities Act. We may suspend the use of the registration statement for a
      20-day trading period for as many as two times in any 12-month period. In
      certain events, including in the event the registration statement of which
      this
      prospectus is a part does not become effective timely or ceases to be effective
      during the registration period due to certain events, we have agreed to pay
      each
      investor cash, as liquidated damages, on such event and on each monthly
      anniversary of such event, an amount equal to 1% of (x) the number of shares
      held by such investor at time of such event multiplied by (y) the purchase
      price
      paid by such investor for such shares then held, provided that the total amount
      of all of these payments is not permitted to exceed 10% of the aggregate
      purchase price paid by all investors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      foregoing description of the Securities Purchase Agreement and the private
      placement and the other transactions contemplated thereby is qualified in its
      entirety by reference to our Current Report on Form 8-K dated November 17,
      2006,
      as filed with the SEC on November 21, 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>6</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="RISK">RISK</a>
      FACTORS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>In
      addition to the other information contained and incorporated by reference in
      this prospectus, you should carefully consider the following factors before
      purchasing any of the common stock offered under this
      prospectus.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Ge</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>neral
      to Our Businesses</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      should be viewed as an early-stage company.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      combination of our Enzyme Business&#8217;s reliance upon the expansion of the
      capabilities of our C1 Expression System and the early-stage, developmental
      nature of our BioSciences Business and our Biorefineries Products require that
      we be characterized as an early-stage company. Our conduct of the BioSciences
      Business and our commercialization of Biorefinery Products are subject to the
      risks customarily attending the operations of any early-stage company, including
      the development of new technologies and products, the assembly and development
      of production and R&amp;D capabilities, the construction of channels of
      distribution and the management of growth, as discussed in the following risk
      factors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have a history of net losses, and may not achieve or maintain
      profitability.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      an accumulated deficit of approximately $41.7 million at September 30, 2006.
      Because we accelerated our R&amp;D activities and expanded both our sales and
      marketing and technical support staffs, we have experienced increased levels
      of
      net losses and negative cash flow. Whether we achieve profitability, and the
      size of our net losses prior to that time, will depend, in large part, on the
      rate of growth, if any, of our Enzyme Business, whether our BioSciences Business
      is able to generate contract sales or other sales, whether we can commercialize
      Biorefinery Products and on the level of our expenses. To date, we have derived
      almost 100% of our sales from the operations of our Enzyme Business. We do
      not
      anticipate material sales from the operation of the BioSciences Business sooner
      than 2007 or later. Our Enzyme Business may not be able to penetrate new markets
      or enjoy the improved profit margins we anticipate, which could materially
      adversely impact that business&#8217;s growth potential and profitability. Sales from
      our BioSciences Business are uncertain because our ability to secure future
      collaboration agreements will depend upon the ability of the BioSciences
      Business to perfect our C1 Host Technology to address the needs of the
      pharmaceutical and biotech industries. Similarly, our ability to commercialize
      Biorefinery Products is uncertain. We expect to spend significant amounts to
      fund R&amp;D and enhance our core technologies. As a result, we expect that our
      operating expenses will increase significantly in the near term and,
      consequently, that we will need to generate significant additional sales to
      achieve profitability. Even if we do achieve profitability, we may not be able
      to sustain or increase profitability on a quarterly or annual
      basis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      could fail to manage our growth, which would impair our
      business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      business plan contemplates that we will grow at a rapid rate, both in terms
      of
      sales and personnel. It is difficult to manage growth, and our future success
      depends on our ability to efficiently and effectively implement:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">research
                and product development programs which overcome scientific challenges
                and
                develop new products and processes;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales,
                marketing, technical service and customer support
                programs;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">operational
                and financial control systems; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">recruiting
                and training programs.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      ability to offer products and services successfully and to implement our
      business plan in a rapidly evolving global market requires effective planning,
      reporting and management processes. We expect that we will need to continue
      to
      improve our financial and managerial controls, reporting systems and procedures
      and to expand and train our workforce worldwide. We also need to continue to
      manufacture our products efficiently and to control or adjust the expenses
      related to R&amp;D, marketing, sales and general and administrative activities
      in response to changes in sales. If we are not successful in efficiently
      manufacturing our products or managing such expenses, there could be an adverse
      impact on our results of operations, our financial condition and the continued
      viability of our business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>7</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Specific to Our Enzyme Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      market share growth depends on costly new product introductions and market
      acceptance.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      future success of our Enzyme Business will depend greatly on our ability to
      continuously and timely develop and introduce new products that address evolving
      market requirements and are attractive to customers. We are relying on our
      C1
      Expression System and our other proprietary technologies to expand our Enzyme
      Business product line and improve our gross margins on those products. If we
      fail to introduce new and innovative products, we could fail to obtain an
      adequate return on our R&amp;D investments and could lose market share to our
      competitors, which might be difficult or impossible to regain. Any inability,
      for technological or other reasons, to develop successfully and introduce new
      products could reduce our growth rate or otherwise damage our
      business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      in the past we have experienced, and we are likely in the future to experience,
      delays in the development and introduction of products. For example, our efforts
      to complete the development of a high throughput system using our C1 organism
      have taken considerably longer, cost more and have proven to be much more
      difficult than we had anticipated, forcing us to sharply scale back our
      continued development efforts and seek a new collaborative partner. We may
      not
      be able to keep pace with the rapid rate of change in our markets or to develop
      new products or processes that will meet the requirements of the marketplace
      or
      achieve market acceptance. Some of the factors affecting market acceptance
      of
      our products include:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">availability,
                quality, performance and price as compared to competitive
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                functionality of new and existing
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                timing of introduction of our products as compared to competitive
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">scientists&#8217;
                and customers&#8217; opinions of our products&#8217; utility and our ability to
                incorporate their feedback into our future products;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">citation
                of the products in published
                research.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      expenses or losses associated with unsuccessful product development activities
      or lack of market acceptance of our new products could seriously harm our
      business, financial condition and results of operations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      dependence on contract manufacturers could harm our
      business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      Enzyme Business currently relies on contract manufacturers for all of its
      manufacturing. If we require additional manufacturing capacity and are unable
      to
      obtain it in sufficient quantity, we may not be able to increase our sales,
      or
      may be required to make very substantial capital investments to build that
      capacity.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      manufacturing capabilities, and any current or future arrangements with third
      parties for these activities, may not be adequate for the successful
      commercialization of our industrial enzyme products. In the operation of the
      Enzyme Business, all of our industrial enzymes have over the past decade, and
      are expected over the foreseeable future to be, produced at the manufacturing
      facilities of contract manufacturers. As a result, we are dependent upon the
      performance and plant capacity of third-party manufacturers. Though we formerly
      used two contract manufacturers, we let our agreement with one of those contract
      manufacturers expire and now only use it on a highly limited basis. Our Enzyme
      Business, therefore, faces risks of difficulties with, and interruptions in,
      performance by these third parties of their manufacturing responsibilities,
      the
      occurrence of which could adversely impact the availability, launch and/or
      sales
      of our products in the future. For example, our principal contract manufacturer,
      Polfa Tarchomin, S.A., which has been producing a number of our products since
      2001 without interruption has concluded an agreement with us to provide an
      additional 50 cubic meters of fermentation capacity and associated recovery
      capacity with the majority of the capital necessary for this expansion to be
      provided by them. This expansion has been substantially completed. Dyadic has
      committed to direct payment for certain removable equipment for this expansion
      of approximately $1.0 million.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">However,
      with the expiration of our contract manufacturing agreement with our second,
      and
      only other, contract manufacturer, we are currently utilizing their services
      on
      an as needed basis. The majority of our production requirements will be
      satisfied by the single manufacturing facility operated by our Polish contract
      manufacturer, leaving us vulnerable to a failure of performance by it.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>8</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Regulations
      may limit or impair our ability to sell genetically engineered products in
      the
      future.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      develop enzyme products using both non-genetically engineered
      microorganisms,&#160;as well as those that have undergone some degree
      of&#160;genetic modification.&#160;&#160;Products derived from genetically
      modified organisms, or GMOs, are subject to regulation by&#160;federal, state,
      local and foreign government agencies.&#160;These agencies administering
      existing or future applicable regulation or legislation may not allow&#160;us to
      produce and market&#160;our products derived from GMOs in a timely manner or
      under technically or commercially feasible conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, regulatory action or private litigation could result in expenses,
      delays or other impediments to&#160;our product development programs or the
      commercialization of resulting products.&#160; The U.S. Food and Drug
      Administration, or FDA, currently applies the same regulatory standards to
      products made through genetic engineering as those applied to products developed
      through traditional methodologies.&#160;Depending on&#160;a product's
      application and regardless of its GMO status, it may be subject to lengthy
      FDA
      reviews and unfavorable FDA determinations if there are safety concerns or
      if
      the FDA changes its current regulatory&#160;policy.&#160; The European Union, or
      the EU, has regulations regarding the development, production and marketing
      of
      products from GMOs&#160;which are generally&#160;more restrictive than present
      U.S. regulations.&#160; For example, among other requirements, EU animal feed
      registration requires in-vivo&#160;efficacy testing, as well as toxicological
      testing of all enzyme products, including products from non-GMO
      microorganisms.&#160; The regulatory agencies administering these and future
      regulations may hinder our ability to produce and bring to&#160;market some of
      our enzyme products in a timely manner or under technically or commercially
      feasible conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Specific to Our BioSciences Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may fail to commercialize our C1 Expression System for the expression of
      therapeutic proteins. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      our Enzyme Business has developed and sold industrial enzyme products and has
      used our C1 Expression System to develop such products, our BioSciences Business
      has not yet completed commercialization of our C1 Expression System for the
      expression of therapeutic proteins. If our BioSciences Business fails to do
      this, we may be forced to terminate the BioSciences Business&#8217;s operations and
      liquidate it.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      BioSciences Business must be evaluated as having the same risks as those
      inherent in early-stage biotechnology companies because the application of
      our
      C1 Expression System to the expression of pre-clinical and clinical quantities
      of therapeutic proteins is still in development. We may not be able to
      successfully harness the C1 Expression System to achieve those objectives.
      Further, we may not be able to expand the capabilities of the C1 Expression
      System to produce commercial volumes of therapeutic proteins at reasonable
      costs. Also, we may not ever be able to successfully complete development of
      our
      fungal high throughput system. And, even if the BioSciences Business is able
      to
      achieve any of those accomplishments, we may not be able to successfully develop
      the C1 Screening System to serve the functions of gene discovery or the
      development of new and/or improved protein drugs. Successful development of
      the
      C1 Host Technology for these purposes will require significant development
      and
      investment, including testing, to prove its efficacy and cost-effectiveness.
      To
      date, drug companies have developed and commercialized only a small number
      of
      gene-based products in comparison to the total number of drug molecules
      available in the marketplace. In this regard, we are heavily dependent upon
      our
      use of third-party research organizations to assist us in the development of
      the
      C1 Host Technology. In general, our experience has been that each step in the
      process has taken longer and cost more to accomplish then we had originally
      projected, and we anticipate that this is likely to remain the case with respect
      to our BioSciences Business&#8217; continuing development efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
      of our C1 Expression System for therapeutic proteins depends on
      collaborations.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commercialization
      of our C1 Expression System by our BioSciences Business depends on
      collaborations with other parties. If we are not able to find collaborators
      in
      the future, the BioSciences Business may not be able to develop the C1
      Expression System or therapeutic protein products. Further, our business model
      relies on a revenue stream derived from collaboration projects to be conducted
      with our customers to express laboratory-testing quantities of therapeutic
      proteins. A large portion of the anticipated financial reward depends on those
      therapeutic proteins progressing through drug development and into commercially
      successful drugs. Apart from risks relating to whether our BioSciences Business
      can capture such customers, or capture them on satisfactory terms, we will
      have
      no control over post-collaboration project drug development and
      commercialization. Further, conflicts could arise between us and our customers
      or among them and third parties that could discourage or impede the activities
      of our BioSciences Business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      we
      do not currently possess the financial resources necessary to develop and
      commercialize potential drug products that may result from our C1 Expression
      System, or the resources to complete any approval processes which may be
      required for these products, we must enter into collaborative arrangements
      to
      develop and commercialize drug products. It is expected that these arrangements
      will be for fixed terms and will expire after a fixed period of time. If they
      are not renewed or if we do not enter into new collaborative agreements, our
      sales will be reduced and our products may not be commercialized.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>9</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        have limited or no control over the resources that any collaborator may devote
        to our programs.</strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      limited or no control over the resources that any collaborator may devote to
      our
      products. Any of our future collaborators may not perform their obligations
      as
      expected. These collaborators may breach or terminate their agreement with
      us or
      otherwise fail to conduct their collaborative activities successfully and in
      a
      timely manner. Further, our collaborators may elect not to develop products
      arising out of our collaborative arrangements or devote sufficient resources
      to
      the development, manufacture, market or sale of these products. If any of these
      events occur, we may not be able to develop our technologies or commercialize
      our products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Potential
      therapeutic products developed by us or with our customers or collaborators
      are
      subject to a lengthy and uncertain regulatory process. If these therapeutic
      protein products are not approved, we or our customers or collaborators will
      not
      be able to commercialize them, and we may not receive the milestone and royalty
      payments which are based upon the successful advancement of these products
      through the drug development and approval process.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      FDA
      must approve any therapeutic product before it can be marketed in the United
      States. Before our collaborators can file a new drug application or biologic
      license application with the FDA, the product candidate must undergo extensive
      testing, including animal and human clinical trials, which can take many years
      and require substantial expenditures. Data obtained from such testing are
      susceptible to varying interpretations which could delay, limit or prevent
      regulatory approval. In addition, changes in regulatory policy for product
      approval during the period of product development and regulatory agency review
      of each submitted new application or product license application may cause
      delays or rejections.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
      these products involve the application of new technologies and may be based
      upon
      new therapeutic approaches, they may be subject to substantial review by
      government regulatory authorities and, government regulatory authorities may
      grant regulatory approvals more slowly for these products than for products
      using more conventional technologies. While we anticipate that most of our
      collaborators will have experience submitting an application to the FDA or
      any
      other regulatory authority, we have no such experience, and neither we nor
      any
      collaborator has yet submitted an application with the FDA or any other
      regulatory authority for any product candidate generated through the use of
      our
      C1 Expression System, nor has the FDA nor any other regulatory authority
      approved any therapeutic product candidate developed using our C1 Expression
      System for commercialization in the United States or elsewhere. Our
      collaborators may not be able to conduct clinical testing or obtain the
      necessary approvals from the FDA or other regulatory authorities for our
      products. The regulatory agencies of foreign governments must also approve
      our
      therapeutic products before the products can be sold in those other
      countries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Even
      after investing significant time and expenditures, our collaborators may not
      obtain regulatory approval for their products. Even if they receive regulatory
      approval, this approval may entail limitations on the indicated uses for which
      we can market a product. Further, once regulatory approval is obtained, a
      marketed product and its manufacturer are subject to continual review, and
      discovery of previously unknown problems with a product or manufacturer may
      result in restrictions on the product, manufacturer and manufacturing facility,
      including withdrawal of the product from the market. In certain countries,
      regulatory agencies also set or approve prices. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Health
      care reform may limit our profitability or that of our
      customers.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      C1
      Host Technology is being developed to assist our customers or collaborators
      in
      the development of future therapeutic products, including pharmaceutical
      products. The ability of our collaborators to commercialize pharmaceutical
      products developed with our C1 Host Technology may depend in part on the extent
      to which reimbursement for the cost of those products will be available from
      government health administration authorities, private health insurers and other
      organizations. Third-party payers are increasingly challenging prices of medical
      products and services. Significant uncertainty exists as to the reimbursement
      status of newly approved health care products, and there can be no assurance
      that adequate third party coverage will be available for any product to enable
      us to maintain price levels sufficient to realize an appropriate return on
      our
      investment in research and product development. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Adverse
      events in the field of therapeutic products may adversely affect us or our
      collaborators.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently,
      we are not engaged in developing therapeutic products for our own account,
      but
      instead intend to collaborate with drug companies to express therapeutic
      products requested by them for the ultimate purpose of their development,
      testing and introduction as new drugs. We may, however, engage in these
      activities in the future for our own account. If we or our collaborators develop
      therapeutic products, these products may encounter substantial delays in
      development and approval due to the government regulation and approval process.
      Adverse events reported in gene therapy clinical trials may lead to more
      government scrutiny of proposed clinical trials of therapeutic products,
      stricter labeling requirements for these products and delays in the approval
      of
      other types of products for commercial sale.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>10</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          C1
          Expression System has been tested for use in pulp and paper production,
          which
          requires FDA approval as generally regarded as safe, or GRAS, and has generated
          promising safety and toxicity data for one enzyme. A risk nonetheless exists
          that the C1 Expression System will produce therapeutic products and enzymes
          that
          have safety and toxicity issues associated with them.</font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        believe our determination of the genome sequence of our C1 host organism
        could
        help to mitigate our risk that there are unexpected safety and toxicity issues
        associated with our C1 Expression System and facilitate our ability to find
        and
        express new genes of bio-therapeutic and other commercial value. However,
        there
        can be no assurance that annotation of the C1 will be fully or adequately
        completed, and until it is successfully completed, we are at a distinct
        competitive disadvantage to some of our competitors, whose host organisms
        have
        been more thoroughly researched and whose genomes have been fully annotated.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Applicable to the Commercialization of Biorefinery Products</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commerc</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ialization
      of Biorefinery Products depends on collaborative
      partnerships.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
      we do not have the manufacturing infrastructure and financial resources to
      develop large scale-enzyme production and manufacturing processes for the
      commercialization of our Biorefinery Products, our ability to commercialize
      our
      Biorefinery Products will depend on our entering into collaborative partnerships
      like our recent one with Abengoa Bioenergy R&amp;D, Inc. We are considering
      additional collaborative partnerships, though there is no assurance that we
      will
      able to complete any additional ones on terms acceptable to us or at all.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
      of Cellulosic Ethanol may not be feasible. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      cellulosic ethanol should reduce the United States' dependence on imported
      oil,
      increase its energy security and reduce its trade deficit, commercialization
      of
      cellulosic ethanol in the United States or elsewhere may not be feasible for
      a
      variety of reasons.&#160; Among others, there has been to date a lack of
      significant private and government funding for research and development in
      conversion and processing technologies, as well as for the development of
      biorefineries. Furthermore, there has been to date very little, if any, well
      directed public policies emphasizing investment and providing incentives for
      the
      commercialization and transition to cellulosic ethanol. The current United
      States Presidential administration has recently been publicizing the benefits
      of
      cellulosic ethanol, though it remains to be seen whether or not such publicity
      will engender significant government funding and economic incentives to mitigate
      some of the foregoing barriers to commercialization of cellulosic ethanol.&#160;
Our recent collaborative partnership with Abengoa Bioenergy R&amp;D, Inc. may
      suggest that these barriers are surmountable, although there are no assurances
      in this regard. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      United States Ethanol Industry is highly dependent upon a myriad of federal
      and
      state legislation and regulations and any changes in such legislation or
      regulation could materially and adversely affect the demand for our Biorefinery
      Products. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      United States Ethanol Industry is highly dependent upon a myriad of federal
      and
      state legislation and regulations. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      changes in such legislation or regulation could materially and adversely affect
      the demand for our Biorefinery Products. For example, under the Energy Policy
      Act of 2005, the U.S. Department of Energy, in consultation with the U.S.
      Secretary of Agriculture and the U.S. Secretary of Energy, may waive the
      Renewable Fuels Standard, or RFS, mandate with respect to one or more states
      if
      the Administrator determines that implementing the requirements would severely
      harm the economy or the environment of a state, a region or the United States,
      or that there is inadequate supply to meet the requirement. In addition, the
      Department of Energy was directed under the Energy Policy Act of 2005 to conduct
      a study by January 2006 to determine if the RFS will have a severe adverse
      impact on consumers in 2006 on a national, regional or state basis. Based on
      the
      results of the study, the Secretary of Energy must make a recommendation to
      the
      EPA as to whether the RFS should be waived for 2006. Any waiver of the RFS
      with
      respect to one or more states or with respect to 2006 would adversely offset
      demand for ethanol and, thus, diminish demand for Biorefinery
      Products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Applic</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>able
      to Our Enzyme Business, BioSciences Business and Biorefinery
      Products</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Alternative
      technologies may diminish the need for producing some enzymes the way we
      do.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Many
      of
      our enzyme products are produced in fermenters. Some of the product segments
      we
      hope to serve may not find it efficient to use the fermenter processes we
      employ. For example, bio-ethanol and other bio-fuels production represents
      a
      considerable market opportunity for enzymes comprising Biorefinery Products.
      However, research being conducted within the auspices of major seed producers,
      U.S. federal government and corn growers association may supplant the need
      for
      enzymes produced in fermenters, which is the enzyme production process we
      currently use.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Reductions
      in R&amp;D budgets may affect the sales of our Businesses.</strong></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>11</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      customers include researchers at customers of our Enzyme Business, potential
      drug company customers of our BioSciences Business and potential energy
      companies for our Biorefinery Products. Fluctuations in the R&amp;D budgets of
      these researchers and their organizations could have a significant effect on
      the
      demand for our products. Research and development budgets fluctuate due to
      changes in available resources, consolidation in the pharmaceutical and energy
      industries, spending priorities and institutional budgetary policies. Our
      Businesses could be seriously damaged by any significant decrease in life
      sciences and/or renewable fuels R&amp;D expenditures by these existing and
      potential customers, academic institutions, government laboratories or private
      foundations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Conflicts
      with our collaborators could harm our business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      important part of our strategy involves conducting proprietary research
      programs. We may pursue opportunities in fields that could conflict with those
      of our collaborators. Moreover, disagreements with our collaborators could
      develop over rights to our intellectual property. Any conflict with our
      collaborators could reduce our ability to obtain future collaboration agreements
      and negatively impact our relationship with existing collaborators, which could
      reduce our sales.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      of our collaborators could also become competitors in the future. Our
      collaborators could develop competing products, preclude us from entering into
      collaborations with their competitors, fail to obtain timely regulatory
      approvals, terminate their agreements with us prematurely or fail to devote
      sufficient resources to the development and commercialization of products.
      Any
      of these developments could harm our product development efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      either commercialize products resulting from our proprietary programs directly
      or through licensing to other companies. We have limited experience in
      manufacturing and marketing products for the pharmaceutical, biotechnology
      and
      energy industries. In order for us to commercialize these products directly,
      we
      would need to develop, or obtain through outsourcing arrangements, the
      capability to market and sell these products. We do not have these capabilities,
      and we may not be able to develop or otherwise obtain the requisite marketing
      and sales capabilities. If we are unable to successfully commercialize products
      resulting from our proprietary research efforts, we will continue to incur
      losses. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Public
      views on ethical and social issues may limit use of our technologies and reduce
      our sales.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      success will depend in part upon our ability to develop products discovered
      through our C1 Host Technology. Governmental authorities could, for social
      or
      other purposes, limit the use of genetic processes or prohibit the practice
      of
      our C1 Host Technology. Ethical and other concerns about our C1 Host Technology,
      particularly the use of genes from nature for commercial purposes, and products
      resulting there from, could adversely affect their market acceptance.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>If
      the public does not accept genetically engineered products, our product demand
      could decline.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      commercial success of our potential products will depend in part on public
      acceptance of the use of genetically engineered products including drugs, plants
      and plant products. Claims that genetically engineered products are unsafe
      for
      consumption or pose a danger to the environment may influence public attitudes.
      Our genetically engineered products may not gain public acceptance in the
      various industrial, pharmaceutical, biotechnology or energy industries. Negative
      public reaction to genetically modified organisms and products could result
      in
      greater government regulation of genetic research and resultant products,
      including stricter labeling laws or regulations, and could cause a decrease
      in
      the demand for our products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      subject of genetically modified organisms has received negative publicity in
      Europe and other countries, which has aroused public debate. The adverse
      publicity in Europe could lead to greater regulation and trade restrictions
      on
      imports of genetically altered products. If similar adverse public reaction
      occurs in the United States, genetic research and resultant products could
      be
      subject to greater domestic regulation and a decrease in the demand for our
      products could result.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
      Business Risks That We Face</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      must continually offer new products and technologies.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      industrial enzymes and biotechnology industries are characterized by rapid
      technological change, and the area of gene research is a rapidly evolving field.
      Our future success will depend on our ability to maintain a competitive position
      with respect to technological advances. Rapid technological development by
      others may result in our products and technologies becoming
      obsolete.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>12</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      products that we develop through our C1 Host Technology will compete in highly
      competitive markets. Many of the organizations competing with us in the markets
      for such products have greater capital resources, R&amp;D and marketing staffs
      and facilities and capabilities, and greater experience in obtaining regulatory
      approvals, manufacturing products and marketing. Accordingly, our competitors
      may be able to develop technologies and products more easily which would render
      our technologies and products and those of our collaborators obsolete and
      noncompetitive. If a competitor develops superior technology or cost-effective
      alternatives to our products or processes, our business, operating results
      and
      financial condition could be seriously harmed. In addition, demand for our
      products may weaken due to reduction in R&amp;D budgets or loss of distributors,
      any of which might have an adverse effect on our financial
      condition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      markets for our Enzyme Business&#8217;s products are, in many cases, very competitive
      and price sensitive. Our Enzyme Business currently competes with five much
      larger competitors, each with dominant market positions in segments in which
      we
      compete and who, as a group, hold approximately 70% market share in the present
      industrial enzymes marketplace. Each of these competitors has substantially
      greater financial, operational, sales and marketing resources than we do and
      very significant experience in R&amp;D. Further, these competitors may possess
      other complementary technologies, such as proprietary directed molecular
      evolution technology, which may be more effective at implementing their
      technologies to develop commercial products than our complementary technologies
      implement our C1 Host Technology. Also, some of these competitors have entered
      into collaborations with leading companies within our Enzyme Business&#8217;s target
      markets to produce enzymes for commercial purposes.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Well-known,
      and better financed, biotechnology companies offer competing technologies for
      the same products and services as our BioSciences Business plans to offer using
      our C1 Host Technology. Customers may prefer existing competing technologies
      over our C1 Host Technology. Our BioSciences Business also faces, and will
      continue to face, intense competition from organizations such as large
      biotechnology companies, as well as academic and research institutions and
      government agencies that are pursuing competing technologies to enable
      production of therapeutic and other proteins and bio-molecules of commercial
      interest at economically viable costs. These organizations may develop
      technologies that are superior alternatives to our C1 Host Technology. We
      anticipate that our BioSciences Business will face increased competition as
      new
      companies enter our markets and as development of biological products
      evolves.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may need additional capital in the future. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      future capital requirements may be substantial, particularly as we continue
      to
      develop the C1 Host Technology to commercialize Biorefinery Products and if
      completion of the development of our C1 Expression System for our BioSciences
      Business takes longer or requires greater resources than we had expected, if
      we
      continue to develop the C1 Expression System to expand its production
      capabilities to manufacture commercial volumes of therapeutic proteins, if
      we
      continue to develop a C1 Screening System, or if our BioSciences Business
      develops a number of therapeutic products. Although we believe that we have
      sufficient cash on hand to fund our operations and meet our obligations through
      December 31, 2008, our need for additional capital will depend on many factors,
      including the financial success of our Enzyme Business, whether we are
      successful in obtaining payments from BioSciences Business customers under
      collaborative agreements, whether we are successful in our R&amp;D efforts with
      Abengoa Bioenergy R&amp;D, Inc., whether we can enter into additional
      collaborative partnerships for commercialization of our Biorefinery Products,
      the progress and scope of our collaborative and independent R&amp;D projects
      performed by our customers and collaboration partners, the effect of any
      acquisitions of other businesses that we may make in the future, and the filing,
      prosecution and enforcement of patent claims.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      our
      capital resources are insufficient to meet our capital requirements through
      December 31, 2008, we will have to raise additional funds to continue the
      development of our technologies and complete the commercialization of products,
      if any, resulting from our technologies. If future raises of funds do occur,
      they may cause dilution to our existing stockholders. We may not be able to
      raise additional funds on terms that are acceptable to us or on any terms
      whatsoever, or we may be unable to raise sufficient additional capital. If
      we
      fail to raise sufficient funds, and our Enzyme Business is unable to generate
      sufficient levels of profitability, we may have to curtail or cease, or dispose
      of, one or more of our operations. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      will need to expand our existing</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      marketing and sales resources.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
      we
      have recently expanded our marketing and sales functions, our Enzyme Business
      will need to continue to expand them to achieve our contemplated annual rates
      of
      growth and for our BioSciences Business to successfully market the C1 Expression
      System and our contemplated C1 Screening System. Currently, we rely primarily
      on
      our direct sales force for the United States market and contract with
      professional sales agents and distributors for the international market,
      including two controlled foreign subsidiaries. Direct salespeople are our
      employees and are paid a salary plus commissions on sales they make within
      their
      assigned territories. Contracted sales agents are paid a base rate of
      compensation plus commissions on sales they make within their assigned
      territories. Distributors purchase products from us and then resell our products
      and services to third parties. Our officers and employees develop and implement
      our marketing strategy, although we do periodically engage non-employee
      consultants, acting as independent contractors, to assist us in these
      efforts.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>13</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Market
      forces, such as increasing competition, increasing cost pressures on our
      customers and general economic conditions, may require us to devote more
      resources to our sales and marketing efforts than we currently contemplate,
      such
      as changing the composition of our sales and marketing staff and changing our
      marketing methods. These changes may result in additional expenses. In addition,
      we will incur additional salary expenses because we intend to increase our
      direct sales force. We also may hire direct sales representatives to replace
      independent sales representatives or distributors that we use. Similarly, if
      we
      increase our reliance on marketing consultants to assist us, we will incur
      greater costs. If we decide to increase our advertising, we will also incur
      higher sales and marketing costs. Our incurrence of increased costs will make
      it
      more difficult for us to operate profitably, and we may not have sufficient
      funds to support all of these costs.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      we
      expand our sales force and increase our marketing activities, we can offer
      no
      assurances that those efforts will result in more sales or higher revenue.
      Also,
      the increased costs we incur by expanding our sales and marketing resources
      may
      not result in greater sales or in higher revenue. Further, even if we increase
      our spending on sales and marketing, we may not be able to maintain our current
      level of sales and revenue. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Loss
      of key personnel could hurt our business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      highly dependent on the principal members of our management and scientific
      staff, the loss of whose services might adversely impact the achievement of
      our
      objectives. In addition, recruiting and retaining qualified scientific personnel
      to perform future R&amp;D work will be critical to our success. We currently do
      not have sufficient executive management personnel to fully execute our business
      plan. Although we believe we will be successful in attracting and retaining
      qualified management and scientific personnel, such as the addition of our
      Chief
      Scientific Officer, Glenn Nedwin in March 2006, competition for experienced
      scientists from numerous companies and academic and other research institutions
      may limit our ability to do so on acceptable terms. Failure to attract and
      retain scientific personnel would prevent us from pursuing collaborations or
      developing our products or core technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      planned activities will require additional expertise in specific industries
      and
      areas applicable to the products developed through our technologies. These
      activities will require the addition of new personnel, including management,
      and
      the development of additional expertise by existing management personnel. The
      inability to acquire these services or to develop this expertise could impair
      the growth, if any, of our business. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      directors and senior officers require that we maintain directors and officers
      insurance at levels comparable to those of similar sized public companies.
      We
      have purchased such directors&#8217; and officers&#8217; liability insurance. Our efforts to
      recruit additional directors could be impeded if the amount of insurance
      coverage is viewed to be insufficient. Further, if we are unable to provide
      adequate compensation or are unable to maintain sufficient directors&#8217; and
      officers&#8217; insurance coverage, we may not be able to attract or retain key
      personnel.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Personnel
      changes may disrupt our operations. Hiring and training new personnel will
      entail costs and may divert our resources and attention from revenue-generating
      efforts. From time to time, we also engage consultants to assist us in our
      business and operations. These consultants serve as independent contractors,
      and
      we, therefore, do not have as much control over their activities as we do over
      the activities of our employees. Our consultants may be affiliated with or
      employed by other parties, and some may have consulting or other advisory
      arrangements with other entities that may conflict or compete with their
      obligations to us. Inventions or processes discovered by these persons will
      not
      necessarily become our property. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Inability
      to protect our technologies could harm our ability to compete.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      success will depend in part on our ability to obtain patents and maintain
      adequate protection of our other intellectual property for our technologies
      and
      products in the United States and other countries. If we do not adequately
      protect our intellectual property, competitors may be able to practice our
      technologies and erode our competitive advantage. The laws of some foreign
      countries do not protect proprietary rights to the same extent as the laws
      of
      the United States, and many companies have encountered significant problems
      in
      protecting their proprietary rights in these foreign countries. These problems
      can be caused by, for example, a lack of rules and methods for defending
      intellectual property rights.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>14</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      hold
      four issued U.S. patents and 27 issued and 2 allowed international patents,
      including claims that cover the C1 Expression System and various other aspects
      of the C1 Host Technology, and 50 U.S. and international filed and pending
      patent applications which we believe provide broad protection for our C1
      Expression System, our underlying C1 Host Technology and C1 Screening System
      and
      their products and commercial applications. However, the patent positions of
      biotechnology companies, including our patent position, are generally uncertain
      and involve complex legal and factual questions. We will be able to protect
      our
      proprietary rights from unauthorized use by third parties only to the extent
      that our proprietary technologies are covered by valid and enforceable patents
      or are effectively maintained as trade secrets. We intend to apply for patents
      covering both our technologies and products as we deem appropriate. However,
      existing and future patent applications may be challenged and may not result
      in
      issued patents. Our existing patents and any future patents we obtain may not
      be
      sufficiently broad to prevent others from practicing our technologies or from
      developing competing products. Furthermore, others may independently develop
      similar or alternative technologies or design around our patented technologies.
      In addition, others may challenge or invalidate our patents, or our patents
      may
      fail to provide us with any competitive advantages.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
      all
      of our proprietary technology is eligible for patent protection. Accordingly,
      as
      to significant portions of our various proprietary technologies, we rely upon
      trade secret protection for our confidential and proprietary information. We
      have taken security measures to protect our proprietary information. These
      measures may not provide adequate protection for our trade secrets or other
      proprietary information. We seek to protect our proprietary information by
      entering into confidentiality agreements with employees, collaborators and
      consultants. Nevertheless, employees, collaborators or consultants may still
      disclose our proprietary information, and we may not be able to meaningfully
      protect our trade secrets. In addition, others may independently develop
      substantially equivalent proprietary information or techniques or otherwise
      gain
      access to our trade secrets. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Intellectual
      property litigation could harm our business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      commercial success depends in part on neither infringing patents and proprietary
      rights of third parties, nor breaching any licenses that we have entered into
      with regard to our technologies and products. Others have filed, and in the
      future are likely to file, patent applications covering genes or gene fragments
      that we may wish to utilize with our C1 Host Technology, our C1 Expression
      System, our C1 Screening System or products or systems that are similar to
      products developed with the use of our C1 Host Technology. If these patent
      applications result in issued patents and we wish to use the claimed technology,
      we would need to obtain a license from the third party. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
      parties may assert that we are employing their proprietary technology without
      authorization. In addition, third parties may obtain patents in the future
      and
      claim that use of our technologies infringes these patents. We could incur
      substantial costs and diversion of management and technical personnel in
      defending ourselves against any of these claims or enforcing our patents or
      other intellectual property rights against others. Furthermore, parties making
      claims against us may be able to obtain injunctive or other equitable relief
      which could effectively block our ability to further develop, commercialize
      and
      sell products, and could result in the award of substantial damages against
      us.
      If a claim of infringement against us is successful, we may be required to
      pay
      damages and obtain one or more licenses from third parties. We may not be able
      to obtain these licenses at a reasonable cost, if at all. In that event, we
      could encounter delays in product commercialization while we attempt to develop
      alternative methods or products. Defense of any lawsuit or failure to obtain
      any
      of these licenses could prevent us from commercializing available
      products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      the taxonomic classification of our C1 host organism was determined using
      classical morphological methods. More modern taxonomic classification methods
      indicate that our C1 host organism will be reclassified as a different genus
      and
      species. We anticipate that with the genomic sequence and after the expected
      completion of the annotation of the C1 genome, we will be better positioned
      to
      determine the genus and species of the C1 Host organism. Some of the possible
      species that the C1 host could be reclassified as could be the subject of patent
      rights owned by others. We believe, based on our evaluation of the relevant
      field of science and our discussions with our consulting professionals, that
      any
      such patent rights would be invalid, and were litigation over the issue to
      ensue, we believe we should prevail. If we did not prevail, to settle any such
      litigation or pre-litigation claims, we could be required to enter into a
      cross-licensing arrangement, pay royalties or be forced to stop
      commercialization of some of our activities. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      do not
      fully monitor the public disclosures of other companies operating in our
      industry regarding their technological development efforts. If we did evaluate
      the public disclosures of these companies in connection with their technological
      development efforts and determined that they violated our intellectual property
      or other rights, we would anticipate taking appropriate action, which could
      include litigation. However, any action we take could result in substantial
      costs and diversion of management and technical personnel. Furthermore, the
      outcome of any action we take to protect our rights may not be resolved in
      our
      favor or may not be resolved for a lengthy period of time. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may be sued for product liability. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>15</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      may be
      held liable if any product we develop, or any product which is made with the
      use
      or incorporation of, any of our technologies, causes injury or is found
      otherwise unsuitable during product testing, manufacturing, marketing or sale.
      These risks are inherent in the development of chemical, agricultural and
      pharmaceutical products. While we maintain product liability insurance, it
      may
      not fully cover our potential liabilities. Inability to obtain sufficient
      insurance coverage at an acceptable cost or otherwise to protect against
      potential product liability claims could prevent or inhibit the
      commercialization of products developed by us or our collaborators. If we are
      sued for any injury caused by our products, our liability could exceed our
      total
      assets.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>International
      unrest or foreign currency fluctuations could adversely affect our
      results.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">International
      sales accounted for approximately 86% and 91% of our net sales in 2004 and
      2005,
      respectively, and accounted for a vast portion of our net sales for the
      nine-months ended September 30, 2006. Our key international markets are the
      European Union, Hong Kong, the Peoples Republic of China and India. Our
      international sales are made through international distributors and their wholly
      owned subsidiaries, including our Asian subsidiary, and direct to end-user
      plants with payments to us, in many cases, denominated in currencies other
      than
      U.S. dollars. In the conduct of our business, in a number of instances, we
      are
      required to pay our obligations in currencies other than U.S. dollars.
      Accordingly, we are exposed to changes in currency exchange rates with respect
      to our international sales and payment obligations. We incurred currency losses
      in 2004 of $213,471 and currency gains in 2005 of $16,785. For the nine-months
      ended September 30, 2006, we incurred currency losses of approximately $111,000
      as compared to currency gains of approximately $27,000 for the nine-months
      ended
      September 30, 2005. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fluctuations
      in currency exchange rates have in the past and may in the future negatively
      affect our ability to price competitively against products denominated in local
      currencies. Also, changes in foreign currency exchange rates may have an adverse
      effect on our financial position and results of operations as expressed in
      U.S.
      dollars. Our management monitors foreign currency exposures and may, in the
      ordinary course of business, enter into foreign currency forward contracts
      or
      options contracts related to specific foreign currency transactions or
      anticipated cash flows. We do not hedge, and have no current plans to hedge
      in
      the future, the translation of financial statements of consolidated subsidiaries
      whose local books and records are maintained in foreign currency. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      imposition of duties or other trade barriers, trade embargoes, acts of
      terrorism, wars and other events outside our control may adversely affect
      international commerce and impinge on our ability to manufacture, transport
      or
      sell our products in international markets.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Business
      interruptions could keep us from developing our products and increasing our
      sales. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Natural
      or man-made disasters, such as fires, earthquakes, hurricanes, power losses,
      telecommunications failures, terrorist attacks, military operations and other
      events beyond our control may interrupt our operations. We do not have a
      detailed disaster recovery plan. In addition, we may not carry sufficient
      business interruption insurance to compensate us for losses that may occur
      and
      any losses or damages we incur could have a material adverse effect on our
      cash
      flows and success as an overall business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are dependent on several key customers.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2005,
      there were two customers that accounted for approximately 10% each of net sales.
      In 2004, there were no customers that accounted for greater than 10% of net
      sales. There were three customers in 2005 whose trade receivable balances
      equaled or exceeded 5% of total receivables, representing approximately 16%,
      7%,
      and 6%, respectively, of total accounts receivable. During the nine-months
      ended
      September 30, 2006 there was one customer that accounted for approximately
      9.4%
      of net sales. During the nine-months ended September 30, 2005, there were two
      customers that accounted for approximately 10.3% and 9.4%, respectively, of
      net
      sales. There were two customers as of September 30, 2006, whose trade receivable
      balances equaled or exceeded 5% of total receivables, representing approximately
      15.3% and 6.8%, respectively, of total accounts receivable. The loss of business
      from one or a combination of our significant customers and/or the failure to
      collect the accounts receivable attributable to one or more of our significant
      customers could adversely affect our business, results of operations and
      financial condition. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Related to Our Common Stock</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities
      of Biotechnology companies are often volatile. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      trading prices of biotechnology company stocks in general tend to experience
      extreme price fluctuations. The valuations of many biotechnology companies
      without consistent product sales and earnings are extraordinarily high based
      on
      conventional valuation standards such as price to earnings and price to sales
      ratios. These trading prices and valuations may not be sustained. Any negative
      change in the public&#8217;s perception of the prospects of biotechnology companies
      could depress our stock price regardless of our results of operations.
</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>16</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>&#160;</div>
      <div><font size="2">Other broad market and industry factors may decrease
        the
        trading price of our common stock, regardless of our performance. Market
        fluctuations, as well as general political and economic conditions such as
        war,
        recession or interest rate or currency rate fluctuations, also may decrease
        the
        trading price of our common stock. In addition, our stock price could be
        subject
        to wide fluctuations in response to factors including, but not limited to,
        the
        following: </font></div>
      <div>&#160;</div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                of new technological innovations or new products by us or our competitors;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in financial estimates by securities analysts;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">conditions
                or trends in the biotechnology industry;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in the market valuations of other biotechnology companies;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                in domestic and international governmental policy or regulations;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                by us or our competitors of significant acquisitions, strategic
                partnerships, joint ventures or capital commitments;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                in patent or other proprietary rights held by us or by others;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">loss
                or expiration of our intellectual property rights;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">lawsuits
                initiated by or against us;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">period-to-period
                fluctuations in our operating results;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">future
                royalties from product sales, if any, by our strategic partners;
                and
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales
                of our common stock or other securities in the open market.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      past, stockholders have often instituted securities class action litigation
      after periods of volatility in the market price of a company&#8217;s securities. If a
      stockholder files a securities class action suit against us, we would incur
      substantial legal fees and our management&#8217;s attention and resources would be
      diverted from operating our business to respond to the litigation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      operating results and the market price of stock could be volatile.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      quarterly operating results have fluctuated in the past and are likely to do
      so
      in the future. These fluctuations could cause our stock price to fluctuate
      significantly or decline. Some of the factors which could cause our operating
      results to fluctuate include: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expiration
                of research contracts with collaborators, which may not be renewed
                or
                replaced; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                success rate of our discovery efforts leading to milestones and royalties;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                timing and willingness of collaborators to commercialize our products
                which would result in royalties; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">general
                and industry specific economic conditions, which may affect our
                collaborators&#8217; R&amp;D
                expenditures;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                adoption and acceptance of our industrial enzymes and other products
                by
                customers of our Enzyme Business;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                adoption and acceptance of our C1 Host Technology, C1 Expression
                System
                and C1 Screening System by biotechnology and pharmaceutical companies
                being marketed by our BioSciences
                Business;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                introduction by our competitors of new industrial enzyme products
                or lower
                prices of existing products to our Enzyme Business&#8217;s
                customers;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>17</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  addition or loss of one or more collaborative partners to commercialize
                  our Biorefinery Products; </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  introduction by our competitors of new expression technologies
                  competitive
                  with our C1 Expression System; and</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">disruption
                  in our manufacturing capacity or our failure to bring on additional
                  manufacturing capacity required to meet our projected
                  growth.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      large
      portion of our expenses are relatively fixed, including expenses for facilities,
      equipment and personnel. Accordingly, if sales decline or do not grow as
      anticipated due to expiration of research contracts or government research
      grants, if any, failure to obtain new contracts or other factors, we may not
      be
      able to correspondingly reduce our operating expenses. Failure to achieve
      anticipated levels of sales could, therefore, significantly harm our operating
      results for a particular fiscal period. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
      to
      the possibility of fluctuations in our revenues and expenses, we believe that
      quarter-to-quarter comparisons of our operating results are not a good
      indication of our future performance. Our operating results in some quarters
      may
      not meet the expectations of stock market analysts and investors. In that case,
      our stock price would probably decline. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may not be able to maintain our American Stock Exchange listing
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      common stock has been listed on the American Stock Exchange since May 27,
      2005.&#160; There is no assurance that we will be able to satisfy the American
      Stock Exchange&#8217;s continued listing standards, which include, among others,
      minimum stockholders&#8217; equity, market capitalization, pre-tax income and per
      share sales price.&#160; If our common stock is de-listed from the American
      Stock Exchange, we would be forced to list our common stock on the OTC Bulletin
      Board or some other quotation medium, depending on our ability to meet the
      specific requirements of those quotation systems.&#160; Selling our common stock
      would be more difficult because smaller quantities of shares would likely be
      bought and sold and transactions could be delayed. These factors could result
      in
      lower prices and larger spreads in the bid and ask prices for shares of our
      common stock. If this happens, we will have greater difficulty accessing the
      capital markets to raise any additional necessary capital.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      do not expect to pay dividends in the future. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      never paid cash dividends on our stock and do not anticipate paying cash
      dividends on our stock in the foreseeable future. The payment of dividends
      on
      our shares, if ever, will depend on our earnings, financial condition and other
      business and economic factors affecting us at such time as the board of
      directors may consider relevant. If we do not pay dividends, our stock may
      be
      less valuable because a return on investment will only occur if and to the
      extent that our stock price appreciates, and if the price of our stock does
      not
      appreciate, then there will be no return on investment. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      anti-takeover defense provisions may deter potential acquirers and depress
      our
      stock price.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      provisions of our certificate of incorporation, bylaws and Delaware law, as
      well
      as certain agreements we have with our executives, could be used by our
      incumbent management to make it substantially more difficult for a third party
      to acquire control of us. These provisions include the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                may issue preferred stock with rights senior to those of our common
                stock;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                have a classified Board of
                Directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">action
                by written consent by stockholders is not
                permitted;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
                Board of Directors has the exclusive right to fill vacancies and
                set the
                number of directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cumulative
                voting by our stockholders is not allowed;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                require advance notice for nomination of directors by our stockholders
                and
                for stockholder proposals.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
        provisions may discourage certain types of transactions involving an actual
        or
        potential change in control. These provisions may also limit our stockholders&#8217;
ability to approve transactions that they may deem to be in their best interests
        and discourage transactions in which our stockholders might otherwise receive
        a
        premium for their shares over the then current market price.</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>18</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have controlling stockholders. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      officers, directors and principal stockholders together control approximately
      36.5% of our outstanding common stock as of December 12, 2006. Our founder
      and
      chief executive officer, Mark Emalfarb, through a trust of which he is the
      trustee and beneficiary, the Mark&#160;A. Emalfarb Trust, owns approximately 20%
      of our outstanding common stock as of December 12, 2006. Further, the Francisco
      Trust, whose beneficiaries are the spouse and descendants of Mark Emalfarb,
      owns
      approximately 16% of our outstanding common stock as of December 12, 2006,
      while
      friends and relatives of Mr. Emalfarb, who are not officers, directors, or
      principal stockholders, own approximately an additional 5% of our outstanding
      common stock as of December 12, 2006. As a result, these stockholders, if they
      act together, will be able to exert a significant degree of influence over
      our
      management and affairs and over matters requiring stockholder approval,
      including the election of directors and approval of significant corporate
      transactions. In addition, this concentration of ownership may delay or prevent
      a change in control of us and might affect the market price of our shares,
      even
      when a change may be in the best interests of all stockholders. Moreover, the
      interests of this concentration of ownership may not always coincide with our
      interests or the interests of other stockholders, and, accordingly, they could
      cause us to enter into transactions or agreements which we would not otherwise
      consider.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are indebted to our largest stockholders.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      September 30, 2006, we owed the Mark&#160;A. Emalfarb Trust indebtedness of
      approximately $2.4 million under a bridge loan. All of our assets are mortgaged
      or pledged to secure the bridge loan owed to the Mark&#160;A. Emalfarb Trust. If
      we were unable to generate sufficient cash flow or otherwise obtain funds
      necessary to pay this indebtedness when due, we would be in default, and this
      debt holder would have the right to foreclose on its liens and security
      interests that secure the defaulted debt. Further, not only is this indebtedness
      evidenced by a promissory note that is transferable by its holder, but we could
      decide to refinance this indebtedness through similar secured borrowings from
      banks or other commercial lenders. Any transferee or new lender, no longer
      constrained by the stockholder interests of the Mark&#160;A. Emalfarb Trust, may
      not have the same attitude about any failure on our part to meet our binding
      repayment obligations as the Mark&#160;A. Emalfarb Trust might.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are exposed to potential risks resulting from new requirements that we evaluate
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>financial
      reporting controls under Section 404 of the Sarbanes-Oxley Act of 2002.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      evaluating our internal controls in order to allow management to report on,
      and
      our independent registered public accounting firm to attest to, our internal
      controls over financial reporting, as required by Section 404 of the
      Sarbanes-Oxley Act of 2002. We may encounter unexpected delays in implementing
      the requirements relating to internal controls over financial reporting,
      therefore, we cannot be certain about the timing of completion of our
      evaluation, testing and remediation actions or the impact that these activities
      will have on our operations since there is no precedent available by which
      to
      measure the adequacy of our compliance. We also expect to incur additional
      expenses and diversion of management&#8217;s time as a result of performing the system
      and process evaluation, testing and remediation required in order to comply
      with
      the management certification and independent registered public accounting firm
      attestation requirements. If we are not able to timely comply with the
      requirements set forth in Section 404, we might be subject to sanctions or
      investigation by regulatory authorities. Any such action could adversely affect
      our business and financial results. The requirement to comply with Section
      404
      of the Sarbanes-Oxley Act of 2002 will become effective no earlier than for
      our
      fiscal year ending December 31, 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, in our system of internal controls we may rely on the internal
      controls of third parties. In our evaluation of our internal controls, we will
      consider the implication of our reliance on the internal controls of third
      parties. Until we have completed our evaluation, we are unable to determine
      the
      extent of our reliance on those controls, the extent and nature of the testing
      of those controls, and remediation actions necessary where that reliance cannot
      be adequately evaluated and tested. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Future
      sales of shares of our common stock may negatively affect our stock
      price.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 12, 2006, there were 29,748,856 shares of our common stock outstanding.
      Approximately 36.5% of these shares are beneficially owned by our executive
      officers, directors and principal stockholders. Accordingly, our common stock
      has a relatively small public float. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      previously registered for resale a substantial number of shares of our common
      stock, including shares underlying warrants. Beginning October 29, 2006,
      virtually all the shares of our common stock not previously eligible for resale
      pursuant to Rule 144(k) of the Securities Act became eligible for resale under
      Rule 144(k). In addition, this prospectus covers the resale of 5,581,484 shares
      of our common stock, including shares underlying warrants. The selling
      stockholders named in this prospectus will be permitted, subject to few
      limitations, to freely resell these shares of common stock. As a result of
      our
      relatively small public float, sales of substantial amounts of shares of our
      common stock, or even the potential for such sales, may materially and adversely
      affect prevailing market prices for our common stock. In addition, any adverse
      effect on the market price of our common stock could make it difficult for
      us to
      raise additional capital through sales of equity securities at a time and at
      a
      price that we deem appropriate.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>19</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="DISC">DISC</a>LOSURE
      REGARDING FORWARD-LOOKING
      STATEMENTS</strong></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      statements contained or incorporated by reference in this prospectus that are
      not historical facts are forward-looking. These statements are made pursuant
      to
      the safe harbor provisions of the Private Securities Litigation Reform Act
      of
      1995. Such statements include, without limitation, our expectations regarding
      sales, earnings or other future financial and operating performance and
      liquidity, conduct and completion of clinical trials, product introductions,
      entry into new geographic regions, and general optimism about future operations
      or operating results. Some of these statements can be identified by the use
      of
      forward-looking terminology such as &#8220;prospects,&#8221; &#8220;outlook,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;anticipates,&#8221; &#8220;expects&#8221; or
&#8220;plans,&#8221; or the negative or other variation of these or similar words, or by
      discussion of trends and conditions, strategy or risks and uncertainties.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
      forward-looking expectations are based on current assumptions within the bounds
      of management&#8217;s knowledge of our business and operations and which management
      believes are reasonable. These assumptions are subject to risks and
      uncertainties, and actual results could differ materially from expectations
      because of issues and uncertainties such as those listed under the caption
&#8220;Risk
      Factors&#8221; and elsewhere in this prospectus and in documents incorporated into
      this prospectus which, among others, should be considered in evaluating our
      future financial and operating performance. All subsequent written and oral
      forward-looking statements attributable to us or persons acting on our behalf
      are expressly qualified in their entirety by the cautionary statements in this
      prospectus. Readers are advised to consult any further disclosures we may make
      on related subjects in our subsequent reports filed with the SEC. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
      information on factors that may affect our business and financial and operating
      results can be found in our filings with the SEC. All forward-looking statements
      should be considered in light of these risks and uncertainties. We assume no
      responsibility to update forward-looking statements made in this prospectus.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>20</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="USE">USE</a>
      OF PROCEEDS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares of common stock being offered are solely for the accounts of the selling
      stockholders pursuant to their contractual registration rights. We will not
      receive any proceeds from the resale of the shares of the selling stockholders.
      However, we will receive the exercise price of the warrants when and if they
      are
      exercised to the extent so exercised for cash. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="SELL">SELL</a>ING
      STOCKHOLDERS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      shares of common stock being offered by the selling stockholders are those
      issued to the selling stockholders in the private placements completed on
      November 8 and December 1, 2006 and those issuable to the selling stockholders
      upon exercise of the warrants issued in connection with the private placement
      completed on December 1, 2006. We are registering the shares of common stock
      in
      order to permit the selling stockholders to offer the shares for resale from
      time to time. Except for the ownership of the shares of common stock and the
      warrants, and except for Abengoa Bioenergy R&amp;D, Inc. with whom we have a
      collaborative partnership as described in this prospectus under &#8220;Summary
      Description of Our Business&#8212;Recent Developments,&#8221; none of the selling
      stockholders have had any position, office or other material relationship with
      us within the past three years. Under the terms of the securities purchase
      agreements we entered into with the selling stockholders in connection with
      the
      private placements, we have agreed to keep the registration statement of which
      this prospectus is a part effective until the earlier of the date on which
      the
      shares have been sold or can be sold publicly under Rule 144(k) of the
      Securities Act. We may suspend the use of the registration statement of which
      this prospectus is a part for a 20-day trading period for as many as two times
      in any 12-month period. If we default in our registration obligations, we have
      agreed to pay the selling stockholders liquidated damages in cash as described
      in this prospectus under &#8220;Summary Description of Our Business&#8212;Recent
      Developments.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      table
      below lists the selling stockholders and other information regarding the
      beneficial ownership of shares of our common stock by each of the selling
      stockholders as of December 12, 2006. Under the terms of the warrants, the
      selling stockholders may not exercise any of the warrants until May 31, 2007.
      Furthermore, under the terms of the warrants, a selling stockholder may not
      exercise any warrant owned by it, to the extent such exercise would cause such
      selling stockholder, together with its affiliates or any other persons whose
      beneficial ownership of our shares of common stock would be aggregated with
      such
      selling stockholder&#8217;s beneficial ownership for purposes of Section 13(d) of the
      Securities Exchange Act of 1934, as amended, to beneficially own a number of
      shares of our common stock which would exceed 9.99% of our then outstanding
      shares of common stock following such exercise (excluding for purposes of such
      determination shares of common stock issuable upon exercise of the warrants
      which have not been exercised). Notwithstanding these limitations on exercise
      of
      the warrants, the shares issuable upon exercise of the warrants are deemed
      beneficially owned by the selling stockholders and reported as such in the
      table. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may sell all, some or none of their shares in this
      offering. See &#8220;Plan of Distribution.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 12, 2006, there were 29,748,856 shares of our common stock outstanding.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>21</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ownership
                Prior</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>to
                the Offering</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of Shares Offered</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Ownership
                After</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>the
                Offering</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="43%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Percentage</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Percentage</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Abengoa
                Bioenergy R&amp;D, Inc.(1)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,136,752</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7.2</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,136,752</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Emerson
                Partners(2)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">96,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">60,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">36,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Emerson
                Family Foundation (3)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">85,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">60,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bear
                Stearns Securities Corporation FBO J. Steven Emerson IRA R/O
                II(4)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">461,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.5</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">161,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bear
                Stearns Securities Corporation FBO J. Steven Emerson Roth IRA
                (5)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">770,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.6</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">660,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">110,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Pinnacle Fund, L.P.(6)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,473,557</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">8.3</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">412,200</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,061,357</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.9</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fort
                Mason Master, LP(7)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">387,097</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.3</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">387,097</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fort
                Mason Partners, LP(8)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,103</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,103</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Associates, Inc.(9)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Health Sciences Fund, Inc. (10)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">330,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.1</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">330,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Health Sciences Portfolio, Inc. (11)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TD
                Mutual Funds-TD Health Sciences Fund (12)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,400</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Valic
                Company I-Health Sciences Fund (13)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,
                360</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,360</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John
                Hancock Trust- Health Sciences Trust (14)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">36,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">36,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Raytheon
                Company Combined DB/DC Master Trust- Health Sciences (15)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,840</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,840</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price New Horizons Fund, Inc.(16)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">960,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.2</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">960,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">City
                of New York Deferred Compensation Plan-NYC 457/401K Small Cap Account
                (4137)(17)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,200</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,200</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price New Horizons Trust (18)</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19,800</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19,800</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cowen
                and Company, LLC(19)</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100,332</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100,332</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TOTAL</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,581,484</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">&#160;</td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
      ownership of less than 1%.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                2,136,752 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on November 8, 2006, which may not
                be
                disposed of by the selling stockholder in whole or in part until
                November
                8, 2007. Mr. Javier Salgado, President and Chief Executive Officer
                of the
                selling stockholder, has voting and investment power over the shares
                owned
                by the selling stockholder. The address of Abengoa Bioenergy R&amp;D,
                Inc., a Missouri corporation, is 1400 Elbridge Payne, Suite 212,
                Chesterfield, Missouri 63017.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                50,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 10,000 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement. Mr. J. Steven Emerson, authorized
                trader of the selling stockholder, has voting and investment power
                over
                the shares owned by the selling stockholder. The address of Emerson
                Partners, a California limited partnership, is 1522 Ensley Avenue,
                Los
                Angeles, California 90024.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                50,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 10,000 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement. Mr. J. Steven Emerson, President
                of
                the selling stockholder, has voting and investment power over the
                shares
                owned by the selling stockholder. The address of Emerson Family
                Foundation, a California family foundation, is 1522 Ensley Avenue,
                Los
                Angeles, California 90024.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                250,000 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 50,000 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement. Mr. J. Steven Emerson,
                sole
                beneficiary of the selling stockholder, has voting and investment
                power
                over the shares owned by the selling stockholder. The address of
                Bear
                Stearns Securities Corporation FBO J. Steven Emerson IRA R/O II,
                a self
                directed IRA, is 1522 Ensley Avenue, Los Angeles, California
                90024.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>22</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                    550,000 shares of our common stock issued to the selling stockholder
                    in
                    the private placement completed on December 1, 2006 and 110,000
                    shares of
                    our common stock issuable upon exercise of the warrants issued
                    to the
                    selling stockholder in such private placement. Mr. J. Steven
                    Emerson, sole
                    beneficiary of the selling stockholder, has voting and investment
                    power
                    over the shares owned by the selling stockholder. The address
                    of Bear
                    Stearns Securities Corporation FBO J. Steven Emerson Roth IRA,
                    a self
                    directed IRA, is 1522 Ensley Avenue, Los Angeles, California
                    90024.</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>&#160;</div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
                343,500 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 68,700 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement. Barry M. Kitt, as
                the sole
                member of the Pinnacle Fund Management, L.L.C., the general partner
                of
                Pinnacle Advisers, L.P., the general partner of the selling stockholder,
                has voting and investment power over the shares owned by the selling
                stockholder. Mr. Kitt disclaims beneficial ownership of such shares,
                except to the extent of his pecuniary interest therein, if any. The
                address of The Pinnacle Fund, L.P., a Texas limited partnership,
                is 4965
                Preston Park Boulevard, Suite 240, Plano Texas 75093.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                322,581 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 64,516 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement. Fort Mason Capital,
                LLC
                serves as the general partner of the selling stockholder and, in
                such
                capacity, exercises sole voting and investment power over the shares
                owned
                by the selling stockholder. Mr. Daniel German serves as the sole
                managing
                member of Fort Mason Capital, LLC. Fort Mason Capital, LLC and Mr.
                German
                each disclaim beneficial ownership of such shares, except to the
                extent of
                its or his pecuniary interest therein, if any. The address of Fort
                Mason
                Master, LP, a Delaware limited partnership, is 4 Embarcadero Center,
                Suite
                2050, San Francisco, California 94111.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                20,919 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 4,184 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement. Fort Mason Capital, LLC serves
                as
                the general partner of the selling stockholder and, in such capacity,
                exercises sole voting and investment power over the shares owned
                by the
                selling stockholder. Mr. Daniel German serves as the sole managing
                member
                of Fort Mason Capital, LLC. Fort Mason Capital, LLC and Mr. German
                each
                disclaim beneficial ownership of such shares, except to the extent
                of its
                or his pecuniary interest therein, if any. The address of Fort Mason
                Partners, LP, a Delaware limited partnership, is 4 Embarcadero Center,
                Suite 2050, San Francisco, California 94111.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                Rowe Price Associates, Inc. (&#8220;T. Rowe Price Associates&#8221;) serves as
                investment adviser with power to direct investments and/or sole power
                to
                vote the shares owned by the funds and advisory clients listed under
                its
                name in the table above. For purposes of the reporting requirements
                of the
                Securities Exchange Act of 1934, T. Rowe Price Associates may be
                deemed to
                be the beneficial owner of all of the shares listed above; however,
                T.
                Rowe Price Associates expressly disclaims that it is, in fact, the
                beneficial owner of such securities. T. Rowe Price Associates is
                a wholly
                owned subsidiary of T. Rowe Price Group, Inc., which is a publicly
                traded
                financial services holding company.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                275,000 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 55,000 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(11)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                2,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 400 shares of
                our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(12)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                27,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 5,400 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(13)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                22,800 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 4,560 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(14)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                30,000 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 6,000 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(15)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                3,200 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 640 shares of
                our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(16)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                800,000 shares of our common stock issued to the selling stockholder
                in
                the private placement completed on December 1, 2006 and 160,000 shares
                of
                our common stock issuable upon exercise of the warrants issued to
                the
                selling stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>23</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>&#160;</div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(17)&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                    23,500 shares of our common stock issued to the selling stockholder
                    in the
                    private placement completed on December 1, 2006 and 4,700 shares
                    of our
                    common stock issuable upon exercise of the warrants issued to
                    the selling
                    stockholder in such private placement.
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(18)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                16,500 shares of our common stock issued to the selling stockholder
                in the
                private placement completed on December 1, 2006 and 3,300 shares
                of our
                common stock issuable upon exercise of the warrants issued to the
                selling
                stockholder in such private placement.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(19)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                100,332 shares of our common stock issuable upon the exercise of
                the
                warrants issued to the selling stockholder for serving as sole placement
                agent in the private placement completed on December 1, 2006. Cowen
                and
                Company, LLC is a wholly-owned subsidiary of Cowen Group, Inc., which
                is
                quoted on the NASDAQ under the symbol &#8220;COWN.&#8221; The address of Cowen and
                Company, LLC is 1221 Avenue of the Americas, New York, NY
                10020.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>24</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="PLAN">PLAN</a>
      OF DISTRIBUTION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      registering the shares on behalf of the selling stockholders. As used in this
      prospectus, the term &#8220;selling stockholders&#8221; includes the pledgees, donees,
      transferees or other successors-in-interest selling shares received after the
      date of this prospectus from a named selling stockholder as a gift, pledge,
      partnership distribution or other non-sale related transfer.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may, from time to time, sell any or all of their shares
      of
      common stock on any stock exchange, market or trading facility on which the
      shares are traded or in private transactions. These sales may be at fixed or
      negotiated prices. The selling stockholders may use any one or more of the
      following methods when selling shares:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ordinary
                brokerage transactions and transactions in which the broker-dealer
                solicits purchasers;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">block
                trades in which the broker-dealer will attempt to sell the shares
                as agent
                but may position and resell a portion of the block as principal to
                facilitate the transaction;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">purchases
                by a broker-dealer as principal and resale by the broker-dealer for
                its
                account;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">an
                exchange distribution in accordance with the rules of the applicable
                exchange;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">privately
                negotiated transactions;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">short
                sales;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">broker-dealers
                may agree with the selling stockholders to sell a specified number
                of such
                shares at a stipulated price per
                share;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a
                combination of any such methods of sale;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">any
                other method permitted pursuant to applicable
                law.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders may also sell shares under Rule 144 under the Securities
      Act, if available, rather than under this prospectus.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Broker-dealers
      engaged by the selling stockholders may arrange for other brokers-dealers to
      participate in sales. Broker-dealers may receive commissions or discounts from
      the selling stockholders (or, if any broker-dealer acts as agent for the
      purchaser of shares, from the purchaser) in amounts to be negotiated. The
      selling stockholders do not expect these commissions and discounts to exceed
      what is customary in the types of transactions involved. Any profits on the
      resale of shares of common stock by a broker-dealer acting as principal might
      be
      deemed to be underwriting discounts or commissions under the Securities Act.
      Discounts, concessions, commissions and similar selling expenses, if any,
      attributable to the sale of shares will be borne by a selling stockholder.
      The
      selling stockholders may agree to indemnify any agent, dealer or broker-dealer
      that participates in transactions involving sales of the shares if liabilities
      are imposed on that person under the Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        selling stockholders may from time to time pledge or grant a security interest
        in some or all of the shares of common stock owned by them and, if they default
        in the performance of their secured obligations, the pledgees or secured
        parties
        may offer and sell the shares of common stock from time to time under this
        prospectus after we have filed a supplement to this prospectus under Rule
        424(b)(3) or other applicable provision of the Securities Act of 1933
        supplementing or amending the list of selling stockholders to include the
        pledgee, transferee or other successors in interest as selling stockholders
        under this prospectus.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        selling stockholders also may transfer the shares of common stock in other
        circumstances, in which case the transferees, pledgees or other successors
        in
        interest will be the selling beneficial owners for purposes of this prospectus
        and may sell the shares of common stock from time to time under this prospectus
        after we have filed a supplement to this prospectus under Rule 424(b)(3)
        or
        other applicable provision of the Securities Act of 1933 supplementing or
        amending the list of selling stockholders to include the pledgee, transferee
        or
        other successors in interest as selling stockholders under this
        prospectus.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="WIDTH: 100%" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        </div>
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>25</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
        <div style="WIDTH: 100%" align="left">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders and any broker-dealers or agents that are involved in
      selling the shares of common stock may be deemed to be &#8220;underwriters&#8221; within the
      meaning of the Securities Act in connection with such sales. In such event,
      any
      commissions received by such broker-dealers or agents and any profit on the
      resale of the shares of common stock purchased by them may be deemed to be
      underwriting commissions or discounts under the Securities Act. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      required to pay all fees and expenses incident to the registration of the shares
      of common stock. We have agreed to indemnify the selling stockholders against
      certain losses, claims, damages and liabilities, including liabilities under
      the
      Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      selling stockholders have advised us that they have not entered into any
      agreements, understandings or arrangements with any underwriters or
      broker-dealers regarding the sale of their shares of common stock, nor is there
      an underwriter or coordinating broker acting in connection with a proposed
      sale
      of shares of common stock by any selling stockholder. If we are notified by
      any
      selling stockholder that any material arrangement has been entered into with
      a
      broker-dealer for the sale of shares of common stock, if required, we will
      file
      a supplement to this prospectus. If the selling stockholders use this prospectus
      for any sale of the shares of common stock, they will be subject to the
      prospectus delivery requirements of the Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      anti-manipulation rules of Regulation M under the Securities Exchange Act of
      1934 may apply to sales of our common stock and activities of the selling
      stockholders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="LEGAL">LEG</a>AL
      MATTERS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      validity of the shares of our common stock offered under this prospectus will
      be
      passed upon for us by Greenberg Traurig, P.A., Miami, Florida, of which an
      attorney currently beneficially owns in the aggregate 102,056 shares of our
      common stock. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="EXP">EXP</a>ERTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      consolidated financial statements of Dyadic International, Inc. appearing in
      Dyadic International, Inc.&#8217;s Annual Report (Form 10-KSB) for the year ended
      December 31, 2005 have been audited by Ernst &amp; Young LLP, an independent
      registered public accounting firm, as set forth in their report thereon included
      therein, and incorporated herein by reference. Such consolidated financial
      statements are incorporated herein by reference in reliance upon such report,
      given on the authority of such firm as experts in accounting and
      auditing.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="WHERE">WHER</a>E
      YOU CAN FIND MORE INFORMATION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      file
      annual, quarterly and current reports, proxy statements and other information
      with the SEC. The reports, proxy statements and other information filed by
      us
      may be inspected without charge at the public reference room of the SEC, which
      is located at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies
      of all or any part of the reports, proxy statements and other information from
      the public reference room, upon the payment of the prescribed fees. You may
      obtain information on the operation of the public reference room by calling
      the
      SEC at 1-800-SEC-0330. The SEC maintains a website at www.sec.gov that contains
      reports, proxy statements and other information regarding registrants like
      us
      that file electronically with the SEC. You can inspect the reports, proxy
      statements and other information on this website. You may also find information
      about us at our website: www.Dyadic-Group.com. The contents of our website
      are
      not part of this prospectus and our Internet address is included in this
      prospectus as an inactive textual reference only. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        filed a registration statement on Form S-3 to register with the SEC the shares
        of our common stock offered by this prospectus. This prospectus is a part
        of
        that registration statement. As allowed by the rules of the SEC, this prospectus
        does not contain all of the information you can find in our registration
        statement or the exhibits to the registration statement. You can obtain a
        copy
        of the registration statement from the SEC at the address listed above or
        from
        the SEC&#8217;s website. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
        should rely only on the information contained in this prospectus or any
        prospectus supplement. We have not authorized anyone else to provide you
        with
        different information. The delivery of this prospectus does not, under any
        circumstances, mean that there has not been a change in our affairs since
        the
        date of this prospectus. It also does not mean that the information in this
        prospectus is correct after this date</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
        </strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>26</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="INCORP">INCORP</a>ORATION
      OF CERTAIN DOCUMENTS BY
      REFERENCE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      SEC
      allows us to &#8220;incorporate by reference&#8221; certain of our publicly-filed documents
      in this prospectus, which means that we can disclose important information
      to
      you by referring you to another document filed separately with the SEC. The
      information incorporated by reference is considered part of this prospectus.
      This prospectus incorporates by reference the documents listed below.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                Annual Report on Form 10-KSB for the year ended December 31,
                2005;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                Quarterly Reports on Form 10-QSB for the quarterly periods ended
                March 31,
                2006, June 30, 2006 and September 30,
                2006;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                definitive Proxy Statement dated April 28, 2006 relating to the 2006
                annual stockholders&#8217; meeting; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                Current Reports on Form 8-K dated October 26, 2006 and November 17,
                2006;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                description of our common stock filed as part of our registration
                statement on Form 8-A dated May 24, 2005, including any amendment
                or
                report filed for the purpose of updating such
                description.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      documents filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities
      Exchange Act of 1934, as amended (which we refer to as the &#8220;Exchange Act&#8221;),
      after the date of this prospectus and prior to the termination of this offering
      shall be deemed to be incorporated by reference in this prospectus and to be
      a
      part of this prospectus from the date they are filed. In addition, all documents
      filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after
      the date of the initial registration statement and prior to the effectiveness
      of
      the registration statement of which this prospectus forms a part shall be deemed
      to be incorporated by reference in this prospectus and to be part of this
      prospectus from the date they are filed.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      statement contained in this prospectus, or in a document incorporated by
      reference in this prospectus, shall be deemed to be modified or superseded
      for
      purposes of this prospectus to the extent that a statement contained in this
      prospectus, any prospectus supplement or in any other subsequently filed
      document which is also incorporated in this prospectus modifies or replaces
      such
      statement. Any statements so modified or superseded shall not be deemed, except
      as so modified or superseded, to constitute a part of this prospectus.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
        may
        request a copy of these documents, which will be provided to you at no cost,
        by
        writing or telephoning us using the following contact information: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
        International, Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">140
        Intracoastal Pointe Drive</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite
        404</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jupiter,
        Florida 33477</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
        Investor Relations</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(561)
        743-8333</font></div>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>27</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <hr style="COLOR: black" align="left" noshade size="3" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________,
      2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>DYADIC
      INTERNATIONAL, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5,581,484
      Shares of Common Stock</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="25%">&#160;</td>
            <td valign="top" width="29%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>P
                R O S P E C T U S</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="24%">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" width="25%">&#160;</td>
            <td align="left" valign="top" width="29%">&#160;</td>
            <td align="left" valign="top" width="24%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="78%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
                have not authorized any dealer, salesperson or other person to give
                you
                written information other than this prospectus or to make representations
                as to matters not stated in this prospectus. You must not rely on
                unauthorized information. This prospectus is not an offer to sell
                these
                securities or our solicitation of your offer to buy the securities
                in any
                jurisdiction where that would not be permitted or legal. Neither
                the
                delivery of this prospectus nor any of the sales made hereunder after
                the
                date of this prospectus shall create an implication that the information
                contained herein or our affairs have not changed since the date
                hereof.</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>28</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
      II</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INFORMATION
      NOT REQUIRED IN PROSPECTUS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      14. Other Expenses of Issuance and Distribution.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth the estimated costs and expenses payable by the
      registrant in connection with the offering of the common stock. All the amounts
      shown are estimates except the Securities and Exchange Commission registration
      fee.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                and Exchange Commission Registration Fee</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,056</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Legal
                Fees and Expenses</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">25,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting
                Fees and Expenses</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">30,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Printing
                and Engraving Expenses</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Miscellaneous</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">69,056</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      15.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnification
      of Directors and Officers.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      registrant's amended and restated certificate of incorporation provides that
      the
      Registrant shall indemnify its officers and directors in each and every
      situation where, under Section 145 of the Delaware General Corporate Law, as
      amended from time to time, or the DGCL, the registrant is permitted or empowered
      to make such indemnification. The registrant may, in the sole discretion of
      its
      board of directors, also indemnify any other person who may be indemnified
      pursuant to Section 145 to the extent the board of directors deems advisable,
      as
      permitted by Section 145.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section
      145 of the DGCL permits a corporation, under specified circumstances, to
      indemnify its directors, officers, employees or agents against expenses,
      including attorneys' fees, judgments, fines and amounts paid in settlement
      actually and reasonably incurred by them in connection with any action, suit
      or
      proceeding brought by third parties by reason of the fact that they were or
      are
      directors, officers, employees or agents of the corporation, if such directors,
      officers, employees or agents acted in good faith and in a manner they
      reasonably believed to be in or not opposed to the best interests of the
      corporation and, with respect to any criminal action or proceeding, had no
      reasonable cause to believe their conduct was unlawful. In an action by or
      in
      the right of the corporation, indemnification may be made only for expenses
      actually and reasonably incurred by directors, officers, employees or agents
      in
      connection with the defense or settlement of any action or suit, and only with
      respect to a matter as to which they shall have acted in good faith and in
      a
      manner they reasonably believed to be in or not opposed to the best interests
      of
      the corporation, except that no indemnification shall be made if such person
      shall have been adjudged liable to the corporation, unless and only to the
      extent that the court in which the action or suit was brought shall determine
      upon application that the defendant directors, officers, employees or agents
      are
      fairly and reasonably entitled to indemnity for such expenses despite such
      adjudication of liability. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      registrant's amended and restated bylaws also contain provisions requiring
      the
      registrant to indemnify its directors and officers to the fullest extent not
      prohibited by the DGCL or other applicable law. These bylaw provisions permit
      the registrant to modify the extent of such indemnification by individual
      contracts with its directors and officers. However, the registrant is not
      required to indemnify any director or officer in connection with any proceeding
      initiated by the person unless the indemnification is expressly required to
      be
      made by law, the proceeding was authorized by the board of directors of the
      registrant, the indemnification is provided by the registrant, in its sole
      discretion, pursuant to the powers vested in the registrant under the DGCL
      or
      any other applicable law, or the indemnification is required to be made under
      other provisions in the bylaws. The bylaw provisions also empower the registrant
      to indemnify its employees and other agents as set forth in the DGCL or other
      applicable law and to advance expenses to a director or officer in connection
      with proceedings upon receipt of an undertaking by or on behalf of the person
      to
      repay such amount if it is determined ultimately that the person is not entitled
      to be indemnified. The bylaw provisions generally follow the existing provisions
      of Section 145 of the DGCL. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      registrant maintains directors&#8217; and officers&#8217; liability insurance covering its
      directors and officers in amounts customary for similarly situated
      companies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>29</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      16. Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number</strong></font></div>
            </td>
            <td valign="top" width="71%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Description</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^
                4.1</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
                and Restated Certificate of Incorporation of Dyadic International,
                Inc.
                (3.1)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^
                4.2</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
                and Restated Bylaws of Dyadic International, Inc. (3.2)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">+
                4.3</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                Purchase Agreement dated as of October 26, 2006 by and among Dyadic
                International, Inc. and Abengoa Bioenergy R&amp;D, Inc. and the purchasers
                listed on the signature pages thereto. </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^^4.4</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                Purchase Agreement dated as of November 17, 2006 by and among Dyadic
                International, Inc. and the Investors signatories thereto.
                (10.1)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^^4.5</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Warrant issued to the Investors. (10.1)</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">+
                4.6</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Warrant issued to Cowen and Company, LLC</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*5.1</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Opinion
                of Greenberg Traurig, P.A.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*23.1</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consent
                of Ernst &amp; Young LLP.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*23.2</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consent
                of Greenberg Traurig, P.A. (contained in legal opinion filed as Exhibit
                5.1).</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*24.1</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="71%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Powers
                of Attorney (included on signature pages to this registration
                statement).</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
      by reference to the exhibit shown in parentheses and filed with the Current
      Report on Form 8-K of Dyadic International, Inc. dated October 29, 2004 and
      filed with the Commission on November 4, 2004.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^^</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
      by reference to the exhibit shown in parentheses and filed with the Current
      Report on Form 8-K of Dyadic International, Inc. dated November 17, 2006 and
      filed with the Commission on November 21, 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed
      with this Registration Statement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">+</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
      be
      filed either by amendment or as an exhibit to an Exchange Act report of Dyadic
      International, Inc. and incorporated herein by reference.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      17.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Undertakings.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      undersigned registrant hereby undertakes:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)
      To
      file, during any period in which offers or sales are being made, a
      post-effective amendment to this registration statement:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)
      To
      include any prospectus required by Section 10(a)(3) of the Securities Act of
      1933;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)
      To
      reflect in the prospectus any facts or events arising after the effective date
      of the registration statement (or the most recent post-effective amendment
      thereof) which, individually or in the aggregate, represent a fundamental change
      in the information set forth in the registration statement; and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)
      To
      include any material information with respect to the plan of distribution not
      previously disclosed in the registration statement or any material change to
      such information in the registration statement;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>provided,
      however,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      that
      paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement
      is on Form S-3 or Form F-3, and the information required to be included in
      a
      post-effective amendment by those paragraphs is contained in periodic reports
      filed with or furnished to the Commission by the registrant pursuant to Section
      13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by
      reference in the registration statement.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>30</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)
      That,
      for the purpose of determining any liability under the Securities Act of 1933,
      each such post-effective amendment shall be deemed to be a new registration
      statement relating to the securities offered therein, and the offering of such
      securities at the time shall be deemed to be the initial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>bona
      fide</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      offering
      thereof, and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)
      To
      remove from registration by means of a post-effective amendment any of the
      securities being registered which remain unsold at the termination of the
      offering.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      undersigned registrant hereby undertakes that, for purposes of determining
      any
      liability under the Securities Act of 1933, each filing of the registrant&#8217;s
      annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act
      of
      1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual
      report pursuant to Section 15(d) of the Exchange Act) that is incorporated
      by
      reference in the registration statement shall be deemed to be a new registration
      statement relating to the securities offered therein, and the offering of such
      securities at that time shall be deemed to be the initial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>bona
      fide </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">offering
      thereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Insofar
      as indemnification for liabilities arising under the Securities Act of 1933
      may
      be permitted to directors, officers and controlling persons of the registrant
      pursuant to the foregoing provisions, or otherwise, the registrant has been
      advised that in the opinion of the Securities and Exchange Commission such
      indemnification is against public policy as expressed in the Act and is,
      therefore, unenforceable. In the event that a claim for indemnification against
      such liabilities (other than the payment by the registrant of expenses incurred
      or paid by a director, officer or controlling person of the registrant in the
      successful defense of any action, suit or proceeding) is asserted by such
      director, officer or controlling person in connection with the securities being
      registered, the registrant will, unless in the opinion of its counsel the matter
      has been settled by controlling precedent, submit to a court of appropriate
      jurisdiction the question whether such indemnification by it is against public
      policy as expressed in the Act and will be governed by the final adjudication
      of
      such issue.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>31</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Act of 1933, Dyadic International, Inc.
      certifies that it has reasonable grounds to believe that it meets all of the
      requirements for filing on Form S-3 and has duly caused this Registration
      Statement to be signed on its behalf by the undersigned, thereunto duly
      authorized, in the Town of Jupiter, State of Florida on this 15th day of
      December, 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      International, Inc. (Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Mark A. Emalfarb </u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 207pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
      A.
      Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President
      and Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>POWER
      OF ATTORNEY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>KNOW
      ALL MEN BY THESE PRESENTS</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      that
      each person whose signature appears below hereby constitutes and appoints Mark
      A. Emalfarb and Wayne Moor his true and lawful attorneys-in-fact, each acting
      alone, with full powers of substitution and resubstitution, for him and in
      his
      name, place and stead, in any and all capacities, to sign any or all amendments,
      including any post-effective amendments, to this Registration Statement, and
      to
      file the same, with exhibits thereto, and other documents to be filed in
      connection therewith, with the Securities and Exchange Commission, hereby
      ratifying and confirming all that said attorneys-in-fact or their substitutes,
      each acting alone, may lawfully do or cause to be done by virtue
      hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Act of 1933, this Registration Statement
      has been signed by the following persons in the capacities and on the dates
      indicated.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="35%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Signature</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Title</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td valign="top" width="17%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Date</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Mark A. Emalfarb</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                A. Emalfarb</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President
                and Chief Executive Officer (Principal Executive Officer) and Chairman
                of
                the Board of Directors</font></div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Wayne Moor</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
                Moor</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Financial Officer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Principal
                Financial and Accounting Officer)</font></div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Glenn E. Nedwin</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
                E. Nedwin</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Richard J. Berman</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Richard
                J. Berman</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Harry Z. Rosengart</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry
                Z. Rosengart</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Robert B. Shapiro</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robert
                B. Shapiro</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="35%" style="border-bottom: #ffffff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
                Stephen J. Warner</u></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stephen
                J. Warner</font></div>
            </td>
            <td align="left" valign="top" width="2%">&#160;</td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
            <td valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                15, 2006</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>32</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INDEX
      TO EXHIBITS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="8%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="72%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Description</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="8%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="72%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Opinion
                of Greenberg Traurig, P.A.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="8%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23.1</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="72%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consent
                of Ernst &amp; Young LLP</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="8%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23.2</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
            <td align="left" valign="top" width="72%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consent
                of Greenberg Traurig, P.A. (contained in legal opinion filed as Exhibit
                5.1).</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman"><strong>33</strong></font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left">
        </div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exhibit5_1121906.htm
<DESCRIPTION>EXHIBIT 5.1 OPINION OF GREENBERG TRAURIG, P.A. 12.19.06
<TEXT>
<html>
  <head>
    <title>
      Exhibit 5.1 Opinion of Greenberg Traurig, P.A. 12.19.06
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      5.1</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 252pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font>December
      21,
      2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      International, Inc. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">140
      Intracoastal Pointe Drive</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite
      404</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jupiter,
      Florida 33477</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Re:</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
                International, Inc. - Registration Statement on Form
                S-3</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ladies
      and Gentlemen:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      acted as counsel for Dyadic International, Inc., a Delaware corporation (the
      &#8220;Company&#8221;), in connection with the preparation and filing of a Registration
      Statement on Form S-3 (the &#8220;Registration Statement&#8221;) to be filed on or about the
      date hereof with the Securities and Exchange Commission under the Securities
      Act
      of 1933, as amended (the &#8220;Act&#8221;), for the purpose of registering 5,581,484 shares
      of common stock of the Company, par value $0.001 per share (the &#8220;Common Stock&#8221;),
      for resale by the selling stockholders named therein, which consists of: (i)
      2,136,752 shares of Common Stock issued in a private placement completed on
      November 8, 2006; (ii) 2,787,000 shares of Common Stock issued in a private
      placement completed on December 1, 2006 and (iii) 657,732 shares of Common
      Stock
      issuable upon the exercise of warrants issued in the private placement completed
      on December 1, 2006 (the &#8220;Warrants&#8221;). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      so
      acting, we have examined originals, or copies certified or otherwise identified
      to our satisfaction, of (a) the Company&#8217;s Amended and Restated Certificate of
      Incorporation and Bylaws, as currently in effect, (b) the Registration
      Statement, (c) the securities purchase agreements pursuant to which the shares
      of Common Stock and Warrants were issued and sold in the private placements,
      (d)
      the Warrants, (e) certain resolutions adopted by the Board of Directors of
      the
      Company, and (f) such other documents, records, certificates and other
      instruments of the Company as in our judgment are necessary or appropriate
      for
      purposes of this opinion. In all such examinations, we have assumed the
      genuineness of signatures on original documents and the conformity to such
      original documents of all copies submitted to us as certified, conformed or
      photographic copies, and as to certificates of public officials, we have assumed
      the same to have been properly given and to be accurate. As to matters of fact
      material to this opinion, we have relied upon statements and representations
      of
      representatives of the Company and of public officials and have assumed the
      same
      to have been properly given and to be accurate.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      opinion is limited in all respects to the federal laws of the United States
      and
      the General Corporation Law of the State of Delaware, and no opinion is
      expressed with respect to the laws of any other jurisdiction or any effect
      which
      such laws may have on the opinions expressed herein. This opinion is limited
      to
      the matters stated herein, and no opinion is implied or may be inferred beyond
      the matters expressly stated herein.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
      upon and subject to the foregoing, we are of the opinion that:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      4,923,752 shares of Common Stock included in the Registration Statement have
      been legally issued and are fully paid and nonassessable; and </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      remaining 657,732 shares of Common Stock included in the Registration Statement,
      when issued upon exercise of the Warrants for consideration in accordance with
      the terms of the Warrants, will be legally issued, fully paid and
      nonassessable.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      opinion is given as of the date hereof, and we assume no obligation to advise
      you after the date hereof of facts or circumstances that come to our attention
      or changes in law that occur which could effect the opinions contained herein.
      This letter is being rendered solely for the benefit of the Company in
      connection with the matters addressed herein. This opinion may not be furnished
      to or relied upon by any person or entity for any purpose without our prior
      written consent.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      hereby
      consent to the filing of this opinion as Exhibit 5.1 to the Registration
      Statement and to the reference to our firm under the caption &#8220;Legal Matters&#8221; in
      the prospectus that forms a part of the Registration Statement.. In giving
      such
      consent, we do not hereby admit that we come within the category of persons
      whose consent is required under Section 7 of the Securities Act, or the rules
      or
      regulations of the Securities and Exchange Commission promulgated thereunder.
      As
      of the date hereof, one of our attorneys beneficially owns in the aggregate
      102,056 shares of Common Stock, none of which is included in the Registration
      Statement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Very
      truly yours,</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
      Greenberg Traurig, P.A.</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 234pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Greenberg
      Traurig, P.A.</font></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit23_1121906.htm
<DESCRIPTION>EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 12.19.06
<TEXT>
<html>
  <head>
    <title>
      Exhibit 23.1 Consent of Independent Registered Public Accounting Firm 12.19.06
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
        23.1</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Consent
        of Independent Registered Public Accounting Firm</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        consent to the reference to our firm under the caption &#8220;Experts&#8221; in the
        Registration Statement (Form S-3) and related Prospectus of Dyadic
        International, Inc. for registration of 5,581,484 shares of its common stock
        and
        to the incorporation by reference therein of our report dated March 27, 2006
        with respect to the consolidated financial statements of Dyadic International,
        Inc. included in its Annual Report (Form 10-KSB) for the year ended December
        31,
        2005, filed with the Securities and Exchange Commission.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
        Ernst &amp; Young LLP</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certified
        Public Accountants </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">West
        Palm
        Beach, Florida </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
        15, 2006</font></div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>5
<FILENAME>forms_3121806.pdf
<DESCRIPTION>DYADIC FORM S-3 12.18.06
<TEXT>
<PDF>
begin 644 forms_3121806.pdf
M)5!$1BTQ+C0-"@T*-CD@,"!O8FH-"CP\#0HO12`Q-3,X,0T*+T@@6R`Q,#4V
M(#(X-"!=#0HO3"`Q,S0U,S@-"B],:6YE87)I>F5D(#$-"B].(#,T#0HO3R`W
M,@T*+U0@,3,S,3`W#0H^/B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`T*96YD;V)J
M#0H-"GAR968-"C8Y(#$U#0HP,#`P,#`P,#$R(#`P,#`P(&X-"C`P,#`P,#`Y
M,CD@,#`P,#`@;@T*,#`P,#`P,3`U-B`P,#`P,"!N#0HP,#`P,#`Q,S0Q(#`P
M,#`P(&X-"C`P,#`P,#$V,C<@,#`P,#`@;@T*,#`P,#`P,3<S-B`P,#`P,"!N
M#0HP,#`P,#`Q.#0V(#`P,#`P(&X-"C`P,#`P,#(P-C0@,#`P,#`@;@T*,#`P
M,#`P,S0S-R`P,#`P,"!N#0HP,#`P,#`S.30Y(#`P,#`P(&X-"C`P,#`P,#0Q
M,34@,#`P,#`@;@T*,#`P,#`P-#(S,"`P,#`P,"!N#0HP,#`P,#`T,S0Q(#`P
M,#`P(&X-"C`P,#`P,#0T-#D@,#`P,#`@;@T*,#`P,#`Q,C(V,R`P,#`P,"!N
M#0IT<F%I;&5R#0H\/`T*+T%"0W!D9B`U,#`X#0HO240@6R`H96AR:WIC:&UP
M8F%H<6QU<RD-"BAG:7)K:VIW:G9Q=&QT;GAM*2!=#0HO3&5N9W1H(#`-"B]0
M<F5V(#$S,S`Y-@T*+U)O;W0@-S`@,"!2#0HO4VEZ92`X-`T*+U1Y<&4@+UA2
M968-"CX^("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@#0IS=&%R='AR968-"C`-"B4E14]&#0HW,"`P(&]B:@T*/#P-"B]/
M<&5N06-T:6]N(%L@-S(@,"!2#0HO1FET(%T-"B]/=71L:6YE<R`V-R`P(%(-
M"B]086=E36]D92`O57-E3F]N90T*+U!A9V5S(#8X(#`@4@T*+U1Y<&4@+T-A
M=&%L;V<-"CX^#0IE;F1O8FH-"@T*-S$@,"!O8FH-"CP\#0HO1FEL=&5R("]&
M;&%T941E8V]D90T*+TQE;F=T:"`Q.3`-"B]3(#4X,`T*/CX-"G-T<F5A;0T*
M>)QC8&!@8F!@46108&!@M0:1<*``A2E`-A?#H`"&<X%N701TZ3^@LP,9&'C/
M`G$F`P.G/1!G`/%$!@;N3B!]`>CD$`8&CH5`?A"0'P'DEP%Q+E`L#DC7`/$5
MH#E7&1C8MC`PR!@#Z>T,#(R\0/G?0/5`/[.U`?DS@.QO0+%M#`S,ZX!TTT"'
M`"H83.'!H@`D>*"8@2$'G)8V`3$C`SB-,>0!U7P$<J<`V59`S`[$S!"]<E)`
M=QV"F00`,,8MB@T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0H@-S(@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`X,R`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q
M,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT
M(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-"B]&86)C,3,@
M.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@4@T*+T9A8F,W
M(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C<S(#`@;V)J#0H\/`T*+T)A<V5&;VYT("]4:6UE<RU";VQD#0HO
M16YC;V1I;F<@+U=I;D%N<VE%;F-O9&EN9PT*+U-U8G1Y<&4@+U1Y<&4Q#0HO
M5'EP92`O1F]N=`T*/CX-"F5N9&]B:@T*#0HW-"`P(&]B:@T*/#P-"B]"87-E
M1F]N="`O5&EM97,M4F]M86X-"B]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG
M#0HO4W5B='EP92`O5'EP93$-"B]4>7!E("]&;VYT#0H^/@T*96YD;V)J#0H-
M"C<U(#`@;V)J#0H\/`T*+T%S8V5N="`W-S`-"B]#87!(96EG:'0@-CDY#0HO
M1&5S8V5N="`R,#4-"B]&;&%G<R`T#0HO1F]N=$)";W@@6R`P("TR,3`@,3,U
M."`X.3@@70T*+T9O;G1&:6QE,B`X,B`P(%(-"B]&;VYT3F%M92`O4T=25%5*
M*U=I;F=D:6YG<RU296=U;&%R#0HO271A;&EC06YG;&4@,`T*+U-T96U6(#@P
M#0HO5'EP92`O1F]N=$1E<V-R:7!T;W(-"CX^#0IE;F1O8FH-"@T*-S8@,"!O
M8FH-"CP\#0HO0F%S949O;G0@+U-'4E152BM7:6YG9&EN9W,M4F5G=6QA<@T*
M+T-)1%-Y<W1E;4EN9F\@/#P-"B]/<F1E<FEN9R`H*0T*+U)E9VES=')Y("@I
M#0HO4W5P<&QE;65N="`P#0H^/@T*+T-)1%1O1TE$36%P("])9&5N=&ET>0T*
M+T17(#$P,#`-"B]&;VYT1&5S8W)I<'1O<B`W-2`P(%(-"B]3=6)T>7!E("]#
M241&;VYT5'EP93(-"B]4>7!E("]&;VYT#0HO5R!;(#$@,2`P(#(@,B`W-3`@
M-"`T(#$P,S`@-0T*-2`Q,30T(#8@-B`Q,S`Q(#<@-R`Q,S0S(#@@.`T*.#DS
M(#D@.2`Q,C$V(#$P(#$P(#0U."`Q,2`Q,2`Q,#@S#0HQ,B`Q,B`X.3$@,3,@
M,30@,3$S,B`Q-2`Q-B`Q,3<Q(#$W#0HQ-R`Q-#0P(#$X(#$X(#$T-#,@,3D@
M,3D@,3`Y-B`R,"`R,`T*,3,T,R`R,2`R,B`V.3@@,C,@,C,@.#DQ(#(T(#(T
M(#4U-`T*,C4@,C4@-C`R(#(V(#(V(#$P-S(@,C<@,C<@.30W(#(X#0HR."`Q
M,#<X(#(Y(#(Y(#DS.2`S,"`S,R`X.3$@,S0@,S4-"CDP.2`S-B`S-B`U.#<@
M,S<@,S<@-SDR(#,X(#,Y(#8W-`T*-#`@-#$@.30Q(#0R(#0S(#4T."`T-"`T
M-"`X.3$@-#4-"C0W(#@T,R`T."`T."`Q,3$P(#0Y(#0Y(#8V,"`U,"`U,`T*
M.#0Y(#4Q(#4Q(#$P.#@@-3(@-3(@.#@X(#4S(#4S(#@X,`T*-30@-30@-C4P
M(#4U(#4U(#@Q,B`U-B`U-B`V,S4@-3<-"C4W(#<X-2`U."`U.2`X.3$@-C`@
M-C$@-S0V(#8R(#8R#0HW,C(@-C,@-C,@-CDS(#8T(#8T(#<Y-"`V-2`V-2`X
M.#4-"C8V(#8V(#@Y,2`V-R`V-R`X.34@-C@@-C@@.#DQ(#8Y#0HV.2`Q,34V
M(#<P(#<P(#$P-30@-S$@-S$@.38S(#<R(#<R#0HQ,#DP(#<S(#<S(#DT,"`W
M-"`W-"`Y,S,@-S4@-S4@.30U#0HW-B`W-B`Q,#(T(#<W(#<W(#DR."`W."`W
M."`Q,#DV(#<Y#0HW.2`Q,#8T(#@P(#@P(#<W.2`X,2`X,2`Q,#0Y(#@R(#@R
M#0HQ,C<P(#@S(#@T(#4S,"`X-2`X-B`X.3$@.34@.38@,3`V,`T*.3<@,3$Y
M(#@Y,2`Q,C`@,3(P(#,Q,B`Q,C$@,3(Q(#0U-R`Q,C(-"C$R,B`W-#8@,3(S
M(#$R-R`X.3$@,3(X(#$R.2`Y-3(@,3,P(#$S,`T*,S$R(#$S,2`Q,S$@-#4W
M(#$S,B`Q,S(@-S0V(#$S,R`Q,S<@.#DQ#0HQ,S@@,3,X(#4W-R`Q,SD@,3,Y
M(#DX-B`Q-#`@,30P(#0U-R`Q-#$-"C$T,2`W-#8@,30R(#$W,B`X.3$@,3<S
M(#$W-B`Q,#0W(#$X-R`Q.#@-"C$R-3(@,3@Y(#$Y,"`W.30@,3DQ(#$Y-B`X
M.3$@,3DW(#$Y."`Y-SD-"C$Y.2`R,#`@.#DQ(#(P,2`R,#0@-S<U(#(P-2`R
M,#8@,3`V-R`R,#<-"C(P."`X.3$@,C`Y(#(Q,B`X-S(@,C$S(#(Q-"`X.3$@
M,C$U(#(Q-@T*.#$P(#(Q-R`R,3<@,3`V,"`R,3@@,C$X(#@Q,"`R,3D@,C(R
M(#<X,0T*,C(S(#(R,R`T.#$@,C(T(#(R-"`S.#4@,C(U(#8U-3,T(#$P,S0@
M70T*/CX-"F5N9&]B:@T*#0HW-R`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E
M1&5C;V1E#0HO3&5N9W1H(#0R-@T*/CX-"G-T<F5A;0T*>)Q=4TUOJT`,O/,K
M]M@>(@(4=I&B2'Q%RN&]5B_M#R#@1$C-@C;DD'_?Q>.FZD."D<<,8QMO6.WK
MO1UF%;ZYL3O0K$Z#[1U=QYOK2!WI/-@@BE4_=+-$_.PN[12$7GRX7V>Z[.UI
M##8;%?[SR>OL[NJIZ,<C/0?AJ^O)#?:LGCZJ@X\/MVGZI`O96:V#[5;U=/(?
M^M-.?]L+J9!EJWWO\\-\7WG-SQOO]XE4S'&$8KJQI^O4=N1:>Z9@L_;75FUV
M_MH&9/O_\LD:LN/I]_L/T%ZV1!%(0%2#3#A*-$.\9C(Q($N&70FRXBB-`2F3
M*>3I"XSP39]C,@,)>0J'M&'(,Y`[CC*4I`V3&1PT!`8E:92D<\@;D`5(0%:!
M++]U"Q01DP8.`AGJ-#`2*&!DT)%`H4&B/X$,[@9M"A0HWJ!I@^(S3-Z@>`$=
M@T0K`EKJ1"L"6MRE(X#&Y`U^AZE!)B!ENC`J<B9SF9D88?(Y'$K\@/*%R0HS
MJS&0NF"RQB0:Y!J,KL$@!60OOQ=P6='E)#WVO[LYYU>?CQOO_++M@Z7'B9S&
M:5$M]Q?C!NK=#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C<X(#`@;V)J#0H\
M/`T*+T)A<V5&;VYT("]31U)454HK5VEN9V1I;F=S+5)E9W5L87(-"B]$97-C
M96YD86YT1F]N=',@6R`W-B`P(%(@70T*+T5N8V]D:6YG("])9&5N=&ET>2U(
M#0HO4W5B='EP92`O5'EP93`-"B]4;U5N:6-O9&4@-S<@,"!2#0HO5'EP92`O
M1F]N=`T*/CX-"F5N9&]B:@T*#0HW.2`P(&]B:@T*/#P-"B]"87-E1F]N="`O
M5&EM97,M0F]L9$ET86QI8PT*+T5N8V]D:6YG("]7:6Y!;G-I16YC;V1I;F<-
M"B]3=6)T>7!E("]4>7!E,0T*+U1Y<&4@+T9O;G0-"CX^#0IE;F1O8FH-"@T*
M.#`@,"!O8FH-"CP\#0HO0F%S949O;G0@+U1I;65S+4ET86QI8PT*+T5N8V]D
M:6YG("]7:6Y!;G-I16YC;V1I;F<-"B]3=6)T>7!E("]4>7!E,0T*+U1Y<&4@
M+T9O;G0-"CX^#0IE;F1O8FH-"@T*.#$@,"!O8FH-"CP\#0HO0F%S949O;G0@
M+TAE;'9E=&EC80T*+T5N8V]D:6YG("]7:6Y!;G-I16YC;V1I;F<-"B]3=6)T
M>7!E("]4>7!E,0T*+U1Y<&4@+T9O;G0-"CX^#0IE;F1O8FH-"@T*.#(@,"!O
M8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`W-S$Q#0HO
M3&5N9W1H,2`Q-3`R.`T*/CX-"G-T<F5A;0T*>)S5>WE\',65\'L]1\^,1I8L
MR0<61XO!QJ#+DN7;&-FRA&UA\`66.&+US+0TC7JFQ]TS.LP1$R`&V1`!A@3"
M86X;,(PPAPT$',#@A`1"`H0K0/*Q7_:W7YS-_C9L-MD?]KZJZAZ-;,/N]]O\
MLVJJWZM7K]Y=U=TU!A``QL%F\$#7^6OK&QM>_V((`&N(>F$LJ:87_/,;"ZE_
M+1!#K"^C/%&_:Q>`E_J^^=WIGN1K?UZ0`PCN)]J&'M5.!R(0(H$*S:_H,0:[
M#]O/[:-^$\G8D=#4^$^V=*\#*'F7QF<GB%!6'KH)H#1,_=,2R<S`\B5#-U!_
M!NF[WC!CZIP_S]D$4+Z7YK^>5`?2G@O]9P),V$S\2DI-:E<_5'TW]7<`3%J0
M-NU,IS%_/4#-)P"A:].6EC[_C=,W`,SI(GFD]W_XA_+).`P^\O4M[ULD<:(+
M(>Y1PFS@:_Y6KE44:/Z3\J<C_FI\$!KD!LQM+F20`#FLH#`S15.H^<$A$F14
MA+%_U/=X?7XY$`P5A8O'E92.+RNOF#!QTN03IE2>>-+)IRA5IT9.FSKM].EG
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MZ:H_'3ER!(#BN)E!'@,_O`*L.+T4?C_($(`@56`1A*&8ZKH$2F$\E$$Y178"
M3(1),!E.@"E0"2?"27`RG`(*5,&I$('38"I,@]-A.IP!9T(UU$`MU$$]S(`&
M:(29T`2S8#;,@85P%BR"LZ$9%L,2:(&ET`IM<`XL@^6P`MKA7%@)Y\'YL`I6
MPQK8!%?#M?!=V`(WP/6P#6Z$K7`'#,$&Z`(5+H`+82U0F"$&<="@&WH@`3I<
M!KU@0!)28$(:-H(%-F0@"WW0#^NA`SKA(K@8+H%+X5LP`(/P';@<KH`KX2KX
M-JWD:^`ZN`F^!\-P,]P"M\)VN`UNA^_##^!.^"'<!7?#/7`O[(#[X'YX`!Z$
MA^!A>`1VPBYX%!Z#QV$W/`%/0@Y&X"G8`T_#,_`L/`=[81\\#R_`B_`C>`E>
MAOWP8XK\J_`:'(#7X0TX"#^!G\*;\#/X.;P%;\,OX!WX)?P*WH7WX'WX-7P`
M'\)'\#%\`K^!3^$S^!SFPCR8#PO@M__C=?GW_GOG:T<:Z(IAAW2U=!%A/Z3,
M-5!4&RA[#937[;!=VB-XJ&)B%,,&JHG?^PY2!5F</I/RU$`U\^^XDZJ"419"
ME,99!1P@N(C&8@21R]B.VSB\DFIH._R+M$=Z17J%CYY-<E<P#G%)>WP'B<[D
M74/9^Q3W$\_E//?[X!TVBR1OI\S^!:?3M17_`0])JXB*3#_)Z27N[63O2Y2E
M?\4*7(1#^"+QE$E7<UN$MLW$<X"N=[@4=JU$`TVT\`:2^87DD6:15%.Z7MHA
MY:17/)W>1;Z#_C+_'-D@*;2":9V.)P^9M/.H\J-T;<Q+%=<O4,+5N`X3>#ON
M(!L.X"&Z_BS52F=3U-EUFZ?+&_;^HZ_7=S]=!_T7R'<'_"2;K?\IM)ZGTEI=
M2*MR!:U`MJXNHU7(KLN=5?(=I_IW484_3U5,.JDN/X6_4'1*Z&)^S<%YN)ZN
M3KHLO`JOI7AL+;ANQ+MP#SY/]KV)[TFGD-?B,LA[8>4UTIW2T]*;TL^DSZ0O
MI'^2_L4#GJ!G@R?JL3T/>1[UO.UYV[O,N\-[G_<3[R<^].5XI,K\%?Y+_5OI
MVB8'Y5[Y6OEF^6[YV5`=[5Q3:4]:2%ZM)Z\&R9,K:$<9XED;H8NMTV=H%?X3
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M,57#1D\)<2EL[4EAV0CJTAYFG;P6IU.F?@-_\02AW?LZK/=<#(8OZBF2_P`[
MT?9>C8]YVFBG?$CNPQ<]79Y#GH=\4_T+1#RE.SV/RH-RE_Q[LO3/GEM]";D.
M%_NVXD[I;%K1%JZ&?\,O:>>>`1GI3-H[Z<F`??3<VAYX'(MIK1V03L&MOOL]
M3WEW>%I]5^$9E,%*WT'/=?0$FD#/M>GTO/+15<%>.)KGS)W3-+.Q849]76U-
M]9EG3#]]VM33(J=6*:><?-*)E5-.F#QIXH2*\K+QI27CBL-%H6!`]ON\'@FA
MIC72UJ7DIG7EO-,BRY;5LGY$)8):0.C**41J&\N34[HXFS*6LYDXNX_B;!:<
MS7E.+%46PL+:&J4UHN1^OC2B[,6+5G<0?N/22*>2.\3QE1SW3N.=8NI45=$,
MI75R8JF2PRZE-=?6EQAJ[5I*\D:*0BV1%BU46P,CH2)"BPC+M472(]BV"#DB
MM;7.'Y$@4$Q6Y59$EK;FED>6,A-RGJFM:CRW:G5'Z]+*JJK.VIH<ML0BT1Q$
MEN1*JCD+M'`U.7]+3N9J%)VY`UN5D9K]0]OVED*TJSH<C\352SIR'K63Z1A?
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M@6CE4]!<7]V9D[K8R'YW9,(%;&2S.Y*?WA6A<GZ:O\Y/R`6FY?\K*9U8WIJ8
MG\.)WS"LB7%:/JW*B-<W=6A5QS1U:&OEM*ZA;9V4FC9:BD-#;1&E;:AK2-U[
M9',THI1&AD;:VX?2K5VN2WN/[-]:F6O>UIE`"FINIHA&KKREPU,I=0I,JO1T
MUK)=TTM[DT3ORQB@]VS^WBW1,QL\F^F-PT-OW)'F$OE=]+Z+#Q#O$?`=\>S#
M?P"H/WRH]!"<_4>Z-\R8.;YJ_-2J\56;/?#59@D.@^_@W^9N]AYD;^Z[`>2W
M'5GE<'OSI$!YN#185!(J#X\K"945CR\-EA47EY7ME:YI#I:'*\K+PZ&2$M:;
M4!JL*"T-%GX`A;WR"W@/1<^+]S27(]DY9M3G?0GGD0<^NGND2K+RJT.E7XV?
M-`_./D2&$M(P8\NXNNIQ5Y:^1G`R1TKHSW4`<1*BC'@ZXIS=\JE_M7Q_^YM?
M^@I3^N&;T=0/WW+XY@2F#M^28`YN]^XX?`(;NN7P+3JCTHVZ%#_RV9]U?*Y^
M$3ST44B;.3[XM.\!+\`+4A/[XI&:GI+_Z!T31V:"ATQ!R[OH/UZA-\8#WD5_
M^XKI*GS.L=J1-L/I7][GV5"R\,M`98"3']I]ZV$&1]Z4Z?O[\*K09W(#=<.C
MGYF4B8;#JP"*M@$<>3OTV3'?G+\CZS8SA#Y.@4D-+((5P>FP/:13VP\KY&FP
M/?@B[/8\"@<"]"TAGPJ[@R5.VR!:T19JVV!WX`#L#KT,NWW?%XWQ>DUJ[]`8
MO:W*M\&*P`Z2>2WA56*<-X:?0W1JWCVPV]]!\S71Y!M$\\9%8_S^E^%"MP7^
M#_$M(]J;I.-9&J^D5D2T)J)=37`";/<OA^VN+M]?G7:0&MGLOYCH$QP[SA2V
M!)M)%MDMD[S`/H+DG]Q/[6;JSR28$KX&KJ/Y9Q'LACVA:KC>2[%CS=5%\5QQ
M5)L[IEU./)<?%8N_<Z/W_=V>7<)GKN?H=J]H_Q6?E_%]4<B#I<[8.X27'%<V
M;Q@]BK;EZWG_>RT0/:K1=UQ`U&_#-[60G^K3+W+.\SY6[J_S^/M.<_K^66-;
M8$BT_/A_C&UY^A5P@#668XXO)EC0/!]#S#,!8H%SZ*L&8-K_ZFO'W_5Z\W_I
M)?;JWV$8ZN%&&$=/AE+"Z`F%?_!NX-_,`*?C1_E].`WN.2!"$#(.+H'L/]G!
M/5#IKW!P;P&/#\+TW2-P/XSW+W!P&>;YSW7P`%3XKW/P()P"MSEXR/<@:19X
M$33Z[W#P,.%OLA-++_O^#ON_XKC,O)"#'`\2U^?R"0Z.4!9`!Y=@7/D%#NZ!
MV>6+'=Q;P..#R>7]#NZ'4\N_Y^`R6.4C#AZ`Z141!P_"HD"+@X>*ELE_=?`B
MB%>T.WB8\"<Y'F(V3RCG>!&S>4(5Q\,%]%)FIX.7$UXVH8'C%04\E7RNT'M2
M`?TT/G<MPP,31^EA1V^+F1ZT])Y$1MFE-,R;UUA+MUG*2CUFF;;9G5%:3"M=
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M;%HJIELQ@ZHN1>&U5,Y'%6AH,::&58N:9-7%G.%N\>Q99E2EZ%$V#=)`W+0Z
M:#710B96SD9XEI9\@A75*E,7]2OFQ\D`T26/NBUM8Y:MS^YLBJMD*2FHT-'B
MI%B;;,R)`%O>*N6+%M(8<].N,B?^F>/L3N2F2;S=%"Z5;QM,;HS,Z<X:3'=<
M%9:0N'Z-[Z3,\KC.9C!;X[JE.<:R`3LS:#`_VZAJ^U1+US*#PM5D6HUE6'*B
M6</0,B('&H6EU]FH3(OM,+RJU[/`,!-'C2-<R,OO"3V:F=0REAY31-I84#9F
MR7"6"M,8[.%;(>U^/4(;-X[VPKK1"*S1>K*&:LU75JZ=S_:N61>2(A:[QKI9
ML_)LM0Z;L[>SY:50Z5`"F%&L#+6D:O4RF\8^6$R+QZYNE$K/$9/G<S"1R:3G
MU]?W]_?7)=WA.EI7]1DK2S%+:_4\/?7]KA7U__6,_'9=3Q493]3SG[8L2((*
M!JREEQ25*'&Z6W1OX3][#1*N\Q_$,J#`+FH-]&(T#QJAUL%F$6TE\<2(TP2;
M6C?G;>&RTU!'^&*2;Q!<DY=E\YY&4".N/KK'.>>HAAEY#0U$6T>6I(E+(3M-
MDI4E&3IA*9)00]3EA,7^OW2MHS$F;SWQI8@S[D#&W<TEBYG]?!;CC',93&J*
MRU`@2E8IT,YCQ'B7<=N2G$]QHLDBD>`Q-1SZ$BY#H[Y)TA6NMQA">;]'9[K^
MU_$("'N/;YOIY(G)4GD$F&4,3SJVGDLQB]$XRR^+5ZP@>HMIML6M$7U7OZ@)
MB^O*T+C"9R4I$\P7)CG%<YUQ;!NK(T.T`3[NVLPP9I'NV"?BY\ZV'6N/CC33
M7^?D<-0C9B?SG7G>PRW685-^Q/7`XG'6J&\[<6`1&JUBA8\<OX*/K8SIE(65
M<`;7X%K-(--R=&[27%H?CX;&]2A.'20Y%ZO>+'&*2!Q;6\S>#,]L-[?:S9?P
M*<WOMI,!8=^H32)+0L]HSDPNV[5/R$T[\36=NAGESO+\6=R20?[3-\MX85V[
MVK0QU3`JNX=FJR0IP:T7TK/.*A1Y$!I83<2X-Z-U;CDQ$[#0^VZ><056T;IB
M>7"CF>%T1NFE.8-46Z:SD[E<0K?(G<5U]A*76"TU^>S$>3;8:NISN.-\=??R
M?&3R$E1G/XKQ"K+'C*;Y?->_&J?N!SC&^-A.59.OO7X>02/?/YZWW7S-N#5F
M\'JQG-4:)TJ,O!O-@/!8Y7,*<1:3`1[I&JY7YYD<7?<QXM')^K&Q<_/=S^UC
M/D4Y)B)2Y^R^C"_.8^7NS#5?L[OJ?*]F>WC<V1$+/>[G$A)\=S`=3.2K4+;J
MQ$M8=KR:%6M)YY&+<<Z8DQV;[U*)@OA;CF1W%9D\QH6UGG`P.[_OJ'F?6*4;
M^2H8&\ETGL?F.Z/-UYJ;N:B3^1K'VR3=Q6RV!EA]*D?E[/@5D^0RM6^(E,YK
MH,>)][$18/YDG)4W&KU1;PWGZ2)6D=@3DMPVH\"R#-_SV'.MIV#-CY6F\4SH
MQ!GC%1WGSRE1O1:?X<H3>Z#!(^%ZX^XM*L^W6`-N9D:S-;KVF#U13N]QY*9Y
MY=GY?4L\.\2S23R1->>)YTH3]*SSE$_D=ZI51-7'[+^%^N-.!`I'+6<%,[B1
M)&IYS5D>E=%W&O<Y=;P]]'@[IZAK,S]O;`VX3V_565]QYWG[==%-'^/9V/K/
M_#??G40V34=NMU-=:L';AFMOS(D.BX21]SONQ,^-B;".96CTG=2->9RO]6[G
MV2'B&N=UIAT567<&J]=!YZV,Y;/-V6O[N"TZW]T&QV25U9S*I;DK)\KM-3AO
MX3K0G&KI/>J-BFEPWV%&]^KU^8IQHWB\R-E.!D?M._8]H8>_$24YS>(UHXQ9
M;6ZEL.I3G7>(&B?C[$VDI^"M4+S[]8SQ;31RJO->=KP:6,/759;OBA;,!_9^
MM99#]YOA0L<CM^X:2=(LNHZ55GN4M+'O[?%\'8E=1ZP`-U+N;JCQW<_B^ZF(
MTS=]L9A\EELQ=<?E%=\C9L'Z'.3UF"%\/M33U<^O.OZV.W9VG?.\JN?V99TZ
M8[M9?<'JJ7>>SX6QJ/^[Z#CV[;K>V2/C)+\>SBOX*M0*>BI_"A1^)XIW!)?C
MMS2>XC-47J-Q_GT)DC@T/S*7_UYR[-_OG)\])?2@%WWH1QD#&,00%F$8BW$<
MEF`ICL<R+,<*G(`3<1).QA-P"E;BB7@2GHRGH()5>"I&\#2<BM/P=)R.9^"9
M6(TU6(MU6(\SL`$;<28VX2R<C7-P+L[#^;@`%^)9N`C/QF9<C$NP!9=B*[;A
M.;@,E^,*;,=S<26>A^?C*ER-:W`MKL,+\$)<CQW\WW!=C)?@I?@MW(!=J&(4
M8QA'#;NQ!Q.HXV78BP8F,84FIG$C6FAC!K/8A_TX@(.X"2_'*_!*O`J_C9OQ
M:OP.7H/7XG7X7=R"U^,-_%^&;<,;\2;\'@[CS7@+WHK;\3:\';^//\`[\$[\
M(=Z%=^,]>"_NP/OP?GP`'\2'\&%\!'?B+GP4'\/'<3<^@4]B#D?P*=R#3^,S
M^"P^AWMQ'SZ/+^"+^"-\"5_&_?AC?`5?Q=?P`+Z.;^!!_`G^%-_$G^'/\2U\
M&W^![^`O\5?X+KZ'[^.O\0/\$#_"C_$3_`U^BI_AYSX[K<8T?YJ=D1D!][2N
MQ$5BV0P[9QKG'/`YYWM>=I;GC9IFKS^FIN*&-BZC&5HZ8:8TVS3T..ORDRDM
MPXYPPEJJ3S/,M!958[W%;J?;,E.9<<X)9[>A]L3[4\4%W6Q:#`Z8Z52W0=V2
MPBXQ^\6Y:4@`DI@J9L>I&=4PV.%W0[BP-V9H9A'KQ=2HGM(RP829M;AC`??<
M-\R/?1NCY+R9"K)S7W[@)J5C`7;\RXY]Y6[R(3TXTX&S`NP$V-(T(\@<9P>E
M6G$>,[3NC(_U^OSL;O;*F40V&<VF@QS&S?Y4B`VD,XRS2*#\UXV`P(E3(.0V
M)R54(Q.TD^0%.S8L2FG9C*4:#`]27/M3#/.RL]82NS=K&.Q4R8ZR]'A9:&6*
M54I-90*J;J4--:4%[&S*3E`TY#@%D@(5M%-F/['V:H$!=@86->(!?FA+2!$E
MR"4RW*6'N18SFS%(4!'OV`F5G!-X3#,R>DPP)<E\S=:*V+F=V1U7^W0V6R.>
M5(;1Y$$]-:BF>B0SZ>M/4%1][(30]F?4K)6U_3U:4D_I?GXZ;7D,S?3UZ5:/
MZ3/TJ*7*=LRTTKI99*L]/3H)T[-V,*:F+9WHJ8#*CA*)Y$_KI,XNSI_\ZADC
M5E30&[<Q:V:T>-0PNC/D7;';M5A/)B_847_8@;SL@]$LK06U.Z7EL7X7LT<Q
M;5P?!8BA4:K<U%'=_C%=^ZBNYHL1;ODI5%1O,ON=A(P-;*+Z)ZMMF:68P4P_
M[P?Y3S(,"W13E0M$[Q,\MC[`>6RM3TMQC!\#<Z:4[@H20T6N!CW5%W*4,-31
M0V@XKXHZ1:XVCCL*&;^CD_'GU;).7C.;X"KG"O(\LC@-;G1@DP-G^RS:F!KY
MO8G?9Q>QNUB\C7YQ3CS..4KF]4A;26&7UI0L#I@;'=CDP-FTA`8:V6TFNS6Q
M:G=%A/,X6Y-6@M9:UFYRD=D!P]RDI7JT)A>9':`5S6J[,<B7`,-"M`XS*D<#
M"6U`C)HQAU04-^.T23%\9I[:1%MQC\X.V(6)^:[P*!#+VFFV%09=I"$PX-CD
MVYC5K,&0XSK)"O%C<^Y#D')JQ@PSUANDE`JLB&=4X"&64!>E?#J\E$Z'EV?3
MP7DR'6:62U>PRQ"F>LYSAS/]FN$*+.:_5%!`V3[84.3V+-K,.9Y-\X&0T\G3
M&36;=N@60XOS=)KO2+(X'MZ8U8V,D_"2P@X569"MM%BLGY:K@Z7RF*WE:9I?
MK&Z_6-JB)XBV%HJ3?V+3+Q(HW\J#['_@:F34$,<X4>8HV]X9Y`\"D1\^6Z#B
M02#P;-H99ZST9+*B0B+'A$2.DD0.&9N@I/H=J`EH.WWRBL&FO)BF43%-CIBF
MO)@F1TR3(Z;)$=-$.U.4B?!'^70//=Q\XL'&R8[,;)J1/-%4/S7-$[4)VIH_
M&E?M1(,`C47.+YWLEYCF,+2UT3MFV?A`\S)EKS3[J66-!*[A`!\7X#$!=@FP
M4X!'!'A`@/L$N%>`Y0(L$^`<`98(T"S`(@$6"C!/`+\`7@$\`F#S^00_H?8Q
MM8^HO4_M56K/4GN&VI/4=E-[G-I.:H]0NY?:/=3NIK:-VC748M0V<)E/"M&[
M!7A4@(<%>$B`!P6X1X"E`BP6X"P!Y@H@"^`30!(`FIL)?DCM/6H'J;U![75J
M!Z@]1^UI:GNH/4%M![5;J`U2BR]KK`A6!.<,[\6^YN7R\'WR\*WR\(WRL"D/
M&_)PMSRLR<.7R,,7R<.=\G"'?%K@U(`2.#EP8F!*8')@8J`B4!8H#8P+A`.A
M0"#@#W@#4@`"D"OWM$OM:Y=@>VY_#-JC2N[?UD;V8FCU13E?9`GFRMJA?=V2
MR;FYU3GI>OZOP??BD1'$FZZK9/\0?!\@'KGNQDH'=G;"Q.IC_R:/Z;6O&GP1
M3L$Y(--]YA[YE-=D1EU+U&%.'6;484Z=C$^M@L9V=6O727`<P:-_^(VC8SA;
M=>;NJHZ1`"SI;+E$P#U248C\Z:JLZEPRL32]B#NWH&KR597/>P%W0E%U9RX<
M69(KIL:&:A?7+F9#7N!#X]B_O7>&)E^UH*KR>=SI#)42>3R%\C\!S[?N00T*
M96YD<W1R96%M#0H-"F5N9&]B:@T*#0HX,R`P(&]B:@T*/#P-"B]&:6QT97(@
M+T9L871E1&5C;V1E#0HO3&5N9W1H(#,P,S$-"CX^#0IS=')E86T-"GB<U5M;
M<]O&%7[7#/_#3E[J=F1T[Y=,IS.T1#G,U'(J,I.TDQ>(7$IH*(`&2%_RZWMV
M"2R@B`0M".BD8UL"O8NSW[F?L[M\\_/H[,/H#$?2"(3='_^D(\'W/Q8/HS/B
M1PBB$A'I_X<BBB-CJ$8:PP@6&.5V=/832CTMQ84C)+1VOU!^-SJ['YVM_N)(
MN3^-_\`1YPP6B#@3#'XQ0^GC<<.%&S=,N7&M)3M,D*+7#%-%D288,<(X\YA6
MGL']H`R#C-6`W\Q'9W^]BF\7P!Y#<WC!"\(3K5@G!@8Q5F@.W+_&$>8@I?G"
M/U.,X?G3Z.S5N$"K9&V7Z%.RO4?;>XMF=K'+DVUB"Q2G2S3YO+B/TSN++K*'
MAZ0HDBQ%\/?2+NS#K<T1)><@62S_C.;_&9U-`-@_>X'/0&_&$(_>@:<\@#?N
MV8&_L7=)L<WCK0-UG44(5GF$8T_VYJTC^\EA^GYT!H0C@8PV\!-H<VK"Q_7H
M;-8+>,YP`&]HQ#&&Y]\`\>N3\.#51_`8&P(>;\AV;Q6O?B%,G?KW%>CY(_1&
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M/)^\FUS/>T>B08K`JT<"U9&".L7KZ\?KR\E-_V6$0IJJRCJ,QC0P+GC)^/R[
M"6J&Q8LY>G\%!13KK.2V`.1>_:,&(&7PH`$HT.]JX*[T.YSZH-3W.<XI6D5&
ML+U90>JCM`Q`E_\:7TXOT/1Z/KFY]F8^_L<Y?+R(^M:S*^H59U4X5)Q4X9!1
M]^S0_`(]R.1SO-BB-'ZP*%O!$OMZ-MVBN$#%QBZ250*U>9*B9%L@*,3SK<WA
M/3*$ZBD;5O45_<XEVU&GX@H)+/IQJH$=C&LQJ)0#_0&DS"%\F?ZE/)"D7=4Y
MI*0#_=YS-:4&\O6^BC<B`@HJY"RCRH)YO-GDV>?D(=Y:M'0_('XLH$6W*33F
M%B((?(89FZR``%+$:XNVF>_O-[O;=;+XMO>(AS5BP0F)TJR*>)QJ%C8;B@Q:
M=0ANFQP"7[*(;P%8O(*H!MB2`CWJZ&=;X,OS<FN!-5L@NUI9>.VC[1RP6PR&
M#NR:=##7E!A16=7>Q#<XI>@%*\UENO+*S]+U%U34.SRW%IJN,N_8'"P%Q.X5
M<97E#RC.;3DC`\&[X<TN+W8N/X$Q+9./R=*F\$X.&<J]7FR!5))^A`>OMLTZ
M3HMS^&7CPD+ZLHM?/8J^^7?*$R2D?BE#C4>T\U(G@%6V7F>?'"^WV>>HLXH)
M.0X#:IL*!HB>[+O<OV&LY=_[MB9<<SR,.3%>\D$)KCU981;,*4Z_N!CC]/DL
M@P++N;7!H%PT0$N[CK]8;TB++-TFZ2[;`:FX@/>:%G>S@VC!B4"[=.DCQC"F
M1%3E2A+7KD1IZ4J-#=+QPL=9URD@5\XY1-\\'O_&E6OG*(,AASA.F]*JI0!N
M"54><)^Z``=2\?NQ7^UBP_H6QG\(W\)5W^1RX]ZUQ%7_KL7#2H.X%M%56T"(
MJ=L"C7DC4E<.DU3;\V#]E5.A>+E,G(W$ZZ8MK<!&P+J\23E5/'4<29V-WCJ#
M;'C08W/]WT1K(F4E`ZQ,D($B!^S)GT*L@?,#:$/'Y%VF"/5"NO-G$V5XLG&^
M3N!CJ!Z.O>9$Z./9OA_;"S+J)H`V8U:\*8)!,X42/"PUC#GSJB6`UV5MSN[Y
MD#G'"$K2;>\V)4U`TG+@TL=*BC5XQD:$0S4FW=Z2X[DV-#"D=+FW+>_&QYQR
M<<(I:V]L\8TA')71$*Q40[M"',R%_Y_N**%MJ1D=U!TE46&I8=R1A!9,D'!D
MRC$YDEWB8\)O6NI;F]H<LLTTA8F[?7TRC2XC5Y8,X\\""LV*E6']66#5%!JC
M06:LQ9M=-6=]0QUO47$?K]=ECSJ$$YIPK&)P73!4N_8UO-T&]`)QQ@6'<)S?
M.+8_%GSL<RN"Q_7>``XI5<WTL/X(U<?+SL3:W5&3/TARU"<O(_24&VN.":DY
M5KK-F;+C8>AIVCP:C%H+Y0'<4E8M,N$RU+"<X/*PH=GF/8*R6,=%X9N_9OE^
MH,]EG<KUP9U3Z9KU89T3FKYRI2&VLS'B5:/?\V[V0#O:Y3'F8/N3ZI"H71&(
M^?[D;D^S?MG=9OO@IRCH7IF!,DH\\Y*:YO!N>3PK(Z7<#K*+39=V'7^*<_M[
M/CE,[KJ8@/ZR6BSHG(M>E]"BYJ<UUKYL%?.4$<RU5/R)W9U<I\T!F0[K//5`
M%P(!2!OAHVH'PM*$U@)379<UU6&M"W[^!,"%S_=^^^Q[B'S%,O$Q_Q"?7>$(
M\)L*CA&1)FY/HMSD(LWCVFET$\TB-'G8K+,O-C\D$;$7-7NN1*B+K)5*L3*\
M/C`V9:4'"6.:+K)\DY5IT@DFOXO3Y#?_^=#!\%=`:HDX4K3<1WH):5F3?F)7
M7I,=Q2B$;(J1JK!W396J]JZ74%@DJV01[HT>$MS7H#AZE<>_VR*Z%Q&'Y'Q<
M>$XI0-%[@7F^OMO.3#WH-MIM$4L(2.6EAW%03!GG_34<46ZLOXOS7]'8N5>\
M7L7Y[2'>W,%K1]YHR]46SUL;[3;>L",>;IX(7A_7$E5M"5W<)W:%)I^A>O/5
M[_L5&*`K4=,E^B&WA=OF?U+X.]200#HE5@RU$^;A\C>N3W$HKRY=$JB!IBD4
MW8LLAI)[C7[(W"D#NLP!XCF:[1+XP#$_**V.P-R]G`H8Q%KNI%Y)"]-R6^GR
M2PQAWF&S>1KOZ^9S%_R>G/N"B(26W43$M<^DE8B(#KT_9:3,0M_O-B"$_!Q=
MK;,\6<:(,:X.)MFN,-RU_":,7C7EQ*,Z6A`TX4*%8T!3YVC!FSE:2.);%,6?
MW)9[P>H4O+5:O;V0>M$BO,%B64?IWW^)X"O6:(D\5-"PQN%<UQ4]!)I`^87V
MZ_@#G!TCJTNZK9&UE78;A](1-R\QP9<L+T$CU?*GB_GNJY@&DRU&>'*1MDK>
M79$3QRXL.1V"P?AJA#_SVH^+Z.$$B)OZK@"KOF+D-#1>+B')%3Z&KW=+MSOQ
M[V2#+K(E1"^7`^=V;3?W66K1M3\L:,X<YS;N$[.&T$*KY@-C6G\=051G_'M@
M4'#?A"N9?RH@42?I(ME`^/U](B^.E9!=,7(8:0B6T.#;S'^5HA+L=?P`0%\D
MWCYA"Z(:LB6DL5_M"H;]+3"GSB#@\5UUU#.S^4<0Y9$NALO][>0.\8G+EOCD
MQL$Y/.EG!F`&!007.!2UQ#1JVG*'=YR"9CZA283>Q.OL[AQ-B@^'BAAWVM`)
M`]@(+[];X^\'ZM`X$D%*$&]S:U/0^AV:YS'TT`#CAVA\$`;I*@J).*WN9Q!I
MZGLSQ)21&FR8H#=YLOC5KM=H_-&FNR?;.PX"[B@)IPW<D(2BM22J;/$NB1^2
M9C(D[)"Q,=U1#-2%9UQ_Y;(^3J)8EA@:OIA%W_I[0Q`K?0(3ZLE7GEZ`A@L3
MT)RLH3HO(EE8I-Z+$OB0H[6NT?J-/Q+6.)B]F.IH,U``,A6^F29$2%^@D7*[
MX"I>%,E#LOYZ=74$PZ&IK\"<5E?7121M<%RI2Y%#)6'K&JWJPF&-I[O)KQEH
MTY,]L)OLQH%Q/\Z/C8/%N7%Z9)QP:"/;)E!,VB<PS$CK!(ZE:9T@L&FG(-T]
ML[8)BI1?QSDV0;N:H&V"(:R=3<C.JATE(<2<$#8E1K7/8)2<6(53*#=:9PAW
M(;5UAJ1*ML]0C)Z8H9G")V9HU:YXR':B?0;%^H340:2X7>J42M8N=<KD"7E0
M+OF)&=!EG9RA]-&C(3]#,GH"J6+BA+]J9MKM@X)>3M`P^H3+,NSV'([-@-@U
M^7ET-CK[+RS::(4-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,2`P(&]B:@T*
M/#P-"B]#;VYT96YT<R!;(#(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@
M-SDR(%T-"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\
M/`T*+T9A8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P
M(#`@4@T*+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W
M-"`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO
M26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B
M:@T*#0HR(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG
M=&@@,C$U-0T*/CX-"G-T<F5A;0T*>)RU64MS([<1OK.*_P&'/2@I+H/W(SG)
M&VW*58YWO2N7??`%'(+B.,.'9X;2*K_>#6`>I$B"HDF55.1P`#2ZO_[0W0"^
M^W4X^&,XP&-I!,+^+SSIL>#Q(UL,!R2T$$0E(C*\H4@H,S:&:J0Q1MP05+KA
MX!>T#+(4%UZ0T-I_H?)A.)@/![._>U'^;^L%'G/.8((Q9X+!%S.4[K8;+GR[
M8<JW:RW988$4O:<PF")-,&*$<19TF@4#8R/I&AGK%?[N?CCXQT<[R<`\ANYA
M0``B".U,!PL)EAC=@_6&CHG$$MW_W^N',=?H_FDXN/EP^\.'GW^XO?_^TX_H
MTT?TY>X_WW^]_Q)_?[R[^QNZ_WTXN(/9?GJ]3LI#?E@G&$DPCRK=_$8YOOH$
M<FL"]`;J:ZS?5/M._ELHKV!UO*7RG?R_IGR"S$!CQ500_AZ/"6:@11:?A6JX
M?#]WZ(M[R*NZM,L:S5WI)L_(+MQR6J%ZGE==:YVOENAK;6L'C36"']4FFZ,I
MO$"K,GQ7R%9H89_1Q*&ERUQ5V?(9U2LT=06\S>L*N=G,977^Z.+`S;+."YC'
M7=UX[SF*6^.Q(J0S'L1&X[<,K^:V*-`L+QRR:+8I0:4RPA"L?9KG8&NU=ED^
MRS/H^HRJ.EA<SVV=!"I*]O*<G=4@=>*RU<)M(9$OD<VR53FUR\RAI[R>OPD:
MF'5H<-."00GA$8RO7AO07/^&!;;P0=!J%EP#+9LRKW.P]C:K_5MB0`%P>N^^
MI/%[%N^0QU9!PH?58I%7%8P?`1QUOGQ`ZTU9;;QW@$)O@(C4,L9Y-8;U0$*<
M]_Q0?I"'I++Y%.WC,@H<GSIPYB)?NO$;!!TIY9L&G4[^+JX@DV(#,<F`X""T
M'^VS\!^AB]$"4440X^=!;GR>P;(/2+BC(?&E10Q(>0UK$#AV9X$@'PI;52_M
MOT`%J6"H"1K`,F`^"C;K0+<1$:;>(CPP;]*R&U;P=,\7F@5E"!9G*\.@I.H`
M,6RLA#`M";'R[[T^MXO5)BZ!R8$H><'T%/RQ!08WM`/#^.<^0GK#D:<_\?1_
MJ0.#\B_H`/E%D/-TX-@7-S1&)L/'BA/=K4.A&RT^EZOUJ@(=_FN_Y8O-8@^&
MBU0@HO<"S.H[1AAD&P<^0>`J?4#Z7.;9OA,NF]UL.T$IU<[.J'\.YD/2^#JW
MI0L^H(=\("AO5!!GJR"8OH8/+E-!;?L`8.BRM0C/82$\/)3NP6>,SA]7U6$G
M-A#:%PPL%`\1!.__HUZ0PL3I84]R=F226]$1,I(47+5>H!*KG6``,6HGX5Y3
M$07548N#SXPA2H,>-Q_="^KW8T,8@FWC(@9G>"J:)^V?8G-XG.\D$GCGH[A0
M9R=((\WQ!'F):-F+WH/U%7*/NA>&"MJG/MG7XIPU%9BO@$+UM,K^-T)K6Z)'
M6VP<>N<WGWMDNQ`_1M\,OU;T,;:$>!G9TA)GER2QPPN^M.T^U9VK51B;8LQE
MPE6",Z^1?+1`@+C3LL;0,<,JAH0;,1*:C+CFU[6#I6EQ,4BGB!'"=R1&RY%=
M-L0.+XC1MH?T>Z9:86R*&!<)-S1!C-=(/EHU<'J8&._D6)FKVN#'IDAQ,4"G
M2!%R621%RX]=)L0.+TC1MH=*X$RUPM@4*2X3KA.D>(WDXP7,D6CQCJF1-GI$
ME;RN)3Q-C8MA.D4-C6E+C98ENWR('5Y0HVWWQ=&Y:H6Q*6I<)%RR!#5>(_EH
M34?X$6KP$19[K+@8H10K+D;H,"MBV:*!<O`/VYGS`/)E"V$=/IS'4_^;;M/K
M+3D8_F284X7J_<Q)63\IE(%,=OMO1C#ICV>S6!96OBQ$$^?W/66_+<]6RPJ>
M*[\G^&?8FN3A[(Z.0.)(@=,KOW4,[3N2\JK:P/AZA>P2Y<M'!Z_+<!:)UF7^
MZ/=9Z\)F\1P/1JX+5T/_`[N-"S'0IMOW-0="!-#0S8[GQ]6C6TQ@!ZQ'B,+^
MZ%_1QM9(I=4(8WS:R-;"ZE4F_MME<5829P6,ILW$<>9K8Z"ZC:>B\0@`MKY2
M-#L#*=1(L:0K[:1P:+.&=^Z;*[.\"H=H3[;TQ]O5%A#^K+4'P]OEW_0XV`?_
M"2"%UWLP7=MP2;O3.!IWW#X^D>;4X:A3KJD&`:[U>A"L1,-"T:U#SX$Q^KQU
M'OUE`WASB!L'#\E'\7S[B+_BJ7B^S(K-U,7EUYXF!S=>&V,N&MMH..8)&$,)
MV9!KN0F@@I)'U`U7',VU3L.CAA[NT<73"-M:MBYR;WSX,<T?\ZE;3D=@8IU?
MTRC)=&<5Q&N.<3R]OWE_U5F@RNZQPQ23AA>22Q&QF^;%)IS`V.GOFZJ.-V,E
MJO)%7L#^_=J.I+J/$KS-%K`--%$;?Y55V7A=`4M\53SZ9%&_R"'COZ36T8V=
MZ/4ZF)*5PCXE'SR&2F=DY>\$#F5D>B(C^RF],>?.R?HY/<2J#<32D`;ANZK.
M%];'HVI5N.(9S<#;(5!N2G\\&M:.+;)-8>L6^W+[I&[FW,ZU5@PC0GFSLL2E
MV\16,0CZ-OOH2@C3;=<K(Z!XRW@MNOL1QD1S/S+/'^8A;12K)U39`A1<^V/1
MJL-B)WCLQ&T1L^G(W_F5;KTJ/9*3YS#J=N%`C&W.O]#=MVQNEP_[MVNOL.YX
M;<HZ\_9OOGQAZB^^R(&+K]",0S,_W"P@B?AF>KCY/8.LDFHW,MU.C";I"3`Q
MR0X<\[0$@:'>2'60&+)DJH/"*MU!`Z?2,!":5A)2,FP<DCT(X6E?P!SRQ"R,
M2)WNP8E.HT4$I3+=0\*6/-T#JCY\HH>F:;\3K?&)'D:?0)V"W]*H4W)J!0`:
M)_"@3)@3/3@[@1B%PD8?O<`./82_64O*D`RG:4H5XVE^4/#+"1E:GUBQU!!U
MW/L0M>Y^'0Z&@S\!F@VUP@T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HS(#`@
M;V)J#0H\/`T*+T-O;G1E;G1S(%L@-"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P
M(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@/#P-"B]&
M;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-"B]&86)C
M,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@4@T*+T9A
M8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G
M94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*
M96YD;V)J#0H-"C0@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*
M+TQE;F=T:"`R-3`S#0H^/@T*<W1R96%M#0IXG,U:W6_;.!)_-^#_@5C<0^_@
M^,1O"?O4-MF[+G:;7N/%[@)]460ZYE:67$E.FOOK;X:4**>UE=W$.A1!_$5R
M.//C?'+TZK?IY--T$LU5(DF$?^Y3/)?"OV2;Z82Z$4J8(E2Y7QBA43Q/$A:3
M.(I(HABIS'3R*RD<+2TD$I)QC&^DNIE.UM/)ZA]("O_V?HCF0G#88"ZXY/#&
M$\8>CB="XGC"-8['L>*'"3)RQF(-M&(:$4ZYX(ZGE1/0#[(PR'G/\*O%=/+/
M']+K#,3C9`$+'!".:!!=P&M$$[(`Z1,!("E-%O^=3LZB>:2U(HN[Z>3%U2^O
M?KQXO2"+2_+Z\N=W/UTLWER^G9'SEXN+<W)^\?KBYU<7[PFC,\*B2/V=+/Z8
M3BY@]__\>1XU'L%A'BDC2>(Y?/$!&#XY?=73)Z<F+B))4)V>Q[TZO@&7P'[D
M-TC47%#XC@?XXMW[RZMW<&J_7#W8TE-X_R^D<(?;_SB=`(TYL!E)>`4R0NKP
M-9].KDX&1!R?`(ACJLPY&*VF'@@Y%XJJ3I-IQ*37Y//[=&DS\J9H3%6DC2V+
M-)_!UVP^@M;&DHZJM8'^T[1V",LH(3$7CGHT9Q0\Y")S4`K%6J<@9S*F,Q$+
M<K5.*U.3<O54&8^Q(6C/1L+F'#R2U^TQ]$>`@PZ;Z3G5E`;]`4F]T*_+S:8L
MR%539A_'T!@JQM68COZ3_=Q1C8&8JA/=:HQTZO+B`^7ZJ?\CH*NU'A7=0/_D
MZ*J(:/CWX((W2SISY$K$7C,7:T-ZDZP[DR3EKB*9U]H:M19^6YG*+,GU/6G6
MMB;;JJRW)FMV-;%%EN^6AGR(9&3A!?*#&>5JIB7;H_B`FJWK'1!K2I*2VN2Y
M+6Y.+CT>'60]7OHHEL$9<:%;O^Z869?YTE3$+DW1V)4%MFQQ0$;@=%O9V[0Q
M9)NGF=G`=!1JFYL&UH!H;\M;L[D&4K'/:+[WB'20Z%C/(D@/'X5D#"#0_7H@
M-`2\#@@N=0M$>P9[@-0G0.3<9!X1VB&2%LL6%0^+DGJF^5$]&0.**.DL@D<\
M0(&)MH,"SR&]S@W9;4N4VA#SV529K0UR=Y=655HT]=YQX93#^/GE?Q&C.?FA
MK,AJ5\'::@P`5,(Z`*0*+D&(N#4*6ZS*:N.R'*!]DU9+E`RXJ0_(4L_@LTEK
MA,"</CR`VG;LJC8X,,9/O@U_@$J4]*Y")ETQL]MLTNH>CJO.*KMUZ+1^\M6N
MMH6IZU.S)6%!QQ;E0?PGQ[BC^PCU0"D@)G=*$>%G%/\]:"EH[KFY-7FY=2=_
M\FBE^('#%J??)@G;C!!R];XJ,8F5A<<2;*U5)="<;7ICB$`%<FYU#"O'&.>8
MX!IX<G#VWGN,ND5).6J>%.B/D2<I'H>R)00%H;D_L5\-@?!$BK()GCXM[H?2
MI5V!.<67,1.CWYW-<T>I`I.RM\91<HJ`[K7,C%G69%65&_<+T$]STXV/H2>,
MAG!(D[UPV(K>RNC2OL-Q;D[^7=Z!7ZAFY,YX\3K1'D1/B!U9D"3$T;NU*1PN
MU@W<.Z"[-2&^FL\-NI]ZE.1(12)DB4R&PY==EMAS`X&19&F]GI_\P@?8D/&X
M55R@/X;]2*5#@JE$GV#J-L&\_-)`FBI=HNWX'.GEQH!VI&V)3"X^9^NT`!?9
MF1%HWOWFNLS)=^=O?II_1R[W\R;I$Z>9FY>G-9K6MJPPOW+&$Q1O!-V1LJ^O
M:)]82]K65U\YAK3NN7M$^#N8^S<U!V2W(*8SQ#'\MN31N'K7T1]%[R@/L;:W
M71EN[A9'G-:,E$ZO;(7YZ_+&&/AI61;N'72SJ+'<106M2.DR\7J799#DE=7I
M\SSP/YT<"8.D*_)72"_.3K]3'';"JWHL_S*7\I]\)QK_OV2"PJW7@D@H%JR0
M:=&5-`V<9MW,R":]]U<9WJGXX.:CK=T8%V[P?01/(1(5`BWO/60BVT#;K*MR
M=[,FV]UU;C/4NZ[8<NJ89EARH-X63B=7JR'?,2-I`^O-;6J=ZD/I\M$TWA,Z
MG7;#CGQ^3PIS4S8V19?D9\S)`D/Q&"CH4'TGK*\S!&M/"L]GDWXTSG/79&DA
ME6B`13B8[:X"X6JLK-%V2V_!'C1(IUTM>EV5'TUU\OHPC@+CXRHSAQB]!U&4
ML+U*M+V@6!J`QH/@PN-=91M,PT[MNF64!%Y.W^%"79#CMN<"_=,W.J`L!IW]
MIJ^ML3$Q*KKL637T`+H0UK'MUP4I18.?8!%M.RIOBEOPY^C:;/%U]66+VS*'
M"20E:PON86EN()AC"EC9^N.<_%[NP/>7NWP)ZXK:8I*902A8[?+<%SHXCZS`
MZ4*\)]?FQA8%;M:5[J<664OZ0.8HZ>N0)&ISF6?=%@QL#LK"XSBD[W0O@-+6
MY^S5L%@#I>"8ZVQ7U^TMF+\<1,Q&N5G@ZKD-X&%5#O1'<11<TF_:47`^;K\Y
MT!_#4?"V-7GFBO=P<T-CVEZVO376I>]HU%<FVT&PM,;?Q(1""]NSUBMS@=J-
M5SL-9EYUOR#KYT`20M(MF,0MUG`5VD+_M3.&O:7E$Z_QATV6M6W31,]5PI/0
M=$97XFTVK?'.(K0QT@PX2K-[E_XMS:>=^[SZ\I)J3EZ"_%"C0F8,297O`[37
M,.`L(1FM[HE%UYI5=F.+-'<)=5&/4IRRD9NO;+3F*YH^"]W7;]/T\3FN4=$5
MSRK]AYY`BSEA+%1]6O05%1.BK_V7:,9?*SDJ\!#6[D9)CZ+0$1\7\H[^&!D[
M5>,R'^@_9!YAD[$F.@'"CFB_VCWU")Q1&;EQ>FQ<4#<NCHQ'.G;C[,#X)S<E
M$<+-D/2O.0(H;9,X=(2H]D$*/HI8]8JZWW4]U&VO7<^@ZQR[^(6U\C4X91?$
MEJYF/]R(+M+-X1X^4NB:&FW<^O)4GRFXDN'2H[V8`0NEBG6/'80@N2L:F[<M
MCQM;0YAQ4+@X[)KF*YL;[)XTZS\;RT%6`Y$I:^RM070.(IH6W7U0Z6$X,0"B
M2ZRI%B&Q%DRP[M;G8;(P\[V0IF.O+G.;V<9WG'I.KW?W7^<9^$0&A.X_X'N]
MM.Z^"-LKE>_#^+40^]V=>$M^:ZJ-;1K0GB>(?<R0-3Z\*HZEU&AL3'I;E8>=
M/COZ,*B`P98P^])%4'R6ZH@%P_"9T&)PG$*E-3B!27;<1^`$+N4P!2'!P0U-
MD-@P'IJ@\)G"H0E:)L-BQHH/,PDVRX:!BI0<AAJ.0@]O0IG2>G@&A[3VD0/3
M7`[/D#I^9(:*63(\0^,CPH,S8DX?F9'P1T"'L*V&46?NN93!&8P^@@?C-'IL
M1OP(8HPG?#`4GS&AXT<XE?A(Z>`,%<MA_6`:K]$'9\3\$8-EL=+'3Q_<RL5O
MT\ET\C\VDU!`#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C4@,"!O8FH-"CP\
M#0HO0V]N=&5N=',@6R`V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y
M,B!=#0HO4&%R96YT(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-
M"B]&86)C,3$@-S@@,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P
M(%(-"B]&86)C,30@.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@
M,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM
M86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-
M"@T*-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H
M(#$U-C(-"CX^#0IS=')E86T-"GB<K9I=;]LV%(;O#?@_\+(;$(_?A[Q<TF3H
MT*\E'MH!NW$<)?7J6*ULH^U^_0ZI+RN3CU2Z"&"3)O7R\-7#(TK*^?OIY/-T
MPF?6&\;#7RRYF='EQ_)Q.A&Q13!IF;#Q%\FTXS/OI6..<V8\9T4VG;QCFZ@%
MV@0AXUSX8L7#=/)A.KG_.4B%OX,?^$QKA0/,M#(*OY27LMONM0GM7D%H=\ZJ
M?D')SB2`]<P)SI106L68[N,$RT;3-"K5!GP^GTY^N5K<+G%ZBLWQ@&A$%*VG
MKC0.PX5G<YR]MS.N`<O_3B?/YK^>O_R)S?^93BY1YX\?,QJ8@]'4S&J<>QCM
MC./(RK#Y%QSYDKVY8A=O7L\O7\]ODD*`PQ!$)P3PGGEGR@CD3'&`<KY_2\T[
M@Y7]KW\+QWX)`_\^G>#1,X/'*_Q$`<=%4UU/)S??%:$]8I*0S*@RP/\']2/T
M;:O/.N(XLC+:HT<H'$7;HR.3DDF!'Z%='&OG*K;K(^U<\]@N^]L%!W>TO:V!
M0=LM#^<`#PJE=562H50VQV*UG#XWS8#K!PG\+LL`5ZJW]L@Y:?L[+NNPZ@B[
MT90=G@16MVOH#XQ84&##H2X&ADL(0L<EQOAV\9`]Y2;,'U=[\OPUP62<`HH?
MFP*E[1VM'>+F.L:MX/L6>SA4-NXX(:([F&R4"N60;&[VCX^+XAM[GFV7Q>K3
M;I5O6'[/WNP+=K[?KC;9=CN8%80,64#:,BE(H9MJDQ1&3(+(!YZ[D_PA4D$C
MS7K/*0KC.1WV_<DY!=,8WTFR.F&0XU`:VIB3M#WA##KN+*02Z;QHB.2F)9)7
ME[_KU?8CNUHL=WDQ$CWG?(D>0%,[)&\H6((\!X(D+UG:MM*]Y`7A1/)J@SOD
M0<(@%'FD,2=I>\*9X+CBR>3AOK<F3Q^0IRORGJ^VRW6^W1<9N\X>%L7=:O/`
MKO+B"Q9'DFAD2:(`U50[**9&#[H)'\^KYER4Y_5L.##0W<C@!T?F#HP5@OO&
M6!O*P=B7>?XQ>'FS6^RRQVRS&[&PP1U&+5V:G\<PDZ[U,PDS*F<H3>>,5&G;
M2O?G#!1.RAGRD*TV9\C^A4V/0B8-RIF3M#UA3=RQJ^2D(:!B6ZIP22_9UBZ4
M`]M_;K.P87I;Y,LLNQM[Q1*FY-J[IG:(]5"\!'W@@:0O6=JVTKWT!>%4^BJ/
MN_2)A%$H^DAG3M+VA#7!<F-3Z0/'ZTN6M6UF%;;*K#?9>EUFUGSY\4.^OLO&
M;IH@)MAX`\F;:H?!@:@I!BVG&4R5MJUT/X,HG,A@[?08!NE12`8I9T[2]H0U
MP7*\+TUE$`^K&81VVR2@VC:]72_B/2-NGW;%ZG8?[B%',JA%Q6#,@&6UP^!`
MU!2#4M$,IDK;5KJ?011.9;!RNLN@21B%9)!RYB1M3UB#EELGDQGDMMYA:JX:
M!GTHQQTF[M?7[-5BMQN?`+FNGF*:IG;(WE"T!'O6'7M6=J*T;:5[V0O"J>Q5
M#G?9LPFC4.R1SIRD[0EK@N7:I+(7+[R/$3C!9?D,[=GEUT]9,>8^)J!F+92H
M&=[4.J@-!$>AICV-6JJT;:7[44/A1-1J0\>@1H]"HD8Y<Y*V)ZP)EG.7C)J2
MS:56R_92&\HAS;W[D!49^RO?LPN\YEZM-G?L58Z_O-C<Y\7C8OR5URI>W5C'
MW5]9[2`Y,`D*22%I)%.E;2O=CR0*IR)9&3\&27H4$DG*F9.T/6%->*$&(A5)
MXTU]Y9486HTDA')`\L5FF1>?\F)1OSJXP+RX6&W8\WRYC\]ZV.TW=IW=([F;
M938.3^.K-XP2;%,]Q'-H0M3+1:!?MB1+VU:Z%\\@G(AG?1*Z>/8^TQT8A<*3
M=.8D;4]8@Y9KO'N.+U5-_^L_>418<\T,K^YZU--WN=H=?Y6*S6=&TNW"6$MV
MD&9@!&6Y(#OH\(B4C-$*NH,-F8OJ`-;203KKR5?29]YZ31O%@0]8*4`8NH<$
M17LE%("B>V@G!WJ8^,*&ZF$5T&==@#(#/9P:\%QXS6G3)1>*=EVBJ?1LI11Z
MJ(<?<`Q[@*'^(^),*B<'(M7.T)#B2O(T'Q+/RX`&J*'U"B".GWU,&I?OIY/I
MY#^=FCZ2#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C<@,"!O8FH-"CP\#0HO
M0V]N=&5N=',@6R`X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=
M#0HO4&%R96YT(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&
M86)C,3$@-S@@,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-
M"B]&86)C,30@.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2
M#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E
M0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*
M."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0U
M,#(-"CX^#0IS=')E86T-"GB<O5SK<]NX$?_N&?\/^-2F'44E'GSU/B5.[B[M
M])+&SEP[<U\H$I+8HP@='U9T?WUW`1"D;$EN;2&3<6R)$+"[V,=O%PN]_=?U
MU6_75\$\2D,2X#_]5S(/A?DOWUQ?4?V$$A81&NEW&`G%/$U90I(`G@3P=B.O
MKWXFM9XK%B%.%"8)_B+-ZOIJ?7VU_#-.A?\F;P1S(3@L,!<\Y/"+IXP=/D]%
MB,]3'N/S)(GX\0D9><UB&J<DH0'AE`NN:5IJ!LW#R#WD?"3X[=WUU5^^SQ8Y
ML,?)'7Q`"T)/ZEB/!;#)X#%PG_*YB(.4W/U^??7J]LL__D3N_G-]]1ZF^>=%
M%N,!G2PFYCP!^>)BKX-YD`!?=SM8^!]O/O^;O'M_>_/YPZ>[#Q]_(A^_)Q^_
M?"9OO]Q^^.G][2UY%EDQ;O%QLB@#J@)#U:M?F`@NOD`T6>#9Y)^2:A20-(GT
MY,&<"MC0NUR+5`1I:D1ZMRY;TO:;3=;LR;I<K2OXZ>`M6<F\DP4IZZ5J-EE7
MJIID=4$*)5M2JX[DJNZR$MZL*M*MY<'`;IUU!"8N-UO5=%G=D4Z1O>KGY-^J
M)^U:]55!\JR1R[ZJ]L!45ER<>=B[%#YMF&<)CC/,AV%D]:E#YK>-:K?`:]]J
M_I"50N7]1M8@AITDZ^Q>PLI+V30@#F`">0&^+TTO!P\R$!QI6D'C&+_X,N!:
M1KE0)N)!+CS&OU$N'^I<-;!S9C/5DMS(1N_U.R>8Q9Y\1IG(.I<75UNPBL>2
M$!=?AHT:XL'V6#B1,Z<@]D'_(OP;Y0S"W68K^1+'<G+Y>+K-0<(B9_OHC'!U
M`O9Z:-X+U7=>[#!D@[XEP4B("*T=6M-3?4.699W5>9E5I.VR3FIEFY,W+>E;
ML+XU*%Q9S_1H^367VXYDK399]$;R:T<VV9XH>*/9E2V:[6]]V<B9'M+)9M->
MG+TPX8X_CV8;)NE$C`$31IU>W:C--JOWLXOKCSC&UN5M4*0/EGD=S<%RC(+Z
M$"1`-+=B&L_CA!N@\6HG+R_$./HF0DS8MQ9B2B?:R-/8!!$PY(O+,`[B;R'#
MF#[4=]\RC-G4,<("5H;@!2^^E`B^B0S%J.Z7#ZBQ./"`21A:>35>0A8/?;MT
MFKA5@)_8KO1NGQ5E?O'P$1WAR`.B<JMX`%3A1%PTB!V>YV%L<<1&9@`.<E5A
M[E+>RVH_(T:>Y`/`@Z;6.">K9O`RGVL4@=D+`-P2("U`B%9599%AVM/VB[8L
MRJPI93N_=-874GH!09U)6E,:>LU9W?S/(Q[3ZC,Y:Y(F>G;,_3ES^\QH;/.3
MCP`4W_9M6<NV]2"])$Z\2L_-[R/A3R(ZV$C$76XG&-BFEMW/DD#>33*RJM0"
M8/:B5)W,U[6JU&H/-J#A)%EDK<[]R=_Z;0F6,R/?5ZH!VYB17=FMB=I*DQVV
M.`C1]9>Z1+NY1=3>HDF]V<BFS.$#/ZIZ1?Z._Z'!>?#5B1`NO:!T3"^X370V
MD+I6N/;-&K*+&?FD]"O\N0/*?Y*8+^!;D&E8\<AZ!8F9ED`C6YDU^=I4/R1X
M%;7%M&1F\XZJ@KP)A7$O257FL@:]7*$`,)W9@C1JE(O.;W`=+P)@\2"`E(Y[
M'@I;Y-DV:@N.K,,:C]ML<&Q8R;`<:0(W6=TOL[SK00*@%S@H!Q6!CQ=]WHWU
MD>DX?*_-*JF]:%WT;==@]B;KW_<;V4[XAEDZ2-Y:G7;Z$`)\TL;2-`U=<!!I
M.!1[Y(3`&3+82$@W)0@%J=RN,TB$<]EWFNEAJ&QG\'=>]05LZU\]>)LX#;QZ
M&S>_CT`3\\@O\</\/HB/A%\_[^;W07P8QUZ)=_/["%)A--@J`R3G'%8\QBA=
M=;6^R;K/OL6P5?>;!7@3\#93K[;LP6%CS:C)T,6`7S-.2QYQ1&#X&W#+Z`7`
MMA=]IWV:JO&'[-8EN/J=].&A0L$'-\W'<B!/(V'8UCP#2W5>;C.LBR]5KLM>
M)9`_AI)VWW9RH]VH]:F#AX9X/".3M^77+42O5K_M&,N'@OT-)>_=`'*K9YT3
M?2!@7N"Z/L3`(E<X"!RZBW4"C&(PV`,+S],`^CR@R<]0`@!\0DJ03`X($IM0
MW*R;?:O:+4"??D.J/O^U5CN(\!<O>;-T*A?&$0%;8H)!/;22]Z"R2$2-A<\;
M.L-?F+RL5=M-U`"T8)7590L;^N;D,ZU7ES_(P"T.TN.`Q!JXH\!HY1J86$A9
MDY6LI0Z_H/Q9!38*&P^V;/58/SXP;K#]E43M>&`(!L@599NK>S.)T?=-F3=J
M9-\@5P_\BY0-QZ8I;JTN,&[*XN*'.71<BLU%$%"SU.O+GQJYA;#V$B0COA(6
M9=,T#?YH_&P)N4"I-W'TX&5G4@=E_6VVW0):=B=,&P4Y>U]EC06>D+E/]KD&
M5-:`?\]E5<&@5AH4B0X"J_YE-<6D"+]][&GLB@]AR">G*5:GP55W"G(>T+VW
M>P+22&;H;A<2M`UY08;W$SZMKC^`R"ZB'>9EG5*5UGQ08O@_;R3X10@*XY")
MA]>'E3C,AQ3"Q#FIR!WE0*9AC[3L<0R0^2-ZG3M'W]P'"!+<+X)S\_L`08(-
MF7H0C'"`1;$#03OP7=9;_PXFU-<%[BN(M\XV(..;3^1GU53%KBRD*6GI<)"1
M=[+*=IC&'ASC0HR76PCK")\8GQ$6!&Q./M;D8]XI_6:JWQ0S3_A'!,)E:,EX
M[!P%UH-@\:'2[EPGF1)\>S,DTK7<@?48O3=P<+=6Z&$@%$[+=6`'*)<W^6]]
MV9::\1L0`DIF*&%,I6++&<9IH9&Z01[XYXE+TQD&2,M_(@;VQ\W"0UG9`'LN
MUI^N8SK+M[;7]LU]>8]>\,$I_D2JR/!"YJA&*-T#6?K@/![P/J5BS,TC87/S
M<?OFY'L@1>V0_)'>V:`#DXTF^3JK=8T&X(\V"-B_8U(BOP1A\.7V#?RBMO*+
M[US^A#9R?/H\"$ZGXO1\;!#QP"WF%V!$7+B5L.X;IY8Q:X\^^B,>[];E3T0@
MBSXJ0%3&RP>5Y%"(NHENP"F#FUDV:C/8B0]3#[G3342,UM0U"C:]14<<V-#]
MH<T8_=A@VR=,VIJQ9N5(&/2`-/`S/I&&F]\'TN#4-0%&T=@$R(8T]T.-AU^U
M-.FACHA3W[O3J=16Z;3<A&-X7)-68=G7G`2`NSZ(P1H,DYLF6W;D4Y;_FJU@
MR.-X-:FS>TK%6#JFHI,FJ)`FMC8^$$<6]D0)Z[T`!(:BMCTAU)%U#:"J-:^R
M;AJ+L"6PPZ1$8[3OIA_2HE++99E#;F`.$<H&1*V:=AABFWCPJ*%<80C6BNU#
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M:<INHYUH[6Y,BCU5;1][RUU3PJ1V*'A@@S"Z%CS>03),ZDL`/^2_0EI:2!,G
M/<4<$3CB/,<<(29B".+)`1`;^L$?>%I]+`4IN1$`.JO_P/-N_V##+IYA"NXH
M%2XU8I=?)IX(A-/QS#ZBU`;AEI1MVP_M$WW7@L$7.N(X)):KS49Y.<1@U+65
M\/'J#$]BFTAI#24`<&U1;H#+NEN@Q780(.\1H>93EBT+>VV]G.25&II'\.UM
M4]YCF5=#+VPY\;SQV-4[,.UQX_&VW2A;'HQG71'>B[,;W\J\!V7'+A7E+3F@
MZ5"18YR-J")A`QEHAH4NM;>3/38H!S"Q:HX@CJ[)ZC8SN50)*0YXV7O()<PE
M*+W=L/E9G1O]T.K@#TW@":AETC.:H/%4G`&;G&"RY-"_(?S296S9$;`)<^!A
M0[B/74[&<EDRZ0SBPVGD@54-Z>EHV),-A>U<+LW%./6X<&YRI;JL9CK.XG0E
MC(3=14R99]NRRZKR=UW$\'(>0B._O41N?A]5"NK:(X*`N^24A3P=NS[E5W`+
MG?&MF)6UNENO4KDY%NA@D@!+14V6JPRB144^*8")DKP#7RIGY+8OX87`,XZ'
MG8V$<Q''8RVJDY7<KK$MQ+:<@"UCW3B,J"[>Q>+R5P(`@@]2\&NMJ"NNW0"L
M8FRF=D6A!":=ZP;)K"CT\;NM_>PD9'L=NC&RV^WFGH!9'#@*/0,SO.<\MEX@
MPG:.*[%QX(=&]=LY6+01B+YLAK<@'T@$=1&OQFZSQL;J@_NEHVZ98B9XOT&T
M?CIMZ-B&,4GN!K=GNAH'%/+@)JSN#"GK3/?1ZT/V'HRI&:Y\@O>K]H=U5CS@
MHV"KV&]H2!UITM?6&6ZJZ7>D)YY'*=?/Q:GG/-#/V?'G-(J2L\]!TT\^_\T.
M"4W+)!4G^HFHDS=]+._0"3RD1N+ZL-/&O[ML86J*-U:!#@1HIOG\`TZYP_W_
M&U(T#W':&'X92W`OJ^NKVX'J.(0?1OA1FL6Y.T@DCDWUAP&RM>51#@C<8MQ?
M\#CZD6HFPJQ(D^-+GM%*_&CLVN`"/E;>Z-!"8.YJZJZ.&4"K:DO^`!:U15<-
M\70#:KB4LH`75:X@09SA3=$F7QOK6BI5V-/->]ED*WG0R+O#"Z2Z":YO0(^[
M:H\7W2L`(0VF6Z#R`@1;`F(KCC:KOY#QT'G<=.R=X.'`>`$HR+0KCBW7`!E'
MX@!C3'NL7<>)KF5MX3-?2^QL!*["@.@\?V#[86<(V#?ZH?=FM>$NQ7?/8?@4
M7,#3GX'CQW@!VV\C@0H()OO_*RU-GJ.T>D7XZ-$EG]@[FHY%%P-M*6R=K4U-
MFTP;66DP,FW@&=KH`;#8WB4$:%CQ*/71"ZBJ3B3NLZ94Z'Y739GW5=<WT_9[
M1!]ROIKCN7YM3K,/!N+Q0=$_3I1>R'G@^KXB>QD'JX5#M>DQ=46#H+<H6[#@
M"K5S99IR<<"[=S]<D#HL5P_DG4E87[("I1,!L'#\MH20#;BT-5L!O@7/A`!Z
M[HPK:OM5UI`\`P2YR%:8WN!`W'CCJ&"[.K!X:]#[8?LFDMRA,],>\(0S>L&V
M1HDKJ*?C73I!AV\'R-?E5G-F&F/`;V`%0@<PS9AS*WE6FS.NA327]&U18]IP
MNL0<JBAM/P8R8SKY5%OF1*)O0S^>X?=M@#=&YS3TPQG=NC#KD2N@TG#L0TIX
M.'3R#<&AD)@VV/.XK>P:5<E^`Q&GQP2QQ<I,ZWKXMJK:HS>>]EI/KB(>.-\+
M,A0%W'%TIN_D12ND$YE-OTN"<V;5Y>WD-LTGNVT7)`'=[V,F'[5KO&0%P/TC
MDT-8>74T)#Y[#<XF:X@@-7;W"K3G&:N<#+SAN,K1P!LBRH9?]/\/O`C`GQ%X
M]8K`RM$EGS#6\>@@M3U!=![SV#K?=;\Q_J<!A(A7MUPK>(ZE8JS=M;;)3]^F
M(/IKC+IRH0H-C;`4A7%XL7]X`4R#R".7([$BJ3O-'UT">`&C<9HX3L^GNR^4
MIJN[!I'])A8^CUV"DE=E[9AW+XJF7TUO/DY[MXWKP]JV;/!K6VQU"^0Z=/'I
M3VMT>H^-.R>QZ&49#5TIDD9C1A]%PU<Z@+^ZS4M,95L'?Q^7Y/X'&DY9(0-L
M,A!QU`IC:O+,\,B\$6:3)TX``_`*9A-?B8<)>,3.I;^OTS@Z^QR;UL\.X`&E
M9P>(@*9G!X0!.S\@"L1Y)N)S23P.2&APMDKP.J4HPW-R`#;/KT$I!4TZ.X)1
M<5Y6E-.$GQ\A&']B1,@`B)\?$2=/['H41T^,B.,G9$X3K%*=UZU0G)<Z"\(G
MY,'TS8NS(QA_0F(P(@G/%:E>,\[X$Y3JZ_1G1X0\.*\?+,1J[]D14?R$O;*8
MLM.[#R[A_;^NKZZO_@L2"6-5#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"CD@
M,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q,"`P(%(@70T*+TUE9&EA0F]X(%L@
M,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@/#P-
M"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-"B]&
M86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@4@T*
M+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^
M/@T*96YD;V)J#0H-"C$P(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O
M9&4-"B],96YG=&@@-#0P,`T*/CX-"G-T<F5A;0T*>)R]7%F/XT:2?B^@_D,^
M&`O/0J7-3-Z/[>[VP@-X[.WN@?TP+RDJ)7&;(LLD5=7RKY^(O'64RNYA&@;<
MK"(KC\B(+[XXR.]^O;_[[?Z.+O,J(Q3_4U?E,DOU_^K]_1U3=QCA.6&Y^@TG
M"5]6%2])2>$.34HRR/N[7TBGQBK2#`?*RA+_(</V_FYW?[?Y;QP*_PM^09=I
MFL`$RS3)$O@GJ3@_O5^E&=ZOD@+OEV6>7!^0DP>>,[A;,DH2EJ2)6M-&;5#?
MS-S-)/$+_N[3_=W_?"]6->.$)>03_(62A!K5[CW';<*0G_:X)E;0G'RJ[^\>
M8.$<KY_O[[[](&O93>2=?))M_[B'Z_%OY-/_W]^]AQG^[X^OHT`Q7U\&+I%R
MO8QO_\53.OL$>3`!^=K1;TH1Q:6E2(O42C$I*==2_*DC/]53OY(#*-R"<'A^
M09XE`7'*0:Y)TTT]$624]6%HID:.Y/$PU#LQ2B*V@Y0H=_(OFM%I)V??0)IE
M?@=:!>`8>#+[/#D+)46KU$LJQ6N4U)OO/KPC'[T<?K9R>&/E,/OYY5>WG\X^
M3Q%LO^++E%)&/OV.LU%`@_FG*T-I\[PLK+0+=8W2?FZF'7FSDMVV%[.O`.RZ
M*BLU/TQ*4P!!LP!.87%J`=\UO>SDL#V2#__U;D%^Z.JETO/9UY)0MYB(*LZ2
MW$TS/]*PI'*C5_FRPJ&4`J'1S#X9X-BEQ&:W"E;Z@P&C2'*:>:-8S"_"RD\'
M8,W1*Q@(*O`:=1)P^+`:FW4CAB/I-\X^O*Z^[8?'?A!3TW=+\J8=>])?`_AW
M1[%NZMD-&ZA%(#$/(P_SSY2%PLJ+S/$#AM<HK._;?FC6XMR3=7TW]VJ*@O]%
M^T;@@LG,MC.<TVR;XC5N6WZIV\/8/$D8>90"?!01W9JL/4T*'+=&671LCW*8
M1-,UW9:`F-"9UWVW/M03ZIEX>:P8D)@GA=MF1$C,@6#:::IL6:8)U\<&@#^_
MSZ-7MA3!D^=^2_$=>9F$ZIARY\<S5A@__CCTVT'L4:E6\Q-$M`?@B);@^C`A
MR6R84/?[QU9.``#]$V"@0$UO^K52ZT=8W9=F+R;9'D'GP2K($=1\7)!#MX:'
MGW<-J'P<L$QA@7;M<4$CA3\+I)0FA0=+2[<L6#XW;0MD7W[&`P/Y@%R:"3C_
MT#\.C9S0[TRRWG5]VV^1!!NL"!$AQAE#Q*M7GQ3,^<6<,^,7X2SK?IR=?Z>5
MFSGN"<%?^BU23`E8-6:5\69RLY'UA+`NN]^/>TGVS9?I`+"L$'F0K4`5AW.J
MY3@BBN.O]Z([;$0-SRE<#P]NTP\@L_U>#G4C6G743:UX`SA*$H.VY25SNTP=
M!/+YI\D"8?*B<#ZR4-<HS)&L@#%-.P'BB**OG%EKPZR-!46:&7U%IUG+MCVT
M_=C4Q*Q$832<('I=/`=SF-&B:YX6;J41W2Q'[78"H31S`N%99H(M\+CQPN@D
MY5?V.;OO3=+237,1+RR_^O1>2ATEF9_NZP.Z&YFOBK*HB2\W?HR\5UFF5N&R
MI/1PFIFTUS^5?T>K@N!@/R(;P!]>S_$L]#--]R1'1-QO8(E[<)H&.`_`'1!:
M-7-H@&&+D33C>(!'^0*"\$4!2QAW`I$;)HT`/F5>V*V7N2=$26X(47_0R`\+
M'J>^_DS$1+Y)EWF)S$@OS4%.C0`%KD/_%BA`+4\"RLP&E+#+04+DJ7A6IV4)
MO@5<2D<^JEG>?P%)=EL9)V*HF-MWS(BA*MPTF#C*M69]^^;'][_.'E1"B'NY
MI=E1JTB]Y!"U"B`]#K7^,^1Z<<HL"Y0T+8P0?XD2'I09M:XX83ZKJ]SR:7@P
M[1HDNLT3,"DRBE9I^C\@:-BCJI=:TY=$(T>MPV52-T-]V(^3Z,!5*S-8R[$>
MFA4,N`)*_*R2Z7MQ)#L!W`WHL@(#(M;K!IV\:,/4ND&A&&)($J>UE#M^"13`
M\,NW(`?1'7&%"'#+"`ZE9'$K*6[\&`ZEJ'(?0`5IE]10.M!>%3L=P%G@&2KR
M)M=`M(=^?T6W0,X;"#+ULW(`G[%''4(50(!&0M2OVF:K*/EHXE%\^(0J7<:T
M$71'T69C0@7W)E0:U;D11E^SAS"T?I;7(DX4P)^).%%F'8AN(/M^B&(^1>ZR
M'-P3>I"&09%Y8K+Z``YYW_R.8-1'B<$RN&/W$C$&RU@1B(RS(`9B5F2G206(
MQ_8"8AW,;T\#R&U<DD]&VV.<9^J31IE7Z=QFK;R!U7TW27`1N"10/.!*5F>-
MU9)5/^T4J6E4`.<RI:"56\S*GT77-KMZ$?Z132/;-:#"`/>5<J`=R"^3[$[3
MN3'DP4L7L/I2>VH8XT7^&'YNQ;"5LZ\DR]U2(B?2$=+]IE%A74[,IES&&H'Z
ME1R*CM?QEI((>>K;PUZ[<D`[E98R9PUA!"#BEV,K.KQ44NSQJ,E.[AO_3)3S
M92[^+GQ$P%)_ODJ!+S5X?)1ULP$E#518;QR56-2[!O3"@C#^:MN+]C2<0A/^
MV6>!C2+!]HD$XP*\`S$#Z#\U8M7*,"<500YYE;HC+Y+@R+G+5JN4B]U@D(W!
M`ST_89>46_C#/G<%P5`WT.Y$UHVJ6,%8(*X80B@*!W[45QESB\R*_Y$?.@M?
MBL)B_`='V*%'\R6F_AF>&'?-HTJG`RCBTML6A'*``\0M`T\^XM_;8T?.W'>=
MU$)5]2?E[D,*Y'B/X0HQ9)!3EQ\H?5A`2V,2%TPK!B'.4QJ5$+OQ8Q#BG"?7
M*%&953<S+"="79!F@\HQ'FHTN\T!@<!J2DCI_@2_BJ$LOH<*<XENJZE!C1,7
M@6=YX244$.+J\`*?D%\0Y+0;(/VC809X!U`6'+X*/J,4J].R<!N*7'>J6"BZ
MM/(^-J$7U>J5&!M$1/`[H?@6CF^M5%-:,[6:'D<XY\QW%*2T#&(\O=9!UA)7
M:D]H(W%Y;K$0IP`^CAO0>KRC=;0_BE:']IWC>8%361V-:FPV3=N@(UC8R,AL
M&2;MMYV*"2"8`K_<R?7\R>0B3=WNHR23L[R*"G5N_!A0EV4N^J-5%41_1C&^
MUY1]$43I?R21#(JMDD*J'4/IM$T>A$EEFRBX\)(;EX2*80J)KQ>707--8B!O
MT\.:A,E@H::?\$/'()ON=K"#?PD;!.8#%UT_D1;9%SZ",EAZ*<2J@>7`@>U>
M8R:..0U$"B%G0#FL%J%G_(B"0$_VD^-`LV=?<WIEQ_/GE?/<31._$Z4`,N_E
M"]LQ.665'HMA'LPU)*C8P30D9#SS]+$&BQUEM)PNS=PJ8K:-,A9LEN'9N0X;
MO#Y17/*C%"/P,Q4/_JQ2DK,7D\ORRK9GUUX.<:*=9GZ7PH$)V='/;6/VTEA"
MPQ.DJO!B3[#(O;J:%+**OSN5T+C2.:H`VT!4D.@%CMM"`(R__3A)G;R*8774
M9S&"5J^$^1K&OIE@`;JSZPE<D[&^I@,W##]^G(!CV73%+_WP6??!B!;V)`:U
M&=QGH5M\USKGXU+5&`.#M[*)/^?EK',2>_"*$QE[B)#1'C#G?8PAB-15MUD1
MI#'4-0I"=ZP!?<3E#Q(HZ:`)AACC@%%1N37%!"-@(G[KM`CJ>=SFLMYH'H*I
M)(=+LYL4_-GE=N=O*`%>:Z>9L:'DQ>EX'DJW*KV%I:4!BA]4N+X:I*AWKDYU
MA;0LD/G9&B<JGJ6J.B`ZSN[_`Z.(&]06+)022[P_+(T[W``L+J*TF>?)7[1)
ME&;81>+3.TE>G@?N.AQ62--L=]-H\;(_M%CS<UE#4])RV423YI/K!7:@Q*AV
MI>#?[#XB5KO2D@;B8FGE$9D7S%:[9*MSG@L4A&Q4XA\=QQ=%B"^[`ER+$)I9
MC`-VC1'@3'W#*:]\8X1O$>KU6H^F/@!>UAXG$>`^QQT9#WME]&9G3:=[(C#"
M59DYL@:*`-X5G#)L5/Z&^6%3"C-N$UREUIS3R`\43=715=%7CQ%#&HG/9GJ/
MZK.9>MFVK''%QRP4-6HV]N!0PR&<A]_#7QS5CVJ,-2J[*I0`B$X@*1C3J\%Y
M']:)W$\:LB"BQG]-2U:TOI&4N=?T*/=M#P4UA5*KIJ;EZ\?WO]KK5F`!8Q#*
M,ZS%T>8";D4+\R>V8`N)Z=R(E7IRX\=(/26^]X(&=6H;>J$_!H,#T>+;:B#E
MD(J?]RY==/6ML1O%Z([*78I:YV^"HK>BL#<S6A&T+O'M%HKSV^P3/Z_."]-!
M<U)5T.3=9M=\@Y>P%39T1L='O76_;>SI[-LG'=K8#C`-OR=8B%)4S?/=$Y":
M!E$@A@A\AT+IWT9V+R.'36,*<%7.[%D,Z&Q'Q`U=5!@5<@#D"`,5H!OVZ3.P
ML9VMXTF:76<H+_R2:6G5"+['D$?U1N"[(C&$X2OU-$B=N8JE[L95&@'+-P`[
MBKUI65V2/V<G5G4P(?FUZA-#"JZ(SUA`R7)+R5[4V*F?A/(6`A.LB,O?\).N
MY>W0CZ-K65,NJ[NJ#;8$HF+_V;N&@'K8/49^?92&TN1E[C`F4]<H394+<`:%
M8;\%O,-CI/H3=]T)E*8N3</SU#A;H).+!,SYE!N>]W)C8X6I+GIZ\$VVA.#9
MV?K76D1H#3$$X#L35%+'->O:]W;FP.\S[`Z05"'[)9IJ\O6:#<40AVM28'D:
M-"A9?3@U6UR$(M`7P3>*``';U8T"<2A'J:,/N]_7[5_-T#;RX-A###PH\LR)
M(')0GU>AL#/;UZ\P(,;!ND_;<);ZZEJ1&^_N3\(!D(FC="\%TAY\/;O1=*U9
MXQG5/J*Z^I0Y*C>B<>%PDJKH'MA68%,X!J9(8PB!N^^M%$%;,2\,R]/!H-)"
MG4NPS@<4G@QB$G8KL$FP9K&5,7IT.(T;/;CQHWS])_B>A/_(2E)9(HT=MA>$
M3DG\RJL/`!2#YD2#W#:C_JB"KW@'H<$;_=4`5B6):@$'(J:2X=&*N%7AMAHQ
M_5S0))1HYK,F`$VF!'$JA?G+G.65C<Y?NRU3-\U?4+NM6"!66F:9J=U&01WF
MOU>0)\%7Q3+[,D-W!,>H7M/P1]F*YW&)$2_ZT,FB[!_L\?#M'9L&^(8PYJ,_
MTJ+G\M_B.+.D2`UMS'P-0+W#YCM:@`D:\NM>UE,EM7&T+1CS?S>H=(N)63B"
ML)GY;RUP?.E-*?3']V_G[RS/KVQI_J\3%3S<4F0;Q0(?\Y^0R*C/2."'I4S"
M^$E7?E&'P:48_CU=^)@KOD6YB6?9MLI=G&<;5)LH&.9"LUAD[6(SQ>GL8/X[
M#%7E4PV9K8!=OA#XRX6):P%<-7(0B.8UYHVP'FG7=!A5WH(\BB'$@?=O,?GV
M#FB/FI$G01&^%M@LUL3J$6?^A?V<^I8WS@US6$D((J1O@#]=M8DL.7LULM3B
M&U!>OQT:4Z7^+.7C'Q=BC-U35^`K?8=\JC*]YC6!RW/SLC@`&V_5!B!^@#!I
ML':@$ZZ=6[VS#!5<KR1$76,/3%?U)'18/%,_/AY6;5.W1\.V/AQ`QP#2$)`_
M*W./^-ZH"\@Y<VJ0J^M+NG.6OE=]4@`:106SJYG]%.ICHIPD!2O5??;2?5`^
MO)^^<#]/<W6?7[_/<Z`RM^[3ZN9]AI\#?.G^;^:13"^!I5>D"[+%/),1+[M4
MM,SS2::#(%5[-RF]3PKLX'C?8D;^_`NG>I@/_XM#/N-Q_QU7M,2/1F8%_*-=
M@_NQO;_[:%>=:K&R[,J:<US92Q\M2HEIAOTV.S_LE-X2Y4-5\IOW655E-Q](
M\&V56P^DE-U^(*/\IKH\Y#2_O<B"WE:HAY*6+VN,$@,6<F[*@3*C]"\^P1B_
M+2JPUKRX_43"V2M/I``>KSQ1%+?/G&5%]LH3>?&*R%E1W#;2!U9F_+;0696]
M(@].L^25)UCRBL3@B;RZ!7</X#_9[97RA-^&M`>>\O*V?O`4NV]O/I$5^>US
M@;-G+Y\^&/S[7^_O[N_^#0P27Y8-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*
M,3$@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q,B`P(%(@70T*+TUE9&EA0F]X
M(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@
M/#P-"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-
M"B]&86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@
M4@T*+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-
M"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E
M#0H^/@T*96YD;V)J#0H-"C$R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$
M96-O9&4-"B],96YG=&@@,S,S,PT*/CX-"G-T<F5A;0T*>)R]6UMSVS86?O>,
M_P,>,CN[.[(6`$&"?&S3=F_=;3?U3OJ0%YB")#84J?!B1?OK]QR0`"C;HI)4
MR'C&L@@0P/EP[N?XVU]O;S[<WM!EDL6$XH_Y*UW&8OB5[VYOF!EAA">$)>8)
M)R)=9AE/24IAA').&GU[\Y949BTI8EPH3E/\(,WF]F9[>[/^,RZ%/Y,'="E$
M!!LL111'\!%EN-9T/!,QCF>1Q/$T3:*7%^3DCL>,P^$9)1&+1&3.M#8$#H/,
M#4:1/_"W][<W?_E!/>02R;N'%PP09E%+>H)4"DKN@?@_ON."_HG<_W9[\SV\
M^I_/VB`ZLP'C"&-D-J!++@",^_SVY@Z`R?#O`^S[5I.=.I*V;_>Z6I%NJTG?
M:E*OS9^-WA1MUZBNJ"O2=JK3.UUU.'K8%OD6YA0MV3<UO)QW?4O@FR)[U71D
M73?P)[\Z33&?$)7QI:"4D?O_`25WU]\JF>+')/"4Q4^D;,!O!>`!0*NBVI"]
M;HIZ-9#>`JS5$3^[0TVZ8J<!G8K@LR#73!.+2$2E'!!A_-I;<7&R54#P00VX
MG8!W&?6\*YD<L-_55;<=45^2OU<DUTVG`&7]"%S:+@#PO.S-U<!#Y&<S\#LY
M>U7#559U1QYT7N]@S?4:IA2/.L3%9FEFV2_+/`1Q-HHO,E9Y),!QN58M'*RK
MX5R3,ZWZ!NE_1O+(JZM>XRM/@3MHLE7PMMHT6J]PQA[YO";??/OF.Y*K=KM`
MUBZ+#WVQ`NQ@(;53&PVOPMHA<)#<L@)-$X=#(N,!A[:'.QMN5X$:@T-H!4\,
MAP`^JJH`C*95S1&OV,\&,D`H=W4/+^H/O2J12/:.@K&!>>]H3#_"+V;PJ_K=
M@V[,^UO5`-9;7:[(PW$`175&RD^7#P)%'#N6$)XCQ"@3?=D5^[+0YF1(P-$1
ML.^;?`M<`GQ=Y/!;%?[XJ+3,N4?:8'YE"%R@%#P6*V2#K1J$IZL[0&J$#0A6
M93E:#%Q<'5&4C,B@F(2`($HM!"`6%@,P\\D``C#WKNBZ@7/UQQQYF%%[JTB!
MV@!G;X!SYT!9?O'9SYE\/#M+?[_%/[M^XM>_.O#@KV2H[PWPU`EAQ/DHA/^M
M5B`?"*]AJ5]T#LJG*X";?K8@?X,*96<$S\R!AU;)#![#J)?@FNI*DZ-6#0R4
M97U`+?;O^E$;&4P7X%K`$>!Z=Z"WC.X*P&=I*BR?Q4CD*&O,$@RL5?8MJMD'
M7>EUD1<@%O6A`DVS+?9`A-&2!PWB@716Q+\`9J6O"M1'<'P-$M?!'XN))%E!
M-.H,OH-X.CS!LJW1E8#/MNW50VF4>-$A,\-W-'%U$#P2::\_D@X/GF6C\OFT
MJU^2'_H&*=K5C;[,!^@_(1^T%QBAT>L&^6#=U+L@Q,?4*QUGBJ/$FN)5T8#-
M'8QQ4;EOX(,T8)J-$P)*\25&6>`KSQEB8=@;,$+%6Q$66P56]\W('<L`"BJ-
MKA"2S"@HMWX(!94RYZY'DGG+D(V6X1XX%!A,;VJ\D)5N\Z;8&X=HE+K+[&LD
M$J>^^<-WDZ=@[=!_*-9H>H$-\;+A.;!!=T2#`NP)MUKE.I!LRBQQLIDYRGF:
MC8$*,LWKOFGPK&_TO@9/%JC^H6YV)+WZ<9+4G2=LF,"DIQS(I7&66M)91OE`
M^C_)X*/^E'<U*@V>#%K#:.=U4<+0H>BVYE)_^?XUXN(4#!NF7EW0XDBZ@W^Y
M),R(L91)4#%VZX<08QG;L(>F$P<OL0[>3],;DO8V(6K11G>B`(*4J8G)]'Z>
M<B*+WC'>^;4)@+#$43"X27`)/+KZ-C*:`,5$ECS7=[.:[.H7%V4OT"VNO@U8
M0;O-B78Q@<[5=XOY!&5.O1\81_@843;:P\;01?4(QKMNVE"*7MA0F%'OA$6)
M'!6]8W1,-V%4\VC"G%+E`]?SA4SE@E)J/<S1H\CKW<[D0NK\/4:S:HR(8/B5
M6()&W^O1[3`6\*":1F&8A\D!NV6_QZ]Q+!?B9/T0,'`;!M-8>G>,I=S;NV<D
MH0>NF[QPX1X2ERQA>T\<^I^;IFY-^@=#1T/!*Q8MJ(@6+*%+\E;CTOM2FQ!S
MR!0]A1GV_4[GSHB$0("Z*)A39_:BE(T(&+M%7M<'79D;>PU'-D'#CS^^)BK'
MLZMV2(OYL,2=7VWP-X)A4@?/Z,.1(54&:A?#D"':AB#D'&<$@"#)F//)F7?W
M)!TSA'""-%HD[!*OOXJ77'PZ@[-D(3F_M.8I7UT_F2"3Q`$0Q(4P*B6@"^'6
M#^%")+&+W:-8>,N83B(!=\6>?Y'9O0:W*=Y!:9A`&Z[X7^H(AS)>!_@>^N.^
M,#$:6-4Q4,7@5JLUN"(+8(LA/3'H&[7ZK6\[%T:$$(G(Q>@RDSY)DXTB`115
M]:[(8?^NN/;^`*[=/ZS?G]$)H8P+;P"D</%XV9O(;JU5US>8-3E)QER?>A[+
MKT0^3]B4_LA7!B#X>T(^6+$.BP'UF!H9%%2[+S%"129LBUU1JL8E_RW'EO`<
MC02F^TL-]G!B.\$PKA#3(!S,;:*%,Y;ZLD\TVC4\,RKI7)6E$4F(KON6]";[
M:+VPO&CR?M=V"B+N=DEFI/VIR<.EV_X!7^T*V.)(BA4&\OE0'.A>7BD$#C3R
M09"7Y,A*\HFJ6I@\][X;DO08V10N[S\>UYCL4W.XM6G)9T[1$X/8*)."-(FH
MIPX3WH?9T.UX'*M'$%P_ZFLC(S/AH`F<7.`D3A,G9#X.34<9,^EIT/*[$WS4
M8`NNGU1A[CB!Z4[B*>%3QTK*IY3[VY]<_U@R,AS75SXO-JM*IAB>USTA+CEQ
MX9W`.B,&KOY<0:I`L<B"NE9N_1"N51SY")1YURJQI@?"HT,!9A8;28;"<XM5
MR6I#*MV=1%5J#]\^%CL(+4#/OF)\$5%J8E,L2H,=*JI>DQ58IK+>VP*]R60R
M\K>Z[<B]SK=57=:;XU`WV(-9RTV%V[1;A&`6YLNOV:02S6*OE7>J>:\Q<E#-
MQL2(8*'PU`\09%7`S>B+N(SCIE:FYM-VC:XV6'=%I'`Z8+/J<T"LV.L27C2R
MIO)<EQJK^&-9'^,.E`U8I51]!0$9+%;I@WT]B(T6F8\]A6>!5([>-3J\?;DW
M)]ZK/3K"JH)[+L$;P[C3%;44%D<6Y@$XTO"!9&%FO:C6C0),@((>C8QWW5I5
MCG6Q`6=\0Z_A^KL`LIJ`2K/$!@FRA`Q;#W;KA]`$P/96<T9\TEUF735TNR8Y
MV&FU\C30&AL+\K(VE;*Q&/,\ZW"`P&ILOAG[64RZMW>5YTG"\QL0'=0)U7%H
M\`DB!\)7B"?M84S8OA1_G%(=@#]_GE1HGYSWI2+Y\T8<K%>`BW&F?^FDCI'7
MCWK2_8-R$R@9)[B-17CJRVZQD!.E.+J<YT)MX`![^[;`YO,K)[D5<]GET1)V
M,8CW*YO,W0AE"!08]9E9;Q:3Q"6CS.7]OO:SDQO&+Z!J@=M6ZC@MD$]3CZ9`
MCICF"BURT0U-8B:S$0"%*/-ABV_5BH0M1/K>M)=(8=%%6H9;Q*!$?^B+9KCR
M]UKOOQS9$#!(YT`+'[T)FHX>M+E,CT4/ODXY)&-54Q9#GQE^Q=(E)IWLZ;6/
MW4S?B08JZW)E6@#!<0:]:+[N^P?PA,"I&E3CFQX8CPF!GOI[XZ>/RY_J2P,M
M]@.'`,07480O4(O,\L7GM2"'ZB_F6>Q.&CB'DV433)B8A%D9^_+NXNLW_<8I
M_TJ08-`Y@22)O=Q(6]>YV/0;@G6%[S[UJ4:1"&F]W:_:9_RI3;\AD'!5-QY+
MEYN+7=7M*GW&IG77VN^+W<876G]#@.`+;ZD'05AN"-ML;)9SX+S<=3S7!!P`
M#Y[Y*(!QK]EM(?),B^TI)>$:D%_J!@Z!@G2A0)IDSY7$9S8@(TG.APV2@^)C
MA2Q4Y.G6#Q%Y<E?]X#3QWH3$@L$G-?I]6H_?\PC4C@SI"U!S5:OR(>&$"2N]
M@ZE=(`[CO@/5RUF4,*]\&PVL\UFMB%^S+U#PS!$1UI,0\(+="?L"1>KT-.=/
MV@)?Z"2[W!?(P_1T<%_8\/_'%:0!$?]K+(V"*@"W?@CMQ9+`AT]"'EX$/KP(
M>7@>^/#\Q<-C110;[V4&"YM%_=OFOW8QEQHG9IR=&Q?2C(LSXTDJS#A_>3S"
MKI^Y<1;-CG/&DKEQ1F5Z=OS#.,62*%X`%E0+AHXCLNSYOXGZX"H>+0@HQRRU
M1G/H<%F3UVC)P(4ZN8!AF3=_Q24/>-/_P!,M8UQ6PL>@MMS7\O;F%WOJ)![.
M'+]P9KSP<UJ<"I*,Z>OD*3/$LU#>9;&<'6?9>*AS$W@FYR=$B-O<A)CR67:Z
M2ZB8)T*"ZSX[(:7)_!89E6P>!XHIJ=D9X&QD\S,XDQ=F1)Q'%V;(>>&Y8^#=
M79@1RPN(LT1>X!LF13:/.4OC2WAD(IN?P2F_@!AX`A&;4W9WV!TS?U)P=>@\
MBW((Z.?Y`QQM?F$-<4$M@D6@\OSM@SA__^OMS>W-_P'G*Q[4#0IE;F1S=')E
M86T-"@T*96YD;V)J#0H-"C$S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,30@
M,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-C@@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,2`W."`P(%(-
M"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P(#`@4@T*+T9A8F,Q-"`X,2`P
M(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W-"`P(%(-"CX^#0HO4')O8U-E
M="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-
M"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HQ-"`P(&]B:@T*/#P-
M"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,S-S0-"CX^#0IS=')E
M86T-"GB<M5M+<^.X$;Z[RO\!AU1JDY(5``1?V=/.9C;9Y+#)V%6SA[U0)&1A
MEB(U?%CK^?7IQHN4QZ(3K3!3-98)".C^NM']=8/S[N?;F\^W-W2=Y#&A^%=_
MRM:Q,/^4^]L;ID<8X0EAB7["29RN\YQG)*,P0EE$.GE[\Y$T>JU4Q+A0G&7X
M@W2/MS>[VYOMGW$I_#M[0-="1+#!6D1Q!#^BG//3\5S$.)Y'*8YG61*]OB`G
M=UPP&I&,41*Q2!B9MEI!/4AS/QC-!'[W<'OSEQ^*39FB>@_P!0V$7M2ISCAH
M*2AY`.6_^066^A-Y^'1[\QZ^^I_K;)#,-B`7K0XK1&=6CQ*T$A5Z^5RLHTPP
M\O`%MOKPX_V_KKY;/M\M6<=YDNC=[NB:13D\/Z*2/WSW_<-/'^ZOCB0G>2:"
M6LJO?YFA`+BSV(&A\B35J\-AH.#Z#Z4&+DYR@]N/#2FJ2@VJ;<C0DF$G20O_
M=$0UV[;;%WJ@;)NA4(VL2-%4,%*VW:'MB@$>;)Y!I*WL9%-*&($%5$\.7=L?
M9#F,_8H\MR/I=^U85Z0L8.I8U\^X8*\JV`7WN[K6:+.86JTYA`*GM<CQ,ZJ]
M;>NZ/:KFD6R+<FB[GFPDZ"O)8>S*7='C2-$\DW:K12S;_1YPZ(>V_!6>H;X5
M&1NCP8G"ZQ`.&(4-%7[],*;`06T*EN>Y-X7(K0=^4/VO/?F[O/K><3[;F],L
M\7O'^!GW;F17U.CW/XT=>3>"V67?RSZ`#;,\"FI#O_[5HST*GR8N^B8)1BL;
M?05+#8X?I3OC&TF>E#QBJ.CA!!%9=/7SU47*XDDFOA:4VOQS=_V=\KGV4<9G
MN8?;W-,/Q:..$0<(&5</`#QE7H0+K?N&:\9)6->,?Z_P"^DMBW(77=B4WJ($
M/Z-M'DSTWJC&I#((Z"V<]??-E^>]]$?^VH+QC'G)A!8*P.7\^MO$<P`BD7H`
M,F&/9@]+UJK`]#P>,,D#(/(W\-3>PJ'S6W$H-JH&&B![!]'WC+S_[=`!.CCQ
M_KD?Y%[G?[W"Q<=Z09T4J(I3YPK'>F$G]'JH#"QN<>H=1]"4S0[UBE3R2=;M
M82^!`=4$G&@$DF`1>J?:^U(A\^F])VF$[""P'7C6(:;_[MIJ+`<TQN=1P1+#
MKAC(46*\!+[1`0F!B5^N$#:7\(41IW98?%-(#!/`/,XS!W"J/W\=-:\>&]#$
M-'8F%M&4_6EB)<"D#TP4#>,.PJ))D07*KE1%K;[X:#+9^7FR,A!=TH^;3T`)
M':ON-,TI1^"0^Z)30(*+89!-A4SS8A:\K'\*%;.U`.,^-(B$V]#0'H#^H![Z
MS"/=#>)V#$BW$R7PL8;@,5,Z$K[<H31YQ>M66,O4H[?![+`C(HT\DD&6NZ:M
MVT<\Q>@(!VOCE?Y&`71QOT%CPM"+K]N9Z"<AC(N!RCAW.A4X46H+')3GPQ__
M=A+95[:6:?JALX*!F!!^FD;6V@<J!4-J,^HQ%^OW10.8.:T>N_8X[%88IV`V
M^',O*U/X23)55>CMKK2Z_&R?(Q4I)'ZG?Q!*E,8L*"7RZX=@ZVGD>R7``F9L
MW?D&L/5=\03.2Z!V!0L]&V<?2-UB];/2EM\7SZ1I!U*4.P5^3=H.'BG=!T#/
MWJK!^-7U"2^JP,*V7/SZ(2AIDKN."Z73T>0I35_`#T>L+,?]6.M.2@59I%3Z
MC!4'0/@WM8?G$%K^(-@Z)7M5U_I4#N1>'H"+;61'(KHB'&+;FKR393'V$BD%
M+"IK:=HSF+8P#,!)5$^&WJ%Q`\2C)*-3J3WQ*:NS9IP5]HO:8:>EZHO:"@/I
M\%<YF(Y+90*N*H%L]>/AT'8#@9"]W8)7'BUNL!:2*LC1NA?5R0)#4(W!MS_U
M9+U@(Q\AR3TAR>UW9`L!*@C92!+?YN!Y//'PS!:)'W=2]]6T@<R1.CE&*Q]O
M>^"!CF+.=#ETP#0,FP`?&-0>V.D1G`(<YP`\`G,9J8L.LMNAZ(85L5P?_6`>
MMY7.]"NW00@D1.)+LEE%DJ:VX?.B]@(M+#1G.;4"2VYJB<H_RD:[MNY)(FVV
MC@30F+ZE_G5:\XAV;TZHFSSA;"$`X+XD2Z-LRLVN^3C11"26QDS:?9U1T,,;
ML/F:/+2D`FTGYZ_`]9^P3*CW;3]@8_P7*F+W18/%MFOWII-[0O!>J7O7!()1
MU08!@?GZBJ?)[#Q8$'1N:08(>0<T)\:Z3N&I/Z/"(D/OV[;1O5@P-<3#%-T!
MHVJWUIV]%UK[W`;%E_.K``C$N2\_.)TB0DHM`F!C.6A?1J)IHJ!V9-E\:I^U
MLFH/,0+-;4(%3GI48$T,(AX[='95[L#'L0'G@$1.6CW)KL<4`NO@4=&18Q.H
MYY'DPJL<L.>10/TX(<NAMG3()I3FKN=AHATYM%!B#>A6(>R;9KZ\%+,&`I\8
M^"E1(O>3;Y_O'T#I.,*C3C.MC4WK.-TN@][:RQ+[$-M1MR-*H-W%IK7GI'CL
MI&;K_3P]F.9/"!02YHM,3($N[V<6!ETE6<F7CC!H!4=]BQ6S[3[]`P/<@ZN_
MM-Y%575Z\@X/C:QZM^1A5W3[HI10N2!U0.PWJD4N`6FQ&K&JD;^C$%G27PC'
M]K*ICQ0)ZXKW"H@;5M6KES8\GY)\?H"\YUU!AVI,#*:ET&NC]NJQ44`;(1B0
M8M^.:'08W(ZV^D,<9+/3W3_3P>B"=!IBGOIF6L2]$S!AFVGS*GI-O@,OARWZ
ML1YT8G-:871"*6W,!T+H$J'Q9$?VYFIC<&NL/Q20`62GFY0K7>;*SZ/$*2O?
M;M/KH.>$BOF,^FXL]T$ARD5D@/#TY<1R]@+69S_T]-<XXIJ\?Y(-4KBC3MMG
MB.11OI;A>C@%&%+:;@(R``(B]SPXRF?]Z-Q6`B>R(OLIR.<1"*N$,X*R%4TS
M`A";HE=!+E-%&O8BSJ\?HK07]BHE3]<TQLQG2_O8^==':6G`ME#Z8M,T;_2Q
M<A6`80M'/0V)@3+,V_&"(*!'8:^8_/HAZGG!\BFX31?8V&ST;60''CG4A7E?
M0NX/R$#[T]"#-L`2'N)?<5"5KLY6IBC&,`;12Z>TJ3B&4-BWV)];DQ\'3`B5
MVD+8@-`YLZ[OR84I[07E4Q\]FX):9/OHZ#V6BO1C62(,AG3T>+Y?I#V)XBL=
MEDUZVF+.AYK&T-1:4Y>_!O#!*.-!?="O'Z(A&8DXK/!N_2#"TRRL\&[]$,+S
M-&PKF(?L8_,H;!_5KQ\B[G(VD<IL:J-P%DUQ=Q98]&M9_GI&QY9>=D\*JPP;
MELS+9[K/UD[!YB3[F0"N&A>A8;Y\:NLG9*./=;L!:F(J=7>3VX>(N)Q.-#*:
MBHH\MK=8/FAJ<1L0;@5[8+?4M5%GES8`2:E?:SHI(5XCQ)BW5#-*"P^V'C0X
M4)=`":%L8666ULT:W81KZWX5`@26^9>W&)NN+U-A*\M)X5Z_G.#OYTI9C9W-
MGYAQ=._9_-9I!@PJ'=ONUVW;05T$G^KJJ"JIX2GJOGT5#]!ZQ`LM??\_SAPM
MA.:)[Z`F\=1:X.[B^F4.M:*")32#KCX!U7<O>ICZJ9/FD@%F0EVXFGKNJQG7
M,,6),7)1[56#MX&F=SZ[/P```=P#EE=Z8Z@N'\WC$$@(S[WR>"HLW3G0L@,S
MT@41=DZPYID..PHUQVJR(7K-B17U]1;XM7:G$?BQ@TY?FG:.5F_,M8UIK+FV
MFB4YIJ(-XQ`1GV"80J&('0/;SGJ]JQ=G%E]Q4"<WNLZO*_*D9KV9T%4`8V$9
MF%__U`1XG\A93-(<%M:+3M_6+_UC*R_-]#@[-Y[D>ER<&Z>)'N>OCT/0$HOC
M4,$MC0,>V=(X9Y`P%L893<]__[.=$AL5F#CSGBWSR+.O_S=#/-5(S)Q3NJ9Y
M9OWS03<AP,6^Q\JH&4Z;SV:9#W_')8_H"?]$B=8Q+IO"#_/>B/^UOKVY=U)'
M"0/C$D@/K\@L%EY0PJ\:[L+7D7LU.%HGS%[7_<*3E'QUE#-A=F39ZULNG&+]
MU:EMG<^N2'/F$EHOBPYBS^P]DY.72N#98U=`HC,E/*3GKFSW4'7I`(?M)`S'
M=2UU1)Z]DJ)O&$ZHD2<%WUZ@X]GW,F+NE?R:$J*YN+C87+;%^/^:"W>\T%S<
M]_>3B81!W<]FR><DE<[NK@WSU%";=[[P:M)>:#LSO@K]&_*>@UX(Y@5^%7J>
MI9="SW-Z"?1ZQ\N@U\?#YCLV^S\#+'_QYIIE*R?)3O,@2PF_Q>$+9#L'<Q11
M+]SK,,?T8ICCZ"*8<<<+88[]W44^W=U$(HE<0"J[44VO9B![QE^<`W]%$OX'
M<<Z^Y@Y<QLGS*K*IR9"0R%_MFO)S!X/"]TSH^"9]R0N2>"EKWF';?FD<R-CR
M!([_5VUI@J"4+TZ(*5]D!G<)Y8O4X"ZE8GF+C(I\&0;Z!DZ,`L%8GL%8_,8,
MSBE[8T;*%EG.'8N2_(T9(GT#<)`S6D:<)2)9AIRE\5MX9")]8T;.WT(LCVB^
MQ&KO`-%X65*HK+-E#^7P9]D].'^#_=[Q*%WFITC]X_/6A\/Z_N?;F]N;_P+;
M07):#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C$U(#`@;V)J#0H\/`T*+T-O
M;G1E;G1S(%L@,38@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-
M"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A
M8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P(#`@4@T*
M+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W-"`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HQ
M-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,T
M,34-"CX^#0IS=')E86T-"GB<M5M)<]LX%KZ[RO\!AZFIS)2M)L!]YM3K+)>9
MZ;BJ^]`7B(0L=+@H(&G'^?7S'C92LD1WJX-**E8$$,3;O_<!_N;GVYN/MS?1
M)BM3$N$?_:G8I(GYIVIO;Z@>H81EA&;Z&T8RMBE+5I`B@I$H*H@2MS<_D4ZO
ME2<I+I06!?X@ZO'V9G][L_LK+H5_%E]$FR2)X06;)$YC^!&7C!V/ETF*XV6<
MXWA19/'Y!1FY9W%41J2@$8EIG,1Z3SLMH!DL_&`<SQO^YN'VYJL?^+:B,8&_
M#_"$UH1>U<E.&8@)2SZTN"<610EYJ&YO[F'C*7Y^OKUY]Z,</@SD_4%4<B<K
M,O;D/Y,BWW>?7UI!OID&V8EA^`MY^/7VYGMXY_]^^\YR5/S*QIC9V+M?6!)]
M\1=DBQ>0JU;/WM!KE.G5RPQ\"KSOX;-6+$U9:A2+:FRY^B!&,NRY$N11]<_C
MGM3B(+IZ('U'JGX8FQ?2B6=R4'T]52.1W6@^R;X;".]JMP:O*G$8>5>)30!K
ME$46U!A^_>MLD5^V11:1,BNMB],B*[R+)V5L+/&P%V0WC1/88)A`C0,H?T?Z
MUVY.GF736`.!N01'ZX"=<"K?RD:.+Q@@5=^-LIOZ:8!A--$H6P$?:_$DFOZ@
MOW)V%-JZ7UIHM%C*G-`YRF^%CB%]::&M0PUDW'/PGKI6**!XZILGV3TZKU+B
MXR25:$4W&F]#1^7CJ#AXX)/0TD[#V+="#1ORD]#C"H3%-:QFOJ7D^T\'7!Y\
MEKQ_&4;1ZK5PL!_W0@61/TZ]_`F;Y4\S+_]!23%R!383U;[KF_Y1B@%%$I\.
M;G^G'N#BL('_&D.V\!5H`B=#!,,44-VC['0`C_M^$.X94-"_=N09?(W+!E\3
MW@=HX710TMD'4F9]P#ABUS]Q;4RWSSO<9-5/3>VWVF]'+CL0&#P%7(*/:&6(
MF,X9^<<_?P=+/8EAG'W%+-&@"HX2':X'CU1]>Q"C''N%;]S+:A]$!Q'U?D`7
M?A#G1@>M?-R/9"M(+7=0X*9F)+U"JX(IY;;1NU7B$:3?D*^[%Q#21OH=V<'$
MV74JWN"3QJ$A-PR0H._P:1?V-K?LIL:FA6/[^X`,H(2B2%R1I\F<`;/$.H*Q
ME!)Z,]:3L18I-+03ZEF"(6O>\D<S9VMC(D2]*;(D:+WQZX>H-T62.Y?#)&24
M'9>9150_3`K5>0?VAP0!8<>'$2-NSR$&(?4(2$M0QNL[[23/)J<V\@.6$/N(
MK58F5=GY=^!H#7\9W!SK=AB.1]Z&R`'K6P@WBR,?:]'L9C'+CVO.AOP`3B4^
M\?;0P+[1F<0.HFD<3/G$K\'Q3J6`37.RAWB%$=5/C_O#!"G%U!/TQ4=7;GKU
MR#LYM$:E(_\@$$MU@ZR%XEM08]-WCVB!$#J@L0<;9;K`T[$+-;!VVRM3/?0&
M=0'I4'1(0^T$>5"/SPD)2G1G/`0*,&"+2AX@,&N=@2J4>]**P^QZ`.D&2$6"
M;'GUP>99#4=$?:1,I_``*LC+S*L@G5N*)(GGLC,(\0&LB8FOZIN&;WMEBQ!7
M8R>4!A,M!_#;Z^S,;2K^(,0!YD":>I;C7KN(X@=9VU2U(Q7H"A*4-&7)U)T!
M<]@B$Q^EVSX(_,ASCSD9]:$0%_$<"E@,A,5?&EBV0HQ&HB7J`IGP.R/)H4'1
M8<N\VDN0Y@SZ)^\!C;FG=H#3H+X2OML)B/P9V,T/.*P;0@D9\[UEL<`?^/D(
M@\JN:J9:_"U`)='@+V`E\>M?K<"US4=IV,V[]4-L/LN*H)OWZP?9?$S#;MZM
M'V+S:1D6/?GU@VP^S<-NWJT?(N.EB4-`C+',9[PB+6:J`2%;AYD?TC@T1_B)
M#T-?2:SIIJQ-W=PL^);S"-!A^RU':5?1I7YW.;<?%3P#]D,(SSST*9%;.>59
M!D"JAA0!H-(>]1``9:"QZD`'#>*56FJ4BD!!B0$@D&%D`.IR37R%:#DT0@OI
M=U%`NC&Q_%F9;_(<\89E&_,\F]E&0UP)[1<:$&L:![RFFQ`G0$>AG'>\,E`(
MC2=96%+1KQ^BR0.WMLX>(7OO`%X:L5GAI^11-2D%T0L!H$2C8_>B&9!;X(`)
MP>WE."P&`<,Y'LG"1"3O=+Q`[!S-(Q4'I(RD9(!@AZ[.!7NV`/DLI3/(Q\9U
MZAQTMQR21!*;#!,V-Q)SV<<)>QHD5)[/0GX`ATBG&-)A@-8&LD6O],RM5T*-
M,UOH],B34-`"3=MAQ&4QGT!_,,+/$$J@J4_W*+A50NZ4L&3$L+V;),26!OS.
M-"'B*B[#HD:_?HBXBG//62[<"GQL>6IRZN2:D9/H&-KMNA<7:N@HEBSA2F%G
M:(QAFT>I:MUP8BQJ-F\OP,_FXGIWY(^.^;0S0SA4G'FVDI;9W#92*_X"%E1]
MVPJ%%5-^YH[4P1"173T-HT+7%R8!+0AHPPWY2NKZQ)-,=>=RS]GU!D-;]!!I
MP?20))Y"8#-KF\2.O4?.K!85V.3.GTL@L*H00_F=@:7`H$)GDIDSV\(S1B4P
MEX^VO5[Z%'RR'J4IA;,I>D.^!N!F\8G.72'TP!R5R&BY(&Y+Q^`C3V3+^DBF
M0V\I1:%`]%9#0-3.H8%<.)<#;73P_2^]X1CRGMMQR39)A-P[()%W]U_^3>E"
M-S0N%ZDB29R/*)#UQ&8/>R0.]2D,*$@HJ,73@-7CN;]@9VW:!F!U"/-23YC&
M2!H[JCBUX:X/%A^5T%G+)*V^L^0.'JM<``\0"-(2C%W_#(\8*;'T(JK6'"JR
MH+*5&"Y;/DA0S1G$<H?>I`2&T1T&A0C"%[+2]PV,SE"J<(94^@H"".T940Q,
MU,:=8[:%4M/!G(G+[N[(_[<O-JT?IWN3^.1I-8%P/B!3/%<4G2\K4T],1Q7L
MK(KEGCBEU'MTG,?E\IB&UY#>!GT:T![0^+A#_L1EXT^F&CYUL$50SE>]Q4PN
MFR\XM\51PAE&_@#Z0**Y.>]E=^2_?;/C0=20>NXT7Y[862T\<%7M^Q;M_'[S
M]<:='>[Y`)E==%9"-"8GW=1NH1:<R@[>#:9DF)_0C?II/'(BO19(K4G)6I]Z
M'@>AX=M#B)YX5)UF,W]`B]0SID^R%N8@UJ/^-`*\LY45:<6(\0_B[H3"[9HB
M[Q._KI0SUZ!$U6NX["=X4KWEO_;*UPKA070G$'_@H;E!03),1F#IK`:V4(-E
MS_4!O;Y.8`Y-K%IJ&^PMYGDYD'F:=XY%8P`!Y(Z:Z@WY[H77H$%C^182XVAZ
MBAHR*;C^@;]H\Z/4E5"ZDU&B[9\TM@BA@LC@8)`[BF<VA='(Z0#ZGH/?TW@L
M+QZ5'4`KGV0+E@9)_T0W$6EET\!HB)Z#%F')7K]^B)Z#YAYULVQQ8NONP/VS
M?Q9/F/)\>.@*>X2ZSR1)G8).JC>VL`(9+E.Z=&GNS7'PA31K#X`#N)ANL(S8
M,WR*J"LVGJR81B@KGU$:4S$'H9YD9>@+3$0#9`51ST#BX21_+%(O*NSH=$L?
M?$$$#Z#,82=]"&.*?FQ.<7D()<3Y7'/+N>;F-N/:5N#%]DQF@R@1E#\Y["]9
MK1'\R9[,/DU-I\^==?/!]9T:[$1`,R<X18Z;$(PZI6$9=;_^\>;Q,)RQ@N0E
M+*P7G9_6MUP9R?*2ZG%Z:;Q@>CRY-`XFPW%V?CS-TWQUG&:KXPE-Z=IX3,&U
M5L995*X^#\F\N#C^T4Y),Z.BY,+M7NHM0U_?0IVA5&IO/T$]*=TEP`?ME>"(
MWX(78SP>&=`L\^,_<,EG])1_XXXV*2Z;PP_3Y?G_-K<W[]VN<P9RP_OS<WM.
M+@=DCH^:K,2@`[`(*-YDU*;B7QA8[%60%(EY(RW.OW(E!>A'/=J@^4RZ9(X[
M/\;6'R=N/KQJLI7$3QH_0)=AX(.[Y+:\7_?W*[9_*?Q2=$!VB8_#$-&+7V6)
MK,BOL81^XW66R(K%A<49_B;46L(T+%UE<*\M+WBXA?H7G^2@KSBLZ?FMS5W2
M,^;%["(&03U#_WZMGM/H*CWC&Z_4<^H`#XOBQ<4,UV*AGD?9ZBM5NU<WQXY:
MJ2O]_:W-7_;WR._^O!U@PK5VL%>W?J\=\(U7VH$Z!!;'S-CAW:!/1<"57_U6
MQ1]X%UY$="\S6`_D8>R+OJ'T;WAMF#^R<,(6>F+X^SG67]-D>9'9WT/_@N]F
M+`JL-L:2,&IC+#]2V]Q"IOY`OC_(3G-F)T']!;<19Z$U&&>!-`@`8*%!NKC/
M:K2GVR)+JIS\!HCLJEX=>GTGT?1,.^B0](U,2*;F^KL]C_!)$M>Y8O>7$F5>
MLA6U:&P<7YLH4\M3_LY$J=]X7:),<W\.PA:\6)Y98%#)\>@\:\ER'J8M=FJ:
M[QH$DH>O")#?L+F+P`#RMMO=63WGID.AZ?E+'>S"NDF40/MDEBU.^ZH\6NLJ
M[LMD?9R6Z6K;<L_*8K6OND\BNMK8W*<1"+PV(8O8^BOR*,Y6)Q11RM;5$)7)
MNAXB/"Q:G4&1>%J?D96K/>0]A7AX8T:<O:%OFN@&86U&FJ3K&J=9\I8^\B1[
M8T;!WM)8P<ILK><'[Z/)^DY91/,W')0RNNX=,%Z^L0;#!F=U1AS%EZT/H?C]
MS[<WMS?_!TW-MI4-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,3<@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`Q."`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q
M,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT
M(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-"B]&86)C,3,@
M.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@4@T*+T9A8F,W
M(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C$X(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],
M96YG=&@@,SDQ.0T*/CX-"G-T<F5A;0T*>)S-6TMOXT82OAOP?^C;9A>VPN:;
MQYED)IL%@NS&#I+#7EID2^H,R=;P(8_FUV]5OTC)%ATX:F`Q2"R;9+.KZJO7
M5ZWWO]_>?+Z]"59ID9``_ZE/^2J)]?_*YO:&JBN4A"FAJ?I+2-)@511A3O(`
MK@0T(!V_O?F-M&JM+$YPH23/\0?IMK<WN]N;S3]P*?PW^T.PBN,(7K"*HR2"
M'U$1AJ?7BSC!ZT64X?4\3Z.7%PS)?1@&>4ARV$U$HSA2>]HH`?7%S%V,HFG#
M[Q]O;[[]R-8EB!>11WA`*4(M:D6G(4@)*SZ"\/?!*LCBD#R6ZC/-DIP\/MW>
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MR^(`HFXZV9PXG'X,KDSRH[O^\-//\(%U(.2X_H.7`WIKYYR;K(^X_(;#NJR^
M(_W`!GY':@F+$M;">V3'Q;;UHA9XVA@Y3ET(BBFU1I8'WK4-;P?"0-)2\%[I
MXW''P8[V3X15C0!Y!U`,>`#_`A_Q`\BN`PUA^WT-2EK7?"XX7*_Y5O3F5XQQ
MK80WU;5\PK>,/6I*^Q=7JO"A@B2QR)B"<%B$6@$-ZS[Q`3>#T7;_(@30OAA8
M&1E$PQ$'K&UYA^(I?).!E[O68`3^6,JFX5TIU.\;SGJ!>BEE6PD5['V$Y2)*
MO$9EM[Z/H%S0W*(T"6<H30U*?P3=5UIY=Q9?LCL25EJ8[<%<X%600@>QU6@K
MY5A7<'<_U@-:CW_9\[;GX*D5K]FQQ\<@E'.5;GDET`D0CV=8L-E`^8@/>&*4
MU[('E+K`E<8&H+"-;<<:M5W,[!.XQ%?C91LC);JD1;#R8@)N3'Y=/:S(1RDK
MY6#?=^.6O#/NW#&M4ECZX_?O[D@Y=AV(":A5_LQ[]<:>-7RN=0]*R//8*"%,
MH&RS23F,M0X@8K85ZZI9N!BP9*HPU71RW.YLF':9"G7A\I&6ICIYVI@5_VJ6
M`'5HC$%8;C@\6<E:;FU$_)X#?"I<UH?\:69!D.4N>\5Q8$`@6Y5G[>[_UMN`
MJP"`=@7[@()JWO>(!P$"0M12J68$Q$-9B<%W?9*A:M#5L#NBZ>'Q@^!/O5IJ
M;#?L(#L5S/%:Q2'N`V!,I2HVB(K.2Q;/D\#J(9V*LQCK%:4'E6/9AD-!#.&T
MA-2E_$)O26VVW+%V"\!%#1@XS["+6MQ+4-QQ\H\/8P<P8"WYM;7.@(M]^/4.
M2IA^ELYZHV3$`-XQ"PQW7I011:ZD"::2)DX2%QD0#!8!.I.IM+R98.X2&,K[
MM!/E3A4JZ"X=YB?\<P/U!X:0H1.PW$'5;RTL`24`:$_%CYD6M.8^@IKX%];L
M:RAE6"/QM2J8^E`$M95J$$5.$6$>&51T_/,H.JX"^!T8#M0A&G#B#>?*,5RD
M(^9.S.;7WF<(>+4;]5N]AT4T4PD-)T>)BL*HY"`.*I'Q#9:Y)?2/7)5L=V1>
MK,LOHE0Q#BM1<P>B!X!QWOQ`#&G+>JSF.<:'K;/"U?%1F$ZVQL\HF,*SA^X+
MJA#[:K_62^.9C#2:1;D@,C)BY#YMLZ9H-:]^7J[.!UVZ8U^A:_/NC&;8"56T
MGK$+\RI\W7G*<UENVY$@G14[%#^CY+KZTI%,=XR`1MSH>2O^?UZ-9VGHM1IW
MZ[_-2&"B12O%MF,*XQDS4$2F'/]%])]Z\K#G)3;1")Z?P43OA7P`.$)6[LE[
MI$J@%O&AVM!OH^/6?YMJESG!+,@=)5A@=>LHP=BQ3^BB&R9JU.N\V.?*$;ZC
MY,,73,T]YK.'(WA]@P2"JDCX=$7J*HWM^8AE,3C.P`6`_<U>O6"2-,^]FL2M
M[Z/W3#/;?X4T<R$ISH-(6^1=#9T`M@>H_0\Z#%EXJP)Q:B0P=/82FDX(L"-6
M4^Q9&E7WX%-CCS32)8."Z2T)Z2$*ITGL\L\L_80F"/<C%(E3WI<7?%N)@73.
M$6(U`!4JP0%D>K$__0O(]2%_E$UTPUP!A2NLC;/\N+DL/OJH:D@K"1L6H*DG
M;KLL$*O4_:9MG;@2\YHQ\I*`29$X"76$`;\,P^N_II@KLL"/MFW%SPI)!/RB
M,Z4'(K\64']7J`TQ7#WO9M`\VAV]/50LQ3F:^8US]*]N?BG.!;:U#H-BLE52
M&%M=2N&D@5"&F.8'5H\,79RA[Q]L&ZSI(542.,)%M,@0M)IW8UU]O#KZLDDB
MO_5ZDL5SW16Y:TK2*'3TU):3M9"J\L2&ZJ@"(M3NH,@U+QE$>Q^!+,DCUP72
MQ)73&34,`9IG3A0M16*,5<\",7R^^NP)]&GW[7G*E>5S#06Y(Q:CW*2ZLA:J
M4U#!R?WR>63M`,T![R^5443T!+IE:),!X#,>:$5^\V/HU+7[Q33=BI,TLU,,
M/5D!-U6T'4Z+QQ+<N-^,V/;L6*=\&2U\R?JLW`FNR!_T8*EH0G'@D`4_CATJ
MP26XLS<!9%!]N+8/T6/7+,=TWBR;^JQD>]W%3N:Z**+M<:<:A1QD/38+AF9(
M'[)>MDQWC?T`"GE7]_)$&Z"WSJG$AQ(BVS>',[HG+BP_?&YO6XZ=#"^,]V_&
M=@N"[P12WIKZWH_0;2LM@6QM=8?RM)95?3$I`/ZM^2UN6'O46I2>@AUU7:EB
M2HP.4A/K6*F$%OW.\(`O@_5$3;;&-IAY*#O.6\QK$V1ZWAVX.5+1EKJ2`2F1
M/R65Z$N<GQXM9^QY5!07;DR6!3-V/*9VQDU:_H2Q[%M]B*23!WTV!+%,JF[<
M`G@?G`;.T6'4\$\`.7F<4IFIT<&J^[';@W5[\H2ASY"II!?;5DW36^_#LCB?
MFK5BBH.II3TQ#HD6@M:@6?F)LW3\IPX#!ZXF!(X>5?$?Y+YZ#DJHV[3G;)<D
M,_70A#IV(0Y3PRZ`N#JHHP^OR"/T+NHH`B)C5K&HDQNG;>T)$0&-:XLS0B\6
M3FUO&L23EX>%Y4;[!LGI=FS62/EI1[S^-A*W#[]&H]!R3A+3:#JB$16YR>UK
MUI\=\%*6@HH;<INIV@8YL+E6E$$;6?-RK)$@/D"OJB*@.1ZF&=9]S4H.36ZK
M^E<SW5*!$T=$.PXU?NUEW!O'MF^,PFPZ@Y5EI@&OU*P58\BXQT(4LA96T"I$
MB:ZZ^H[RQ&W)L[TA>4_"TSR;G#2Q]`N8=CCB.`X:IW)GCAI]-4TTYENH:B!`
MC^ZLWY^*XLK,9NJG.1T\#]&IO.[%Q)%KF:)9MBYLSX3DT1JRK3XKQJ&(@(*:
M[ZU,`/?2<DP#^P3WU;+=`KAMH"9J:*G*#YOW\<$6T;MC>$)+;$6K.']8"VM9
M#M#&IQ'>4-Z78J]9&7B]@K_P,L^*J6M`9O$L<O&L%I]PAJ$.C#7,2%^"RT..
M'78(@[T9UU\BHJZ>2-)IUQ[YHPA:&ON:ZQ,>45K,59_%$[,;VG*IE`"#=L3J
M8.Y"D"1E-UQ_+)3$P14$7J"G`%1>Z2FWOH_)2)29T7FV2D/D^[^:R8@E9;][
M"Z_\O)_3J05J>$RC-21%:?A)'V/`*$G]6L2N[X,PC"+7>`?3J0MPVS<99'V\
MS*1?M(F.@?I<":9%/(N%G+RI4+"U\Q"RH]"=F4UF3*G-S[:3W`B5BNQ^97=V
M^/[N<O?\0E]ZUHH^5^#+@/8B?Y`XLFDJ3^@T'-$'#"=:"`V[=K+)BF-OJ(X/
MXM$D/%O&VQ'ZQ*'CK#D]6GMB;YNI59FSUC/Z$1.WP0&\IAS[00+L>D,\H9)\
MZ"#,IQ.I&@+?.#M?G<Q.,_<^O^5G1F>"A32-IG&G/8!A#@&]3H&NR#M2LVX+
MM1JDRVEP-RNN*O01UBJ>K>-/T%S,7=U^5>"%(.W#H&[,2[/90?@XH`[66^5Q
M:JJA#X2J+FI>&FAZX60N#[5;/R-4-,7R#H.5!K@>C(`[,*57>/9IQU5`NQ@.
M2^;%K4,W]0V#8,8AV[.5)=NKXT)J_.O\3)V'M)=@WPV:K@=A^@TKU3$DG'!J
MNDVQ0HH\:%%%[=#)FB!!!A"Y/K62A*F3R?,("'J927M0DLR."<2I+29?"&0O
M(\B';:=!;#P-@N(@BNWNSG+U+'J#H3:UP*BK3\PCL\`A_`Y/V)Z->G![&GL!
M$OK(IP*$)O^A+[<Y6C=5>C7%D8X=#LBD.6G/?8T*X'FGA>DH1U1D-G,C]^6"
MVB7_\U$(AF:`Z*L0=.M[^<J<FZ&%03Q5!*F)&P\"*01P_TJJHF;Z$@%X?6^G
M3O-,T(/J4>,MQ[C)NN.\`'K&-L(R`ZR'CRIW<DR80AF64N8['AX01:>Y6YK.
M"-4LFIU&O53SNJ/DD\0Z=>C1#,Y+V!ZY:)#,\!U(K:LSVN8<B:'8JSD'[P[F
MX(`#9_.@'/P2"^8E'RIP\[<@+29Z,J+T6>##(5#7X?E[^UV:!:N>V!*J^@$)
M&.2D5,%G:!EUDG6^I$HQ^H`-0.H+WHGI1Q,[>`U6$'Z^FT#=#([.3N.G%@IL
M@U9@9E=(K<E*E42BX:II`6F.KFT!#^%/ZHN$.&:;G&=F2QSEG"D7OSQIIEL(
MNI[5?%()P&0L#5V/5WVHP(W@@L1Y`WYO]:0SF+<WIW.#T]"*7WX*HY1D!>Q'
M[65ZJ?JJ=D@R/"J-U^G%ZX&Z'E^Z'F;J>OCR]31+D\7K-%N\GD"'N'0]IE`K
M+%R/@F+Q^3#(TZ7K-,CRB]<_FUL2O02-+YP$IL[@]/F7O1-'`B14>S\>7<U-
M[']4[2N@_#NH]A"8)P;6R_SR`R[YA`#\%^YHE>"R&?S0A9O[M;Z]>;"[SK39
M`&\O$DGA!8S&@,7<I,+B'&SI957!U?LB7C3U/2WR15O>1T$0+=X`)>HB&N^3
M8!DN]VD0+@N1!7&\>$/^"J+N"QHMWT`#F@>OW(%?WEJ\@R*-M'A'F+ZB;AIE
M=%G?-,99R^(=2?R*.F@:)Z_<D86O:2S#KGLAS-W3'*1Y!7UT.53=AP%$BU?N
M2/-7UJ!IMFP72"'19>N#HWWX_?;F]N9_-!\@]@T*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HQ.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#(P(#`@4B!=#0HO
M365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#8X(#`@4@T*+U)E
M<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@,"!2#0HO1F%B8S$R
M(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@.#$@,"!2#0HO1F%B
M8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&
M#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y
M<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,C`@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`S-#<X#0H^/@T*<W1R96%M#0IXG+5;
M2Y/CMA&^3]7\!QR=E$8A^.;1:Z_CY.(D.ZGU(1<,!4FT*5(&R)'E7Y_NQHL:
M21R7O:RMVAD-0!#]^OKK!O3AQ\>'7QX?HG5>92S"?_1;N<Y2\U]]>'S@-,)9
MG#.>TU]BEA7KJHI+5D8P$O&$*?GX\)EUM%:19KA05I;X@ZG=X\/^\6'[5UP*
M_TW^$*W3-($7K-,D2^!'4L7QY7B59CA>)06.EV6>W%XP9D\QCXJ8E3QB"4]2
MLZ<M"6@&<S^83#;\X?GQX6_?B9<:Q$O8,SQ`BJ!%G>@\!BEAQ6<0OLK7.6SY
M^;?'AZ=HS=,H8\^GQX>O/DNV%Z^2M<VA&>2&]8IU/:O[;E!]R_I7J=BPE_!>
MW8^JEAH^B8&)[@QSVE:\]$H,\,Q!G-E&OO:#9$//8"H[JGZGQ$&O_\*>?WI\
M^`C[_??OEZI`H]V6*D?;Q4:JK_X7I]$??<$]M=$+HIQ>$*WCJ*S8<TUJ2XLH
M7EYMF[$>])I]#9/[+?UQ.PZCDA>/:GKV2XL.'E.AN"0Y3WCJ)$\J6(HD[_J!
M':7:]NJ`(C:*]2]MLQ-#TW>:"<WDKT=9@T[6['DO]:U=OR@IZCWJ;)#JT'0"
MQ:>EQ$Y)>9#=P$[-L&>CQDD]C*E3`TMM1=.BHD#/J"3[T!)*@(BT2L@*KX24
M5Y510I"I`2<0-?QHA@;,K,<:K*VW8]N>P=P;UG1,L*$Y2/A\$%TGU9I]-RH4
M:46VO5:/;$%_#/4,HH)WR+8_>K]@0C6ZZ7;P[.#<8PD%9)E30)5[^;,RNRF_
M4J+;D=W(8-:C];C=-G6#UIS$04^!8<7"1U:HEW$+2@0?QP_J9SG@,EJT$D4<
MR(U"8/QC2X'D1V`I?/$26DA*'PM%YF.A+*P:^KH>P8PG279#B[V`-EY:.;4<
M6FB0];[KVWZ'/M*CT0\'J>I&M,UO\C+NOS1<HAB\_/-H>7?]/*S_Q6T`4%Q%
MW"%Q7`17K*+2V.!?X&K=`)I$;U#B*,>AJ4.X6"L`1+^<+9X0M%#HC7KHP0[6
M)-,X%`K]]^4GC$2PI6"M[';#WL3TV-52#0)"6\G=V.(3BT!Q6:;._=*R\*)'
M&)$H.@B)8$,184+AC0H&"7N<((<D'Q5'^-.KW)#C(K[.J^+4M.U;W[[T7WCK
M846:@067T$->.!?(L]CI(8N+PNC!!9^2M40\0H`Y-*T$D3I)^U+]6;3#F1W%
MV:#4:=]`!D*-O`@-SC$>^XZ>"P#.Q.95@*4I'5W!$'Q4_;C;&S13XVX1P;/(
M"9ZF@854J4U#$Q0E,8UE(12<9RP`)F42+0HF?OTEP*3DB8NHG'.OT)A;A0)C
M8=]]^S4[0#BX.*%D<P-;(!Z`!$G6#*P6'4:'25V2DCZZQ7\[XH:?!B`X$*4?
MS/SKI(^/;\%?`68Z>5K,FXK*<5H>EW%@=MPR.Y"W;6HB<H@"+PTEK!HX;BT[
M</WI.&'H8+2UHE^<5D"83;-!2D=*'+N-5+L>6"'`M*;HA+@$`K,"+=7MN$$N
M([KF`%Z++KP?@0VPNFTZ>%6[B!H*3W#+-'"[U"7U00&LZ96%"+3-('Y&XX(;
MG*7`Y("((G\9&Y,D]"!,`D+F"\(CCP%S?RL&`=P8\P0XP5;U!P27O9/?IAA=
MR^/06%A]%>J,0TT'Q/BHY&!9]1):R`/#S4,D<)M5K?#]V&X@A;;BO#*E#CH&
M;.S5D#J?_!SP0"H"OKL!'<"^5ZS>(R_4[#)3'GMPHS/;]I[U!.#:C`H50`XE
M5=-O$'G=K"74D'J>6\0!8>/X#L).9=[)#L0`9300M+!-*FK`'T!-&/88RF]"
MR@ER*Z(PB=5BU-+HFQ*QDDA`T`6^.)(76>&%_^-0.Y,GBCA;-$_X]9?($T7D
MB'^<E8%P8,I`K_@@C:7>4(*F>^U;RS\N++\E9[@H`M"9J!:^8"`T;9)J*"[`
MK:0FD#V[1Q:(A+SB'A8G)6]FD\.$#$\ASWH_<.L=-CVZPUM@&(=]KTQM#"*O
M?L<T%'$'!>5-@(%AS*%+R%]XLEWQB?@V*^BV/[4&M*Z((*;O$-T:R@S$,-IH
MW7>(E>`%6*!,'&#-/N\QY9^07X"IFZ/I@H@!'M2^M+]!Q:GOM(0"LB)PHU!M
MQ(EU>LQN"JKY6CJ0,ZG[PM5M>8\<"C1"93KZ\RU;GZG^(&FZWJ3&\`I33G2R
MH:=/.$5=M\^6T$(:A7+3*Z$L;#[8"PTD8)C`_!L%3(G1^RH@O\$IU^P)L@O@
M`+YA6FD@ZEC7^(8O(G_L&#*0XC@H(+8X\/%72/]:HZB?SGK`P@]-@WIQ4G?O
MB^U*T+O<.N@A%/"C[7LM)KKO^?(H\;9/\BR_(SI9;UH*&Q>XQ?[1%62KY0ED
ME6OVP\W&WU61;;J<G@P[YH@U._'*);20^?YO'$V(85Y:+:!HG<3J4ES@,A'<
MB>/?M3YB_-:V'4)3[YFZY9?DBIIE6YPLFUTW21W:%FBM[A=1@>_^QF49TG]2
MEKY0HL*0.GNWFDZV,IR41=K5B+IO;7W88RB3DH!F=U!UR$7J]2R+%^5A?OTE
M>!BE7]L!FS1`7._O(^16)K90+"'WLM&AP5>:+00,,`ALO%,FF99F]_KN&'XV
MKFXP#Y?ZFZG7T@::K>%F2W@B#PWHN`PE>VH[7Z[C=6._2!@;';9/)PO=@"<H
M5,G9TM*VO1I03DW9!C*,B4]3`D+J1<^U77GA9)\>8B`C6+81FOD>,,]#YR)-
MHF(:D"`D".PJ;F`0H2'CZTP\D4'X""<.ZFVO%P_QFF[TY-90D4VC:\2?LRE(
M8:0?-1#"L?NYZT_49078/FA#`!;001J:P7%53<[E+#WSIF%TKCB1#RT/;C^V
M@RG$-6!-?6%]^^3JC5ZH1'%_P-""WYJ6F%OHW:"\&R5.H"_3)%VR7$]])YBG
MTZY%;NF93T+&\M2.<+UZC[*KFXF&DHDV)T\.X(^@**3J"\!RFA:+PK)?_X]M
M?OY606I[M%4!SHC,T-XJR');+7TO13M@\TPA--!9,7JA;2&9Q+\%#'HA=Z*3
M8*Q\7-'C#B.6R(<I7[9_[==?(A]"N/OJ)`I%>IE8<O:#(<??8P7Y[*K-,\+B
MB\1@#60:#[6`R^KAO>,?RV:GC3#D9.9&PBWVLUHB\),B</,LW$HH+/@%.#KN
MA3J(FK9D#D(F!-/[VZWB^NI8Z\Y2$R7ZDT2G\R4DSWR[.JNR4)9'[L@BF-G<
M)D&B@U8["C4X@*?N.V4WD]6!4!]>1J7-X99E-B"^MB==_;3!05T'K$M>@3Q0
M<4(P.^GD[$VX+R%]ZMO4:36YC8*_4];;'*`X@HQF2J])C;%"]'[%"M+NKNDT
MIC73>C/$NU<[T=FRC5RD49LO+40*I:23HHJ!NT;F%M973U_\32F?ZBN.`E.*
M,NLMZ!1T#"KM(3=$CI("*VL@,_5>M'C038%$N0_=X2`W2YW%)''F\:P*[9:*
MAQ-N>W8--M-2O9I\_&E"\?UA/,@E?P57H$M(M@]UZ><:2.^H;3NVG70A]I-T
M%6`,WXEN(EWMUBU2;2:^U\RS4&VFW)WR`TR/"@^B[1VRC?QE-+U"\%9F#$K4
M%*C,K5A]TV$"S<B.1D92TP%5)^B>`"B7M0AN>GIW!^:`AQ`BFEZ7ZF$J[F`!
M9<2^"QWS."2X*O$%#^2=#F$-8=<4?61;PVRE4'BLWP7&/\E;B_"XN."+T@F_
M_A(\+LY2S^.2))WP.%M@?[T!OPI7K"P7V#:RW5BV?]W\P"PDS',88]LMUE7V
M)M_;I+L$P8N3=%F+N/67('@Q]U==.`_X7:2V_?K-J!28HC7-<W>C!R`;@I^R
MOO5W>XAZ;1W7><.:5=14$ZW8RX@!I`<I-G3VW&T,&W*6DH;I+'4Q(8ZBT'/.
M)SUG[FX;'HZ0I\WM06FZL+>EPU-Y0`1SVPNO)7EN`]5O<T!)CJ,Z]MI=+&S4
MY55$?SA/'&HPZQ*ST/YNQI\H".=N:I?^:DI5!IZ7N2NGG^F2X8KM^Q-L6*VL
MT6U,ZHM;J"Y.#4F_87*Z,C:Y_75!A-W%Q=ODWKQL"07D_LIU'HAN1KATP05,
M)XOD``XW/8VT)^<A#*YO1FU&Z<C!]5$D&?K6/2KV!@B7$#^M0G\GF=S.*5WF
M._;*7B["LR%KGO/D>(`NKIA"&R,9DSNVH2=RZEJ!.3O;Q.HQ$#97"]P!]A4S
MC2/0.3B+;#%,EM!#XAELE00P2%V):R_>F&.`&\>QU*SS?F"/XHTUL>PCWC^<
MCX;:7L!BJ/[HZO$B7US@]YKQ]%V-.,U94<'BM'!8@;XS@O=!H>C#<7YW/*+Q
M],YX`30*Q^/;XT519+/CO)P=S[$/-S.>\83/C:<\FGT^P9NO,^-Q!/QY9IQ'
MQ?WQ7^R4S+R"IS>,"WZ+5T"L=?GUEVTFM;K-WM$ZJMRYT3/1;G"[;WI,LH.^
M\`"SS'_^CDN>T-O^B3M:9[AL`3],_>@_MH\/G]RNB]3L.;O-`.-[!2.4HH5M
M$_(K=\QG;?U4%;.V?.(5H-C<A+BJ9KWQ";8W_XHLXK/V?LJC))V=4$3%K$<]
ME3R>GU#Q(IJ?D!>S3OT$D)*],X/G[RD[+J)Y;>-7R^;5S=/T'67P+$W?F9''
M[^@+9M@@O`-R3[P`:>;7*'DV[YR\`A+USHQ\'NR>XBB?AS/,!O%]XT,4??SQ
M\>'QX?\"Q>*4#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C(Q(#`@;V)J#0H\
M/`T*+T-O;G1E;G1S(%L@,C(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@
M-SDR(%T-"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\
M/`T*+T9A8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P
M(#`@4@T*+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W
M-"`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO
M26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B
M:@T*#0HR,B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N
M9W1H(#,V,3`-"CX^#0IS=')E86T-"GB<Q5M;<]NX%7[WC/\#GK9IQU8)WOGH
M;)+M[DQG4]N=[$-?(!*2L.%%2Y!6E%_?<W`C;4MT)VNDDXEMD2"(<_O.=PZ@
MM[]=7OQQ>1&LTB(A`?Y3?^6K)-8_RN;R@JH[E(0IH:FZ$I(H7A5%F),\@#M!
ME)*>7UY\(JV:*XL3G"C)<_Q%^NWEQ>[R8O,WG`K_S2X$JSB.X`6K.$HB^!45
M8?CX?A$G>+^(,KR?YVET>L*07(=!D!0DIP&):!1':DT;):"^&;N;430M^.W]
MY<7?/[!UF1$:D7MX0"E"36I%3U%*F/&^P271K,C)?:EDQ3?>'RXOWOPZ]N1'
M2MY_V?=<2M&UY.XH!]Z0'9-DS7E+!@Z?*[+I>C)*3D1+]F.])ZRMR)[M>4_V
M?5>-Y0#/7I'#3I0[6.0?HX#YR(=W-X3M8<`#JPE,N.4M[UE='V'(EO45S`M7
M_TKN?[^\>`\"_>M5Q*8AB`UF-V)3F$F+'1=1KL66;,.O"(CTT^W-W9429N?6
MA^+"FALA1;LE.'0XJB%#]T64`CY4;&!*(UW+"6^_'AN^(C>D%_(S:>':L.,U
MJ)/P+T(.D@P[-L`/?EK3!U'7?G00%$8'(3H!J.!:Z4"K0)N-X[IZL.,XB-*:
M4BIIM5QF]3OVP$^J0D@YPB`F95<*I;J#&'8X:[/Z5J'2,T(E$%-.JC??K+-S
MTX/.BMQ,_I\P#EY]_G2:_]4-#K%>9*'U^22?#$Z+3%O\$X>(K@4'2W80]A4?
M>-^(EF'HDFZC/!0BH&O`TA#!O`7O@,N=AHA=)P>(F"UKA6Q(V8TUQ`P')!@Z
MTHA!;,'X:JR*`NOR/2<,_H\M_[+G);J'!T\ODL0)'H=.\`#_MM'^/_IM=PX/
M\>$-*T4M!BLH6^.G(RI@(^"V"AK](&GY0:&)1`VN1??:4F>0P:S810BR!I3<
M?P59KU__3?%,P6&<Y5;!F?H;%3S'$-2"#QLC=&L;A[%=093'9@4=+@&\LFEX
M#_:L"62<$4#Y']T!_+V_,KY8LA9B`#`:#3_VK%4`"*[*VK8;'D4">(%"9AB^
M&3%E`=RS"N("S`^?X%7[&B*HTMEC;`=1$S&`7WF1/J36`$$PA78:Q<;#Q[($
MM],+G2WMH,,/!205Y"+1EH.ZSP<(60`"N,BJ!]8.;,O1D25&OPEZ.Z[K)6;V
M#K+_(Q"0.BLHEM!T\!H?@H/W&<$SZD([2<+8>E[7=^-VIRB%Y*PO=UQ'HEZP
MQK/Y2K6.C+UYM?*11O(\]II&W/S?MGA0^)+.\S2S.D^CQ.F<XM^H\UL`>$EN
M]OM:E&Q=*[]1$>.B3WQUH?16@&<`//+^2#X:>N%#XW'F5^-V_F_3>+JL\"C0
M0)X",R]2#>1&FZ_]NC297I>MTA@1Y*LR,,TLFKQL02`/>]Y6D-U:@(FZ9NL.
M>#,"RI[U`PR5.[&7KTX`45<T\&MH.[\/AI85KAB#RM#!>!P9AO:6EPR++(#M
MJH,L97@W!E?#VA'XQS#V6)2(=M,S.?0C7N":G`"3:U7J`R`$^"Z1NG=@J`=>
M=WM2LQX07I:LYJ\N&)TD\\M%4AK/=9ACD6<S0I9J'>JR95:5^F(D669+S&#&
M.B.:4[V0QQ:#]6"&!J-@W8@6+4_!)>;=4P%W]91QSI_F9Q_3%$8'*\:J#S4D
MMLJD41%/Y#LR=28NC;=0:FB_54L_!QBD%I]-$<%+>$C5UXJ7WZQYN^T8"HDU
M^O9(;G]X=T5^;LL5^:1)3MFU4E3Z/:RJ!*H4HN'QVWPH(`X=-TO3B9MEIL4R
M%Q!Y*-(50T>!+#ZGH@>NK693JZ5SX,?'N6"=JBZP0=,#%6-``/>#?6:4BJX"
M[:OKUV<X:9X[J;V4X5D8>@5Y-[^/;)X%B4VO49ZY[)KG!N1/TJ0?>5V/=2>A
M@'H/7M!V-2#^4:4`+$`XDP),ZX6LIGGB5=EN?A\9-4UM61C264;-4E,7WM0F
MX,I)P=PH6.Y4$Z/GM@]&_MT*[`3<864@_V)P4_=!6B*:?=?C[4[45X!D90]6
M@1@&E#60)'D)8&\Z#69:O#WT4#CZ@)XTL64AG4%/9(6O(!V48K@ZG6I.:$2T
MS]6`0,)KR0\*L4XXI4IH#`KN7F"7!69&Q0`8K]"AR$W3`2"K^ES:,MR'*B)7
M*(:SYE<1F![0U,_NL'T+:`J4J/R,RY5BVPK0%%3!D*;%@[H+%MQV#[QO&\Q#
MF[&M,*^@J+;.5&,,O5*#!'+A%IZ1EG68I(]/#KS<@8J[K>"@!C]=[Y3:PBW(
MD8,9=XA#PT@.O%9M>,M`YHO7;2I#(&"-*_)A[-%:6-E;NSU3X@.2#:`D0PUC
MQ`93%#8=D'.(7O?[]N.ZQM9R!S]A7L*;/4PCOJ)2?.@@"!P="2965B0F)@08
M2`Y*9&.A!U%I:H*,`SC"$D-3+43(U5(E896=GT71BMSCLV/?XTL>Q])'<![@
M*/`>YJ7GK_J^IA,:T:D%;"IW5C6B%5`W:&G0G)IHU4=M5VTL;1S4`+`N\(A!
MGL8+QV;$`/,T3+2JY%AC_Q@F`\1073G0)D*&'"%FS`L`)WQM>R1I.F&BRPA1
M1F-;'VP1U/M'87\BU%4W%^*Y:T#@F7/,V]VV6X:J`J?AVPZ?7+,>(JB73VGZ
M*>3UH8#8$?(L=.V;.$JM`HR;*G3^=>+:9VGYRPP<LX(<MUN(+-?YA]3H%('T
M'#ANTXVMHJ@`@/4C(NQ##9&CY<GD!XGZ6\5"_[@/+'7V$]+L37KA6@GU2VS=
M_#Z(;5PX8@LJ31RS36W%>_^,.U@N^W-;C0`[N.U"=D*U:RVY&LBX1V0ES;$7
MK,+XV/`*MXE5"$JUW5+SK9#UA,%@HE%_U'N56!J5\*JM-J."&A\:R'*K@3P,
M4Z<!NZ<Z7Z9B"G:59K^L85@',]V`AE572!9P-X%M-I`M35)N5#L'=Y?/5/5>
M7#-.<J^NZ>;W40;$L2/"13&KP>/H_^B9WVBFI>9M$3I1BW`5!9FN+_^4S<Z_
M+)GI-<H3I]<L#4RS[>9QW'F`\3BTO#XHXHG3JBQO=KYVY+O%W0<LAKXP;,A<
MD5'1"'SVO4Z('Y'C'KUH(7#,/J,NIT<1-3VFFU(Q>#Q*=*5+N-7=BKSCF,4M
MO=>+O#)EBAQKL]]ISVOH9^XXU+4#ZU4A=[/M10D#;8_Y]"@[,;*``Q.F8>U!
M"U'AN#T-)VZ?Q2:EWP(Q.:@6V(<12E8,];:"5*Y.^MQ^N,,EMJIN43(#%]\K
MZW>JSPACU"ZFU``A-*V[F2AS-YV9L,=B!'H"*M@29G/T"2]Y*?'P/)EM-DZ.
M$*>6X1^4OTO<\T;_WK&^4>O23%9M8JN/[8/HN]:Z!M-"`RW#V#%1]*P3<*6O
MNH,=`F/>;HE#SMWO:]6:;C@?O+E`DD[=YDG^(##D=J;_%6"[ZY?JJ#@5$."R
M<JI6S\7T+,`TK6\1$93BQ@J*IR/YA;4C!@0,27&(#^$CQ^R3;';`QV*A\T[K
MO.#SNLY2VTC,^(7%/_1>AG(90&B0J@,Z*`E4XM-G@Q@4>MHML.O<F\2WAB(>
M$/$MDUQM+6CO1UB1MB12NKGRHHDP=%DAF(J\)(C<@913&$4:R/4``I^Y\G15
MG"$@F%I>F?WC#;9(X),M7ZTB3;L0JEL%<CI5H*Y6!-.@NMA;T;7FAV]DH2\(
M'[CC3G$\]3R#E-H86,(U^/@4_93!-7),J;';;"3$\2PMVBXA?,9P&@$0*J'0
M<3<?-L^<'J0/<]?QU?'_QJ5G#ZPX3/VR8C>_EY,<H>L/1V$^G>3(\A,G.5[]
M_7DP>W\8THF69]0`EMVNPB[$>[UO^W:4F%[!M\"/[DK!56ENKRH6\IV.E(01
M]6MZ.[^/2C6DL:O5XR"?:G6+D#<UY(I6]WKFO6G%XEQ8(Y2UW&"=WE)79Z*Q
M[S6=#T9$/.I#"SYBD!9^3U.Y^7U4IC2SS)WF>3$=^;`M@W]BZ\)L_#\^NJ#;
M9N:8=H6)>0/976VE0]Z]F[4>S0.0WK>:>![PI-Y>'^CC_<.T;:/.J8J!\`WN
M#"$/4IO%7J@:^-IT/F(ZLAG$\92CG42S\Q&P>`ZTNCL^*;<\G*(-"^J6Z??D
M2@AD=5)(F&2NE$V"C#YJS"J,T^=9/8@<!\5W$CG&Y.!$AB";J$INZ?I&U6FS
MLSH]Q_/3RHF9.]&ATD3#^L_`1[H][L*.+6XA("CY<-SI*S,1G<AEX1KH!OCP
M8$:OOR1RNEO@#A^[+<,UQ]&F>C!GSLVF*QOE7I3ZP'C#?D>>S?4743#^<>]4
M5=ZV`S7;L?"A@NGK,T4R0RW[M2%TT;+K6[+M0<9^.D>/-M2[`4`J<&?E40:Q
MFCL-:O;K0T*:&O7I02Z#$8@09GL->"J@UZLG'?7],*,"+P=<:)#Z36G!GUK\
M"\=5=14*#A&$4P\B#!VKY,9@JIJ\_>$=68_5E@^:6\Q:;I+5VM]5P\U0//Z$
MQZ.V:`B.EQ6P8+78:57JRW3XM1VH!_$^/7<?Y,'[\9G[61*H^^'I^WF&)YX6
M[M-B\7Y&\W#I?@J%W-+]A(:+S\<T*);N1Q10?N%^&!2+]VF0G9?O#S,D2;4)
MXC-U`G4>19^'PW2(,#''_+&TS\VF_;W*`'A,J@.D:)_0?3W-[4\XY0$]_!=<
MT2K!:3/XI3.=^UA?7MS952=:;/#BDT$0GDVBE"2&-%+ZU%WC15M=%_FBKUV#
M+RTZPW58+'O;=8Q=JJ4!"03NXH`T2*/%`1FERP-RFF3+`](T7=93&B\/`)!+
MEA5!:5J\H.P0-Q@61T3Q"[J`X(U>&)&$+Z@+1J3)$L1=TY32%U::T1=<C^8T
M7_8,"F9Y88XB39;M`ODE.&][B)'WOUU>7%[\%W(K:;8-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,C,@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`R-"`P(%(@
M70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-
M"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A
M8F,Q,B`W.2`P(%(-"B]&86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*
M+T9A8F,V(#<S(#`@4@T*+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(T(#`@;V)J#0H\/`T*+T9I
M;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S$W-0T*/CX-"G-T<F5A;0T*
M>)R]6DV3X[81O:M*_P&GU":ED0E^\^C=K!VGRHFS.RG[D`M$@1)LBI`)<L;:
M7Y]N?)&:T7!24XO45.W,BB"$?NA^_;J!][^L5[^O5]$VKS(2X8_^J]QFJ?FG
M/JU75#^A),X)S?4G,4G+;57%)2DC>!+%,>GY>O4SZ?1<19KA1%E9XB_2']:K
MXWK5_`6GPI_9!]$V31/X@FV:9`G\2BJ<:_Z\2C-\7B4%/B_+/+D]84SN:!7%
M"2EI1!*:I(E>4Z,--`^I?Y@DTX+?WZ]7WWS'=G5!8,`]O*"!T),ZTW.T$F:\
M/^&2:$G)?;U>W>'JLX+</ZY7[_XY]J0>U2!/O%=$='4[[CE\B^*LKX_X&1MF
M`V1#)+SQL?MR.7'R?E2BXTIMR%D.O!L$:\F^'P^DEJ<SZR[/7WPOY.=:\*[F
MRK]-_DSN?UVO/H)!__HJ9M,8-S?W9N?%9'=5&;M9MY\MFG>\/USLL@6LK9&]
M6V_/&UAF?R$_]7(_UH/:DN]:^#VR0<@.,2/#D9-/?_HKV8W[`Q^TL?"1>H(C
M?"-\*F#B_@#?\L6^7\NQW8?!(*HL!G$\05!"I&@(CNR!$T:4.'2B$37K!L*;
MAM<#D<:D/3_AHAT69V__)VN6MFG/'W@KSR>`T@/06(!@CI&309+ZR+H#UV"Q
M!R9:MFLU.C`ON,(FA/D0Z,X#<-.M]7F:&^MKP%ZV8J]WP6WB^<CZ$ZOY.``>
MK3;/NH;H]N#+O<#%JC/O]J([`"+@'F)`A\&AHE.#&$:<$%XV6#!PG#-\#S@]
M`(?1YMR>NZW?\2#F%YDS/Z\2;W\2V]U7'!8_JO9"]NS$#AS6<2$8LW-_V/.Z
MYPP<&?!I1<.)<L$+]GX#?M$#/(]Z,YN1MTI'`?]#XS.,L+\XJ0D%_H<`=`"T
MZ\CS#!'&![)R`F%B/XI_:Q:H&3BYJ.=;!RLYR`?>=]JCP5-ESP:).P^!BUO^
M@'[=R+$SOJ.V;UUXOK#PQ"S\W7_B-/KJ\^?3_&]#/5]&/:86]8B:R'OW078-
M!,'P1K)?^+X\\]]7%=LRSE-R_T5O,RVJU&SSHQB.FL)JV?H-=>&'(:\?[FQ@
M!MG/B(;=3S?_5X\BT!!EF;H\$N53%.4NEWX+_'DZRWY`RCBS?G#9'@@38D6S
MYX-L'S3C=9A##'E*"";#D"Y/XH>'GIV`*G_FY,2`.\=>00J19YQ_[`S9`ALU
M@K=[!=R"\B14!M7*P=!'D<43AY:)SR':JXEVL.$H@>>LZ5>>MB4_@HQ`4MF0
MO5#LT'..[*+(HF?:S$KP1=*+PQ%>@%R*PT4W\+;EF&1;C23OA\N6?`O\'0*'
M+'(XQ%7N<`#16]S"X25S>@Y;S_5CMA.M&"[:FMW`<#]'S!>S]S`KSX#"K-'Q
M`WP.F%S0WQ@*E1%34&MX^"C.9@$^U82`(O%RNHA3[Q)QG#HH9H9OR.-1@%<_
MLU^QE@?AF9(F07G&SQ^"9XK*:_:"3MABB:6Q_0!.CKYR*\0LQJQ5$@05"'FN
MU3R'K"Y[+]*-EQD=MA1Q]E7#4EKT0HG3<U,<C4$JEJ)P8CW2"MW&6.9BK.GE
M"<3H`+(-E@7Q+Z^#13D2P@IC9OJ&-*"W9Y$VB!-&4,\/8XNV@^H[@Y4/`-V&
MP/0GT:'`,1,]I2JP'7`X,801)@%!%`**W"OWHIK5;E"X&RBL0;!;H".)&IL&
M]34D'U]1X&-3PDS%"5((``-BLP;E:>LO=*:IL$'^],7;[-UG6L&^$L3ZU`OW
M-*(3V496L\Y-@GH-TF(0)BGB+"B3^/F#,$GD=']431Z4Y(DM_D!</(H6ZG[P
M:=Y?>07W[H#>-+::!73PV7WWHL5I%4CI0`V#"8?AV,OQ<(1JJ>:=PG<Q\MRW
MF.Z"%C>Z^@[@/KK.<;DZG=PGL23:BI,8H-K#*JW7Q1R2(Q3Z8P,9=>Q=B79B
M_6_7%*@;`<^KY`W9"0C#^MC)5AXNMXOF+?D!0JW?`PPXRZ@#-(3UA9.J-*/Y
M5/"EI4O/\YTV<>[M<_L(:1O\0P=\QP$J0S48=!O<8L>C=J?E.&C2T<#U/?8Y
M-&5L-%8U.\_$C@%50Z1`OP5!('.:-4XF^DBKR(KU:YNU*^XEZ>1@/-(\]JO6
M_0Y<[J.1XSANQXFN^"=8-"KHXX\"%;##!SL\OX]"@;_-W$D;C_HGB/6I5ZI1
M,L5]9IL><[O`)1LTBX'L'#MGD1IK2!^J&=OV\D9>\,6,96?C3D@WH)/A-=,1
M$UT-[[42&T';-T/Q$L$65>FQ>#O#+J2'/(Z"I@<_?X@&11X9%0N^,7E)'!L?
M^6G<`7F3!\$?%79"^7#TS4`ET1F(4%"3*AT0FDZ!SWSAYYG0=07_'[(_*\/*
M?C]_B&2=Y;EO+R23[,^+>#JBL&%IPFC/L<&(:4LW&\8SRKCKJM(1TXS;58UU
M--*Y)^Z>?*#D;U(-Y-[GKRWYWG?_6!"&SM+*R]LTFY4YMH1DXW!T;64M.S<Z
M9UK?<U2+G9&S5,C/Q@>1;ZT?'B#_0FY&ZVO3:=:=2WD4.SOPW$.R%[7WVELX
M?)PY?@@8DOAF<\5MNQ--H%!ZJ&Z@T!F'%]:ZT8X@:BAH^O;R%`EE:+K318N&
M<N+U&8JZ+_V<XG$57,\0I$.=4:_V$SI#@<9.L.BR=@\NJ;#B8N:$QE1G3DY`
M;)P'!D!]_40"ZTBKL)6`GS\$U:>%J02J?)LG9>Y[PVED%>$/C0D(P_I[">Z"
M(L=@ZB*)H1K@W4&`'D0*F;H"\V+0GI>Y5D+=PO`0;)]F80\'_/PAV#Y-?7TR
MJ^TS=RAY?^3S\'2\;VEJ.C?RD7HK(T`^L/LYA8:MZY]0Y$L;&R+4T]BWT>.\
MFIW'6MXWA^_(.7B&CAVGEKG6I_YSIMH_M$R<;/O[-5.,P%6L<>37J?%T-LT/
MA%3A*?`>ZY;>M4U"6!_Y7GHV.X]T?5/>/8A>FC,WU%6B:]I15Z=N)P<\H-N[
M4]37C';%R@%+D>?.8.N3!Z8/07VABM5L`-N3RE<E6DDYVVU)OEQ/PQ[=**?_
M87OASK:>8T+'@WMYA<U)[D4C`!ESZ4"=U'6B<ZUI3'>(R@$F&GB0MAY>A7&1
MGT^I+BMMAW-VZFJ;D[8_Y^1,/[]V8)8\CXH-F2((8:K1CI;M>(N?M.Q1RZ!I
M:IOS#0(U&TT<S$Z\`T5"DDUZ-Y^\(<L3U^"[?>TB0"9)DCQH)O'SA\@D"9UT
M=%+,!&0^I1(U[G[5-UJ:UZ+BR%#UU1QB:CIILM&%107XP\<1#]JTTSAQ.G;V
M3H@YZ,%)&%07"JG(!&8(!XJ\<D[I5$#HXLDXT`YB>$L0`*L<;QIB/+_E3+>X
M7.3/8D]?6>J9N1"F(TH?-$AWWJN>XLK:X8J&=8]%07D"PCP$$G&9^6;7U.JB
M[H[7E>T31<JZ'J<SH7]WNA_Z>0#K\>['_T8VT]T=YV(S"/?R!'CI2:ZP9$$P
MR%VO.Y[?\,M+?UYPS6@OT,M5)@C!-7$:5K7Z^=\&,CQ>1#GQLK6L9G5:Y9H4
MFA#\E<9/0OVF(`!!GOW,R7>0W$,@2L->*O'SARC,:)6Z2SN%/OMTEW:*TI_1
MG$#NN*:IYA<)U6\/[/PX4[?(4;.>6PC7I?94(130?OX0:9+Z`P&\:#S)#7<@
MA%EBTK^@-?%JK\'U6HA.\E.7%#6H5H8:2WPQEP=[=A;SO<#>D;GWN7&77_%%
MYI+&1+%"A:%&.IT&I+2:)4KK8GK%6$#@[23=S\=;1:;`L!=2;C4>G[<;3U!E
MZ$,/YH_>M7J02FCRUV?G8.[9)HIKD"!/85&"%VLUA"&0B!-?>R93JBR<$UPO
MZ.I*[\6('5-2387"5>YX&H3F"@8B*G=*MGP(T@>A4=BNMY__>D<TG'&5D0+*
M.C/K]+J^W8]+*[-2#Z`O#D@K/2!]:4!1YGI`?'M`54+MO/0\3A:?ER`7EIX7
MM(R6GN<T6WP_HVFV]#RE(-H7GB<T7GP.V6G1/@3PQ>>_VR&9@9BF+R@"ZKV#
M/O>^S-<?F6W=XGV#TI++O3Y2!*[[``D,#X2OG,A,\^E[G/(1O?7ON*)MAM,6
M\`LSX^R_[7KUV:TZ-[""\K^9<^,7'!HODUBI^([&3STZ6_2UNRI=W.L[7=$O
M#8BKO%H<D%3EHKO<9=&R/]SE4;$\H*`Q71Z0)XLN?U?F='D`P+",`XWR;-%M
M[RA-RE?`CM-7H`"ZJUX9D=)7T*(ID-P2Q]W1;"G$]`C`:]FQ\*;?LF/0(H]?
MF:/$T^+E$57Q\M9#!'S\9;U:K_X+BI+0)0T*96YD<W1R96%M#0H-"F5N9&]B
M:@T*#0HR-2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#(V(#`@4B!=#0HO365D
M:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#8X(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@,"!2#0HO1F%B8S$R(#<Y
M(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@.#$@,"!2#0HO1F%B8S8@
M-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO
M5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@
M+U!A9V4-"CX^#0IE;F1O8FH-"@T*,C8@,"!O8FH-"CP\#0HO1FEL=&5R("]&
M;&%T941E8V]D90T*+TQE;F=T:"`S.#8T#0H^/@T*<W1R96%M#0IXG+U;2X\;
MQQ&^+[#_H4^!$G"9Z7G/4;+DQ`&,)-8&\L&7YK!)MC6<H>>Q*^K7IZKZR5WN
M"%!V`@$VN=-L=KV_^JKY[M?;FS]N;Z)U7F4LPG_TJEQGJ?Y/?;R]X?2$LSAG
M/*>_Q"S/UU45EZR,X$D4I:R7MS>?6$M[%6F&&V5EB?]C_?[VYG![L_L+;H7_
M@C]$ZS1-X`O6:9(E\+^DBN/+YU6:X?,J*?!Y6>;)]0UC=L?A-)R5/&()3]*$
MSK0C`?%A457N89+X`[^[O[WYZX]B4Q>,)^P>/D"*H$VMZ#E*"3O>'_%(O(@Y
MNZ]O;^[HW#&[?[R]>?.V/;-3WVVG>AS8>!`C>Y1L*Q]DTYW@?=]-^P/KII[]
MP-G?NV%D][(^M%W3[<_L434-J[OC28Z2J98=U/[0G,U?U*@>)#N*_K,<AS7[
M6<`7=3O84K*NWXM6?16CZMJ!_9G=_WY[\P'D^?>K2,UCD!JL;J3.HMQ)S>-,
M2VV.V.Y!AO'`I@&/CT<SYV6[KF?#5!^\;@X"Q-GW4HRR9[4XJ5$T<+`!=%/+
M8<5^^=-[)MJMV0&W'D:QVPWTQYVH50,:D?HM?%QLS!]6])=%E!!55@DIFMLH
M(:HJK00KC/QRDKV2;4U&[#:C4"V>OY?[J1%CUY^9.($>'D0#ISV*=@)QQJG'
M-4X]%Z*OV=NZ[OHMO&S.*W(?ZQ1=/\"Z,]M()C:-9&/GO&T!'4"T&Q7$6>S\
M(..Y\8/1.K.UC)/GV/6223$H<.C'@P)/>.RF9@LG:+>@,Q3IY0_CF_'0#1(]
M7DO?-&+3]8+D[S9#UV#,+&3YJLBLX:NL=(9/\35*W79M$*-K]M..B<!`UB`#
M1`!Z1A>("C&,T@SC:Q\[*;D[=Q6#ET).O/\*A[U[_6_*`@W%>5HYOTCC0FM(
M[G:RI@0F&@B15N#K`9T5K>GLW-%K"/\!XQ@?;:9!M?`>WH'J!.6!)2R,IC19
M/0FR>FK\&O+2U!A'W*E6M+42F*K;K<*D"Z_0ER$&![3O-("3'T1_E%MPAI:)
MK5ZV`D\XTA9=?RDX1O"C%)]ER[83!7$O\0GN#3D$<^%FVNZEUM$2"DBY4X`W
M8!JG)K<UW3!@\&W5,/9J,V'<8::E&J3C^0C5:M1I7:#,#[*'@-669R`'"GQ%
M=^OOE2:?D2;6TKSY+4ZC5]\_]_N_NBD`8E2`H[0IHJ*PEDAL)-T_*:JHU0_M
MU_-1LG<F5E[[3'%PJ)0.!'J-X]?_FC20G6>`0)T;%JF6?@AJ0B]7&!M'=,):
M4,8`E[N$2[J*J!H#LQU,>O[G<Y6Q>NJA$HT0MPL$5UD65JHD29U)J[0,T1/D
M0P)/.\)YB)4:T>_E1:E?00G%THGKMMT1HVDT[L!.W:`T`@2M#')_!'GHM2FW
MTD%+U,KCH8/X!34"!NNFTXH=NF:1XED6D77GRB&&)(^,[(2$OJ@C("=0?A']
M%D'.-1(-D$.E19(GR,$@$;S=3IB#((=(,N)@EI\:48-U/Z""-#`>Y`5,.@BL
MP!N`D>T('X>OLXC-I:75(AK(@I:A"%H&DUM-9>M:_/Y!-/()^O.H&!N*EAJ*
MCI:0OP]JWZJ=JM$5+J$GE(TU^W'J017]ZHI"L.J`UPP8`!TN6D3ZQ+4.D??]
M''W!^GXCT5<%R!)"P)5N&`3%/`2QI!5;U4,]D:`>@'PUX&G`VP]=,U&I]+!J
M98N2AL8:?7H0`FYDOQ85#+*K983GKF7(N>^;8FA?G^/E`+J#5HZRIT(9-I.M
M@_[75>:E>J'%A$:B&2#PA^XH?9`L(7@4NY17N5XI*:OXHF$T<0DF@3-+P#S@
MMJ`&#^\IGU&Z:Z3`_H>DAV[79$O5_C\J8`:8T$JT8`7,DBQ47%[Z)C.S32;X
M`5:%T8$`4)=V$>GRX6X9C%B4%N1'.?<VY=S;U#GMU$-BD<,2X*[(LT7!G=M_
M"7!7I+K1N$,EZE;RS2?9-*_]56`J^U7+=G]EY;X(FC^>^>:IC`QD_=QVCZVF
M939R]/56;E=LH[J@%_:QW4&N=L@',W28Y="_$1(,XB@O20)HOQX4%DJH&I@7
MEHB"Q'5*69YZ*LP6M'>J^UA3"1X\O`1LTNIVE^3"/^]?3-$_`+Z!_&P+="]W
M1"I!YV7SWQ6==`^&1;$[+B$Z=^@\KX(NV12S4`;$V%<U(:#^('UGB3K#>6(=
MUHTO/D-@/P)@]W`%J_NN[XY/N$Z+$`@I/W&F!1205X7W="=_45:^J)'[$K)^
MA+`FA%T+:/M53>(BB!4]'%JU8,YQTF+@DSU:L*7:+?:@-"4-?XP8&/+I,,U8
M'_0F6^+_3#B@OI900&G!?)P6OCI5A2D!&E+TXB1!,BVQ!I9PK%$J(RK8Z=6;
MQR1RAULVX<70P7DU\,AGO*0HC",8;$IY+,1RBD`.!">858+30P=74R/RH,AX
M2`0.:W9/J.S2TS$5+$CLYGG0H\1!CW(5J%JW='SF-5;O6FK[A,TG>(8Z0=^E
M]^E>RA24&3`;@-IJ:-0&0(=A.EA""ZGK52K,:I;HM1D.HKF5CT&9(M1*(E@X
MAOX-RXRI-!3?H<>C[NH0SV/;\K`,1,K-N&8IB.3V_SXCY/-&,&.6*H<D@PN_
MDA5XFG-MA4^2HJ&5X!"66D5&T<R0#%^PF\:IE^OO=I,9]69EM:AZW?Y+(-"L
M<`T&.+GOS!*3PK%R:]T%4[D_)FB[-:%D.NJ`2%FQD^@AJ+$9AUQ&I>^BI/OQ
MI[PV]J2&S^9(]761?C3+W`B'^\A."CO"@0P$.`L2#W34_PH1I=J9?IMRCAFX
M/HEND^T^?$&.:L!U'\_#*(^.H+V:WT;Q&=XV78L<'RPT6EYD@)LE;KZ1%<'\
MMLHN1Y?/F::#V!*KA)S+"K4Q;]OG.D!H\N5$JAR'$)Z$0UM<Y0>ARWA`['`[
M`/>@9C]K7I%..NK:'8(9"V'FM"!0!Q^A6DF:^&H5K-"Z:O>R)[CYH&#M=-R@
M.^P648%CU^.$^SEFE1@=/)&6@@`9H_%`MQ9`YHUL%!S676P@ZF:8=CN%0HW(
MPQ]PUG.@B2V`^0D1(,CM.$[#;4JI*W^W:=3>/+"W(][+6I(6%E!!ZJCXJ.)^
MNH($#ZD@X2L61U&IIX]48C"(KY09@B=;>9(HH1E#H/L22P^(I9FVAEH,IE[0
MK]123]*NT%9(6DJ"RZ!:L4P8I(Z.YWGA!WU);-I7<\+=U%Q>7CB)L\[_U(5=
M=>/:]:T3S?0#%@\Y5\@QNH0\$_/)=X)B<."YA/".B8^*S%>!Q+*2<@?&'@WA
M^'8CVWTG4%8)=0$*%9QJQ7YJZ_6%!#4D2HT#B;L,7>5"`5@D89_AH$Z:P@B+
MGK#EQ20)5XR6T()CY&->>A<HC1)L^5N9L4NW[ZEQ1WJEACA^?@?#3MI4J^,!
M,P%:$#[[N\1""L$/`A\AF#9G_5GG*G1])Z1[G9[T]R\AOR?EB\3/8^+DXK("
MBHDQ+6HHRW:RAJ*3W>V]!.DO>2$P.D)-OP2@*W-Y!;-``X&T0JT,T!V2K/A,
MMJ";6EHP@9T19M)&J./K-P?(U5GYOQ]>SF#CI%H6&[O]E\#&26FQ<53&CN!)
MTL3T]3\9SW]Z6XWI.650"!'/V!IW%48_*W:^\H`O47&AXHI7080:9)A7L*H2
M9%H@.)+<`66\/.EFU78"[U'/=1S\[!*70<_Z`U=3WLDE'$4AMV+ZN@V6'<WY
M/=F7;EB9'F4)%7@^.[CKF)L"2=:@3*#-L.U85]>3'K">*0O48@*#;96=2FH^
MQ#&XD/KJSSANAR1'E`AUL]T8WN%[P>8TX^R/`06SA/R>X4Y+3W-&MD`(J-:G
MT9YTHBM)E,O.YG"/<+BA`]_H"?J:W`C23>VE?$'`/$=89&7X[$ZHYNI'2"4Z
MOR[$]2>>\$Y\I4PJ2_@^O46BAD#$/:(&I+F"(S<8,(-Q^AU(20W0>65U9$,>
M_&E$L1$E(/-%>MRJX:3O0,+;%@E"/=<VD><A]B*D1UREBR9VM_\2G%)<:-A?
M%>LL26/'*>5VK/K)Y%Q"_+YE#>/VM8\50S=FSX4%)_,.YJZ&!)=`"'_1Y1!7
M=I:@#N.L6-;,=O\EZC<<V6<NCVRYO6STZ:`@-FW?VD/II2M?VMAR&Q"YEQJ'
M3$.<A;F4^C3L+SPGI`6,%T%A(!Y$U`?JGA?(5''L^/L\N)L>6WI#`W;H4J`8
M"[P^(]IV0DPB1EW,]GWW"$U/>#OU.FO5!>U:<[97M5ZD?VP477SY$@J(''7/
MXX#>,;#E"BV#@U9SZ8_R;X\7T$Z]`HGPDKJYL:KO&UD_0*#NQL__:14*\W$D
M'1I%:,C3CKV`3U$?B9E>ZP0)`'V]:T\8<(D?*92NMTD*3_'03Q>H=L/QPCN\
M3A@:3;7F&IH1YH+'>-2NW4.OIDD1J?8MT<!JJT!E",O>!\HZR0YP'V$4RJ)@
M^^XL#2BDF:90\&(1)7B*FW"KNT-CQCAP/KPY=6H`NR`B560=0E?:/@;)?9;V
MCI&^("8&O&N'82[['N\ND=`_&&O+[:5U`QDW4,(IU,P\$)KDP32[>(8E5.#X
M[CA*R@#$)I[N_-_$?A]ZT0GJT0&%=-,M`NZ3_>F&;&GR#6GRXMK[Q96-);3@
M:>\T]6Q?E5K"LX.SJ7ZK!Q@H%4X_.H1KEIOP?NLX7F0Z+N[9A3]10BOC]4,1
ML*;0(M"<=&NFO;+=@X\`Y&]?6^:"<R?TLF/P@F>!>J-,:_>-5=<BUG0,?L)C
M%]99'OO6%-M&010C!"35\.&"E;*9F4A:K,C@VL/H?Z^F?["`'.`EMB)?2GC!
MB@I.3R?W1Z1?(,("7I81+>`O+B@X+4A?7`!(!1?$+RR(RC2?7Q!GLPLJA$@S
MS\LXBN>>%[R<_7S.\V+N><8!VLX\3WDZ^QP\9U:^F$>SY^-1\;*&_S!+C`IY
M>L5%P4$AQJR/\N<_$LQ<`<[,)4F<-90&@=Y3=PA5`*L&EHD+-]/;_/(WW/(1
M8^8?>*)UAMM"Y\)T5+NWS>W-1WOJ,M%GSJXW(?$+897B3V7-,)\G3WT>BN>,
M+N^J>5^ZXYAHYQ;$59[,+H`$ELTNR*)L?D&./\^<79#/Q]Q=@;]@GEM0YO,^
M=P=2S@;5'8^2?-:M[SA/OZ$)'B?%-U8D_!O*XDD<S>:X.SS&-TZ:09*:7Y'S
M>-XO.!CE&WL4635O%:@V,ZD$_/O#K[<WMS?_!<W$7`P-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,C<@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`R."`P(%(@
M70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-
M"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A
M8F,Q,B`W.2`P(%(-"B]&86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*
M+T9A8F,V(#<S(#`@4@T*+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(X(#`@;V)J#0H\/`T*+T9I
M;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S,U.`T*/CX-"G-T<F5A;0T*
M>)R]6UMSZ[81?O>,_@.>.FG'<@G>^=BD29M.T[0Y[B0/?8%(2&(.+SH@:47Y
M]=U=7$C9,L],1LB<BVT!!+$?]O+M+OSE3YN'3YN'X"DM$A;@'_HN?TIB_5_9
M;AXXC7`6IHRG]$G(DO2I*,*<Y0&,!#QF2FX>?F0=K97%"2Z4Y#E^8>JP>3AN
M'O9_PJ7PS^*#X"F.(WC!4QPE$7R)BC"\'B_B!,>+*,/Q/$^CVPN&;,O3HLA8
MS@,6\2B.:$][$E`/YFXPBN8-?_F\>?CS-V)79HQ'[!D>("!H42MZBE+"BL\M
M;HD7:<J>R\W#%O:=XD/GS<,7WPGU48YLWZM2#H]LF,HC$P.KNU)),=3=@95]
M>Y)C/=9]]WC]^3"RDY+#,,%_K.]8/RE63L/8MU(-3'05.\A.*M$P6?9=W]8E
M/-15M!2\JQ47D.?35"O)_LB>?]X\?`U"_><NHO,01(>CUZ*'$4^<Z$48:]&G
M@8T]J^1+/TK6]K`+D`-D`"!P`*491".U)"WAA'++/8`UPI2CZ-A9@L1*R6YL
M+BC<*-M3(T8Y(UG"M`,^-QXE8=D/!`#K]Z]>X06#H+#''P:9Q2#*HU!C,(LU
MC&*_IWVX'>/VY@FM'(]]-3RQYZ,<I)X%.]>G.$S-",K!1*6/%\_\EY/L!@D/
M?#M__HB(G>NF04V"Y1?S`0BA+CY0`)NWBL!S[A0A#U(-@MTIV\E23"`;[+&&
MHP0L0`^,RDN"HP)E+4=S:&0T3^Q'R40S](3$$97Y:I*2:".@(&*L7[1FP4>-
M*/$=E80W5S!H)OL0/DNL!D31K`%%;(1_O;\>A1Q&5>^FL5>DYB,"`K@\L0]U
M6\,I-1?P!'L-TP(<)9M:="`8:/>L-V`5J!VB&TEX,0RP/"SW6A4.L-`H%?D5
M5)J]%S22W*(1A)%#(P5O3FC`EBI9UI5\<_*B>I%JK-'US3NG<]?;/]:'H[SM
M,8Q$W\,LF@ON`D':NQ=4>HI>LQ4?`==1>R0?$,3<6D,0Y<X:$OP>(:CJ_;XN
MT9Y!OYEVDOT)W#AXR9/J]_4H=J@`*"/@@%K?]2,[BA<)3@^?K5&A]U-7T;/#
M=#J!PP2L&I1YU-Z#(/FMTJ4KTH5:NB_^%\;!W==/Y_7O?C00K8L@MMH9`Z.P
M1T.!#(_F6[(Y<%>(_1P\R`_1>5QI[*R`H@3;!C\KM=&5`J//'K2U(WN<%%JM
M,75P\O"\#7*DD;-[)YW4+P7=\*"<.3QMZ<ILGZ"<)EX9*U/R1783.*2_@`$^
M4FA]8TO2&.;N8A"S(>V6B<Z1W^KS++1U3$YN^,SLPP<"66`12(K"(<#Q>^VO
MC>C?3`KD5H\,/[CEC@>,+21T=TOFQZ7U[D!_=@UYO59`[(-_ALX1N6$-O(3,
M=U[(;>3>5I;EB4/AMYO9BH_(D\"KCW#K_[;-I^OZ$6E"#TH1\,R92)CFAM;^
MLQ\&/*F/\L+`;0]]U\'1E?W45.P(.D/GNIL@D`%UO__IX19YY!=?N[X/'YP5
M-FO@63B3Q<CR)61[X`31`0#EGPD<&!FZH9,"&ZQ/P&=;V>XP#S(\OQ6=.,@6
MIZ+U#!0E:XB6FGEK)]:8LSN3$QZD>JG))\'+1LU`!MEXX<A99A.%(`L<*XAP
M*1*[;D\016B3HCS68/LDBA&NW_TL2^*/K]@^$&$UU3H(D<]`SX(_?9I$`]++
M*R1F=04_!#]`#&J!2(R08+(?_O!7=N[51QV2=EZH49;:1('GF"6:LX]C`T*I
M0)12-"X]G,J2C.C'91I8]3<)D?Q%EA-BM%2%*XGW4]-<S#QY9:8,$H8.HQU$
MY^EP1,^]`[(-I^`%AMBE#`&?.7)8.(YLS\```!NGY&\<%5*-E<-^WPH<$G/J
M3,IF5,EJVE>@>WOV87[N>P08PZ`/($*;+01%D2ZRA40C\;=&=AW[EZS.(#W\
M_4XHV'D8!.GCLFQ"1!J33%4C\W=B(TW9J[YEW=1*U0/5QH=$5YL(*TI12:R:
M$-T;-?$9)+VD[@98?*)2"D5Q'^)S[NAHM*"CL1&_@6Q0AQ.QJYMZO%`]!1A_
MC]Y0@&J<1LTJI&K!2KX1=8.FC%F@5I6%GMSV`V<*6R?B&I@T:KQ.DQHFG5DU
MC=CUD)L0#GXX:5I85A[&,R&S?*Q"9M2?++F$#*F:RI'V4B);'F5Y[/JF/\"I
M^DAXTBSV&FS=^CZ";9HXNI^D<[`U9!\39G1\G:P6*8S-273A\%7!"3-TI,%(
M?DO2I;JK)BQG6)M"?LS$Z=2`(S>,5\=M<V[F/.&5XU&1L\5C]:%6L2/Z43Q'
M7%R4I+]2'%-T>P^%UYZRD^>E0P5*TDR4"LS^5R?P^*"1V,;SFXCNO#B8-'3%
MZ;D^RVUI6OX"'O)ZT[-0A`@(MO`\HG1@+,D3&*(N\Z*0,%@/"[DT+49R4RL"
MXZ#Z\WBD\I;H+H\V[/CCRQEX%XN#EVPG#?RR<;>^#P>1Y(Z-\W2NUV5Y/KL(
M76[M3<MAD%T-1]YK6C`L3$37,5UZ>_V8FP^!5==#($;IM->$936["R3GF`OK
M:BA\_55Z*=\GJ27E8>*\8Q*86N5IVC744C&<@6@HL4Z(C^61:B%$I9RD]]YB
M6&1NCYHN@Y*%X;U?$X'$]C7WU[(HB!=`\RA?M$FL+UYJR-W?G_X^(&9>0<R6
M(`8Y=W0Q2J+"TD7KK)V-Z:*XZZCU-E]<!J'93K6SAK0#_+6L0+MK+SV")'%9
M8+JHPH:V1T#!MNTG'2YG?U'VD)]#H&(085YJ>9;4/L+M=G,:N*C;Z9(=%A.F
MSOH6H"$OV'T`X@])TZ@[AK(;A([LZM5TY\Q\P!"Y+#!,B]GUIN8X%ZFM-P?#
M%_OP:!L06]QK[F\;G!=+,']W!\/SWP?$W"N(^16(>3AWKJ+0D(&WIOA>C=NF
MG[VRV>=5M?3N>5J2!W?`9H7D)3SQ2O+<^CY(7ERXIFP>+\INF2FY_GNN8B\N
M'53UH*:3KC_H_B36`)[8WVME*U!PR+H`=94/Z=0).]YU8YI%NC&":V*3US2S
M;4?(T]V,.'?5E21>5E=,]@LZBO40+!]AS<.T6^Z^$7C`[J0(X?7(+G^%UV_O
M_Z9L(7.(M,<Q6GL30]\76EZS@7B)TH]UJ[DW?"6CILZ[[`X8;]^[8<!,$\M5
M4<G++E1%)]4^SC9U):,HF6]=%:FA$,L=8Z(J]9VKN9N`5XG00T%,M9UVZA`H
M":C`M\L:,SS:(LVG9_J&H>_#N9#1+NH%@EJB\)P=7@Z:+-<'$K&K\*3QG.2'
MJ>E6X7VI_B*EN1^Q!`8-$GTVA$6@CB/0J7,]'M%GFX<J+$OHNBBD9[J]32E@
MWVJO3_"8):E`I\QT4;W40Z\N0*<4>A2L+0QZ>1\81+;2$X9\CEMY9(*_WA,:
M.QT&9:JX?=CY'C*\4=<2L9PL]1[UX?:0_AU,Y1/4?J+>RXOV&53V`#*)U7E8
M$GPEA40-F2Z0:']H"DFH3)W$V4+5?CI,,7?%GG2^B)1$E@+M9(GG9HJH6*"Y
M>.E.1H7?>HA;WT?W-\IT/:1(GY(D(4^]Q0#"#07Z=ED0`QA'O(B&D"ZKB;89
M+%3[NGIOU,P/\$GJ%WB[O@^.$D6N0I`7BXLI-G)]/[<#M45I7XXA"'V3O1Z[
M@+K?$?$\B9&<CZ8@)IUSZ9\YPD4#3#L+O)[8-#`R089LS87Z3)[\>!3.=RAC
M9[U`T=*WU6J2Q174:]T8_V]7HPO_,()8PZ*C56(BK:A\I:\WF=!F(0!GM-3C
MFX+/W38L$YBXX0.$('$@!`L0+&-S23R&UE*^-3P46P(P>LBU"#&(5R\0](#-
MZ,)V(\X4E2F48<BO#]T,E<7(`H,XP.<CWI]5>%=@L&T-#R"$N6/K:3'SUH@;
M;C.(%N^HC=3CU4U<*\T;/7@T:M]=%JU/BMJR(VDI9`T@//9R1$>B`LHMJ94U
M#GVYNE:W</!3&PFSF;LO^%V0I*Y$--PX-\LXG1!X$V^'%_*F@4+SHVD5"R`X
MP/($(%=^1.34Y.YOZ6O8-+&2>W/%Z[8_T!C</9O-@,9:!.Z?S8*SI6JWKTB!
MZT>>U^=^U^>%Y_4SS^M[/E_N\WSQURI\GB\,N/6OC0O?'$<A]@QA95IU?IQ^
MKP@F@'N.:0)_=T*6T(3XW0EX]P,FA.],X'C!<75"F*Y/",(X7IM0A,"K5L9S
MGJ\^GZ$&KXRGV$Q<&4]XLCH>\WA5P(@'J_L+@WP=XB#+WQW_9*8D&J+EK[$Y
M_8+@A3ID%(R__;V@Q-'9Q/1J\)*3;:L^$Y6!N/,5_DH3T-,K/=3+_/`W7/*,
M"O\/W-%3@LMF\$67DMR/S>;A@]UUIF'ER>W,)WS')N(`HXZV"1Z_-HIT%>MM
M$:^>Y987`,;:A`B+8FL3(/"O3TB"(EF?D*XKS#9-UC5^FR7%JLEL\S1\7Z<(
MIRA=5<HM*/5G@.`\6C>\+0_Y9[#B81A$:RYNRX&'?V:G<9"O&N@6U?XS:@%G
M\IDUTJ18/Q0(!/'[!P_:^_5/FX?-P_\!$V6G,`T*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HR.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#,P(#`@4B!=#0HO
M365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#8X(#`@4@T*+U)E
M<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@,"!2#0HO1F%B8S$R
M(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@.#$@,"!2#0HO1F%B
M8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&
M#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y
M<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S`@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`S-C0T#0H^/@T*<W1R96%M#0IXG+U;
MVY+CMA%]GZKY!SPZ*8U"\,['V+$3IRIV)3LI^R$O$`5)\%*$EA=IM5^?[L:%
MT(R&6W$-4Z[RS(@@A#[H/GVZ@?WVU\>'3X\/T3JO,A;A?_1;N<Y2\[_Z^/C`
MZ0EG<<YX3I_$+$_65167K(S@2105K)./#[^PEN8JT@PGRLH2?[!N__AP>'S8
M_1&GPO^"#Z)UFB;P!>LTR1+XD51Q?/N\2C-\7B4%/B_+/+D_8<R>>%:5"2MY
MQ!*>I`FM:4<&FH>%?Y@DTX*_?7Y\^-,/8E,7C"?L&5X@(&A29WJ.5L*,ST=<
M$L^2BCW7CP]/L&Z>E>SY\OCPS2^2'72S93L]=DSU_2BW[-_K#VMV$H-LAYZ)
M=LOBPCVBOYAH&GV!OU0[R*X5@]*M:-P;*_BX;L:M:O>L;H0Z]FPXB('5^BP[
M^%6R[SC[_O.IDWT/+[(/UWZ01_8']OS;X\/W8-8_W\5X'H/QL/G6^#*:C$_C
MQ!B/UIQ%I_38,PTKZYCH3[(&J_7.K?1ONA_8LZP/K6[T_KHB"++(@(2_WX*P
M4XV%Z21;PL#`PL3IU*B:AO7L<E#U@5TDV\A&R;-DITZ?U58N@P*:;E"(8X]"
M4D*@$`J;3HLMKF``TW%'=KICZ`[W]FE%3\9V*[OFBN:]AHBLAX\_U)V4+8ZQ
M6XR?`ZJJPR_;CK7UKEH?C[*K%:"W@/D0\,[ZO.+>!Y+$!D"X+VLPY0+;T:UH
M]^W.G72OS+:!5VP4PN0LA:6?1*ODC=,C0"]>!:_I)-O+5G80.U?`KY;=(%1K
M/>BL&W`"G*V1GQ=!H<@<"D653"A4A4&AD7N`'Q>S$_4PPN^?1ME;4(`C+JII
MP%F9V#22#=IYB[&UTZ=.R4%T5]:I_0&V==?I(Q@IQN&@._4%(F+LP=FO`*OJ
MP-=$-P!H3+>`!<R&8,O/A!A1!<ZZ!`A(>@1"'.6Y!R$O,P-":(C?9%PG;A[1
M%Q@"1IQ%HTR,RQ9BI9:$BB-,"!X<+W<[#*>S!!./L-.XV\@,P(:=@$CO)83'
M8-!%"L'8T,025PI`-]T2.*3<.4.5I!Z'+*L,#F0J>O(&2)$VXQ:-=AL$<(\T
MMI48WB<#("P\""3Y68$?P63D7.,P=O(N)1[%%1VL/D"`R'9O210_70*!.'6>
M$$<3*93<`-#J`:;LQV:`K7&ISV[(FOT,@'BKPC0IVNNMA82-WE"@HR4X+]C8
MC[N=JA4,@+TV[$LA!8`!*I2(;`B=.HA&&`I?M`0*H("<-@B4@:6$5_L.3DF+
MVL(Z&WVB_`Z,)0T.UB'6[(>Q0PN.NI,K9PP:KR!G8$XT9MM)6*^.JA$=14UC
M$RE0X<LO7L#ZLHJ<#W!>>/L+U`QH_U;V:@\$W6G(=@&I@RN$JUNS'V'0=FMY
M/C#8NS(:`!R/K`$S!%-!VK"IUOD+OK<3JK$<2YH`Q,E%02"B>RV!0Y%X5@Q2
M0U8EC@UHCVE;Q/8L@,GV8/;O74D^LY+,K.2;_\1I].[SY]/\[PXC*.TR\5HS
M#\(I3JT[_02Q#_Z`&N)ET@P$A>H9*,*]PH0R98%`G*W9G^M:=R@T&A2C/7H*
M.JH"2A$D.3HO5O"+G+X-OW`)+^)>9)9\RJUI:BDU#)D5TF*'B7$\@;`,\^$]
M&5KK=J>0-I25**$I"C/P41AHL)@1R![BHVQQQK%3`Z1?*7H@Y?ZE<%D"AFA2
MFWDY>4%5O988-TM_/DA02'ZE+ELX#@"$/HU('G?PN=$31"A4RLRAU$OY$=%8
M`(&B]$HSS^)`;WL`[@K'8(4HL9!G28*`--(W'H`;*O9061Q-@D5FE*";]56B
M9]6Z:<1&=V+0G2LO6LSD@G+W3RA*`)X&BIK5(N;G3F/R="JVTL@56V\N57?A
M2LD!0&$`86Q57S>ZEW.0F:H4HBI0&4ZJ@T]A$;8;L?`(X3=^LP0&&?<9)9VH
M,,=*##'PTO>MS/F&5!@W/8*CJ(2">%"04BT[WO4C;06,PEK&!\9%`99[JKWJ
M&MQ@J3A(O,3,$L\$>5R6@;RZK0062*D%3Q=-J7[^W[?X?!;"O#+Z%'#C4>X=
MB9>932H_`DN`Q#(%*WH!Q/:5`46HO?&`6H_-%G)"=R2/WXP]%&'],E#G1;$H
MU'[^)=1+GD>^))SJH2RQE?'/E(9]FZ8?3>28*.VQ2,*2'NIYUDI%V0?B$/G[
M98ETIU=`K;:@*[`"`H.MZJ2H#Z9NQ"VM9=M+VTE<(%KSJ4U:)$%_)+'%T,4J
M"\I+IO.I3>[IY%YT5,#-%LI0-AI^HVFH2[BRS1]J?]BZ$3L'C?HH35\$AZWN
M5LN^1%\"BZEKRJMBZA=&-NJPC45TBK]`22CV)A73WM@<!"1[0`M&2&'JBS10
MV9[BJX[J?*_Q7B=1!RW$)1#P'5,(9>\-&9X8&.[N6$\+L4;CKKE"UFA,LS2;
MN<!?R'[<9^R#667^&@K(B-1W[N^W2-YJ29`?+0!#%K1.^<0*L3L[N,AIGV')
M:!XU_,,*^4IB_T(\W$II`L5T1(0+:]-6P-<G(K@NPM%9$2_*T7[^)3@ZR[RR
M3J.IQ"*)A=OQ?--;Q2@4?0\9T0<FM25)?V(H^4[\O3H4_56/X'^V@VM+AQO!
M-KSZ/KNQ2[ABXENW:9Q/$6E5M0N$%V2*ZA\=TB`0A-X-3=M41=EE"CW3F34"
M0K5028;Z$S[O;=QM%3`QD1;,?12MV%-EL@@(L=?5/)UJBZ)(I^,L(WAKU$.P
M+-VVLD%4MG)GCZ/`_%XV9TQ/*(*!?S#!:L<[]L0.&,[TMF\/-(+R4MW57C:G
MNZF7`"%RNII'W.OJ)'?G.::,>-&&G)ST8W`LZ58Y^NZSJYFL(ZOVM[&E)OYD
M-]8=`XWK\.QN9\_RC*.$3?]-H^N/2_49TM*W;B=F3@INVPQBHZA01@UA<'"Y
M:!7H.$S,Z#/@#XU/6BM;-*,Y4\+!J!(7%#K@*6$@;,41VX$!EI3$A`T\&.W"
M:ZFH2(MHZE^60;5IY4JPRZIWTA6JX973*AO<2MC5SF2G$WSDK<+.K_$%W9(3
MH#]-<M0FKH`'B37N5.%V%A-D2Z"0>0&;9)-'5+;[Z%>,:@4F%T`-M#0DLA53
M.WK0-$3QQ)9T&$$86==NX2>J7_"D1ER-Z#<^<^-2IO""H(#),><,()-.`T+@
MZOBPS[\$$E,C-HNF!E04V>[#44)*V_:AAERSOR`_FOQ`]8:X]!#F=.0A5(/)
M)-`M(5]Z8`U*[A!GM+X1(D/%S!FF,\>%[KO?6X841>DQ^/TZ9$9$I3Q?5$3Y
M^9<044GE^]11'K]F3ILVS`6`07S6K3ZJ&MD,*I.=E>*!@C^@@M?=7K2J/[*+
M0-$/[GVDPUYL-^SMNYB2@3Q.!Y(=])=QQ#7[!W+*46\A*I8(B*3T,CXXYN.V
M(?NFC2Y.%.B&&EO/_FC^M=GV=D`GW1SFI%N`.H*,V&%$0+$X&D+%*S:.*3&+
MU.KDI_=UTA(XY-,=B'PZ]L8K6JZN)1QZ2`;`=B8WBMU@;RW)SW@U2&[M-0WG
M!Y096V![$7X"$-%TTI0_%I^-''`V=RO$Y!OO+_3B!-,2"*1>1<=!FZ=T/4F[
M,R]O/[E]7K,/8)%["E;T=$[EWJ(-M.^1?QA*O.,7_@&.!C7Q&[6D=Z[H=8VA
M"R*T!`P)GUJSG@,R[LZJ-E?F5.0O_HK6BFU$#^O!/<8+`&?1C#=;#G)0XNDH
M`RL;HY/PC-_Z$;Z#G?R1&AS]U!"Q37][AKXS#1#1]"O;6H!D`YKEL`@./)V:
M7E,\N`/PV]VXN#VS)]GNR('DD&^X^CM^U*%`]X;L.)HH<'?=X-?^X+,EY$-2
MC'B+1&WMH1=]O**C30B91BX*0UPY+1VETRW!N(HJIYTF\U`SR/=>0Y7X-50Q
M*A7PPR_PQ4_O_D5%8"R/LVS*?UGVREA3)042\(50IEZHZ82"W.^`#MY[O=CF
M^/\@D\)K`31E$182H80F$==UPA8T*RH7.GT%46NOJFSHY+XV&/4#"-XE?+:,
MW-%(%%0]X+2QO[7Q0I(C(5GZ1M[!BT5G94J6!41B;`\4EA*)?OXE1&(<G`8$
M%P73*/.7IK>:J,J<JAYUJP9MB.\T;L!3W*DM'>8CXE2#^^NB#-LE8C`'W+0=
MH++&?L!3$3I/F!IT4ZL*-:.MH9:JI>.I]5\$]^)\2I`[<.VA#PG;)D(Y8[SM
M+'GC%1[,M:V]QN`DWZRM]HM-QVT2V$L=!\7!E>EB8LDJLCC`<J_LK'0C4!":
M_;O7#O-=(Y-$@UYX*'Q-4RJX/DG!B2W6L+=D+AB'V3:X9;G0W3`^G0"44^W@
M*5'8'30W;EXUC?ZWAND;W<L7G3ST,CT.M64RM'M:Q1((!!>GX_3UP2`9_N)>
MD55,01<(,,$;WEL7[3MQUG3G\=X8O-<C&-X<'`Y7!$)IDI.#.LI%N)K;@X6E
MN-K/O\0E`6Y/!JH<Y5M&^@`O":1\(FO;Y:,SL]W4]X%0LHW296#EY;*PNOEO
M%T\;FB09*RJ8F6:=7J=_?42@@6C``?S-`65%`](W!T!2P`'Q&P/B$HKLV0%Q
M,3^`XTGCW(`HCJ.Y`16O9B<HD=5FGA>\*.:>YSR??9[Q;-;"%+=PYGD25;,8
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M<W1R96%M#0H-"F5N9&]B:@T*#0HS,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#,R(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@
M,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@
M.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R
M;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E
M22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S(@,"!O8FH-
M"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S-C,U#0H^/@T*
M<W1R96%M#0IXG+5;2W/;1A*^JTK_80X^9+<H!H,WCG$VV?5NU3YL;26'7$!@
M2$X$8N@!(%GY]=O=\P`H2[#7I2E7(A(8-J;?7W</WOYZ??7Q^BK:YE7&(OQ'
MG\IMEIK_-:?K*TYW.(MSQG.Z$K,LW5957+(R@CL17-;B^NH7UA.M(LV04%:6
M^(?IP_75\?IJ_V<DA?\6%Z)MFB;P@&V:9`G\2:HXOKQ?I1G>KY("[Y=EGCQ/
M,&8W/*V*G)4\8@E/TH3VM"<&S<W<WTR2><-O;Z^OOO^YWC4%XPF[A1^0((BH
M8SU'+H'B[0FWQ(LH9[?-]=4-[AL_/UQ???>+8*?ZD>T$.XJN99VL=YU@<L_J
M_I&=M6JG9F0/@K7B7G3JO&%*7]XZRN;(Y`!46L$>Y'ADXU&P:1"X4O:-TF>E
MZU&JGJG]AGZK]DQ-FHVB.?:J4P<IA@W[$[O]_?KJ)V#K/Z_"/(^!>5"^8Q[E
MX)C/2\-\4\,^!]CE[Y-^I/T.;*^FOF4*F-`/$KB8^F&2(TFEG;3L#Y[U40PC
M?-\`Z_VTKYN1;N-7?2?P#E(<ZDYLV>U1`"DMA[N!U1KDVP-YT8_P@<1EI7O"
M2T$$$556$%'.G1R2..5&#J"0YBA.LJD[T-!!RV;J@)NZ`W6U['RL]:ENQ#3B
M`L?^L&6_'"5(Y0$M2/8C_.=%@V8D.SD^`H,#$.H;L6%R)%/KU<CV4]<]LD;=
M"TVF<%8CL"Z!NOLEV,0VA"C`_YU)E!`)G$FDX,<DBG>]V_FHF-H15\.TW\M&
M&GU9=LSFZX-@]0A28G73B+,QDT8-(ZI^MB$@!9(!>X>E!Z`(]V>./Y=9T]7R
M-`"="3SRK,$VPIA%561.%FDYNT=4%M8LT(&/<@>*0R-MU.DD=`-[EG\XA_;6
MX$Q8M&SW".Y/`@#--JKKZAU&`*5!H^_V:"_H`L,$2_<VFE@/)'\D`F04EO2&
MOLWB"2&)K+22B!-T%2N)$C]3H"!5B$^-@.U1[%(C>L<P"'"$;]U0OK*AQ&SH
MN]_B-'IU^OE,_]NDF:]+,^9$_`;#39XY<?(RR9R3C4+W9$,@Q:G7PG@,F(.0
MAYXUDX;HV#RR?0<&,-%"YP]U"WXW"`@?]7Z/'H7J``(0L<)H(N)A->'HO[I=
M0_HOR]1Y>`RXR`7^LDB>4P3FJ@$C&:3`T7GG&=SPDSS5(XJ\S'^+`"9A5J@X
M?;2YO!>C_3G$RSB*4EH#'[(-*N<,BI(0'QXW=/W)(]A]/00)<&5>.+>.D]B[
M=8&?D7U`)BZ.73*!V\*0U\M>O/:^0"A^8U4,X18-X`_8S<WK/RE=B"`J<Q_9
M`+9:_'=2_7@<F.A;T,8'2&'BM(.DG$0;W&B^9?\"P=P)#-%+4S$8QX`9%-1/
MDX;8#WGPOSTLV+"_*8`__U`(A_!V"-UFD4]>?-9ME%E,\V^ASJC*]^(\[3K9
MH))_/,J^)@M\U[>R-LS)YWQ`"P-HQZ-6T^'X9%$KAU'+W80YC<@!CU(#%E8(
M:]1##[(<IMT@X2$Z%+HMD\0;]R)G%2YG`?;NII9@*'#YPR#K?MZ4=<16:@RA
M@$_``%[=_"#*N$T&-O2B6(@#\@R?@5UEL3X@"X`47=V#U5*9<JX?$6\/R/T$
M*H+`=4(LTM0#:JP5O3J!N6"4DCXE@3(-K@.5H[5O/VQ9BQ!'AX&K)?<5#,5R
MQU59N@!NH5E/&-(&LMTT0.`:#%,UZR?R:;B)T!/1*]RQ,$R+CQ,804L8M3;`
M2X&_'&S2_4K6?X"(KM'8,,0'D$-1N0(FYO$,5:FJ0SE8;L2GLQH,,PUL\B"6
M##PB@*.K#."HL&9@LQ/!_9>B`19!QEJ6LH$"""LYHM[.#^G4@$5E""&4L<=5
M9>E=GN><.Y<WN1<T_2;FR28M.&W>[XV*#YNB*7>_X?FF*+,M^SE@QDO*>>]A
M`T%2YOY)()@HCV?,DWY5PB/'>%&I(+$0>LTSK]<X\M8=QY4MQ"Y!V!O.^28"
M%%$C)CZ=:^N^3[0,>WWRN[B@GX4$-RELV;$35M494'9/(KG-\#:)JZ_1=?;M
M$?LE/)^7,_O?#NA7JA%L4H:L1CS]$-5($9=S+W).T0Z-_[PL]E;"]K&^%ZYQ
M=L;*`4,<=I;LM?TT3I`+>H%Q^OY)I;CH[IRUI#[.Z2Q&Z5;:]DP(+^?<IW*^
MZ#RY%+;HI%P@CTYAUVU.PI!LNT%ME@GNL[KYB<10."0U;%29^ID)*Y.>Q+*'
MY_4-M:/4(*DH"B""O/+E:!;/!L!M:$8]VDJ>D,Q9:&L-$.D@M<.]P<CD$GP@
MB@?H5A\$I6CP>DG(_!FQ`'=@&X,SF8VS&0(O-;:@0!K8NPX2Z/-BKD?YC&+*
MS'K`C-L$PA`$(^J9IHC2#[5N$?2-ND:+P5[;V35)W$4M.C(A(($(1^ZA!OJ,
M%JSM!UA.OZ5FW"@;>:8?`A`^!I%"'OEF6SE;066#]KY3#P9;M8J:Q4?1'H2I
M5\B(>Y?J1L+S!.!IS64`,)4G,=CY=N5LYP"$1V$*`&Q_`_^JDRTQOBS=L*@;
M@A2P^3R9H43OG,'5;\;O=TK=&7.%2@VLU-6FIN%NO.&I5E\_K^%VXR1HYO'T
M0V2>/)H'0<LI6&*!\RU8BCSYT`<&T4XC%3S:U3P:VP&[6H-1:'!0\QWP1*T/
M"NLIXXA[!GZKE9;#"9!D;=L#A@3U\6'--()U"=L=!V]5'07H`":6E:YJXCSS
M*2?),UL]?M9+O:Q^;,-?$`\@'HD9Q2:,11Z=QU]B8_P-^VHT_!)==]'*1VM]
MMI'TZIW;(HT\^T&06)970?W!TP_1H<^RN9*$(GJN.!*;BM_:3&2TI:?SL@5_
M)\091SQ[K4YN[N/Z3%[39#-]HT4]N'M430<)3ED2AU6&HQ\B.&5\+O]X[MTT
M3APP_F=MAK&*8,ZKQXFD]%L(6[+Q-/9/NLQZ256ZD@W#:BL'P/449X>I.2+\
MVTN-45;4>CQ^G.H[_'*$?">;NL?/9_4`(=:4Z1"%1"<P>DT]W#>FNZ]E-VES
MTT1H*!S&L6[NX-()@QG"OP!!F#J0%O2E^0+T65=;PMRGN6(G'E7??I8JO%.:
M=ITG<(&:".^#>P).Z$3K94HX`L+^(X&G+7N')4%+>6]C9OEAI%"ZZB?.8B^%
MC+N1(&ZY@>SZN)RV[YZ+0HL9/#8]L'P#"#L*BDC*V0`V*<UY`]4TF*]P[-3/
MC1S-VOI48_WD^CTVN%FYA1!!GLZX=RX`2]?+Q3:-1FCZ?(E&<)S`,3$#CM&@
M:&K\RN@P`B1;)[$0DU`H58,&64\_1,9+X\('V2J9>Z=9SOU!*$36K3ACNZ@G
ML0^"Q$KSKV8:1@5P*(QHHR*L:!W]$/DKJ:(YI"=S2(\*/Z,P@V",;'A>"&>&
M#VJ6J/'5M;DSCVC8+&I(!H"Q_:"6PA>VO"^(]RNT`_@UGO'S_*<+_FUC!]DY
M``X:W>C$<G/)R.U".$<MQ((%UZ\WI:BI/""*"WE/YXUV=4<S'28@,6*HA^>9
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MG7G\3IT"#`ATW`LP^T[V]?+HU2`//7:H:P!>"\7W[?=V6&G+-P/YNXXF]G#Y
M&:ZQJJ/#.?0%Q_KFN2'D4,PCG7PAA\3/FK58YW#E3.,\#'AA)@)&,;>S\00(
M%7%!^BMQ%O80I*?_;9L'':VJ*7&%5\+GN6.61Q:4O*=S^>_G>0D.E'Y4)PC(
M[,.HFKL0$N5ABRE//T0QQ:NYF)K?)X@3A_@_"*BGI6F@[]E;J?RK'H_FQ$(O
M[2$[M1]%S^X53F@P8`60-"_"UE:>?HC:BOM9&<]F!)AR=T3_UHRX6O->BFR,
MQ'?/2/R1#6C*5$T<1$]U+<B>[%U\@K`B!;94Q*=1BY.PP_'E^6N33>[KSHWH
MX4%T8"[$"RM^-A:G<TF9`5F;;5\P*3S1I::1QGER&&E$:%^OF(]RB5H#F#P,
M]L08B,].?R4$X*,\'*&BPCDS>#_0P4:<&55XUG%VV+<U#N.H/1E"`/[-)1!`
MOIB1.N0U6`VA]CP_>$[-737\4K(8W`M(3RP%UR_TZ5[.V>'+&8,9+V[9#Z!A
M=Y3"GCGPAR_H8.UK<U^`DAW[IIH&SXWC5W],EBRD7-G7P[X+4BIQ__I5G,ZG
M.#/NQH]GG+*='1XBT6I%*.]%=T9K-^"A)0`Y&)"!+FYM0(/2=-L)`\46;TE<
MXH@0AZ!RS_&3H(BRR),4SW,":2([_Y[>C$3?KP!KXP+^TH(2W``7I"\N@#WC
M@OB%!4D)R&UU05RN+XCC/%M=`"N*U051'*U2J'@5K]TO.9C2ROV"%ZOW<YZO
MLICQ>'5_*8]6A9Q$5;5V/X[*=0E&1?GB_8]V268,@:<OH$+N;91_[I29K\<S
M^P8!-H==._Z6Z@=\:P#J<IS&7%BR(?/^KTCR`7WF[[BC;89D"_AC.@K^:W=]
M]<'MVIH>SY['7?%++00\\&A!'<^?NE6^:BLW51FMWH^C9'T!8+M5:[I)LG+5
M'&[2+%]?D&7%JD'<Y'FTZE(W19*NFO1-F7Q!#E62K2^``N(+DH(5Y6J`N^'@
M.>O[Y#$:Y^H**&765<Z3K/@"C30KUE4"L3A^6>U@>3_]>GUU??4_QK'7?`T*
M96YD<W1R96%M#0H-"F5N9&]B:@T*#0HS,R`P(&]B:@T*/#P-"B]#;VYT96YT
M<R!;(#,T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R
M96YT(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@
M-S@@,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C
M,30@.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*
M+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM
M86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S0@,"!O
M8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S,3`X#0H^
M/@T*<W1R96%M#0IXG+5;6X_;N!5^'\#_@4]%6LRX(JD;F[=LT\L"1='-`-V'
MOM`R;2LKBXXNXSB_ON=0$N69D>0L,T2`Q)&H<_D.+^?&#[^N[KZL[H)U+"(2
MX!_S*UU'8?=7=ES=4?.&$A83&ILGC+!T+01+21K`FR!DI%*KN_^2TM!*P@@)
M16F*_Y!JO[H[K.YV?T)2^.?J0;`.0PX,UB&/./S#!6//WXLPPO>")_@^36,^
M39"1!\I%')"4!H13'G(CT\XHV+V,[$O.1X$_/*[N_OPWN<D25.\1/C!`&**#
MZI2AEI0\@O+O_L?"X(_D\?/J[B-\^I_?Q8`O,6"181"L:8229*N[!P"&<GA\
M!K[_;@ZJ(IM*RRTYRNHWU1!9;DE>;MNZJ2YD)[-&5S6\NY"MRBHE:T7@&])4
M<IN7>W*J\DP1O2.ZK4BFCT==DKK1V6_W(.Q>5MM"U?7P_J2JG:Z.LLS4FORK
M8[<KVJQI99/KLKXGLB9>8(!/>QB2(+$P<$8[&,ZJ*)#W7I6JD@4YZ2)O\@Q^
M(1HJTZ4^YAGH5VYS(RFIV^R`7YQEA9IFH"4\)[H"[!I5J;HAE6P4/LC:JE)E
M=ND>O-"WJ/4\N!Z@$,).B`2U?XG$K#W7Y)\ED=M._WOSVCSO9T"FVV)+-@J`
MV7Q664,:3<[Y]KF^@`T(7)_@I\(!P^S*RZQH4>-[LFD;4NJ&%/DQ;]061MT;
M2'Q`D7:30B3KE*<P\!OHO]-%H<\@RE^<62XL>!&S'U_O2_3[Y>Z'?CS2]P%.
M"GN[3^$M?2_"1V^PDR\)/]#W(CP-_0H_T/<A?)(D7H6W]+T('P9^A1_H>Q$^
MX'Z%'^C[$#Z.8Z_"6_I>A&?"K_`#?1_"1\+G(1B/]+T('_D]82U]+\)3OR>L
MI>_#78L".GBN<<+&4`9_H^<*[BDZBB=9-_>=:WK0Q5:!>WF03^C2-JH$3[-N
M\J9%S[)6X)B#-ZMJDA42@A1P1M&%1\]_;_Q5(N$;$[7D>FN"F"==P!L8<4%7
M%MGU09-UFR4ZS2=97MX:@80G%H+0:`]69.S-V4!$.B(M(.(UK+R$96$:VE@D
MCJQ%6=P'IZ.%(/A`:*^L2G8Y1);X;,:,=9M#++N7:''20JAU5N1L@A2(-C!X
M:3=U(\LFAR"O@$BU(#N%!"'>P]@&@E2Y5T=5-F^.,)QJ@^8^#0EQ[@@PCP0?
M`$XPC]$!3&0#JZ*;ZZ"X#QO'22\"8]R*$":\%P'"08`;PN?>.!!!;O,G5>$*
MW57Z2#0L/UAS$`VC639MG9>848#HL8LD,40T*W%<MVL/6V<8^O4R+7TW(\3+
M1N"=%PC(TP#WZ,X*-`E$GP8":$>@`=BV:+JU,+7'=7&_C?C[35&M?1Q9(?7K
M(%OZ;S[Y8_A*<#OYH]!.?LPW6MB_M!(F>U5<)@Q@#JXA@:*VPYF#1YPQCJQP
MVO^FX&-8!%M-:CV,V;5-6X%)'@^J?I&$Z0R7R19>C&D<#VN?)[%-/H97R<<T
MNLXU81YH4)'4^;[,=WD&&S,B4F%>K(`5OR:?]-%,/J-<GS<Z'_+L\$J?US@^
M8]$EF]3;YW=B,.N@LA?WC4=^0Q9+WXOPU&_(8NG[$)ZE?D,62]^+\*'?D,72
M]R)\X#=DL?1]"$\3OTE!2]^+\-2OQV/I/Q?>P,:CE"0"*!NJX^>F/`<#(,2G
M9@"='8#Y*1@0S@U(0V$&L)D!89HFRP.86![`64H7!S`&COC2`!BQ3"'`Z;LP
M0+`@6'J?4K'X/J')HHXQ#1<%C"A=1#FD-%IZS\%=77K/`A$N`Y3,X_.E'P*G
MGIE*X<04!O>&4CN'Z>O"8B3&^FJ7E`C6@<!*`WHXCW)3&*_E)UUBH%4_F^H=
MF5_^CB3/N*9^1HG6$9)-X!^L35W]MUC=?1JD%H@[KI0IF<.%J!`_[8)"MN9I
M[Y3Q=8P9^K-9[!"PO=I.((XT'"%VF&2YX`>:3X>:(PN%=8,C%O29&UF6NBTS
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MNZ'PG.T2]/'BN32>\6*%L^T8<[(=<G2T';,YP\&C-,X2FUY")XE^I;&>V;/`
M*SI5N6ID=2%5OC]@%E%AGG8P,OPP(V=L<$/PV6WL2O))&\0I<[5!G$8N-C`<
MW6P0IS9QR:[6#Z5]WK;0M<%2?3WE55<J[#OF<!,K"H6IQL+80E7-8(A)P&])
MN71F#V).`P[.JBO@8>H$.')T!#P<PBB(B<<B4<^QD&>LYN%\A]W'9,(WYC08
MRWOO'>29@Q;U&P2:AA:#;D=H*76"%CDZ0DO9,)=YT)5^WG45[3?D0^&;@1&$
MK&&`%61LIWQX2R:,76D3#J7I1K\E#W!7_2O"DRM%6)#8+28RO\_61*^Z9R?K
M&],;RPWA9C>69$1Y<O9'B7/J(4J<4@^&H]OLCQ+;[HSYO&%GL3R[,AFI]$46
M)I@U-><^M4!J62AP:?(=.*B7>[/IF'K92\_G_63U_#LDGSU.(4(=1)\V`G?.
M-D3<*=M@.#H:@:<V*@AM]3EDPUPW,$_UG(]NS56ZH8_;8!64??#VNO#\'?+.
M0L^9%7@2>LZ=#U;.G0Y6P]$->LYM?M(P[Z$/L!R+/)][,+"?*%F9DFH)DQR3
M:^>\P?\6A=QH&`AAP7U?=L5;"]BIOX'EHTIUAE/9!&BG0F9J.[DGW5)D-CH#
M8`9-)FW"A/.)S`.G$]EP=+1)8+=^'H_)MT#TWB7.[KK-\$I)?X>D6QG;O,XP
M*KX0M=OI"HQ3J.Z>2*/)$=NA&EWV+4QV0YNTPRWA9]>&&*6?MD/L?#:PV.EL
M,!S=[&#ZS(Y]PMYZG6`2-MJAR8\(,$)ZSHL"?I?]?:9G:P(M@!N7JC!3FG_K
M&A%LAKI;,%V#4W=FFYLPRS:ZH=AL%P)XO8-FTS9BSD<'8TY'A^'H:"-FCXXP
MMOL7%W%?8!DN;#V[M%:?5(9)BZF+6]>[E]SM\*92=^I<6?,-58A"9G58:/;[
M(0ZQY?#:WC]$6%S!'X3"WA9C0O2WQ7[YPU\Q"%:(+J9[IL*P6_QG)W)$%Q3#
MXEOJ7`'`LJ?#1#8<W28R%;8"P.EX[RZE=-QLY%:?;"^FA`/@U.!5R3&W8.:W
M*<64WR['H5MUR/O8:E@&P_115=:G^FB&DP]]\^24E6ZI-FLEK)R*A=H!1E1X
MS$Y65V]8*7*J'1B.H,HDRQM6BFQ'<AIW5J+`G//O-M)/E/Q#UPUYM(6#>WSV
M\>NIZJ^(?KK4C3J:S^'%IZQ2JL0SIG\.]GM>=Y@)+7Y$2VZS]#RR01%/APK)
MZ2"K(SAQ;7<%UA8^P-5#03NGNT_"@,H?<OTIRU6)3;R+4^R&Q$O!T"#R3(G$
M=88)M\R\<$8^L(GYH2$;KS.(9)Q?.7C>9BGC7.D1?I&4Q^KWJ\U@W`'`"R_T
MV>P)>=8%5NIK7C?==>U^$#@L$SO#VRF;"&:U73[XG!G$5W`N7%3X(8.E-AD?
M)]U^\,[NKE-S_`:GV78H$#]=R)Z'79<,C:9;O]G<R@DP,]^1I<G+-BL>+[7.
M/-"`+O;6/+`@6FP^>F`8MRT-X%&X/"",HL7^H0=XO]@@]!!SMMAA])#P>%E-
MV/V7!PAZ`RA!XWBIG0V@#I;[H!XH#99[Q1XH"](;!@5[W*#!HVC9()2+A8XS
MF%<??UW=K>[^#PIP`:,-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,S4@,"!O
M8FH-"CP\#0HO0V]N=&5N=',@6R`S-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P
M(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@/#P-"B]&
M;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-"B]&86)C
M,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@4@T*+T9A
M8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G
M94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*
M96YD;V)J#0H-"C,V(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-
M"B],96YG=&@@,S8U,`T*/CX-"G-T<F5A;0T*>)R]6]USV[@1?_>,_P<\IAU;
M)4""'\W3)9?K7&<ZUS:>N7NX%XB$+%SXH1"D%.6O[RX`@K0MT3U%S&02.28(
M[/?^=A=Z]]OMS>?;FV`59YP$^,?\E*YX9/_)J]L;:IY0PF)"8_,;1EBPRC*6
MDC2`)P$/2"MO;WXEM=DKB3ANQ-,4/TC[>'NSO;W9_!6WPC^37P2K*`KA@%44
M\A`^PHRQI\^SB./S+$SP>9K&X>D-&;FG+*-`$@U(2,,H-#1M#(/V8>`?AN%(
M\+N'VYN__236>8+L/<`+1A!FTX%URH!+%I('8/[-[RP*_D(>_KB]^0"O_N<Z
M!\23`\C5=V<D2^-%J??[7YWX."!9R+Z=^'!F?\K-_L$JR+*4/.2W-_=@BS'+
MR,,!COV!E*)]E&37M)UJ:M)L2-.W1'[9R5I+340KX<Q2=&HORR/9J"^RN".J
MSLN^4/7CN'#3M&0C<E6J3DE]1^3G7NTJ67=$U`79R58W=2W+%?DASYL6WRV/
ML-&&:%'"ZX7,2U7+BT5\3@1@'RGR;41`,_!$)X*(\\2*``@O&E(W'7ELFP,1
MP'3=J5SM1"<+4O22=`WRJ5HQB*B56HHVWY*\J;M6Y)TFL,MCLY=M;7CV"QY;
MV$P;1D4-#&^$*OO6;-FL.Z%J4LO#TVV:;BO;1021TD$0"<2B01!AY`0!ZNN:
M%H@]2%*)HQ')6A*Q+@V]H#9@:]?45GEP?-'GTIA+`_H%X4SL845^&CD5^5;)
MO7PBUQ)^46H4IC6`O.E+L"SD78(MR;M%)!!'@S>D$V?@J16`5H^UVJ@<Z`3^
MMJ*MGG$'_/=E9XU=D)T`G\E[<"#P"YV+$LU<-<5JB2B71M&B4<[O?W6Y0Q1*
M6>+DSH)LXH+X,PK^1^MDH'P(1%JK-8:1(QK'INSSKC>.IR'L&'VT8#IUC\$)
M(LM@<,9JU[(TAM9M14<^]Z`?V5Z;'0Z"&OC)V"H*`O"JK\#$_?5/2B>2`S1A
M!/>F:ZY^$,^^%TN`<2;&0'T4XO@CFH+3&L2#"OQ+:=2[2THO_7")$`%ONB`9
MQXDW59;$ECY,B!@8!83[I@"3+"!>3%/GIN\P[`&M$"4J4>=R17XY23V8LVXJ
M.1BJ]D&WDK(SSH#&G7?.^C%4=DW^"9:UGR3F55$>]3)22++0.VPX2B%)7:I`
MSU/U7FI,&"OR<VU=+A<:`C=*P5*Z:Q5DB`.&=OBY64,J.0ZI?I$HF23+(EF_
M_V7$Q_-"YQ9H9LDJ8;`3NN`]HA;JP-JO)_-R!2C"(`F4^P\5I"!(8.2C4<"'
M+_E6U(#O2J6-[2TA\W!9_.WW7R(S)2A;Z^X4SW&0((FLQ-%Q(1)5X-[6HK<`
M#]=2UD:@`&.:VCCJ.;%K0,J2_`N4QI([*"T#OD(ID0>$.41IT"4`3MVW&">L
M#T$:.ZBRG&IX"0</F*\+1B04#4`(0H[>'.=8NS9-``P\49%-=+\SQJY^##P9
M>:><13ZX!<PI71L\K@!B%-YO=`<A3[0%XHRM`F!O2R"(=@*,X]&"=GA8J5I5
M?66M9=N4!?SVZF;+V?<050SA:#AF`=_CV=0(*=:I`Q3`GU$16$-V4#2YA+>`
M&\2I+X\#[OV`\:$BR,5.=:)47TT.OH,D=G7#IP'W9"P+OBBXV,@P#;SIA]Q9
M?B>^H&$C*'%5.]%;1#RV1C/IW`:PGRW8>1(;%9;QUR8ZBKZ7>*)H*AXP!V^1
ML)6S2!?U-VU3S05'4XQ8V`-A''!@#B\M$\CCV'<W*!TC><+BD>*7JG)IZY>'
M]^1=7Y828AQYUT!\PP:$`:6V"_&Y;RS\!$Q:J+ZZ`PU#O65:/XU%',(5:XA$
M!MRJ`;9B(0W<@`NW$GLB!L`N(0#NNQIQ-$9S%KO:LMLV6DX8T8"99:6M&7^4
M96EX>2X@K[RJ`?,OU&:#E3[BKESTL)^N!(@-!81-#6QY&7R.SJ+=RZ7ZA"TS
MV&/=](];VPC3D!(6D4(8><`>>QP3Q7$\`O8.4(86N:TF\H'!0I;B*(L58A)@
MS#6!W'-;JF"E4C8'8-=$`%MXF[XA&`N$1%&88@8UOU:%>2KTIV$Q-DN<8)HG
M46,),="AMJ11,OIOECC_-<I=8?3JMA"NMF*'W8,[#[JV8B_)(W"$):C7^I&(
M'#C1:"G(I,L*+B]I-/U6*(U!$Y86A4(1P_-:XENB/0YOK*[>00;]#CPOTESG
M6;(HN/?[+U%0\=36\AE?40;O#P550!-?4+G6KZVT49,[`.N%VJL"PIPW:UO4
M+U*R\CA85L+#_DN43SSR?8*$^>S#PW`4L'&I6NXQ>@B(#KG0VXF`71:Q41<C
MAU/(V"M&C:#GS;TXJ*G!QKLT==.@,@AK2T0:SN*34X78<0Y$FTD`A+R7-)MH
M:(8"*)<[&WML9AW62-'6P#6LVJ@:JD,%\23'WKM)8B@HFZ'7/80EB#*V&0HK
MF@KR[A#%Q68#9HW2ZQ?I$_$@\[V\B122R'4LH)[5/51+G4)(J6V*L#@#Y=)*
M2R9V-8!T#6+"]FXI]Z!^$Z8/WD.?^.6TR80O0QXK40A[4?9&^T.>%K`=V$%-
MELDW4>9+R3@)7X(/VR,SAF!TW-2`")H\!^+-1*@8VM[R2X>+3`?@>?\,DA0(
M2H$K`-^F\[:QK7+SU.54^T+12&W=Q[]C9BJU':SXSD*]"!8U*=?Y!*,^&L0)
MM=(853'*99&8&G&^:$SU^R^1M:+0(GK,5'04(PV3;&Q*87B\]ME0D0]G7Z'2
MFCD(O.,)DW$V,AG2H13])'&>"F%Q@P,>[!_OE3;8%3V^D`C1=@VZ#<9&D9M*
MH[6!$&)IB_'@F2M='7]Q('=@91'\%=%T64NFWTK\##J(`E^:!4$RSEM#-^MY
M+UO3N)ZH=J@0X(F9Q'8FP&%/HMTUK>O"K(^E.%A%_PC5RP$[%/!QAQGF`!4=
M?N9N;P%HWM6?!P=&#JK;NEL.,N_Q9H->9-H<II%/#J,?1VRX>^%+,$A4\'DT
M-`&K?;7&7%")6CP:TFV7_Y,D"M/I&GN1:/.02IY5IW8N#:4-)%B<3A_M]-UX
MAKUDT)0HSUX/Y=Y$]$M((![*L2`<N^LL#>,A/9HFJL-N)=28`%7^OH`;F3L.
M"[J1WW^)&!#292L$O_\2Q+.%)W+LVR9RKQ"_\&B+??-H:^Y:7Y8M>ZMOV'\1
MXN,KW(N;(S[^UL'&'/'L"F8S$U:IK[IHEJ1CLR]P5<>+T&X`D]*0<%I(*3XW
M=L>=;<H]Z0P"-F_*/=:,`M(GWKXIL2L\0BTWVX0-7$HYD4SP1%'JAI2J4HN,
M;GSE!<56,LZ.ALZ#1WX+#>%HX$E8<`9'@W@XY?H(#<UHE&*8C%(,@J%^'YO[
M6%$V>+=J:BNF7H7L?7287%:X="U=0T:U\+/&_C&`=8EW50PX'RWQF>&YV2KJ
M;HF9]SCZ&GD->9),>L/.6DBEL&-O6BP'[.Q",2T57F'$$6"E^LI@+<OBT-S&
M:@61C*FWH<1O+8HSL\L3Y0<Z<@I5%DDRX,AP,Y)M;H!C&,R@6,(%].P"'ID%
MT;D%:4;-`G9F`<\`D,XN",/Y!5'(PMD%(4OY[`+&XOD=*./![(*`16QN0<;"
MV><IH[-,)C2=I3"F\:R8.>7)W/,(I#CW/,3K*3//&66O"`@RQ;GGG]T2;H^@
MT0G?`L^BU#L7?9F3N$]*W-WK,Y=+W"3]P;3E(->\AYR!Y=@37[#;_/<?N.4!
MG?V?2-&*X[8)?-B6A/]O>7OS<:0:K1,^DU-$1^<C`KX31#;^L568NOHD7,74
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MBSQ)/$QB`&ZT_<XHR5V2K$3=XX2D;^U<:2=R<]V\M1=XQR\NK%MWT6$RU#WS
MLKOI4/A[$+@5(*8_9(XW1J[,,?=CAY!:(;_!+Z]TVQ<=SO_CH/.5#/<GG;22
M$.J<"YTZ9-DE5F).O,REP]!?[$[I>$\D',YT7WI16O=8R<B-;%&=[CH(^F>+
MF%`3+6N%V`\'-WBUI'EY%>KM!:2?;3$#0AQH/ZD%EEZ<_UAV4?HS)UZF!>8O
ME@.D&^.J_S[:T*,5)"\%!,&-`AV\&R:&/PX3PU,"?HVJ<P)F&?=DG18POSAW
M,7Y1ZC(G7BA@/B2NR=76H9KSJ>K0JJZ3IH#76*7`KYZ4/\I.$7>RK7!A<5+>
MKQ!Y3MYAEGDJ3\N;\HOE32]*/N;$"^5-)[!W<IEX.-,@L!?V:^Z1V[EO7O8:
M(8")+AA5-CBCW8L<A_[NKI5V]^IJ'`VT3V;G)S7S"CMG0\V$G],P+DDO1G'N
MRX=_%L0EZ<48+O6]C6#R31Y_0R/OJ]Y^L97L&W-'PF&X4YX@<#@!?G`.BKU"
MYGE?&.D\+?&(7BQQ]XV^/RMQ//%"B4?C_)^.$H^&ZU8'.<`D`%1[\Y4'D"U>
M8L!F"MY<J?U7J<;+(:>T@DYA[A6.OT2PM6NT*/4I#/0:5V=+FVADZS0&LE4]
M>-S)$3@[=]DXP+]V6YH^[PNQ\Z4ZQ4980&=[`?>4L]E^RSWCP?R"D-/9=L5]
MQ*/9?LD]9_,-D_LX9+,=F?L$X<G<@C1(7EE`63377KM/LV2>2"B3@MF^SCV%
MRC=Z905GK^S!.)W7!V5I?%[G8#4??KN]N;WY'UT[IZ0-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,S<@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`S."`P(%(@
M70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-
M"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A
M8F,Q,B`W.2`P(%(-"B]&86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*
M+T9A8F,V(#<S(#`@4@T*+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C,X(#`@;V)J#0H\/`T*+T9I
M;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S<S.`T*/CX-"G-T<F5A;0T*
M>)R]6TMSXS82OKO*_X&'/62W9"T!OH^3W<Q6MBHUM1EO)8=<(!*2F*%(!22M
MT?[Z[6X\2-D2/9D8*5?9L@@!Z`_]^+K1^O;G^[O?[N_"=5HD08@_]"I?)['^
M51[N[Q@]80%/`Y;2.QQ>KXN"YT$>PI,PC@,E[^]^"EJ:*XL3G"C)<_P3J-W]
MW?[^;OLWG`I_9F^$ZSB.8(%U'"41_(D*SB^?%W&"SXLHP^=YGD;7)^3!`V-Y
M"EMB81"Q*(YH3UL24#],W,,HFC;\[>/]W=_?BTT)XD7!(WR`@*!)K>B,HY3P
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M7NYKN0WD9UF.0PT:;2!:!3\(]2GX[B":K5";53#L53?N]H$(!C7V`PITVM?E
M/MC+H`:HX`\]D)*FW<A6PD2U4.<5/<3I4*_>K=VD7H#(N%4",!B+0QH5&H='
MW.(JZ$YM_^PP>?@U1SGA^GY4J"I:V/=*@#[U91>8!4_[KI<S4&H)ZRM)@WV@
MD"1+*/3';NSU.56R+V5;B78@P9X=^A6<6/I'<$(DZD8&6T"@K;3Q^9`?;4";
M0S[S!7',-0!*-@*U7<NLUC.1X:3H9-INN.8N`!-UPUT07,_0$O!&5=5#W;4P
M^C5OX0,)SIQ3A&AJD<@2JPK+6OT.C@C6[,=F(,T&K;D4N=[BVR!H.3AW"2#6
M30/:'H@-G/70H7M1`\S4U[NV!DQ!W4#S=DJBOPGJ=MN,LBWAGR>I"!P?2(2Q
M12+.74B/&8\U$@?1BIT\2-@::J78;D5MP@-M"TYTP*"@Y&]CK9X%?'WL3Z(!
M1-JR&>E4T;AE`WH#IX]R7L8<^PE\,L>E[-2Q4Z`^/D#(\\R"D,7.,("/,0W"
M`(ZK%[1CX##?3]J+IP]N'@(AN`L8964"E0=0]O41\#G#F3;PFRQ$/A&2$%]$
MNX,0T;H@"I\:-02'>K<?$&F)V@-H'<#]R`'MJY363GR@D(4&!1[-4"B2U!C%
M'CP`*#?*``X!?CDY4,H-B8/[W4B(A'4+>@$OR(9$TSPC@C]T2J("Z<AP,?A+
M($4_Y`.")'(0%!:!)`R-6Q#-29QQ;^CH*@D&/>SI-&;[5R\%ZH@M77H(.&CX
M58):HU$TF@Z<8>JQ`?8A,!"-/3D)G`GGZX*Y&N)"/@"('%M,PWQR!_B:$$#O
MA-Z@-SSG!"C0GBDRH*"GNJ<,H`>$U-H#(\]9ZI60N_F_#N#E'"HK"I="39&'
MY9G+H##,UD!$-X.L4`%0OQJA=FA4%S;D`=HL*[Q"Z^;WD>IDJ26Y(2N8A9;G
M8:*Q?4?&^%$>!QW/H]"Q+W"K)T3[!B,GNNH.I96]=FH7G.8O?!V#ZX:D%_R5
M222"C:HK<(]-)UI@#4WCT7MCQ<%8;E),AFL]5]_+09/K0Z>&'<3TBB)2(ZN=
MUK,><AW#O6?;-L!TR]A`4-R2*P"G!\);@K,#9D\QNQ^1,]88^TK1[X-MTYT\
M>;",6Y++$S;Y<,9-C6+R4=UF$!"QMB-2[A987M]#7H;[/D*$H2AT<>04\JI1
MKB:GIV->);>"J"!&;_H<?BHP'$B/I+H(8J@HNL,B6XB`98,)D`\4F"6X/"U<
M+$^BT,1RT-$:]*&!(]&D@TZ_'LZSR#7LQ3#7"B.FK$B\66Y'KK\%&Z",]SEL
M\@D"`01S0`L(,;"8[E#W?:<HB$N]"GS&`PAIX;AM@GS6VD1<S&C=%C04U14V
MAXCH0UL%FW'`8];QN)(4[N'0%&2JK4!2_E)06POH:W`#0AGH0.Q.J>X$4;Z'
M!*\[!!O1?J+XW9DJRN$@%:2_C1<,LHG:3O$\*@R];V2K^=B[]AQ8/##_4&`1
MIT`_QA,&9P!$CVH^/8RK6WV>J!=SPO^,R"VXC)7C<<XT>G'P8@QI:HDMB[)X
MJH%E!@1(8>IAK#`Q@_03S.$<0);3H-XC]P1_?12*;/8@@8?C&YM:IZA*@J^@
M[*C;-/5.:&XF^E=""5%\'P$\C4.O`=S-[X,;I=R5EX%P.J_%4LXOV)'\?`2W
M25'I""ZD'=!V5-U_ZDU2CB=#IH8ZK#-30UK)VX!=2T@QQZ_.)A?$B--\+D?(
M4Z=P/"E,#-(^A'8M(:L==+&#\L#><(>/)D&.(3\WIN0#<5,<QIU&F.?!3K_Y
M"'HJP*.]]7I`=^UZ!9"E,(00]3]8[^'-%\HN!,.[&6OS/#>^_\/G!M*M=R65
M;($%\K>_FV`9<_OP<C61Y'X3(3>_#[:>I(4+SKFKQL8\9)>VK@T5+<0EVE@T
M=.8"_`MR:+`8\`:B05XY*UE1Q$8+"[!60T4KFJ221XQL,$+)7=UCS*J"XP@N
MO*2D?&RU#ZG5`>?P$).2Q%7DDW0JMH1IYF(2)GQ#M[HA-U7?KCB2%48?X_,H
M1%_Q)'_(PA?D2GCA!'L#$U]:"3XP00B9]*R<720W3?PG7:H".HI'#`".+003
M`$AZ*;@GD<O)V%11B[+,Q#,J#)(*UP?(Q%!E;87T(FKIPCP^Z7Z7)B"_E)AG
M4,I2BA;I%N0LI524^FB^0Y=4P%G1Q+9>8&"YXZ!38A['-C$'!@S2NT(?J+NU
M>JJP@AW@WM!Z$9"JUC7!62&,*FZ'(U7;,<#KDCP.>*H'O%2BRCOQ3$/HNJ-4
MAJSUM:;SF+H"I6_]F'OH+APR7LPJS(:"'B$7E.20Q!-03YN1Z!H;$4_1VSQ,
M5*`;HCQ;L`B^&I,24G#1]'BU<*3J,>H+9"'SZQ9\U/92IWU5#<K3&^0]R!WG
M-@4+$VT`LQN%MUXO*]QZ.N)#8.3\K5?)HYE4P$TGA;9W)CV:DT0_;&^)$%W0
M.##%@S7P_@QAYV#NV;M29\JO:[WS[/.X1QIPUN5H3W>G<9I-KHS-7%GTXIX(
MO0M=VV@S;:O?&7!UZ+L0E]R@+3+9>TA;94*PF_.?`D+B$LFBF*PX9;F]0)TY
M[1Y213APV`T<U2P(DR_6=SP;K(QM?C66VH,).Y=6MT^H`3JC1%<`N(T0!;!N
M(L9AWRGR;#IQ[T?P$MH?FHJ%J-"N$18?,$3VE@1486H#*ICQY^;JBO+D$=PK
MZC:JP3Q&H57`[A\O0]US9?XSN4M<.,$\<Y<D<BMA?I*QU*6(9%M7R8N]/09X
M@!43PMB8XB=<Q6Q*GUB>SC)8PURD4$V-SF<O6M1R.NQMW9=PN&=X"!2+ZB/N
M\CQB5&S//*19/(@*OXF0F]]'(A1E+A'"/D"7"43&FBZNFVM-7TSPH"Z!YW3P
MI#FN0N/OVNDV\I(STC6KJJBR17[D^_89\[+TXL6'5SXT+IHN;XJI]!,YA<.2
M.QJ`O5BTG*^Q<<;L%L0F*O1[1/\O!)\&<3/-B\1&9?6"B9K8,]UO^,#!7>-P
MEDQY89;9C`'$`0ZAF:#\/%#I\9KH72]G)S8;C9ZX%0-5-[5+M5R#_KW\W"W2
M/5V7^,!@NL*))ZZ1<$N63\35B>D[F:?D1M-CNI.S5;Y*W\R`F++RXX#"W*\#
MLO/[*`+R@DVQ:'+V+&,&[_<C:4LO&MT:IAM!9NG'U.!&-7VYHS8R;/2:F(!^
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MCM1VC85Y/BO$FMH`9C&0N.#M[C4!](77BZU?:[0$?]5C86O$)KPG^C(")9`T
M#XB:K)*<K;`\\V5JXP.+>$;GDUEA?]Y$>5U1,1F&G/W%UV:`KAUTQ><Y"+:C
M^(BD<`!VLYH7%+9X@U_#`UWI7-%[2DJR05S(^'D?*$1\JG=.K1>1*Y&YXYD?
MS45G]8S6WG;(JQDKF;D/<<"*TBMDA9K6J9G54[F(,5?^Y_'D)7+;4#M=7J,U
M4!&'I-&M$1B6E0Y_U!CM*CJ&5*%;$#4IR[Q!N'?I^"6R%\:$+0YF0E-+L/F2
MEV_AN&]=9+.O7:2NP_QE=_.%#]05K8/X!-G<`)$>@S[J!\JI>V25P'ZN68V[
M%$?0^F9JR;%*@J6FX6R[G>C[)MB.K>NUB/)`+4JX%1_=M6S2APF)S'[_PC8G
M5!(+PTC.8">@!9=\&16KP$ID5L`^:`_38O2%0(Q/(>P#![";`\*8!L0W!F1%
MS&@`OS$@+;)B>4"4+P](\`N-2P/B"#SHT@"(N,LS\"@,%P<P7O#%`2'/%P<4
M/%V4,N?1XA8SSA9Q3GF8+3U/6+$X?XSUNX7G$<L6$>(,LO%%@++;SW\S0Q*]
M!19?,1DX06Q6-#;#7G[_,ID:!9BV&BH2F9K[(Q5CP+3_T;7H3B\+PWJ:'_^%
M4Y[0AO^-.UHG.&T&?W2QU_W;W-]]M+N.C0$EUQ-J?JL!*,0F($VX6?'<<J-X
M"<N'.%O4]P<6)\L#.-[3+`T`5K:HK@_Q*_KZD/!LT2`>4G1N2P.RD+\V((N7
MW-M#5O#E3>9%LFA5#T51+!\%"^-L>0K&XO25XV+X78);(T`COOOY_N[^[O_1
MV_AQ#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C,Y(#`@;V)J#0H\/`T*+T-O
M;G1E;G1S(%L@-#`@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-
M"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A
M8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P(#`@4@T*
M+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W-"`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HT
M,"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#(T
M-3D-"CX^#0IS=')E86T-"GB<O5O=<]NX$7_WC/X'/*:=2,4WR<=<SLE<>[W<
MV>[D'OI"49"$"T4J!&E5_>N["W[*L7@S*:GQV*($"(O][2=VX1]^7]Q]7=S1
ME8X4H?CCG\*5DO6?Y+"X8WZ$$:X)T_X33I1FJRCB(0DI)8I&I#"+N\\D\VL%
M4N%"*@SQA12[Q=U^<;?]*RZ%/X,/Z$I*`0164B@!+R+B_'(\D@K'(Q'@>!AJ
M\?J"G"P9#3GLFU$BF)#"[VGK&:P'63<H1+_A'YX6=W_[$*^3`-E[@B]X(/RB
M+>N,$T8Y(T_`_)M_<TG_0I[^6-S=PU=_FX:`'A`@W[4ZK""NK,Y9!,M3Z9>/
M]$I%&C;R7R#UXT^/[R>G)H?4Q$IS+CRU)5U1R0/R=`+*/W]Z_-?#/7FX__CN
MX<>??OE(/GQZ^`R/4^]&@C+VN^$K22FK>5].3^J2<::I[ACG0<?XIW\@OX]/
M[Y[N_WG_R]/CU,JD(MGOXSNU:=P8HE#]_[9P#49-2:1#OSY=<28!M\1C*+5L
M,'S:&^+*N#0'DY6.)'E6QC8S&Y(7Q&9)7ASS`D8W9'T&VEM3F"PQ,$+*O77D
M6.3N:)*R<O`^+DE<&)+E)8&Q,B]L$J=D&R>P+@YL\^(4%YO)F511Q^4$6CE&
M"3QFCR=3X&`;/+5_1CS3//]BL]V*`+#.?+?&7-L":HQB[0ZD4IU$:2#K'0RD
MB:@?XHTAQZIP59R5I,Q!4"#Q>&O(/B[6(&60X;-U-L\<R;=^]-?"/L,:Y-$D
M56%+:QSY&5YV<0FSR(,!01[(NZ3$^2R*U(H\5LE^J$:@.6FU,6_)R9;[O"IG
MP4'(%@<>1"T.(F*-9J?V8$N_Y;<DKPIB_H.:ZC]P0&P'J@B"`BA2X]X2$Q<9
MO'6H]SF`4)!M55:HM3:+L\2")L<96,71@#G@]^`!<8C1''`DM5\KN['E^2T:
MT:8">/#C)#\<4^.!`[3F@`'Y;102THQ6'5BH:QB2U&;>$,L"F`!.0=Y^=S8K
MZR<$!`"`MV?\,">9.9&=R7=%?-S;!+&JIR`_.Y,!`BD`40*^[D#B-<JW`:N!
MQ^M2,0"K,*Y*2P>*DA_,7$!`_M1X.C$`(E2-793>((>^+L[(&GS9!M[9K:U]
M'.I_Y?P>9_)7`K[6[G5>?R7@JSTJ3'=&HBB7%^Z*E*8XV"Q/\]V9.#3FV$TN
M(PFNL]V.]EN!H,?%Y&2"(=="RYKM-VVL<F^GIJ@$?84Q.3T9_8+,4J^XJ@5)
MYH!20<8W4"`>A#5W8/&H.-,#&48W`3)2-P924WD)9)V)O5F;U)IG,[U*:D@2
M;H"D5L&MD=1ZB"28=\V=<1"/P+5/#V7`;J*4`;^U4@9BJ)0\D*SF#G(`DVUF
M`#)XJ2SS`!F*CLSW']E&$HT0",P<PUC848F"E6)1DR(<XO/D8I'B%8XFEPI$
MX4LJL\>N'L(P6DF):2!">+)I.KUJO^1N%@Q#=6,,(]D1!`<1-4'+P8DNW4R.
M(1/R%B`R26^,(AOH/H2L(&K\+)S';6*/LP0MSEYR.0N8G.D;@\FY&H(IFYK6
MF_IT[R8GIU_:W#PX!JPC,WW,@M`^P(R&3=7H#1S1)R<5AK>(C_S2,['V8'),
MXVQZ8Q+\I9;/H@1"\!F50(@+PXGZ:H#4HK%84`BL?V0&2WW/IJ^%/<>%C=LB
M5EU(@3%G#S:-"W+*"T@7\9/UF6RL2RKGVKD%II*S9&'8>&G+/5UA@^NF^E?7
MWK*-;<I;KL0R]NZ,NRRL^^)\-:O*$E-@P1N+G*LYZONAU+/VNKKU)\=80P3A
M45=;I+V^4'QNF@=NMKH^$T&W@7GK9`Q./CVKG`D^,(W+NOYE%1GKZ^O88;<D
M(TE5@+*7)':N.ASK"5C^]KT2F)=7:`E@$X<XBW>^!CFYR/#<T#`B.T?%)R?#
M^0`O0>$$T?9!_+/O0I`O67Y*S6;G:ZE8@%]7SF;&U98WAT>`WT:$5(2]"!N/
M,*A-XP9.>YOL![(@;2W&2[4PL<NS>)V:MI,S%"O.<-7Z#]`$[*A<\2=UP3Q.
MRBI.VPHX^"3(G<%);K=F^N@+``21:D'HVU,RC!J+Q1()]@'2,]D6^>%2G=<F
MB9O:MP5NS2L\=<7A<I_#S-0Z[`V"9ILZ="2QAVARSI3N69LQKU`Z'"!(0]I%
M%B%H$R0?0-KD`X@U+R9/-S6<@;YE<_JR'9R!6C(S!`[P`3V(+-1=,T:Q:!">
M3>K,";*+OIT\AST$7?^[]PF*LL:M#QK8N"78R"9/JJZ)V;>_?6/L9<_;^Q`P
M\T,.D<%G2IAI^.,Q=I8@_W`6+,-_G9CG.*WJ=AAZPU?;BW,`H+MVL0@[28@P
ME!=N\;*CN2+OTA1=G#-?*W2.I\*6I<GJ'BCV_^9JCBG:[7CFYIB2`VS@(-M'
MC+"]8-(&_6%+O2P+NZY*#`WH^RO?Z03HG`\,22W?K`YX9A^G6Q\MP,]"!'#@
M=N<0L91=X&/]C0#-PYJ-KQ"`Z@9GG8O8`KN]MC#EN6UY@N-'OQT7Y\LV_DN5
M7Y$'$X-*US$PWCQ;S'X`!]1U"'"@(!!9JL*?&O`HD.8.U!Q,!6\BG.'WBR$S
MQ`=$@0=]B:7+2*2"H[5'H3"IM^0F<'ON4$H#+2\,F#N,;"TD+CYY\^`\WK^?
MY6P0T&#6LT&W_AQG`QUU31@E^[,!TTT"^&Y3G[W`5]C,^Y7Z_)CY&T$0.^L;
M0Z@4,21#>)OD98YX[>I%ETO5#?PM9M:M-$%T_AK'-,(;43<=U&=IO)$6J`X`
MYMLH'H!T-B\9].3G=9*![@AA0BET)^=`Z*L^\EH$3.UN7_85A*O'\,]-MHUW
MR5#81UQE#8(%?X4N][C!VTES80L*?!MP48F4[L%E?15#L*O@^OM<KSGF&1R4
M%O,6+[KU9]D\N[9Y&.141IAJP^)^X7X%?Q>:$Q91%?@)[.H$&?H)\LJ$$.]V
MX@1^;0+E8G1"(,7X!"U9,#I!B2`:G2"%&E]!""E')W`!4AR;P+!^.C:!@H#'
M)D1X7V)D/.1J%.B`*S8VKKD871_LD8Z-2\Y&(1(LX&/CG/'1<4:#\.KXUV:*
MJC%F\A5#`7@9ZRR%?7LA7_5U/E97#2"J16&3/S[Y9!?\]OL<KP:\Z++4RSQ\
MQ"5/:+E_QQVM\*ZX"N"E]J/=VW1Q]]CN6C5\0=+ZZO5P?JV93+&_V]SQY]\8
MM]*C.K^4;%0=EDR.V^62RW&%6PHP_O$M<'Y=I#@!CLI_,B$:40J<H&FCM5<\
MW%*'X[YA"6.C=K$,(S5J&,L(_TEA%&H*QO,G,X(1ZP&!W_^^N%O<_0^0/E\9
M#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C0Q(#`@;V)J#0H\/`T*+T-O;G1E
M;G1S(%L@-#(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]0
M87)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q
M,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P(#`@4@T*+T9A
M8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W-"`P(%(-"CX^
M#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO
M26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HT,B`P
M(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#(V.#(-
M"CX^#0IS=')E86T-"GB<Q5M+<]O($;ZS2O]A3BDG13'S`C`XVI:\Z\2Q-Y*V
M=@^^@."(1`P"7#Q,*[\^W8/!`+0%[,:%24I5?&'0T_WUNP=Z]>O5ZK>K%=V$
M<4`H_IE/:A/([B4]7JV8N<((#PD+S2^<Q'03QUP112F)%265OEK]0@I#*I(!
MT@F4PC=2[:]6AZO5XU^0$OZ-?J`;*070WT@1"'@3,>>7UV,9X/581'A=J5`\
M3Y"3:T8%`]X9)8()*0Q/CT:^[B)U%X48&'[U<+7ZZYMDFT8HW0/<8'`P1'O)
M&2>,<D8>0/87'[FD?R8/_[I:W<*M_UQF@W"T`?DNZD!!3%`7`;Q2*@UYU!R`
M^/!OV.GG^]O%]P(]#7M)L*$X-IM=TPV-.'P^HX@?WI"?[CZ\OKV]N5\<2[!.
M);WJRM'_/E5%T_"%X$YA9(C3#:<*\$H-=C)BLL/NX:!)?4@J79/RD:3E\5@6
MI&[*]!/9ZJS8PZ^/NM([`DM(7>8Z?R*/944:N"])T[(M&G,G?J]UGN,MYO9#
MF>]T59-36]5M4C2D*7%15L$F15,E:=,F.8BSSVKXUF2P[=+BH^[`6#OQ&8M4
M+[Z(\#.*7V7[0U-OR"^:G+,\)T79P!ZISCZ#>,43.55EJO6N)H]5>31"`E))
MKIW(#KHI`#;DQ_*L/^MJ3<YVDWX#O$5_T56:U1IVRE)'U@<2<(]%0DKI#(&)
ML$/BG%15@LH\'W0!LN](9GAY,IKOV=Q9-<(/C0:EUN7H$MI%FM2'S7?S/^>%
M3/CUPIZ^#^95[)=Y1W_Y:,\CHJ*P"\!BPP-EH_W][;MWRZ<6-6PF-UQ!-N^C
M?2AY9ZAOW_]`[A\^O/[[CQ_>W=S>^8CX*@C]JJNG[R/B*Q'W$9]'W#FZBJ/_
M,N)OGZ:C.L:$YE!"W,KJNAW"PK.+L\)<@PCW.6F\!#<%A9X-;@&4#"ZX*2OS
M*4]2?=08WD#@4ZX;8!G$?E]^UL>MKH@R$>\&`K/YRM:$4QJ:'P<QDRT$_CE!
MVQ/0=!'=QG(76"U2F9=$I^!NBP`-AT071A8!2+J%3DV:/6?-X4(A#IU+<+Y&
MPV1)5'R7M'6%\C?3U@2"EA7@@I"=='7,F@OD/(`009-@01#<F;Z(F<WV%\H"
MKHRECT7`#&83?)?PLV.G<7C?D-LOJ3XUKOPISP70.62G;XN!"QPZ(QH,86U^
MT0,Q'TA$K$="88:W#B$Q3R`2+[>ZV)<)>965&J38/Y&[/]VLR=LBW73V<3Z`
M^%"P'!*LA$"@/$^V)19J\/V45$TO>U*3G:[3*MMVMMT<LAK+IOH$YM:"3Q1H
M`HO'.1$X&3OQ(%9SL?@VDKEM,`DQYH(+&!CKL+QOC\>D>@)_01A.QL?`!CZT
M?C0;2*M9(<.@$_U56V>%KNO%Q6=N.RLXHAPMO4TD1U)!L\T<QDI:C.\@%D%\
MNH%".B]/)I*O%P<W'O@8;$HNO0V$4K?-\@4`IV(,9A@,/9^@MM0ORD+/]FS&
MZ0_)KFN!RCI#FUYCN#0]2D5*N+4BQP23@.GB<M/!F8!@P@<X/K[;S._##<30
MUXHAXX>RS_A)C>FFTIH\Z03;L)]-($)V@.OCJ&=+VPH$U*9530\)9.YD#_=U
MY0*$0'@W]5!60"9PR7.JTIE+M#YPX*[!55$P!'K\?%GYK(=PCN*9DNV3UB?;
MU8[Z\+H!9DT]`!B=#UEZ^":JP[?$I`&B(8>F)BNT19/E77.85'D&8%N(=R@[
MXF%)^0&"BF'0,?2WH;*##IN<#0!;#2UN#3HCIF,MX(?NZZG=YEF:/]FL==="
M(0#M\D<:T$_PPGJ)[@>C>9DVIC`Z)D^D;@$?F^W;H0*<!M<##J$*>X.(@P$'
M&5@<?D^?6)`D$$86#TPL<KS%?",I[7J[%]>+[P2)>82"9&Q4"=I\L@-M@49V
MZ,%0FV9E-[V`8N:(,0_>FW-7]AFGQM\87YK1@,K_$20!52-(:#Q$3!'9(2K4
MJQ"M.BPVY.TC1HN=?DS:O#&5?%MY']:%H>M<Y6"Z`>V+UA*<<]\EFN>"V2F9
M:5CS[+<VPT"T@W!T3/:=7G%:]?^J8!5S`ONL8*$%[K?I*MBA(%!JIH+UH=^`
MNQ`=NQY5!K%MSVS1[*N:A6UZ#GQ6LPQBS"#I'RYG-XN'03'PL4`Y.S7.XE"(
M]=MXF9V&@GL=QCGZ/H9Q(7-C&5.:6I,W@[E^&->8N=(6+.$,8:J&HG-Z[`;%
M15=[9P7DJV,7BB$N)]6NG\9`9Z^A3L>Z_&)",4PG,)9?SOV>?+B[\>M.=CZ4
MID)9;]<)U"%S74ABF!VF4+P?0TU4\L-\99(D%FEXQ.-F=)C8_9VY!,I-82@?
M#>4$_^K,I2N=_P'<B6[8%FW(F[9"31_+2J]M#IH1.7E.X.?EM3<9ZS!3WJQ9
M]V--'R"$KALUQQ1]U&<6A/XDJ05S<'R>RQ;*\33!*MI<>48Z9'JOC3>83BL#
M(!-H4?,,TGR-I;W1KED`=4T-90..M>II%T''L&[B`P@9.2"&.9(43+CT=^&5
M'09;+''VZ.)8NQA!IP!9FF<118YIZ3+(XF6P`"\98</"4:R(K9'4S^L,:W;H
MVD^@5.,3][;S9@);MMU$RW;[!=K\8N_'VH7KQ_$TRS4>@8UZT"XB1RP6<HT1
M+H'DO],[XX"#B-"!@I#@U$5K8M]\^.Y:NLY<<*P,=A)OXO@CE4&_OL%#W;)M
MH/LL3*88R/D`@0UGS:,>E/:]Q@7WCV4.F<_P=!$"4(,@3=X:?K_6M%F[TQ@-
ML\)VUA/'$/W)S?SIC`<89.R:T.%(1O(X'G?BIHG!&&V&$NXP'4UW0]Z7#7J\
MTQIP#*SGV3%KNCZ(S(BT'A]*_$$4\'C'!Q*1Z^R&R4SOVSN<M>V^L?[?.X&$
M4JC2I[+"L`B.9`S"SAM-1>7E*009Q%Z+44??1S$JI>M*N`Q'0Q$Q.AF>*IOP
M`@'=K$E='LT0>#1&SES>[/MG<[0&A#80>)<WJ8`I)XW'YCG@<@0:Q2E*#QJE
M-J#_E"?FN.<&1R/9MD6W7+R7"Z&7^U;>Q8\F0NCE^FV6[^5"23U21^?D?CM%
M1]^+<[H#?"J&`HCV3[V\?+X9,C$>8O897WB\CJ1:X],E,]7"J`I8/D2"($(%
M_K2`]$//]*5G^MPS?>J7/O>L7^Y9O]RS?KEG_7+/^F6>]<M\ZA>?K?>I7WRT
MOJ=_&3QA9\XHGK['0-E0'6XW_UT`K,5!&)H%;')!$)D%<FJ!Q*<48`&?6*`"
MP6<71+&<7P"%>3B[(%!*S2Z0*IRG`#E"S"[@"E">6\"4F%]`\9G`F05QI&9Y
M5%$X"W04@2W/7`\C.4L_B$0\=UU&?!8B@0=(,]<YUHSS6HSF`8RFE?R;71)8
M:Y;/>!$4.WC::MV(??LO,$'?$S(S"TR[H\E^//Q@NE4H8%Z7!0X(+X^#.C)W
M/R#),[KUWY"C38!D(WCK3E3=U_QJ=3]PW<G-@N<?3N83KB\IGNUTTYT7G'WM
M_/&L2US';-::KL&Q9\WEFH=JUMZN1<1F#>I:AFI^00`]^?R"@+.Y^'8-#<0\
MDV#T\S@I*6?-]EKATYRS2,=LUO$A`8!O3*X`;=[^>K6Z6OT'6$7)B@T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HT,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#0T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@
M,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@
M.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R
M;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E
M22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-#0@,"!O8FH-
M"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`X,3@U#0H^/@T*
M<W1R96%M#0IXG-6=;9/;N)''W[O*WX&O4K[4K!9/),B7?EA?O+>[]MFNNZ0J
M;^09CD<7C321-':<3W\`")`@T:30[=FY2VUEK/P%JAL-LO%CDP1?_/GID[\_
M?<)655,6S/[G/M6K4G5_+F^?/N'N&UZ(JN"54T11UJNF$751,_,-XZ(XM$^?
M_'>Q<[^E56E_J*QK^T]Q^/STR<W3)]=_M#]E_XL$ME)*&@,K)4MI_I&-$./O
M&U7:[QNI[?=U74GX!T7Q0R.E\9VS0G*II'/IVO7/?2?Z[Z0<W'WQ\>F3'U^O
M/UWJ@LOBHVGOPN!^,G3<=*]DHOAH8V':7#Y]\NRO0NA_*S[^S],G/YD?^,^'
ML&*V?`0KLGX,*V;('L%*I1[#BM:/8:5ACV&%,_DH9DR>>`PSHGD4,^I1CG]>
M/F@"J.;,5$,&>%8\^(@4JNY^FZW*K@]_?.@.-+T-$Q_%'CH-RZ@+0JJN%S^8
M&:JVG[\:J^_;NT-[;'>G8['_NFL/QYO-7;&_+K;M\5B<;M:[@O^5J7+UP!T7
MD@T]IX[<;%3-R%7?']7YO6[X^=_!=:G5[^EZ__._@^NBKGY/U_N?_QU<YTW]
M>[K>__S8=1LS\Y4LM)DSNU\=-G=,:!JP4E6N`9]M(+5KH.8:*#/HMH&`&_"F
M-'^7&M2699<:F.^JQ095;9+U4H.R5LN_H&HI%QO(VHS14@-1\^4&O&;+W62Z
M6G2RT6HQTK56;.E[K<7B[U?:3!D+WY>:+<9(515?^EY6?/%[459Z\7M6+H\R
MT_/?_]TW*?WNKH##S,QUQL-PG/'D,&9EX^<[;O=I.]^Q%6O,Z9N;[CZN/VU;
M.[^]W.].=M8;'8[=S[S_=_N37^UA_[/UR$S^YF>U^<?\;A/]W^W3)Q_BTS99
M6BHU`W#K.V(^;L-';3_Z%N[SS;C31I2RL42`3EW,1@3,79%O9K\-OO5^#AZY
MSO@VY=B[OH4Y=LPY*<J[;EMS5,+N#1N40@_N!5<G+ODV4_=""V[V;`GM,M4\
M("EWRB^Z:<5P$=-FI_.,Q+6=;NQ.\[8'HW>'S?XPG1V^TP.W<=-[4(FZ]Z#6
MHO/@M#<LUA9OKZ_;PV;W>6:,2W-"'(+8!W02.-]F$L2^!>?H/=!OVYP=XXH/
M8]R[.G')MYFZ%UKHQIZ.HP)<*G-0,26=>XU:597YL8__[`)<2MX%^+?[VT_M
MP2:&Z>A^E^VR'G8O0^"*^?.(#S=K0]T/;"O:D9IJU51F(&T_G[F]IKV:V6DJ
M4?:CTH_09"1\F\FH]"UJ]#[C-SV_S^AF2*F]IQ./?)NI=Z$%-X<G]JBL*C$,
M7*-7-;?`[W<:,SB3M/#\^M0F:>'['##`U@?(9`7FYS)C7[AYS66%\RG!\DR(
M7Q_+2<Q\FTG\^A:$E."W/3^\=GYHS&E@-V':3UO_287)R7\<S996<Y.EQD75
MCH1#`3NJY4H)T:6"9[^M;]N%B=.[&+P=>]8U4.FD:44S9V*#UVTZ=S8RM%<F
MIP7'O(]C;[H&4\?\]UJCHR?KLG<L368SX5,E"UX&A\>N=0TF7H;O-3IZW9;G
MHV=GK>"7=W'L3-=@ZI?_GA`]5>HH>JSJ../9N_9P:3AT_7EN_[-S@G<T^#SV
MKFN@T@G=[7^T^3PG@C:'!\>\CV-ON@93Q_SW&H^ZW:9SCHUG-.]8\''L3==`
MI;.9%6F364[`-%.]7][%L3-=@ZE?_GN-3W>5(ARPVB?BV\'AL6MZR,_1;.&_
MQT>OVS(C>DT_5>AAKHB<Z1I,_?+?$Z*G!2,=L'8Z#8XV_801>=<UF#KJOR?.
MM@L17-7NDJ.4X6S96*]D?+)YW<^K08="M5PJ;RH=(F6)V[.*9,K#TO-/[>[S
M?EV\V.Q;@TV?OQ7O__#JHGBSNUS]E96,FS]\V6\W+QH'ARGU>IAJ1SINJO6.
M9T3.S9W&DIXX,)7S[;LM\^UKV1EB$P<B'3ERLBE[#QIAQLO,;(Z(Q`67U84N
MQ;)+;KI-0Y+(N/D[/R1N0@;L3^5\^VY+A'T-#DFL(X>DC(ZFT9#HU9G!<#-W
M):,<<CW`@->QSKA-PZ'--??7\I@JS_AB)VMCLYZX,I5QLW_^P-B:N1N`:2PB
M'1N+JOFN8\5Q0AJ21,:!1WY('$D`]J=ROGU1HNQ+"0Y)K".'I&IJ>$C.N.*@
M(PU%(N,H)C\4VD^V4_M3.=]^E#1R[`L&#D6L(X="US,SR3E7&@XFK53'`=%L
M,`92LS%3"B8AM5!A.$-"JAZJ-BJJVJB.A'ZZ;0_'_:YXMSZ<;`')XH](\&=\
M5<&Z`W*/HI<8U/DS*<<G2H'`HRAGY]V6&88MT5@+$.EX'3DRBK/>]&C_;*H+
MQN8<<3B21B"1<7R3$0''(8#AJ8P#FRS#&@Q]K*,A@D5'!7@K353O$)T=$&(4
MO:*1T76'&$J!S*(HY[;=EAF&E3^@(%CQ.C;FYEP2W-TKMK"[.Z)((Y#(.$3)
MB(!#"<#P5,:Q28YA*<'0QSH62C2'0R^7,HTCB#0"B8Q#DHP(:#_=02Q",QQ-
M@HN&!0-#'^MH"%'YF<9A`I!I4AU''K-=!TLQ9C\%`23H!``1P]5DLWD`$&-U
MQ!^OU[>;[;?B]?Y^=[4^;8QB241F%F)$"0/)2,<!B9B]7@068NR]/@"7Q#*.
M2Q#V+8980Q">>)V")]Z#4=*HRR1IP%68-!Z)C*.4_'@XM@#L3V4<K&#L:W`\
M8IW"+*)9RB1P_464,+H(\LT5B$`XX!`E2#""<J&^VS+?OO)'(`0R7J>`#'1@
M`"`#EUS2>"0RCF?RX^$H!+`_E7%8@[`O)3@>L4ZA&V@\1$:B<DR2QB.1<9"3
M'P_M9U:(=6CVH_DVM^X"C$>L4Y`'F:@<I@")*M5QY#,;B%'-I39-+=KX>V)Z
MY)GH*.3AX2D'5NK^_CFII'_*X46[/A0?3N;O[EA\:"_O#YO3ICT6+_>'N_VA
MHY_7+]X6/Z]LJR_MK@B4-+VKY_O\K)LRW'RB[8$4;BGBPA>'WKQ_7KS_\6WQ
MYHV%,76F+&0]L7=EQH&,=#&S*RU2&)-992%K0D\L]S(%OT)HSI6%G`4VL3SH
M:.XR":0?E3B=J8I?E(MU(2`$@TPAKIP06#*"#/<R!;7R#&LP]I%.N=(%QIZO
MRADO+`^YO9N/O8ATRB6NX,72):YQG<@:JR<^]#*%LG+&P&*4B_6T]X..[KVN
MX3&0[%RA"`C!(%/`*B<$%H`@P[U,(:HLPU*"L8]T-$I5Y<S^OYA[M$M920@&
MF0)1.2'0?O*;&NYE"CUE&18,C'VD4[!I..HS*D50UHET"B_-=QVJ%-6EAK%I
MK*-P1->/B$W?X6?%^XI6+?J[B[A#*/<4Z_YT4UAVLM14YI6PK#\@/'4Z!9[J
M"E7"LI8@AG(RB:&JN0>!P!*6,P2A5*>34,I[,+YQ16><JCL`2@,RR"2BR@^(
MXR#`?B^3P`IC7X,#$NDDOH(&1*RJ\Y4L=QQ`F-7I),SRSJ#O)+(V(=IR,HFV
M\@?&P94=``BZ.IT$7=#`5+E%+2`@@TQBK_R`.&("[/<R"<$0]J4$!R32220&
M#0CG&0/B^"D-R""3@"P_(-K/KA"7T>Q'B2.SJ@4-2*23\*S/%OE5+2AI13J)
MTF8#,:YJF:P"7<CK=?R%O%J)'GNBQ3N$75VE>YKYIBW>;7:[]>6V+5[?[ZXN
MBE]6[]P-U=6YTI%]U!"X@#?6<?2CYM;<F)2.C`G@RMU(QF%/CF'+-=8"<,DN
MZ(1[IX/IR?V@2LN+LM0SOC@R28.0R#C4R0B"0Q+`\%3&,4Z680U&/]8I<`-%
MOU[)I>*1W;^!ZW-!IU"-$F>I9E(\LO]++]&-9!S.9(R!XQ4;:^#:7-`I'`.-
M@>+B0BP7C](0)#(.8#)"X$`#,#R5<>228UA*,/:QCD66LIK+/JSB%W(V^SBX
M2(.0R#A:R0B"]K,A</&-:#A*`6?+1T#T8QW+)WHF^M6J62HB`=DGUK%>-#PK
M^X#E).,$R"M!)_"*D,$5%I637&G)XLKK_>%4_+JV]2'S]]0>#*Z\L["B,RLV
MQC60648ZCEG$W.4NN&)C;$#H$LLX=$'8MZ1B#4$$XW5*Q<9[,"[^U_J"-?I,
MQ4))*"")C,.8_(`X^`#L3V4<S6#L:W!`8IT"-="`\`G4P!4;>QQ`;.-U"ML,
MAS2R8F-L0H@3RSC$R1\81S1V`"#2\3J%=,A'BN.3-"")C`.>_(`X3`'L3V4<
M]R#L2PD.2*P3GOP"!R2G5I.&(I%Q]),?"NVG6`B":/:CE)%;JP&&(M8)3WZ1
MAJ+A8,I*=5R]9C88XWH-8S#_!)W`/TR%RVFZZF^\EL)^GO!/>/@K$%!]KEQC
M%RJ#T&>DX]"'S:TS.BG7&!,0\\0RCGER#%NHL18@V/$ZX0[K8'IZXR)G<S4#
MQR1I!!(9!SD9$7`P`AB>RCBZR3*LP=#'.N%FZN'@R'@`S.W6$,F,=-1=U#E=
M=YQA3$#@$LLX<,DQK/P!!1&+UPGW3>-W=P<6:002&4<J&1%P1`$8GLHX1,DQ
M+"48^EBGL`D4^L4[>M+.)S(.2C(ZK_V$!]$(S7`T#9XMR0!1CW4*AJ"BWG`P
MT:0ZCC]FNP^5873-00SI=3R&V$!X#+%%PH`AO/3+F7Y<%>_W7UN[F.EE6SP_
M'O>7F_6I/0ZK\31Y]1CK(P0E8QT%)<'WS'J,M02PR4A&L0G&OD$19PA`E+&>
M/T6;`4=X8%$"B$`BH]@$8]\0!61_*J,0!65?@R.0Z@A20$7`@H7;VP%6&>LH
M5L%X8.O7-8>0922CD`5C7_G##2"7L8Y`!M086,(`(I#(*&3!V+?/[0#VIS**
M7##VI01'(-41^(`Z#BUM`!%(9!2^8.S[^1*@&*+]:!;-K*E`(Y#J^1[4J'W0
M<@>4AU(=A3+S'HQ**;H2,,,$'<DPPHQ^%1;-9DQ&B^A(!3',G]KU]G13?+C<
MM+O+]NAOA;$TXVX(YNQ,=<4Z"H+,2,>!3#7W*I1Q=<6:@`@FEG$$DV/8(HJU
M`*&+UPF7DH+I<8%<+CU'XH@C#4$BXQ`F(P0.-0##4QG'+EF&-1C[6"=<-0)C
MSU=S>[VC#+MW0^#B=<+EHN&PS;T5QAJ#V"66<>R2,08.3FRL(6CQ.N$"$6'_
M=ZR1AB"1<?"2$0('&8#AJ8RCEAS#4H*QCW5"O06,_5*]!>A\(N.`):/SVL^*
M$*G0#$>'_KEZ"Q3U6"?46W!1;SB8<U(=!RFSW0?K+0I>^KC7":RB]'";+J^'
MVW1KD0,K[_:'T_5^N]G'Q)*Y'K+U&@27D8X#%X5:#]E:@OA%4==#QMBWN*+@
M]9"#CKY(-'@PO:<WYPDF(!R)C&.9_'`X`@'L3V4<TF#L:W`X8IUPX2AX@%F%
MQ^W_$-J,=%Q-)C\0#D,4N/;Q2,9Q#<*^\@<@A#>*MO9QP\C'A4.2-!R)C&.<
M_'`X,@'L3V4<ZB#L2PD.1ZQ3B`<:CIQ*31J*1,:!3WXHM)]I(?ZAV7=;HM8]
MAH8BUBD81!F*AH-I*M5Q-#0;C'')1L#K'O<Z`8-$_Z:1LN*!@DI6^6>T/[XJ
M?KT_W:^WKCPS?OW(]QGG=O1$O^"F24C=RCK/?GA0(W$7F=+#\UB-+OLN0J6H
M#NG2-9[S')H;;6%?&RO@U\J.JUL"7CQZK.,@4>0M'FU-0'0HJ(M'9QFV^"?@
MQ:.#3KAW*-K#HK/[=/Z;%+?2""0R#@@S(N#`#3`\E7$DF&58@Z&/=0H""L3B
MT6ZWAMA/D!>/SNFZ8S0!+AX]DG'0EV-8^0,*HCU!7CP:O[L[+$LCD,@XSLN(
M@.,QP/!4Q@%>CF$IP=#'.H7LH-`OUK+2SB<R#NDR.J_]W`6Q',VPVS)OW6@H
MZK%.@3A4U!L.)II4Q]';;/?!6A:#UX[N=0+$A1?(ZI7)/WIXYVD'./^UWFXN
MBY?[V[OU[EOQ!J(9HFUNWSO.FDR&(QLI>R/V[JAJ>$B-5_XAM7F`2Y?&SO-F
M%N#*(=X3@(.+?0Q><WNLXSAN_AVM8+&/@6MNCV0<SB'L6WIC\)K;04=?L]3Q
M/A<5-?2%<2^GW)<&))%Q=)<?$,=D@/VIC(,\C'T-#DBJX^Z^RO?`H1F#U]O6
MM#<7=YNBUMO6#%QO6Y->C-UMB5IOV\4:8C]&7F][[J`X>TPX8DOCD<@X!,R/
MAP,WP/Y4QI$@PKZ4X'C$.@4(H?'(*?6EH4AD'!?FAT+[F1'"0YI]MR5JJ6UH
M*&*=0HF4H6@XF*=2'0>+L\$8E?JJN@(IL=?QE%@U+)3ZI.[OSE*U]G=G_;R_
MV15_6N\N]Y=_*SX>[H\G`)NH]KD4O0-G29%NI(IZR70EH\?Y_(M4DEJ?ZVG'
MBNG*W7G^S+*B;GI_%HM]U@`$B6,=!8F]W3/%/FL"H,.1C*+#+,,&_YP%``N#
M3BCV13M8YON;++T!$4AD%`[F1,!B&V1X*J,X,,^P!D,?ZX1BWW#8913[W&X-
MX-]81^%?3M<MIED3`/>-9!3W91E6_H`"@"_H!.##[^X6S(`()#**]'(B8(D,
M,CR548B795A*,/2Q3F`[,/1+Q3Z@\XF,@KJ<SFL_=P$T1S3,19YAP<"HQSH!
MXW!1;SB8:%(=Q6_SW8>*?54IP.6_)SH*XW18W$5H_Z;:9^_7WTXW+;R"-]64
M99?>%*N&E2PE5_[*:2@IFG\_;7;M5?'JQ8^O7OIEHN81DNB09+SWZ#Q"DHV4
M<;?+?D&(LM1C@'Q(HY5;&"[<CL@%'][_9X;!F>UYU9%JYFKIUB%HM72O4U9+
MKZKL!V4=#98"6BV]DTEX66;?..IHLA3@:NE>I]QI&#P83[L7=<Z#GT`X!IG$
MFOGA<(0(V.]E$G)B[&MP."*=4GI$>.!`L13@`NE>)[$GP@-+C*6`ED7O9!*"
M(NPK?^P!RZ)[G7*3(?60</B8AF.023R:'PY'D8#]7B9A*<*^E.!P1#J)3J'A
MR*@\`J$89!*DYH="^_D36`Z=:-]MF6]?,'`H(IV$K)2A:#B8IB*=1*ZSP1A7
M'B7\K$6O$RJ/<GC6HNPYDC<E]*3%;^W7XD_[P^:?^UW\3*C#GG/KHUL?P3K:
M2,?QCCQ_:Z;C$@D^4C&2<:"38]B2C(2?I0@ZX9'08'JTTS:+[Z!W+)*&()%Q
M<),1`@<A@.&IC*.:+,,:C'VL$QX)!6,O5V*IG";AYR:"3G@D-'B1_TBH6WD)
M**Q)ZJ,3.6/@L$7"STP$G?!(*&'_=^"1AB"1<223$0)''(#AJ8Q#F!S#4H*Q
MCW4*NT"Q7ZRLI9U/9!RT9'1>^PD1JJS1#$>'_MG*&A#U6*=@"BKJ#0=S3JKC
M^&2V^U!EK6P:L+(VT5&8(EB/*4(-ZU>(L`;7R\WI6[&_=HCRE_WA;\6K]KH]
M'-HK=W-=NSMV+]=[MUWO@.H0V3,SDP37SM:]Z$:&_C=RQ95=1.2?'MF4+WW]
M]I>79GK4/RK&_P.J?U&-V_J7?X.QO86QL26F<`LC#_6OV_5V6[Q<WQ7/+R_W
M][ONDJWBTBU#[^@P<T%ZZR54%/,ZJ2C&\U_A9]#.6@**8IU,8L79]S^#13%G
M""B*>9UTZ97)-(&(.GF?"%@5`^(QR"1PS(^'Q3W(?B^3^!%C7X/C$>FDZ[$L
MU+#SG[]U!P!0&O,ZJ326'PC+?-824!KK9!)$(NPK?P0"I3&ODR[24@\,"X!`
M/`:91)3Y\;`<"-GO91)8(NQ+"8Y'I)/X$AJ/C-H8$(I!)F%F?BBTGUN!VAC1
MOJ5-A'W!P*&(=!)T4H:BX6">BG02>\X&8U0;*VMX^?E>Q]?&;(X(T*F:_G*C
M20_R;'4LNG7MW%+TUD.H,C;64=`3/#]7&;,F@,K82$;13I9ABS,UO!1]T`F8
M$TR/%^QJ+NK%PA@0@41&\4U.!!S!`(:G,@IL\@QK,/2Q3B":8#KK#C.W6P,E
ML;&.0IF<KCM8J<&EZ$<RBF&R#"M_0`&%L*`3X`6_NSL\22.0R"AJR8F`XQ+`
M\%1&X4J682G!T,<Z@5/`T"_5P8#.)S(*4'(ZK_WD!]3!B(;=EGE+T4-1CW4"
MDN"BWG`PT:0ZBD7FNP^7,TQ:O>THQ'S:=I\J;C^YK[N/-\:Y/\Y4TBIX,?M>
MQR]F7U9E@!K.^T*:O3W?WS?VM=T5Z]U5>"CUHOCEEY>.8W(6L;<(T'4Z]#_T
MM6S<1]>@6>IV:&WK/7R*1%YG!"1"W!QE0<3WPG<HN.X'SS98'KS0&J*K6,;1
M585:RC[TP7=G[+AK<*8/OC4(:EXG7,(,O1C/7(Q=2"ER.F4K/\.>`5=MNIX[
M+.IZ[C[ZGML&RST/K2%`(XU>MR5J&?R^#WKH0^^X:W"N#QH<O5BGL%Y5+K$>
M7#OJNA)Z%?SO\D#78#$EA-8F:X]20J23L+&:/<WNVSM*\^[[GHQ][AHLN^];
MUQ/O>YF$GAG..T#SSJL^D44>=PV6G?>M]33V@TZYCAO<QR<!!W]=IT+_QCWI
M&BQV*K2>C,@@DU!X?D3``IKO@^].<+P[J%V#Y>,[M(:HNJ*^)@&1HQR'^C[(
M?H:)''<-SO3!MP8!W>L40(=FF*SNC'<)N-K6]5D/5*<'K',-EOL<6D-<3AHW
M'5%=YJL-0A]$/S]&CKL&9_K@6X.(3QLWA_B$<:N9Z+O3],C9?70YH&NPF`Y"
MZ^G\$NFDLX79A#`I`$H53A/,)W^:8%)\0.?NHW=^7/0T7X'G!T$GG!_XUY_;
MDP)A0N?F^(]O/S[_9:F.V/4@=*9WO.K!N?N8]"$T`V'?ZQ385W,7?5._#4S*
M*:%+ZG)Z-O!GBW"68GW`M.P#YCY6/9K/!<PW,_0V#MB@H]G4["BERGLNUOL=
MNC!VMFL`^QV:Z;';@TRJM2*\G@SS()-0/F.8'6'Z<)6Z#Y?[6/4,/!<NWVPZ
MS)%.>2`C)V`.+CN_0Q?&SG8-8+]#,Y#4)?D1XGF_)Z3N_?9=&#O;-8C]GFX\
M8+X<,+_+OET#.!&'9E!I.99Q?._S\%F^]UWVO1_WLVL`=[G[;C@YD'K2SZ[!
M3)=],["H[77L64'5])T>`4!Y4=;\0M5JJ;S<12$$9.Q]UP#N2&@&%<5)8^>V
MG!V[U.MZG)<&F83O&7G)@:X/E^S3>/>QZKE]YO@.S:9G@Y&.KV>SK+RD/1_=
M#ET8.]LU@/T.S28G?(-,JL(CO)X,\R"3:#]GF)L>+!V5^W")?HKN&LR$RS>;
M#G.DH_VNE]+X8-KANO>[Z7$R<K9K,..W;P:"/&WZ<9O.3S]0T9[#JTA.]&P/
MW*;YR_I9_.7PPH9C'4?4"`\L!W-P8<.1C`-KA'V+PAQ>V'"LXQ`YWP/'IFD$
M$AD'NPC[%E$!^U,9Q[P8^QH<@53'T6N^!PX:.;R2X5C'<2C"`\MP'%S)<"3C
MH!!A7_G##2*TD8Y`&]08.!)*(Y#(.+1"V+=`!-B?RCC"0MB7$AR!5,>Q4KX'
M#E+2""0RCGH0]OVL!Y4Z:?9Q<Z'#%6`$4AV',0@/&@[FH53'`<FL!QUJR(:Y
MIV9J9/FO,C/-4()5)E6X,S!W^=\]RV',028-6EF3VJU.A[,I!YMLQ9GH;DE@
MJZHN_7M.WK=WA_;8[D['0EQP65WH4A3'F[41[1,_^_M#<;F_O=WOBN/)KH^X
M.1[OVZOBM"].-VUQ;+?;S>YS]]W-?GO5'HK-SGUU=]A\69_,O]OU97MK#-C?
MN=NV)[.U^;7?]E_:VT^F>7U1",:JB^2YFN_L]O#RDZ86OMO:+>)BN_WU9G-Y
M4]RNOQ6[_:GXU!97F^/=_FA]NRX^?5OJW%?SL2WV[O/=^G`J[G>GS7;:(;TJ
M?CVLBI_77S9&^[#>?EY?[2^*=R:NFRL;#7<7R,VFO7[HCOM'<LQXU\-;7R2K
M_$/G/_VCO;P_;;ZTQ=OKZ\VE<<[T>*:[%\7-^EA\V9^L;AW>[+ZTQY,;S;O]
M5[OM%_/';>UWF:]V.:3Y`*Z*C^:+]=65:>QVL(?MO&S"O9)F7Q]>>:/#PDW/
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M^/STP!WG/2J[I8E\FJK",D5`5GJ]OMULOQ6O]_>[*T])H_1TW7U_'7W_4,GI
M7$?GSZYYWU,P.7'6V.14E^CDQ&L.)R=U)CE9D[8O6)MRL&F3$^-^;ZVK\/K*
M/CF)_W_9Z7MZ7:FE[)37U_^[[/0]/>_?*\V;JC](5=G`V>EHSU'-R4YK3O$V
MZ\.W1TY2#]QWV;_:H/+<R%=U$]Z!-2&G%^W:G'"?S-_=L?A@3G8/F]/&>/UR
M.*<K7K]X:X=H'+7BS?OGQ?L?WQ9OWMAT9CIV75QM#NVEW;_-=XLY[(%[S&7_
M<&PTW+QG953*/.?([+4QK7I/P)2IRT(W[CG:]'<K>VEM[CD%6^KK?E9,%O@2
MA7W1EJVPN=\<-G;7(D7Q0W/F>V[+N$L-A#;I8JF!M*\J66J@5'VF@;U%SC:0
M,PU*5P!8^(5*F:EJJ8%6%5]NT,CE7Z@;*98C[=[9.]/`C-5/?W[ZY.F3_P5&
MX8=$#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C0U(#`@;V)J#0H\/`T*+T-O
M;G1E;G1S(%L@-#8@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-
M"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A
M8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P(#`@4@T*
M+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W-"`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HT
M-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#(V
M.#4-"CX^#0IS=')E86T-"GB<U5M;<YM(%GYWE?]#/V:WL*;OE]JGV+G4S":U
MWL15.P_STD;88@>#`LB.]]?OZ89&O@"RD311*BE)AN;T^<[M.]W`Z>_'1]^.
MC_!,&H&P^^=_Z9G@S4=\<WQ$_!F"J$1$^B,4,3TSAFJD,9S!C*(R.3[Z#\J]
M+,6%$R2T=E^HO#X^6AP?7?W=B7+_'AS`,\X93##C3##X8H;2Q^<-%^Z\8<J=
MUUJR?H$4G6A&&=($(T889UZE*X_/GR/=.<;6ZIY>'!_]\L%>QLJ!NX#QW@Q>
M9`!.*#("3@+R-W]0CO^&+OY[?/0>KOSWCL1KQO<G7J[%H]VK[N)ECZIWXO>@
MNMBG4^5:_!Y4=TFQ1]4[\7M0G1FU3]4[\?M0':K*/E4/XO>@.M5FGZIWXO>A
M.MMKA>G$[T%UHO>:IIWX?:A.]YJFG?C'JCMW4P,U7QF0[*6N+_>$#P.($-H/
M((,#N/$#^-``KJ4?0`<&8$'YV`!B#!L?H`W1HP.4UGAT@-1B7(+07(P.X)JI
MT0%,T_$!5)-QF$2I<26Q$J.F-DK0L?-:L=$)E(+^<>2\5&342$)"8SERGDLZ
M>IX)94;/8S7J9HK->!C@$0-_:X>T)B:\)P\A30GI$I$\RW,LFM*-9T3`WQ>Q
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MJKJ$<=B_ULEMDJ/W-TE9%7F$J@)`7B9Y<I7&J2WO`\0>+!%:V`K=%K4[[KR6
MYK=)57L7+XL[`%O<PH>_NK7L70[6N;P?DKAK\+"\#]@QU@$[T9BW=0'4L/,Y
MJ.:]?IK8$H%!;)E7Z&L2K\JT3D'MLZ)<%J6M4W#]A]-_.2<]-AOZ4M0+].N7
MMQ&R#M<5FJ=E$KL(]P?3"HB.4O0^K[+D'KV%2U=)A#X5%7J;7R=94D6[1JZ:
MAM#PF1%4^^H"T#&T#![YF<W2JZ+,4XL,QI3/)DP_W'BQ;O[G79VC0X%=U82T
M?'79-,ST5TVYH6JZ.1V85T_*UI-NJIJP]HG$857-K6#3+GLX]`<A>Z!N-KBE
MCM2/KYJG(.4>?>XM'5NAQZ)%CPUIG$YFF+CNPH'_9UK7D.U5H[(KFC>-0UIP
MYVF>VQ@.?UB!9S[;W%Y[A2'K9Y]F9[/(C[J&0EO:#"UM6>?-Q=V%;^>W8*RR
M<E><#X]WAW<,7;N^J7&\:KLI<#Q5CCX<]K^("QP?.C-#,:WBS*8WU9J8,G]]
M62W2Y<[1*Q+0,['F#-5F.YC<AV(#(X*HCI-E'8(W^>[Z2^>7!13])7!([EDT
MA;X3AM=N4)FD0+3I%=CI?H:><-#%T]@)[K?H(OD.-L[2F]05@38$G`5ZR6,K
M$XAFK]4Q!JPL0@!@WO;3`(V[9N+<08+,/K?EG^BT6&7)K2U!XZ\K4!%*/([0
M>6;SHE5="6S8M$0=XAHF6:=M+]<HXCMT0LRKN483U<\U:@/7N#D]FM=.RM:3
M.JZ1NN4:XFY3>,M_299@<[>$08S22&AR2&RS%7"@DK"$TZ'<"G!OPS4\$N"2
M'\PU'XJRWC5NI;LEF5)AZ4K<72`/_+-U_>697::US:`6?#H#I4NHK8%[!BBA
M#YEUU23`B^W2QFE]'W6VJAH>&ROBN\8NNW49Z?HJ;-KN?!ICO+-YFF3H8U+>
MV/R)K1J>=ESL+ET3MO?K<TOOR>&\ZR9QZW`"#B=\T.'.%0Y:BRFQX+[`B?V4
M^%*22B$CBG*(JW8-G(5^$BI(`YL9VL+>Q(L/7`2?M>LX/IT[5GR79!:R.^DG
M1L=4L$J[M&5L(40*=);D_N*6HJ":PV\PZ@<H#Y`$<=%+IEO!)KU+,6BMS/.U
M&(=$Z&7(C1H,K\;6*O0RI(`@G,B04NE^AM0;&-+-.=6>85(P(:6A:G`?7$\8
MDN+(P`0'1)!;X99=7RJ9"@G$`D/RB&A^J`2Y%6[.?VJ"W`H[53\G06X%FN"?
MER"W`2Y,:`6QX*$')B3PQ"LH\KSEP+^4)+>"KN0.2'*C!F,D&53H)4DNU<0;
M/6)HQ])LX$@WY<3=7['>L,3=[3#)N]MA,_0%JA4LW],X06^KJH#LJ%T:_)K'
M,^24VZ$^%-(Y*-3T?6_^H)3M=(9'D$7;7N*9,*%4#D'>I=V%Z,')=^I9\C"<
M.':;T6TXD;Y\F#Z1>6!02K'J]H#\[V83,!#'`Q*TS9XENDOK1<N(4%*;FR$/
MQE6N8O\"==7SS2!S;I,!W=XU%8XX&NV9EFT*@%9`X\D@>UZM\KG7LH%40-6/
ML]2KGJ65JZ`PP/5"<""W-TGH$VO?8=E+H&9/CFBY*I=%U;1D;D"9+*%,.W8M
MDV\K,$QCCQVC[_:NH44.R<"-XMT6IE/EP1VN]]_CA<VO(3-B3WO$,!ZAH:2!
M#N$>:!7-$]#>MXJ7C26?4JT39;.L:[D:0[<&]$;ZQXZ1\_76->V:12IYNWF[
M`#BWCMD&H27?W?*ARNX?[#K7"PO1"_\KWQU>V;B.!O$V;45GVMGP5$"[=M?P
MN[UKK$VW<<N8:9OE.V@$`5H3ZM7JLDKGX2;O8S4_EL5JV?!!A.X6*6#RZBY7
MEUD:@XBZA%9ACJ[2W+4$8`!7#^#*"KE>T\6W6R"Y-F4"PB&:ED)W$/MI&HQ#
MW4.(KZ1IN+)]O-C1M*NS'4T3/,K3VL^I)'_UI.Y2QI]O]F)_[_3I4E:)PWH@
M8SO<ZTUNN>863L,:7KP([+X7LQ,P#P6N`GX.H'L#EPDS,7"9Q@.!2S8$KIMS
MH@/#I'Y=VMTD8S0PS,/(_:%Q"SU2GQ^W@2Z[_7HC^/IYFO!DQ>$%[2:P@T$+
MG@UH^X,6VHR)0=L^D/4\:.FFH(4YIWIN_138>N.0*65ZJNVA%=MM8*\?`)-2
MKHNM:7LB$?&#K+6;(`^&+1<=YMZPA17!Q+#U+65OV+(-8>OFG.B_,.D+PI9&
M^K#"=AO80HR&+8^$/,2PW01Y+&P#YMZP)49-#5NB!\*6;PA;-^=4_Y&>VS2]
M8<L.[%GC[6!C,AJV\D`[VTV01\,6CRS)")^Z)"-R:$DV_HB\]G-.]%^8]`6=
M+8OH#PQ;R7L[VVV@<_63=;:;P(YUM@%M_Q/*4U=CA`RMQL8?4-9NRJE^6]\O
MV["+`-W!H97:Z;"[FV7^3;D0K20D*I$'\5+'ZR$/[R&H@+G_.8[F%3'2MZ?F
MWE4<$,NA>(N&JM\\N2OC[WN-O==U(O7H>VTG1(V_FW="I1D?P+C:,$!0,_:F
MY0EGXV_WG0B.-Z#D?/3UN!-IZ+@$9>CH"W(GFJKA-P#!%>]_/SXZ/OH_T'-O
MZ@T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HT-R`P(&]B:@T*/#P-"B]#;VYT
M96YT<R!;(#0X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO
M4&%R96YT(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C
M,3$@-S@@,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&
M86)C,30@.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-#@@
M,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`Q,C,U
M#0H^/@T*<W1R96%M#0IXG,U9;6_;-A#^+D#_@1^WP=;X_O(Q3;MB0Y&AK8&V
MP+XHMA)[M25'LN-EOWYWM&RGLT4WB0@4`2R;=WK(NWONR&->?4Z3NS2AF7:*
M4/SSWVRFY/9CO$@3YB6,<$V8]B.<"*$SY[@EEE)BA"1UD2:?2.FQC%0(I*S%
M!ZEOTV2:)C>_(!3^/1J@F90")LBD4`(>PG'^K=Q)A7(G#,JMU>(T("=#PQTC
MEE$BF)#"+^G&V^=E=B\3XK#<5Z,T^?6W_'ILT+@1Z'LW>,B=X8P31B4C(S#]
MI[^XI#^3T=]I\@9>?=\3O@-?Q82'"$6#UP=XTO_2K30Q/6-Y5,=;ZF+"&T>C
MPINHI#>*1X6'=V+"LX@YQ0G6X9CP1D>%5U&S5HNH6:M9U*S5-&K6*ALU:Y6.
MFK5*1LU:Q:-FK:)1LU;:J%DK==2LE3)JUDH>-6N%ZTHK$,(0-WX[W@(?$/PI
M%12X`B$JL$X%6!XJR$X%9KT"[U!@2NF@`G4ZJ,"<4S2H8%U[ZNA2,-:%$;0U
M)JB@K'9!!6E56$%8&3:3(PM""F!&T-6,&BM#"LZ8X`S60!\3D!LC@U[2!@I-
M0*ZT"LJE9BPH9S089\%X4,[9&0^#`SOE=ZU*RV8F3^0J$Q"E?;*RXWY-;8L!
MS9B"WZ,Q?J6^S=I`#H_RZWE!JAMR696KHEPUWR3T%N;#6X3<8.WX`U>4*80U
M\`!<]^CG/$T^'E9-!7;*XM2BH<"(4(_9[DV`#?TU6/<O5ANJ*#/PR;#NG"IM
M<!;RLQHMGSRM?[>=%ES%.6M=)8QQ6U=]*)9UT:"/"!<#!6>79IK#"'JO6M=D
M7"T654F:537^2F9-LRXF9%61U;0@33&?S\K;K6Q:S2=%36:E%RWKV7V^@N<\
M'Q<+0$><Y;Q8P=N`]KJ`T6M09P,H6U23O)P<-9<O-IR:G>$:"B,:/J29Q%L$
M;[D<F//6>B*MES!6_%/4XUGC:84F;O*ZSM%MW^649CV>'GLE>Y;17;L87LSL
MK3YNUK%N0?U_'GM=VRL>D]>>(:_?<YX7PMVDYZG+](]&W9>8K620N&(@?DCB
MGC,YQ-N=S2=I:Z$G`=IJ^W3:,M-!6W>&MC@G&O/42=$/;%]X+)JUC1\SDAWS
MEM*!$/S[@XF1>D%`;ZH:QNM[',\;TE2`V[/Q;?<+V[%`/9^S6KDV9P]9E=_B
MY_.2+H.-?5.4/O<N03$O'P;DW;M+\`#)R0:,G3_T:):6;F\7,$E2VC)IV.<D
M2CQR'L/;]Y8YBNN6.=6F!(<TZ^MF-IGE]</VB(.>Z#>(UHK]\<KM8HBE"!?Q
MMJ[6RP'YO1QG`_#U#.H#N/UN7;7!PGA>77Q\??&>K$LDG2?CP^*ZFO>Z3,?W
MZ]P626C=N.AUAH,GG,D,YC)&_?+/3U=9C_-(24]8(GN=0>]G.*ZP+P%6]#%9
MJ-WOTE*K]BP.T<\G$RAOS8&NIQ+7[_$7]T6YWE>VGEFMM]<K3F6:0[.-P<3"
M3*%E]4N]6!3U;)PW`W)5;,B7JOX*W[Y@D>;T.0'OVO`X='>[Q9S<\/"_9;XW
M4B>`-6YL'>&`PB14"_P_!B&L#':U0[R4#LGA.!)6X%*>4W#!>Y2A$.'F?BB%
M"1NA)`OVUD-EW1DWV/#UP-!PT7U%`:Y^\SE-TN0_Y=1!+`T*96YD<W1R96%M
M#0H-"F5N9&]B:@T*#0HT.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#4P(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#8X(#`@
M4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@,"!2#0HO
M1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@.#$@,"!2
M#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R;V-3970@
M6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^
M/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-3`@,"!O8FH-"CP\#0HO
M1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S,C8U#0H^/@T*<W1R96%M
M#0IXG,U;W7/CMA%_]XS_!SQ>.[9*?))LGNZ:I)-.IFD3=Y*'>Z$H2F+##X>D
MSN?^]=T%")"R22K'$ZZ=FSG+)K18_+"[^.TN^.Z7VYO?;F^"C8HE"?"?_A1M
MI##_I>7M#=5/*&&*4*7_P@BGFSAF$8D">!+PF#39[<W/I-*R0B%1D(PB_$&:
MP^W-\?9F_T<4A?]&?P@V0G"88".XY/"#QXR=/X^%Q.<Q#_%Y%"D^+9"1>R5E
M2"(:@'9<<*W27J]//Q/N&>>#NN\>;F_^]&VR36%QG#S`>`V#%FD7CE^@`1/D
M`=8>JTT0<48>_G-[\^8?W[_]^Q_(P[]O;[X!.?^\RF0J'$W&-Z&49K+[8!.`
MV(<GF)?\\"WY^KN?'G[\[MV_'K[[894.(>[FM`Z4@0J!4>'->R:":\M7(_ED
MI?`Y`%5`XBC4LH,-$PA9JM&302P,?#]G)&DR$'O(VRYK\NI`NF-&VB/\M25U
M1;;9,2GVI-Z;OV=%@6/:KDY_/=;%+FO:#7G;DE.;[4A>P:"\)8]-W3YF:7=J
M[_2W0'!Y];51Z1:G]+I@>QB_]BR,CB"D<<`LA$+@9X1P"I,KJQ%"?'F]6''M
M6;APLUS=%D,>CHU1<H=DJ#\CDGF5%J<=V!T:S97G!T>.PZ"?GC,FG2^$^!FG
M?RRRW2'+P&AW=:5_=DU2M?NLR=`7&E*#7@UI3VF:M6U]]5UF8>1TC-E&!`$U
ML?7^VA-%`Q@82Z4)#(#_M2>*V1=:4:Q&VTLC[D*=D"RVU@5Q*&N[(8B9(-=D
M:99_@/"5[&&`MKU=TF4FY)U%,[)OZI(DI$I*&&[%>#!4(`"]GP2"#BO!SSKB
M#)&&)"TH=,CWW1TQ]@L_DZ:K(`@=\T>R@[#>Y-M3ET,L=R9<U=?>:0YDQ*KM
M=:>1%`SX4,8M/,B*##I)@0=:`7NX<QZ\N?*Y+4+AU%@=*Q=(1\RY3\[AQ/N@
M'#BQWIT`.*K;'M&[X<,,C2!E\GQG/*S+2R`-M?YYIP>3I'I&\TW@HZ$B>>-(
MRIZD=5F"?6MQ2%IPM/DE^Y@>DPJ]HDR:7[,.A8!-[/PX;A3'UC!#9%B]X_(X
M,FO?)VE>Y-TSZOATS-/CF&PA#T/5P&I!2>!2CTW^`0.1MN$D11<&L@7XM?`=
M,'(-&1`TDG1DGW\TWZNR0]WEVO;A^W!0Z6_,(H[$S0<0<,+T0,A@B&`Z*B`0
M>CNK#!4NZR:S]')?%T7]A'J667>L=RV@E%4O`O:?K^]MD6(^O<V)]Q`H(F0O
M'E6WXCVH'H;4I^I.O`_5N=>4T(GWH+J*0Y^J._$^5%>!5]6M>!^J,Z_GN1/O
M0749*9^J._$^5!>Q5]6M>!^J4Z]'DA/O@0"*6-K#'R2YPY]*<9D!`L-K:T/Y
M>EITJC#-^?$$I)X*T?^*9.&G+#TU>9?#F+<II#_YGB0?DKQ(M@70O2;1F4X'
M[,]]YRR9NW9&$"KA5N[#($3H]:!WXGT8A(QLP3B605\P?M?4OV;-E2<#_-UD
M/K-0X/EV'BP+JL'*A>JM?)<!10>CSJI#<@`VOGV>K:`:PV\:3%2``]LL?:L1
MNG:52<3\RV`D@`F,0`IHY')!2:-SD"#9PZI%GN:/F/%`\J,3G`WQ8B4J9E\&
M`A6K$00!=H.<G<3R'`*T@;X4Y2$A$X+:C>`R=AL1R3XKQPPZ;UM,,3$IV^5M
M6I^JKB]YS1KN^T`&=6-B+Z1T6Q^[Q='9>O7]&FS`1S@QRIS!BHBK\6X1R,9;
M77H[9%6G718A>CPUZ3%IX3GDL^;XNAL`=$\!-(HF[F&7^V89=GLD&[H]JK>U
MI#2;"NZVS4:E@H4:P:XF5=V1[".>FKB.-B-C8TFJW<A:0'#V,<T@W#T=DX[`
M@9N>0%R9-,^F.Y21[OG1%&T\+#]P_04:#YNG;/EE7$@!=3[4Q0=<^UNP7.`%
M^[S3'2]4$G8.JXAN&U\5F2":)W[,783*+<2ON4?!"#'*1#S4:11]:>YH&`GR
MI[S"(%V0,C\<.S2C799A.=S8U/4WE<?!%)ODM%=1D[LG)(*@X6")X))C,YVC
MC1ORM?W*'7RAPLX.?N'NE9&W>0G<LG%>@AY1M>CA)OC=^5A[Z`K=<M0("&PC
M(.E,<1\IKRZ8'DUE<&2X3SE0:=B8;=U4F3';"3^_4"1,#DVF)\@!QK+*]\\Z
MW.OH=T=Z(ZD;/PX1`F&Q0'AU"`1<VMHUC886$@_/O*'#T#:B*ZT.;:]CBX92
MUVEM]]QL"=A+D2=;K`3G?=TW+Q]K[*#K\(/2`?FZFK?::^<N5+BE7SUW@02`
M\\\O(2SD%YRZLCL?HAB/?T_+X77'H>^CH3T?8%,[[3$:?3S#^AXB,M2ZS,Y[
M$K,=B:?*)``>##9PA79%!XMEK(\0H%6)X4M'*?CE&;QUGYR*SA['8&E`7\H$
M(M^HLX+K17/<%ODAZ4Q`U*/[%CFNVP[2GM`W(^K]'H^+RG1'IS&Y/@@L<@4'
M/K@M\$8YZI=.;/1D7:!O`S]EY)@`%=_G!;:&27MZA,672/=TH#W_SJA(`1P,
M6?$661Y^X)KNN:0N`3%YJ@,V?/]#C@>,#TB42[S"4(TZ40:1WE[/HPKN$<7.
MX+!6]!@T<?B\LW>#BKS50R<]2I\1^A;'V%[&-RFF+E+X8<-,.BX?!BXL2!:\
MO!``O&9R,5^D;H2*<J^-$"?>0VF'4>&J('R@W%+Q"Z%7U_DP9%C+6`J@8![&
M9-*\24]EVV&X0N9EVZ@IY%4FNQAN[-R=1:OKFQ>-'7<.U4#.N$VVIHS<F9RE
M9>/,>IM5V1XX!9!K/#'@&YA80MJ(W*"=NH^"@18QG`^V+T.?!Q@BQ\]E-*00
M&AU]`OV_!=O7L<\#*,H1]TB,BH.RST3_Y]%V*O9Y@$%8.LVI0T':"NF7C[40
ML"B;HZ(8B`5Z<@@9IQ$\2-`WK#%2<R;T`#H[@$H]0,P-8)+I`6QF`&/P<&D`
M#8/E`8&*Q-(`+%BKQ0&18LL2`">Z.$"I@"\.D#)>'@#.LKA,RJ585A*07H2:
M4BQ$+PV`D+(X18Q%[H7GD8@680J1D2T\5SQ:?"ZYD$O/=>%RX3F/Y.)S%EV`
M.*++"`?A/,"_68R-"E1,.#-$%RST]-Y,7]_-ER[UTRW-5!?:XZB/LP\Z]D/X
M_$L-`:_JSILI1LR/?T613QA<_H8:;22*#>&'*3BX7XO;FY^LUI'`6]G@!U,Z
MBZ6;W$0?"/CJR(;;ZW%\HV@?%-\S%9)7H1C\6<\(YCHYY4(8UE^U^1'#X]&1
M--DGB74#QPV6:$W])CF<WSG3-.-%?6-T?6VZZ/,9&N-K+E;EY8+/9TTBSW`)
M!^HBP_BLWM/60"*P..PJ^.U7*S29.Y1D/.S0:XJ._@4Y+=@-G_2/"[;6UW<_
MT=;TC+"4R2DOV%H0#15EDXO3C6"RSP>V!?)1?<WQ]YK16F48<#"KS44S6C])
M.%YR1%4?@Z1^66ED19KQ)UV7E8^:U;[D[*Z;M#UUFM0#Z\_UM6UT/QBAK\'"
M7YMNQ&(-GLEK#OMYNQC&KEW(!E+/PZCWC*$-`"OI;[7JJZK'L]`QY2:7M)IS
M$Q;&3JUI-Y'!VI`<]C>Y/]5-<,9U(3F4KE,7QJ/:1&P![D--N]1I^@P56,"<
M#I>=8_4D:K10BJ\WNMH<?]%A&K>6>H/'1D9_:^+JZQ>0.GA?/S8.1NN/PG%+
MX;RG@)D^'C%)JIM1DXYS08O9\T4.2YUV'%C`6L?I[_I_JN/@C"L=A[JJBQS@
M#$)[K]S=^#]_]06.&H2VV>E"]U/>F4.G.8W:,Z-J@14RN0\7E)_=!TP,Z=SM
M6"3[H5J[#RJ,U^R#GG'=/BA7]H%CWKV$`^D0=R<$OKQ0/(_?2!B3R"EH+^DS
M>S:H0:%I:#'-6@FM8*N@Q1E70BML\8B'KFJ"";FIFAR!`9B^XB2$%^:=K1,+
MY2:>AA!/C)40!G(5A#CC2@@#]PX2[=MB;V;/D+7S4/B.G>CB&;)Z$L9&JZ%1
M-*HT1V=GZ+A5[P+<7-FP9Y-89\OW.;AF=2JW_<6E$S!R2TIU][/+'T_%\$H1
M]@S-@$D#O+#0V1XT)&1VH9,&*)5<:X"R[X9]H@'J&=<9H%2Q"X_#I3_;D$RP
M/+^%G-M2>?W"&N)NWWO"?8!-_0JYT`K-YD#F$!VL:M,@LV@UR'V;Z5-!QAE7
M@LR'M\S4<`8%MOFDWS+3Q6\#*QINF7?:D$]->TI,?V%T[A?)TZN:\^_0<19N
M8'E6R4FX(U,]$\$G]PQI,%?'_CS):I!\184%G`!+KY'H4J6I`LH)R0I7/"<9
MF961S.3+@OYR=?4>LY"EYS1<KG+#`,67^@7W3"T72.^Y$HM5[GNAHL4Z^;VD
M:EF"PC<O%@?(8+Z*#$!^\\OMS>W-?P&%Q$+K#0IE;F1S=')E86T-"@T*96YD
M;V)J#0H-"C4Q(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@-3(@,"!2(%T-"B]-
M961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-C@@,"!2#0HO4F5S
M;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,2`W."`P(%(-"B]&86)C,3(@
M-SD@,"!2#0HO1F%B8S$S(#@P(#`@4@T*+T9A8F,Q-"`X,2`P(%(-"B]&86)C
M-B`W,R`P(%(-"B]&86)C-R`W-"`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-
M"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP
M92`O4&%G90T*/CX-"F5N9&]B:@T*#0HU,B`P(&]B:@T*/#P-"B]&:6QT97(@
M+T9L871E1&5C;V1E#0HO3&5N9W1H(#,S-S`-"CX^#0IS=')E86T-"GB<O5M;
MD]NV%7[?F?T/>.JX':V**R]]<VS9=>M+NE;'SDQ>((J2F%"D3%*[5GY]SP%`
MD+(ENG'(C,<K400!G-MW;N`/'V]O/MW>T'D0*T+QG_D6S96T?Y+][0TS=QCA
M`6&!^8431ND\CGE$(DI)'%)2I;<W'TAAY@JEPHE4%.$'J;:W-[O;F\W?<"K\
MU_N!SJ44L,!<"B7@0\2<G]^/I<+[L0CQ?A0%XO*$G-PIQ6!#C!+!A!1F2QM#
MG[E'_3TANNW^L+R]^?L+O4I"P@19PGC#!C-E2W@`?RB79+G'#7$J0K),\*N2
ML)OEX^W-D^4N)76:YUFQ)753)K_NRGR=5C71Q1K^G\BJ*G]-J[^2Y2^W-PM8
M\S]C;(R'<;>SF,\EI8PL?X/]W(V]4B3Z/&"Q"EH>B#BT/%BG.D>2RXKH;5HT
M-6EVNB&Z2DE6/)3Y0[J&+YY-#;)L!W?AB0U)ROV^+"SOR%X#PU*R3M,]/-.4
M>#$R0<SH<&CHL:0\^9ES,?8J4;<*<(U&W"YU+$`Y'JNL`7Z-O&2D+A$F1UXE
M9MTJ3\:631STN<9;15-6S1ZS9@=JA.JS3W6!J@3Z@Y?OT^0(/,U`HYXF#>I:
M4A9%FC09:!8^1NIC`G]`3>LY>578R_0!='5FC!25,*MK&%[#CI,T0Y5=G>RX
M22PXC'L:,JD%@\+',?481JUNW(%61OC]L@&WZ'6HRDW6D-*R'4P6!K9<OV+#
MAV.5['1M&0CC]A>MVAL"BK'/?MC#!`P`'^(8$##5,D"%TM&?U4EY1+K-MB[H
MU/Q[-Q5<PU4J_*Z^VXZN38X4*S?WSUS2L:</NNG'%A:XW%@$WMM$7ENE`N@Q
MTOJ0&M=2I9^.6645Z@`:IO.<;-+4ZF[Z^9`6-5QD19*M0:5QE%7A;58WE3;0
M,*C(<P(+[?0#K+:M4KM.!NJQ+[*-4>PI])3%+>E,>CT5@700>#G2V.JLJ!N2
MI%4#WTA>UD#YC"2YSO;PN=9[L&K+ESS3JRPW:CU#WN3'-<[7^_FZ"8RL10%$
M:BV]4UA`%,=36H"??@(+B#!<<'`5>K02-/Y&S&FU=?V0(?H>71@&DCS9.T79
M$#"%M#+Q&*@S(KQ1[CV"_LR*OFY`46!JZPZJ2A=;>]]Z4GQF?,6/`N4HIJ&G
M6'`78/:C)MS5)!Z9">JW,:U#%K)'+Y-![#&.G?MC`"M=K7W,W/G>K+H"6C,0
M<D4R%#V(&81%>KQ#UB5EB3-JXW<M'XE.S!5`QP2"E5$'YF$/S%WH\66@IC'D
M.)2HP"V]5^(,B"Y0%R\8`H1X&_)HO03H?+;);#!R9;C+5J;1:\AQVQP@EEZQ
M5>PBC[T&N60Z[QL:&&L-(5):G!NK8\\DNB]Z6YU4]P4BI^<)#8..)Y*=:3_9
ME-69VE]3^&SC0X$92OTQPT`@@X<TQ.^'0VZ9:OP_&,8$,F:^0J"\*2L6.[0&
M?:X/H.+'VNAE<PV\CW5J=]@]8'A@M/:;8??,XKPA'L+K^KCZ!:9HHY[>E./3
M'\8^SV4JZH(6_&[EF4,^59U:,5EG<C%U&SO&P-V%X91A@)]^@C`@#-JTC46B
M"X2%"+HX0!=--K9(J?1+3^L(X=$>C:P'!F$4MP!99(=C;N/UZIA;S;]/M^UO
M;RX'K(O/D(0"H)J"`#S!8O"ZF(AJ0(03VH6I!N"M\EB=>Q8,E"<P$]GFH`R+
MAZW'=W5$],$/=NOE=9"8PC[XI(FBG_Z[.!H,>!*E2$AMIAB%P$@>6"U]O7@Y
M]E)A[)>*!4`[ED-_,_*C(N96@$]?DS=/E\O%_?OQ911$P90R\M-/@&%!X#/:
MB'<8)F4'80\ZS]99<_K:P7UEF>5F8P*BUN3/O67K_`ZZ-@G0`9Y##PJW(/I[
M"7E.L4JK+5E6&F!B.R,_SI_.9Q.8>J"XCW"DMW4A'*:]R?0^FY$7>5EE:SU#
M2A]W68*Y%=%-4U8%>')`L@H<98ZELR+=9`E$B7!1/A98U#",TMLM9@A-BA7Z
M&57!`.M&+V`AF8)/JI;M]*-#!]BS*0-:!R=,RHG0L?CXX\A+22JZI>2<B]BA
MU.)^.0%0J%A-*1$__01`H4*?*/(X[@*!N%?T@&2Q+@$L0.77$.(7ND"K``6'
M'WQ4^?RDUUE"7F'N5)@80><SN$SFZ/M37;E<]_JXL8GCS%,G?6.&C[Z*ZO$0
M_)+''1[%+LB`&+LHCL"Q^_105@WYF2KZHJSV@!]CMS<"[G<S:0P9!D&WD)PK
MB?J""_W[_0]`'IL`W57@<WJ..:O3U(BY(FV;N)Y`UR"%7X.N/D^3=`^^!U:<
M$4ZIL@4YD^3K(S@_6Z!85%C'_0OYJ3R"CKY^_2-VITS1^8#S0!9KR]?&!QZ.
MJQST5R>F=8%*O<FJ/3Q10^C8H.-K=M/4=)3T[>"0JBXO42X4L@6JRNJ8*425
MA2LV8QD=?\B*F0FSX=>R@G'&HNT-9$25HI\ODG1.WF,+[MN&;YO-%R>;@`'<
M9[P1[8I:@KIZI=\^\K^"]%?C=Q./F(ZB9<V,;"$O+MKFFCXV.P@(;!QDAJ$\
M49S8S*@:X_9[TC8M.M0=N)@@+U!TTKQ9_:$>\H#'Y2$G,O;9*X\CBP<?_KFX
M'SN.@,=Z2U$L;N%:`+]MJ7Y!?GKW7_+LZ5ORXM7;Y^3-N_L%>?7VQ;M[R!5>
MO7L[OMAD2*<4FY]^@@A`*I\@RX![JZ)1Z/M^MJQG?-B,?#KJ"J`P/QE3</&R
MLZUZAHG!Y],91,"H$M$'#`G0<:^[JK,I'BR>S<G2M`B_/</XF")]UY/&7=-'
MJ,!1W]\SLL$X#,AL7',]*TP6!#\C0>6Q(0GD`EO@5F,K@-9;=,A4E>7>%^$6
MSV8N!8&,*B\3@Z#P)*.4O"#O&TB=`*[>SA>0+GW0]0X@IRF+*5(GZ3N@-.IJ
MB=*5$I_/04:<@I>?HY,TQ)<KT_5,RH,KGF`CV-5-#Z`A+9&_5S$V%3#H*NMF
M%LZG:0-+VN:/K,\%/%=G2\KZ9&K:CK(#Y'Q)E:W0-Z9XPN4+UO2I<GLNP:.<
M]<`OZP>H6**[4UN@)T8KQK9]2"M:DB<-%@,(#GL+=8E?1$</@%GXY]`4<M9?
MB(?2+03"&GLI*?XDFF2/>2$XUDBT!3>0F0NSJ1#4`O;X!B@BWYXU!;[6%7&7
M2*$A[,&TT+P`/\ACNJHAB$?C>'Q\G-=I,M^6#[:Q"+&K'?9[`:CK_K:'5G!L
MGOV:^MZ^\8<3D!_X7)S*SA<%@6L\I#FXFJHLLL34I,Y=*()/8M(6XY&^"WL-
M2H$K<GSM$$WG=8D)P/IL^`0<4#['4WWYNV+]"ATL"`%$@(4VM\U_&.';NL+8
MQW`9\WN:]KPO9+$=\5ST^DYQ:WDOJ_)XF"?EWIH?*GA;?.EQHVV_]YSP>;G6
MB![&VPH,I*QZO09/5F,,XK/%21)8(;KSS%WZ%K7'3;[::&W3<-.C24F3?FZP
MB-+YRK+(3Z,76`-\2O[A8'X@X.9=XU9(WA4R)/<!MRE3V'!3GY^=\S:,QFJ*
M2-];S[R>7L5^B],>2@!8[_$BZD[>2<4<+P2V#-OJRQGB_;\]"W,:]DRQOEME
M!E2;1_ZH+V.=[8;,]XS/=3M#]]59J&ZN2'E.GM8869>/_F!OUX[U.<27EK,N
M80!B@'."-C:W#TP+X#SPR63$.P27W/'AY+R4\R5&;-?TVY;STL^[;)7ARPT7
M3I+V^-3Z/Q=\:\Q,3ET2<G$)GVM,P`CI3]-2UCN!Q&07RK@<L<7?')4<#'Y5
M@O$#]7YWXX>4'$**=H?3U<9Y2'M\X"SV.55HOMO:N`\V1@9RP3L:ISCHROFD
MW6$__00E'T[;;)_+2'9GI]KR&=I2O2N/^1K+J"?C:-L4MH\?#EYLO/`E"+6U
M@.Z7[EA8=\@;4<J58']+S<L/90%&G]>3O($4^P.^O#-*:9#*1"`E;O<A6Z<$
M@<JXFW5F'$G1]"FW$9@_874ARFHAV)WNM:^[9%5RW.-!WP3/@>/;-/ZL<)6:
M\X?(#MN>(.X@S01<")7G0A!UOBJ(VI*7@66]V>BL`JEE&&NAZ+$/<('6.7G5
MV`S!^YTSTLY4YH*BP%525A4F+7K3M`<,<+&1"\<A1/,M\6=UB-&Q!\L0[4JC
M8P^^'JFN-9P1F!2^)!K&,+F9N)O!O,&)ODF`F\8![.H`)<T`>6T`CYD9P*\,
M$(+'@P-X*(8',#S#-#2`!I$:&L#B(!B<@46!HH,#PD#RP0$!GI88&J`"-D@F
MDRH:WJ3`QN?0`*Y4.#B`*3F\!%60;PX,B!4?Y%,DPVCH?BCYX/T`DI^A^RH*
M!R4MHWCPOHB&><PC-:S-C`USF`[0_ZGEL64QDQ>L'2`+6]K.W-G7;\XJ?YS+
MI$:);5BTA>FE7MF#RL]<3>`,$NPT]R]QRD=$GW_ACN;XWJH*X<.BH;_,;V_>
M^UT[NIFZC+3\ZOD;W+?K6?'@2X0R)U"OL_,N"`>-ZB[D<@C?[I@*!^5]QP,Z
M*/`[$<A!C;R3C`_/H,#LA@?(X+K1`9\6'V]O;F_^!_0*0,X-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*-3,@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`U-"`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*
M+T9A8F,Q,B`W.2`P(%(-"B]&86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@
M4@T*+T9A8F,V(#<S(#`@4@T*+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T
M(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*
M/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C4T(#`@;V)J#0H\/`T*
M+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,C8S-@T*/CX-"G-T<F5A
M;0T*>)RU6]MNVT@2?1>@?^C'V86L[7N3.T^.XRR20>S$]F)G@+S05"OB+D4J
MO-C1?/U6-:^*)6:BD`B0B&2S;GVZ^E0U\^KW^>S+?$:7VE>$XA_WRULJ6?T5
M;N<SYIXPPC5AVMWAA/MTZ?O<(QZEQ'B49'8^^P])G"PC%0I2GH?_D.SS?+:9
MS]9_1U'XIW>#+J44H&`IA1+PC_`Y/WSN2X7/?6'PN>=I<5P@)Q=223"(42*8
MD,*9M';^N6>B?29$9^ZKA_GL'V^"Q]"@<P\PWH7!B6P<9YPP*BEY`-=_^<0E
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M*X(H(>F:I&5&=N5C'(7Q?F1+I.C<A)0@*6552K@86Y'L`XA3KUTNTE.UR^LH
MMBNR2L-R:Y,B)^!]L8ERLLO2?&?#HLP7Y'D3A1NRM4$"BVD3%.39DC!(1E]5
M8"WBNH([5ZJ=(*\V=A7E89SFED1;P'P1)`78NTZS;5!$:8(+?9^6[3K(HN2S
MNP'W@R0M-C9K'265W[G=!;AVXCUYCHH->.>2QY)@%NF+[JVSU<%"FR((N$54
M4Z98.V6*-4L^)V&:Y-$*#%@1L+]`O'XS:>C!P8V^!_FA!^AT!X`XRIV/%M+G
M\ESO!C8?7_`I]YY6_`2F>\`%)S2]%3^%Z;C>)S2]$3^%Z9"XIS2]$3^!Z<:3
M4YK>BI_"=#$IP6_%3\`0#1/-+J\PE=:;"&L8XF4<]_)=M1'LRBPO<3^!O>(>
M$B;D_!R4?***!O`76]0787TA29H1IO#6"F]5*=CBNV46%1'DV.NOX29(/EMR
M&;H,S7PA%R3(20"*5Z`37ZZV5MA/73IV.U4^P9:B_88%"!<=)'!H[N@<J]4T
M'2V&-SMWJ->1&B'P-\YP/_1C!Y,=\W%L)LQ8YR16C9JJBB)6\!L=(/V0,D^W
MS$M*4[..8%T@/I$J8*WQDG$`Q8)EE$6I0S$.A!>V45+QIV9\N@:8(R_+-U"@
M`<L@*VNWL!C@G4<[0+.B*>BF-BW=U+K-%)*KVNEC+E:&!J>(%UEGZ;:+$_S8
MDR"S59I9DK<)"5:K"&.RP!)UA$0T05@T;XM.T16=3(HJ+,=3WT&^.P87G$3P
M/(C!H,_`,K,*&GD!(QPG?X$@"VB!$#S9Q.9Y(^3$R_"T2J83Q$.JEI!KTQ%R
M+8[#!,N&O('(&4`_#;L?`-T$8>`5R?/-TGA"NX0$<6"FKLXZF(]/1S2=E+^V
MXB>@(\IG#7I8+[,Z\N;H2++OP1A*.VQ!`"J.5>*P-.!VT)6Q/X*CQ0DL;M-5
MM([@<GS(*",;WD$[*J:TUFTFR<N=S7*+A`C6#>:_'53X^3&4-UGA:X&NNTY$
M\)=#%T"8>[)`[2ZN,T<5U&2*-:.4:2??,UW[A=5KINI*Y.5C;K^48$R\)X<=
MF3JI@3-!G*>'\WTD5=1SF:-3F=W%06C15Y#0QFE)#A`'C]-)(5!W\EWR['<S
M_&,0J!":I$6'T@5,>&AW!3+COJD'+RX0'-@6*:*B+`;VY]%;&KC"^<_72D,)
MA#;U#*>TVXXUJ[>?/]*2;`-<^P"A'-=$F.[V]7:9]WH[32?O.:JR`$3E*5I5
M>0#[9+">$HQB7BPPESQC(0-4#?=C&]O=)DWPLL2F.O[`M;A.L<V.5^,C1W;=
M6J-UBQS3)`^WWL.#%N`_)ZB$I=93;CVM^-&+,:`G4OIMH42[4EC@;PSAZWVP
MBD)@I<#6*J8>Q`NX#,_=PD\:HR21HJ&55/CM1LA=VPN-89`IP)(L"-,`TE-,
M/J01&$9>9\``QVZ-4T,D4PV?$;+'9[0PE4'W903J)1W]G,,H(OR63"FH'SOE
M333>E3O0GBW(FSC-HE5`A)#&C#XM@KBJN4XOJCT4D:HY(;@L<+MUB^MM\@0)
M!O+!G8T=6O*Q[?'!'BW;NI=+U42&4EI'!BL/V$I<[6'DV.T%"2CLF3#EZ8P\
M\)6:^B#:`U$CYQFIO5;7-XD&,AS7QE!B?!#MQ';ONV\*8(!"C3B`G1P`&,8!
M\M0`#IL_#N`G!D@.C&!H@#!T>`#7OA@<`/1;#0Z@6@Q*8+[F='"`I[%W.C#`
M:#H\0"MOT$VFE!HV$H`R&&HF%#>#`[ABPRJ8HGIP`)7^8*!\*;VAYQ[FQX'G
M!C>4@>?:DX-3K;#)-?!<>L-!%GAL,/2<>H,AYG38?T;-Z>=?ZB&JF@,FCR0#
MF$`\.ZRS`7OY"8AJ6U^*5<P`3\6;D]:'X#%V;9LK(%G('0]R1B7F[E\H\AF3
MTSNT:(F?NBC8STB5T=K+>#Z[;ZSVP2J#Z^"8S?)TMC3X:I7`(%=Z-1T42\WJ
M,OH39#'R@D-!D>TT0KUU5.5`?G:O-HT?*EG+0+G/:@9Z6V903"4E<)4[BR?2
M)$W(&R"CX/F(EG#`2F/*\);T,TH4;Y7@=BLZOLB97\/BM_M7KDI'ZK^W04:J
MDXS7-K3;1RAD!5L`M*GZ]0S#3NY=P$\:PUZ29,P51IX+*<^8<R#E-)X'*<]X
M#:18]_D2UX)UD/I80NUJLWA?HRH?AM6YUG#=F?-=6)VOQ&N5(*R8:2M8CI_D
M.*<_]F#UI74>:OLH7>4UQMX'&92N-<#T@KPK$PMIMKIT+=)[NRMJ&-:WC\'P
M>XZ<@J%1M'7D.`RA;#@7AG6/Y$=AB!K/A*%D;2UF>K6841T,5W;M&O9/EGS(
MTJ][<M^VVE:N_W2YRZ*8<*^>@\P5!=@8J/IT]<2X]`A50_B_31JO;/:B9O@)
M3_";N,85V9[&\3$U&-%J>#GM/R58]V=!\VH6?ME:BT'\]1Q=)WM4(/RT$XA=
M_&SY3.S6W:D?Q2YJ/!.[5'9]!*_71_`Z[%Z5689`_3:!>B.:@MMR8\OW\^>Y
M2A1OE6#^Q.^7&X^YJ:/\6[T@;\,BQ?S'=2\MWJ1/559DILZ*>/L,$T^AR]6E
M]-2G*$C6I4:DB*,\=1A=INZ._2"ZG$9PY:C*8709W73LF3!53F%+C_'>Y\4K
MFX=9M&L.MO%3T3#=;MUQ)*2YNH,?Y&T/&D><.K8<`.:Y7N")4^/&=X%YOA+5
MBQ4U1M2Q`BI3;^N7-2S?!WM8+!4S7.`11ERN<)\X=N3RDY.GFL,&YLEVH4@A
MZ]ESG]XTASY91=FKV6KH1WW^A+-6[E;5?N;.3WJ3_J(Y^A>,/MV94:W51Q>/
MH%4A"0SXZ/\\X"<[G/A!=2V8FQ<]G^'ZFDL]U!"ZT'2P/+Y@>K@'<0$K=["`
MOQ!,#4N0;+C$OY#2/]VD@"A<_SZ?S6?_!X0[E;L-"F5N9'-T<F5A;0T*#0IE
M;F1O8FH-"@T*-34@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`U-B`P(%(@70T*
M+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`V."`P(%(-"B]2
M97-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$Q(#<X(#`@4@T*+T9A8F,Q
M,B`W.2`P(%(-"B]&86)C,3,@.#`@,"!2#0HO1F%B8S$T(#@Q(#`@4@T*+T9A
M8F,V(#<S(#`@4@T*+T9A8F,W(#<T(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$
M1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4
M>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C4V(#`@;V)J#0H\/`T*+T9I;'1E
M<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,3,W-`T*/CX-"G-T<F5A;0T*>)RU
M6-]OVS80?C?@_^$>NR'1^)O48YIF0X<A[1(/;8&]*+8<JY6E5)(7I'_][BC)
M3IJ*@6L+1F+*=_QT]]V1Q^/KC]/)U^F$12;6P.CC1R[2JOTW7T\GW$LX"`/<
M^%\$#N(HCH4#QQC$C$.53B<?H/!85FD"TL[1%U2WT\EJ.EG^2E#T>?0#BY22
M^()(22WQ2\9"/)7'2I,\EI;DSAGY8T`!I](:-(@SD%PJZ4U:>O^\3&]E4N[,
M?3V;3G[[/;F96W)NAOJ>!@_9.V[P'U,,9NCZJW^%8K_`[/-T<H%3_SX&/D<^
M&9,M/OPDN!P&CXWQV"P2&F;SZ>2413BX)V^XM#_S=P*",7M\'C"^8]+LS(CP
M9@?_LT$,F:[&-5T=8KH9QA8842=:\-A&#I,'9M\H&9FS71:^^73VYNTYO+V<
M75Q=GLW>OKL\^^L$'\^C$7ADX_+(QDL!.^;B,#OX,4P?-WOM0=G[@NEB7-/%
MB*:/F^OVH%PWPS5+LAB,B[NBQ92.^[(E8AK3GJ%/M.,GRBFX7B556D.YA/-R
MO2X+N&[*^9?CLVE,/":;6_@1$L&H<4U7(YFNF`8C1K0=J6'C4L/&BZJT?,!T
M%`JK-0,;([@'WB'X<S,J&(X+D!3XH`)37D$-*3#%O8(84-#,QD$%I5Q802HK
M@PH".X>@`E<\C(!'>Q92X#%V)4$%)UU8P4H3=),;BG](04L>I)HKR6Q008HX
M_`I!1[60`A<V3!1#B)!"S&U0CH=#%9);(X*Q-D8%Y=J$65:&!4F6S@0Y%B[L
M/W<Z+&<!?KYV*KH-$E<_V"\PTS%-^@V#/^\R=5]4N<9G*JI87V-LU'U-G24W
M>=H6TJ))BZ9^LJFT,%=_$.0][5]_DD7822*LQ2\ZX#]ZS*>3ZSXMS.!&U'JE
M,/.$EH#F[;L):CG4F._4M;;^%71U8;0?YOW0T;!5\,/5UJY>+G#UHWPOPVBN
M#A:N@\#C'?CSNO(2<NC@A<GE$X-B:2)MN._5\.#%:8OS2?(>KN`=7,-[N(!S
MF,$_<'U<YW!N+,9C;@O^C+D^303N(OMF(LT=3L4NRW'WH"SG^V>Y&BSU/2.$
M'8N]L?W<$+@GA<"1E'W!_=Q!\)V^8W048+0^>3O*NY&@42L63U=G)_9;(5:%
MO<]..N#S0=AFA_TLPUX$#JQ-,AK+8W>/HJF4TMJ4D6#2M$OS0PJKY+\4BK*!
M9-.LRBK[EBX@*1Y@D29Y6IU`C5_U75K5V">5%93-*JV@>VY*N,UP^D.Y@?LJ
M:[`$0%8LRVJ=-!GI>^5FE:#J*JOAKBH1:MYL:H+"V>OD2WITG[GU/M,>Q+3N
M:I;H7:[2.VS^L%9Y$VM(ZM80-+ZJ/1$UBI"$[)G1$7Q"1]>;NO%Z59H_`'JY
M*1Y1]\C]"&;?.9VU+T`ZRN4R]0S4:9X?G0'&>@:84[9CP/"^$\:HU"F^>;[!
MF&6I#T:YJ:`N\VR>-5WLEA36:F?IS>8!"7DR#RFB5/F,S_4BF_MY]QCRE&+>
MP'VYR1?>XYN44F9-&;*@M^7I;9)'<)EF788</0N$DWWFV^T%HHY==X&X2'-,
MW.J!W/P^-0LTD-SRHK1=`)@@"UPKZ-JF6*#%R;+I[%Y@LOP(I5XE&-EYE9(<
M(YZM[Y#=EEO/#DU^O%B.38#97J%:.L7V9=EB>^0IF..1+<D*#`BYE15]%B3+
M99+A4MAN#'-<O[>H5F?%/-WY3+/*Y;,+UT.V0FJ;Q."5^($;N`C=*!ZX@8O!
MZT1_B.\.X`-!%(-W&8C=76J]$N[[?ATC&6H-3IT.MB:G"!WLG4X%71>$%*0T
MP>[I%`&&&T3TXN+C=#*=_`\M5^1:#0IE;F1S=')E86T-"@T*96YD;V)J#0H-
M"C4W(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@-3@@,"!2(%T-"B]-961I84)O
M>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S
M(#P\#0HO1F]N="`\/`T*+T9A8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2
M#0HO1F%B8S$S(#@P(#`@4@T*+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P
M(%(-"B]&86)C-R`W-"`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT
M#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G
M90T*/CX-"F5N9&]B:@T*#0HU."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E
M1&5C;V1E#0HO3&5N9W1H(#,U,38-"CX^#0IS=')E86T-"GB<O5M+<]M&$KZK
M2O]A#EN5[!;-Q0"#U]&QE:RV'-N1E=H<]@(!0W$2$&``4`KSZ[=[7@!(`"89
M8NVR10T&,]W?='_]`/C=+[<WO]_>.,L@]HF#?^6G:.DS]5^ZN;VA\@HE;D!H
M($=<PMQE'+L1B1RXXL"'BM_>_(<4<JV0^;B0'T7X@U3/MS?KVYO5/W`I_-L9
M<):,>;#!DGF^!S^\V'7[UV/FX_78"_%Z%`7>\((N>>-&04@BZA"/>LR3(JVD
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M6<"TU3ZN.5F5>5Z^BN*9-,E3SDG-FQH&JV9-`';"ZT9LDH9G)"UKN(*`<W,2
MVV0O[WG:R[D5?\:C2(J&B`+F%P5/\5#(J]"KE:L5KW`O.$/\/2TW&[A^9<WQ
MT/Q`:TY=CQG-(<XQI7G=E.EO2_(VSZ4<R:;<%:!=O2Y?"Y)4K=XU:)OR;2.G
M?>'IKA*-X`J'NS_2=5(\<_(.U!!UC:H:#*3>*\[G,$@OF-4@S?(SA(`@G%5T
MN_P,=!5HBP*Z<D+:TI7/HBY=^=<^<-C6;'TQ:A.:`4MT-`-.;C6+7*HU*S*^
M*<1*I,JLP7G?BPI\NZR4(WQ:P35>U=?6W84LURH_ASG.ZTG!7_6DJ4.CL2&X
MP+<$Q]S8:ZF]Y>-OX)PV'(XQD^=5`;LI3N=5H\X5N1E8.RVK;:G9:UN5+R(#
MKFO6B>*_AY;@ZW4"W"FT9>R):#`P*S.0>V360L0<!!\XKM;?89B$:8)W=.[`
MDW2M8M4+K_:D%LU.*?4*J01?D!T(7B&?RT$*196.2.]YGKQB`/B!%[Q*<N!V
MA0@G'Y+7!4E:)%=5N2$0)3AI2OES0<I*+?+#NP^+PY!X?0S\R#<V0".O#7*Q
MJT`0$*%YM1$-'C6(QC?;\A74SU#@3?(;!/L=P"3Z[KTD?=N!F?L%'B+J4Y<0
M[C-1IQ4W5(`G_U0F58:_V%,'I/*Z[!A(4NQ)*1.Y&8`((@,$G*3!`8IM"0-@
M4,N31Z7WY(FW&@,4VUV%N62#F'3M`<\4\Y\_&EXHZS]6DF2<;\`@LA=18R(D
MS:.%'-*BSHK7)L<0RG"C^!SD*`/;?.1HEY^!''V/&G*(V[S7\TVU-N3WX++Z
MZ.!`28<'#5G46YXJDTE%E>XV0*%0@8"A-^4!#W:<P%#B`ITO+_<<ZY>*),\<
MT\T9/($RXPEQ[+49OZM](7E.1%$W-H5'QT[S788Y>=*`S`7?U]]@X@J7?MUE
MSQL4=$%6HM!)KTF5MXG(D!6@7FARCM-(D@++YOE>QY@$O`Z\8H];[*I*.01@
MO3FH#JZ/`HM#6_>TP0'BA"9&68\@(26I.N%Z)QH\%PAY*><2C:>JW#VO&R6S
M`,??)I7,_&%`Z69,9P6KV!BY)\BP\HPK?KHEZ*5F@")R#!24N1:*D&DH>H8N
M5BHBG"PV:,ZE%3R7)03$1.$J1Q(@6SCB2H'2L88GG@N(RC((22[&]8H2\-]N
MRUJ-SX!#8$MA^&-QB'2Z)/D=LB(0I^&8'M5MB=IF1*#:0A6S,`7H0`8-M*.T
M$AM10+:@#*IO2@NR3C+0L`4!5DUV-5<(2#1P*U&A5V0[6/8UF8,<&+-%,79\
M;9R,=)Z_*R#W6>WR);E'78TR8/"@CTX`*H%.<8S-XC"-,+%VDV3@#@4<_`I3
M$-,Z.(4K9D#`M5ES'+4-$3_2:>/)AC_2W\CX"M7#B1U>!+1:LI'7@&X64G,)
MS)%%`6B00%283<SC#-0DSZ[OVN+!IU3'Q]>U2-?*<56>OT[`1.=R]I-\;S$#
M##)#/`Z6OJFA;.<'J+THCPQ<06-,W'"GSC8[N#UQ#@AE&$U!X5Q(`M!Z'^09
M.:_KUBX.4U!=A<T`1&CSYY"UQ:1G.K%IN:MD3\\:QH$Q2\(R$5.IGO$&LZF"
MD]T6J7.[S0UP5A/I+ADFWZ='G`H#KJCR.>C!"ZC%(::M0>C<J<]4((X`#\\Z
M^5^C2$[:@64ZJ*"WHM&UEC2#3A\%K4'D<.-RA@S>8W3.#-XN/T,&[[FL[5RW
M%BF;0:>W-Y[V$-!J58D"73>0^ZJN!K9J:YCW^T[(=O1!J3Z>T2OG-'T.[:`S
M&*(3VO8UABP=J2.3M4&0SKE,XR4U(*&"7FOQ)!J;9JN2!LQ15=W:`9%[`!19
MY-=<(=3%1)5``X!LR@S1Z!!2J1GO^NJ[L6,;&]3M=.]UHG+(Q$^8-V3B1620
M4\B3KH"?:A58Q\]O2?Y5OF*#Z*A7(VJ)J3*0GHOK3H994.*KEINGS^7:1S@T
MZCS"8>81SF$6@L)UJA@!I"22CE'H\*1##8X<@BGPD<<6?*C.]ST$3*2#E7)L
MA<GEVJWFR5G=]D%.''42MEAS\JY9EY7XLU5PH$NCLXGV?!=CBNN69W;\1$MV
MP-"4#CI@BUX#24*"/;99H/!L\LJH;7,QAVHL7H`15()V8,VJ?]&EA+89UZ<%
MV\$<P&;(%-3*:J4.B6@19H#`-8DK]3L!6K.BHGO5OSPB-AD$=`?TJWS?9AZ2
M+Q12.@&I,;773TBUHJ-,.P,"CF_K>=KFK*&CC0"U1IFQC,A>Y#-RFXG(TF*$
MN0YYI'7L6B5P<!<76UW,J(-ODM]DIT36ATC#'#*_E7$WS32S%#`TL@FKZ[>5
M;&0:/!7?0O6I,B[9K\+T7$A>MWEI1G:Y>L:+J;9)2;74.@!T<[Q^WWC$RI[5
M4P-9[>)S=1TOP=`0J1F`"&VGTV$V/+AQH$N8CFAP+"-]SSER3^K/FGO:Y6?(
M/:EG>ZBRD6C:)'$XE'L"$0J967:RC"O+A,1OA%*Y,*#JNM?>A7EVEZO#ZK*@
MBZO7-E^\R#1?NJG9E;?WG/\'@G#+?`AZM(N@$[=-3"]@AOQ--0E,5>\JR?YI
M^:)>N9FH8["#H]OZZ:YNRDU2Z4I6;$2>S%-L4]HVZ?VX3>U\K8QZ9BM?/-IL
MDT+PJ[]>@"^AS?OZW.#;<QC%(WSS-H0R1RW:WBU?O,6TWZ%,3J"C$R`3P`EL
M9$(00UZ$$]R1"7X<.=,3O'AZ`O-"-CD!0`LF)[@>G5Z!>@Z=G.#@*P\3$VCL
M1M,3H*Z:5).&^`K9U(3`I9-04]]UHLD)C,;36W@4:')J@HNIP-0$J*3CR0F.
M$TY.B!W/G[H>^>[D88<^F[P>^-,P^[XSB3(+@TF0O7`:`#?TIP&*I_&A^*QY
MPJ>I$X[+][N>XBN(*!L@&PPOU+(-/7Z/WK<%HJ_;)A@I(OV"VJ,L22#O>U<6
MV,#I!UFUS,,/N.0KDM^_4:*EC\N&\$.]X6Y_S6]OON#RD?S^`'"C%@?,`,0,
MP!:A+&V_)=`=#\]_F].&"MB<=E[VH?9Y_M?>RWSHOI?Y/>=]W0_5"(`R4%Z,
MN5TUCL=/#@?JUK%P<RQ!',N=H@,!VN$S851WAL=?5?C;M""A$ZH=P[XDW?$S
M10GE5TD&1&$+L/^OB`,\.8#+T?#IK]'(.\?.I?T.C&1X-FC9=OQ\RPYC6\AZ
MK-OHU4G0!_Z<Y&BOQK)5*3\B8R`C'1LTV_[X669KA)R"!\U+0GELK[WATS>6
M=WY]8[1#N<.`?9KQL^V3VJU[]NGZ"\<9%41&\",$CH;/LLQQ!(:H-PS]80,U
MXQ<8:&ABBBL?OIA'Q>9!S-LTQ<(!"XQI*QWD6!1LT%A[X^<9JQ;X1([%G89L
MMCM\GLV>OK\T4=QHR'3U^"6FJR7HF:[G')GN(+<.X'$T?)X%C^+1YU9\SWW(
M=,WX!:8;V*=(3MR^(NS'VG0_0UDL#5?:;/%<)2_XVRD<ZP?#9ML;/\]L@[%O
M&1UP+&PQ9*_=X?/L]82-I4'B#D.&JL<OR`',UGV.7?C3%'L,P-'P>08Z"L`P
M97DR%T;[\F0:+#_%^$E=EA_M5VP'2!IF="RZM?3^^%F6SMJ7VU0W_-L?19WR
M/$\*7NZ^1L1H!4HKHZ!5)I0?Y81P2B\S>]`K>N/G><7H&PSM?&F$6GRM25]F
M-6%:?#U[R+.ZP^=YUBG"HP$JX8T>?8G5A$GAS>Q![]3CEWBG%K_GG>&1=QZ)
M$SFN54EKU]=#39A62<\><O2+SD/>.7H>!^P.'J4]'/YI#X>5C5.HCT=?DM>S
M!H,8O2R(8?/,[;P*H5O7CV63Y%,Q0BE@=+%R,^L8ZN.1"F8:B.O20R_6X\X%
M7DQ'4Z*^%VNYM0I]8=6$KMR'-[<40%L*4(>E)@R?FYDVY/MJ^()*VQS;5*7=
M)P&ENX&AK[":,**[O-8R"/4/%%83AG4WTP:I@UX8V.FP]D%\5-VW@DA.T!!H
M-/JBJPDC6NAI0VQ!+TX+W(FO?6,W4O4"`>[CI0,,RL-+,P<,1+W$\*T;'SX7
M\"<;T6_BZ5;W&\JF.]EO7!9,MEC?N!$=[_&"C'>_W-[<WOP/KD@'90T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HU.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#8P(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@
M,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@
M.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R
M;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E
M22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-C`@,"!O8FH-
M"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S,3DV#0H^/@T*
M<W1R96%M#0IXG-5<W6_;1A)_-^#_89^*7&KK]GNYUZ?$28KV@C:7^-`>T!=:
MHB7>R:1+4G'=O_YFEN22CLE53(D^'`(DLKB<W9GYS>>.\_K7TY/?3T_H0EM%
M*/YQGZ*%DO5?RYO3$^:>,,(U8=I]PPDW"VMY1"(*3Z@4I$A.3WXAF:-EI$)"
M*HKP'U*L3T\VIR?7+Y$4_NE]01=2"MA@(842\(^PG#]\;J7"YU88?!Y%6@P3
MY.2<1<*2B%$BF&B.=.WX<\^X?R9ZQWU]>7KRUW?QU1*8$^02UCLQ.)(MXXS7
M/%X"ZU8OJ+:,7/YY>G).%XS#>2_O3D]>_%`E-R"?!7G[QR:]2JOR+^3RWZ<G
M;X'^/[[Z$`8E'#@$KP_QXC<NZ;'IZQY],I%X0()*U[1QS=*QP,V1=^'J.781
MT7/L`J!_AEVT?(Y=C'F.72Q]CET8%<^R#9CC<VP#KS['-O)9[)^I9W$`3!_5
M`XPZY*AS`;,XY":B012CUC1L,*&/SH;?Z9"P->KS.T8@&LNHU@>D'929)C!G
MR[RXS8NX2E;DZA[(7R=%DBT34N6DVB0DJ0,V*3?Y74;2C-S&\!R>E$E)XFQ%
MKM,MO'J75ANW_F)7X'/R,0&J%<DS\BXO;DAT;-],.]8L7TA*ZZSCQ?G1-])]
M&3+F1(BPP(\HPK^3_)J\N8]7Z9+\D%5)D<55FF?Q]@Q^7"[(RLEV!HA"RME"
M5%G=GHM9*NN#_;RL\JND(-R>$4[AVR%UY3<W:5G">5%5/^6?DQM\1=9O+(X,
M=Q%1?^Q9K);J0:N=P7*Y]+O-8KF1)]^SW'.L`?#S_[/I*B@06MYF-5T%Q5I/
MB)WIRO^IZ0I-9&0]3B,AO>EJK>N#>4-DQEFB?H+M<E:_,M5X`_8EM6VDJ6KC
M>GGL>&C]'K-8E>BQ0(WHK(J+QJK>]66<EF`,Z[2L"H<+\JD"0-R`C1S;,7*H
MSCSC,SA&*6O:5BVD`2$[>_MV!N7)>94GK;?F+N();1NSN<S)5=*820(J!&L`
MQQB#QE:H-9(7)$;7YUTC>$KXZ>T?RTV<K1/R:EG!F6KO%W0,:(UIW__"5@EX
MV+X;/C9&C.D$,!DC@0:*Y`?J+MPDDK2!H`'+PX5-CTC)J-\C,L<6F])^ZSDX
MT]23=]Z\=N8O_IFMDJ**_Y-FZ_+8'#$1=2S-``01'6[$@4::)W]L/P>J$+H#
M&6_SBM^HHC'\Q8YMD-+OI]M"5](9/)_M-J(++JSUB4R$GYWG@WQ@AY@KTW4&
M_JAHPA8X/71-X)=V#2*3\F_'SNIE=[Y9\'B$H!+"XZ$^-81'P7W`HJ8+6+0I
MOQ&:#*%)('1AW#HCJUT!3@,BS#VY38HTQT!#[C;I<@,Q"4)+B5&LC+>8PQ<)
MQ#M<?1.OX-68W.9E=60N9(^-6=-UJ65?7L)P+Z_(-/<("4A@6:6?DUY0=]4.
M9&I%/U,KVTSMV&#'I+$]Y2Q@9WQ6L+,#CS[>^HT(AX*KT1ZERFM/X><6[6F+
M=DB?MKM54@.]R,M;4.P.M?C[+BWJBO83ZAJ4R:AWX?A!.!*0H&$1!&O`8*H4
MS`&S-_B662&^.[YBN%%S*L:3GT4Q*FH5$T5=&2RM["G&:P8RV"U('OT.2KBG
M'-35=;RLG`]*/H-YH1-*2^>PKB%-KOL.WDBQ?FX5-6R>!+?.Z_=NP'G!LB5^
M/8<0)&N+UX@WG>D9_"4#Y]!N-:N_9$+W>&*\ZR.X#&O476(^D%\[9;NP<@:*
M7J6?T]4NWF[O4;.-XN/U&I0&BCK#HJA(2GP])M>022"Y*MZ2IFYJ7DBSZ[RX
M:32<S*-$+ML\B$;>Q4@5-2X&#@"5>W.>8<A]A]7;#/Z!REG]0TM^#JFRR'@8
MZ:AK-?;3E#0==-V@;LA2``I]Y;OV"0`&W4;;C;S=0J4-OF"%*DFO=FYAEE?@
M7Y+/:;XK`7OP;+G-RV0UJ,$Y&#>T95QW635KS*?S4M@XZ#/;X!Y8*W?+S0/>
MP]B;8>Y!T5G''EKRD\0/P@_+7[0W*US:SIRM;<P98@\XIF1U1C;Y'02<XNS8
M3264H#\$N)3.B0K51$?09UQA\SQ>%_'MIB0/LA'6?JC-`SM#(\_K!:O<H3Z^
MO07`I\'8"$EMVX3_=.S:Q';"GS5*&=H)V.J%X3SRK1\I&C4+-##'Y[MC;Z_Y
M,_&I=1](5OGVI'*?'9MG#AYS^#'FKSETU]66K.UJ?QF=?99=N8YIX]"=VYVE
MB!10V[5GG%4-0C\41M<EEE+J\:P(JHUJ`Y&G;^9@?LL<TIPTJR53E^/ILFD1
METVC>09U6M_FYJQK<R-1QX`+KV`QU[LB2\M-K<8O;H0<0YUG`19O=T6YB^N"
MV5=6SO*80O^T&BFK'G3'Z_I*UBYQ!LXC7_]K93H<JR81P8Y'.GKO&0R]#[NP
MF+!9:2PQ%L[JSMD=R,U.PH*(2NX6L-$%P",ND",+C(4$`Q?PL044F`XMT)*%
M%RA)>7"!1.,++1!"ABEPP6UP`=0\++B`"A9<P"RW038!5SIX2&8@_0DNT!P*
MIM`"A>.JH062,Q5<()@-"@K,&9`<6N#:A*$%E&H16F"5"FH[4B;XW*BPG+42
M03$K8X-2EB8L`6&B\',:%A`'`02-FM$P"J@9!^+OS1)5DV!R).5EWL.QQV/*
MRCMWQ7@SD$5MU-R"7<976]<SN8#0@PV6!VZK)O/Q>R1YAP[W1SS10B%9`__4
MX=7_N#T]^?3`TX+L;$1Q&4(%/FV;3]Q]<H_=QTV?8?P.,G)AGG8U)JF#:QOT
MH;*L4[\7S1#XE^%C^DX"S^UON#G%=C%N]-,.)R(>2;!^.:+<"Z.1RT,9U`N^
M%$?S7(\=,U!.2>4,.##OMY=Z2-P<C]L-0''93$"]2<IED=YB.!P2N12C(@]U
MZ^&@NNX:6+&PAOL;7:ID,UZ#8U=$+A[=N^W?-5#O6FD"\IM.67>4'R4V3BU`
M-Z3T\:RFDQ16F%W72HBV:_4*\U#(9K`Z^)BXE&5%+I*B2J_39=-#[<:]W,!/
M<#S!=<D7;.C.\VM8&961>S<D_D.(,Q;2`"@67,E$H`KZ54#E3]\U!%06:,P<
M0%EWE(>!"G0G`U507\'R[KY2<A,`ZNO[;7Q7?A4D^2@D]QPZ",F@H`\ACI`<
MES4F4RY<J:$\(`S)R(H6DMQ"5ME"4C07G=\"',73=PS`,3*AN#.=LNXH#\(1
MZ>H)0G+OVFYXO5\.MA/.O2KUPZZ`,A4*^%?K(JG;9_7T9NR0Z6>A=3-/B7-A
M`.+X)L_6^R:]7ETEV3J/R>LT3[*D6-\?GU&C?1^4^Q:D8J9A].,W;WKG<>WT
MAM^B)%NH=H'1O*Y^<0`DKG8%MC+6(!AWWU/EBTEG#IE=I`+CSP<1![/SQ(?,
MSD"M.,7L`*JBR1+EPKH+LS][$^)R(9^^6<CB6&!NY0#*NJ,\J%2D.QF(PG86
MIWH6QY]J<8]'F)]B<HCD'[+/$&)R0/C1N>1MFXD:W>5C7#?Y6&U#>9'V[<<U
M\^EX5K7O0$%;HH&ICX.(HRW1L9D/!*%FD[(JJ(`C%;(E]?3-`K;DU!2RI8F4
M=4=Y&&6:34ZF6@'A,%,WLR?\S)Z[\`!+^24N7(,V+<M=U\OUZ/\*Y.TY9`AY
M8<$>0AP[?N.R!95!H)N6SQL9[4V>'OV^S_X=0_#C41A^$RGKCO(P_(#N9/C)
MR#LYVEWJ<QKM@]]%?I=DS@U?Y#>W<79_1MZ_OYAROB#R@C(]A#@B;URLD)1$
M9A+R(F(8\S>9V/MW/N^E&FQQ[-DE@#;W7R@$T#:5LNXH#Z(-Z4Y&&VLGD2AC
M/J1RS9J0^O-MFC6-B^\A7<@@,UB3RR*&;&)]1CXL7CV:DO^:$X7P%9;B(<09
M"PD2>^1T$KX4T4:V74SCLA&'+RZ&`1;>)@0P%9A5.H"R[B@/`PSH3@58*QKL
MVW`_PR@H;WHX%WGF!M0`8&^+K*S(-^1?^0XRS??O/PQC:\]A@M@*"O`0XHBM
M<1F":MBT=BU@2YAA;`VUO?9L$\(6"_=GIU+6'>5A;+'I_=E6--@U9[[/P$W[
M6_(];(TX+Y>C/9@6V";K>$ORQNW5HP)QV?X'.$35Z=PP,O>P$D1F4/R'$$=D
MCFL`;_ZF]6<!F90.(7/XYF#/-@%DJBC<D)U*67>4!Y&)="<CD[8-6<Y['3#3
M#D1\@%2M</7VJPJ*A2RY=TCT`STX`?%E0RCX^Q*CH-S'10B48<D?0AQ`&1`^
M_N)K?5.KAN_2^.C5I2LT'%GQ\,1X!QV<`CB7X7&*<R;#@PCG+'0'#D=X^^OI
MR>G)?P&H*VEY#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C8Q(#`@;V)J#0H\
M/`T*+T-O;G1E;G1S(%L@-C(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@
M-SDR(%T-"B]087)E;G0@-C@@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\
M/`T*+T9A8F,Q,2`W."`P(%(-"B]&86)C,3(@-SD@,"!2#0HO1F%B8S$S(#@P
M(#`@4@T*+T9A8F,Q-"`X,2`P(%(-"B]&86)C-B`W,R`P(%(-"B]&86)C-R`W
M-"`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO
M26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B
M:@T*#0HV,B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N
M9W1H(#$Y,#@-"CX^#0IS=')E86T-"GB<Q5E-C]LV$+T;\'_@,2V\+K]%'MLB
M+=I;FP6:0R^T3*^9RI(CR=EN?WUG2'W8SEI!`QG%8KU>D2)GWLR\>91^>+]<
M?%PNZ%I;12C^Q&]FK63ZR`_+!8LCC'!-F(Y7.%%6K*WEAAA*B<PR4OOEX@]2
MQK4RJ7`A90S^(?73<K%?+G;?XE+X<W:!KJ44L,%:"B7@C["<7XY;J7#<B@S'
MC='B]04Y><BL)H91(IB0(EJTB^[AD!F&A!B-_>%QN?CN)[?),\($>83I$82X
M8.^VA@\*ZST>T!PFM":/^7+Q`,8:_/Z\7+SYDRK*X8.1Q[UK5V17U:3=>W(\
MU<>J\:3:D:UO?7T(92B?B"M?2!'<)A2A?2&G<NO3]'<^/]6A#;XAW^<MWL6L
M$"OB7;XGS0D^8+7V&_+X8;EX"Z;_-H-["N(]^&?Y6E(*7OP#3CW,O9$]!Y(:
MR0<@K<X2D'ZW\WD;/GGB#K[<PF]+FKTK"K+Q`*$_^"V9UZP87DCM+KR9-KU5
M4F0\6=56N+TCI7^&Q9]"T]:N#55)FM:U/AI9^P(N06QA+H:R&4-9@4\UV`V7
M:Q_*%80__I,&\!X(=(SNV4VNC5/:</"?`0!;W`$#:OO(2)8-&+`^,K`]&@0)
MW`97?(T!L/U-"QA0R9D)@G'5FZ`T?H\F5*4CN[#U\WK/,GN^-^-TV%MDM-M[
M#%8,8[6+8?PZ0_1-$(@UR8PW?W))9UY=CZO/GS\6:R7A1\U8V,KPD2%%8L@*
M%C]44.*[NCI<UM/FA1R\*[%FH-SF)SO![6#I/;D.;SA#1*';74%Q96]3'38&
M</V*0#8>\RX!%9GD>1^`+0!%%TIH'TU5;'O"F#^P2@V\8`9NY!:_1VZ,72V%
MKS.]+Y7U_.4AU#W+HU_]#BBRM#1`1Q5/]!IK8H,U,:\GF1JVT]U&@-;7(W;+
M+3ON`SFNC1@;)^^J_A&R(<J;)CR5D+A]L4.J(XMN.O'3NK\@S=M!.G6RJ9E%
M-\W<+#@QUO058;&8.ZJ3?6'OP+S4U-&VT>6Y#<D&2V0?9LYGW@2T^9F[QHZ=
M4=&.`$"KE.4))$'MCU7=8O":$T889,H[9#@@!H;43UWD?XCO<%GAY6VZG.!Z
M^W>^=^63/PND)/'F<KL"XH.L(>YX+$+N-H7O0CPB[LH[Q-NPH;6)4?PKT8E_
M?S@6U8OWP-.EWP5`H'#EW%;8P8P[!EN<^VK4X*N4)OL/P9Z.:KR.M4Y"`W(R
MKZ#6H?T#.P`=U!ZU<IFCT+PHGRNY/7^0M1R.`&*4OT+TCG^NP?^7(P%^7)P)
MYD="9@.]9>-A"'(_(7$!P#V/!,*<V7)^(C#LLQ/!W##8"QRT'GJ;8+K#X?I`
M,+_:,3R[H]H95I]?[1B:EK;9FO)>8B,IY'=0.W+8[KYJ9]P',B(30V4(H;O&
M_PLH\9VKB4->V_I#&7;0IB(KH*KIE4NLY3HTF#M?TC#DX%ZPSHZH@=HVU=TV
MU$"U5=VLD"]"#O(J$DA>E6U=%;$7SDX+F:6=\US)H1P4PZ,-.@\6-E4ZN5W*
MGHL>@4.`A7^JT,AC77T"'."V%<J""BOI.330UJ^6V#L\!?F2N"W<$(D3^T=J
M$=41&&@\?9P!B:#,#T0V/@MDHQRPO,N"H=?]6!T.H6EB4T`JO\X):'_N"4YP
M#4*T`44#!U[X?,'\\7\?:]^@IYV3F!/H3FA6B7`0Q17DCR_A6^Y1#:W)+VFR
M_X3])V+D2%ZX<+@##&IX9B;H.0R="(9X7CO<>QO1.*\&I(88?+0YN7!T+[&)
M@B:XR@4(,Z#C2SP?@'PXU=A(\=#@0I00;JB/H3QP^+[%(?JG1YR?/3PS7)\7
MQRNUT447$,DAW+M3`?IBA[XE,0O>1$VU@AD@+-'+NLJ]WX(744=A#D&:U)U\
MBLA^T?W.FG`'K9SQX:&''1^42Y5UQ0%FE)U,?`[M_DM/.CXC@N=0%)CU!:#U
M2OV'M@%/3X!?$8<.#CBS'NFC\6U;)*CNFP]T.!<;+D<9+;HS$Q1W[K>0WQC8
M#3`[<J-#T^N8X'#"J:MC'4!*D@\`3K,-"31TZN/)-PG!O8]%\RJ[@(NA_6\<
M,SL,VI@A&S([PM!G0T]J&%7L<D_5)U^7*3ZQ4X02=*7;?CAM>[=Z70S$>O+S
M2RZMS1TEU[#Z5T(]9;B\J^'R5<-A7T$53^(@K3K>'E_/<<(M-2I.8#<G9#I.
MD#<G0)+A!'YC@D$JG)J023T]04NI)B<H">)O:@+4]O0*`E\G34W@`LZ@4Q.8
M4-,3J)"3;H*BI)-&`EN92:A9QJ%XIR9HKJ>W4%R9R0F2RTF@F."43D[@3$U/
M8(SJR0E4V<EP6\TFQXV>!CI3V23.VHA)F)69AD`:,3U.IQ$2UIJIJA9,3MK'
M(0;3`&>WD^!C'X,4(R9O/#E@`V&Q:SK$``YO7UAZ'X4/-/JW%H^HE[&9_`@R
M`/IP<\%K:9G??\8EGY$^?T6+UOBB7&7P)[T]&OXMEHMWO=6:)5R9>L5HC::]
M3K(2CLF:I9/%&\&N:5;323@?A)U,IX=,WF8.V.'M^^5BN?@7"W,)^`T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HV,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#8T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#8X(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3$@-S@@
M,"!2#0HO1F%B8S$R(#<Y(#`@4@T*+T9A8F,Q,R`X,"`P(%(-"B]&86)C,30@
M.#$@,"!2#0HO1F%B8S8@-S,@,"!2#0HO1F%B8S<@-S0@,"!2#0H^/@T*+U!R
M;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E
M22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-C0@,"!O8FH-
M"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S,30T#0H^/@T*
M<W1R96%M#0IXG+U;67/;.!)^5Y7^`QZS6XZ&N(E]BQ-GCIT<:VLK,UOS0DN4
MQ5V)M"EJ/)Y?O]T`04JV"<D4/>5*#))@L\\/W0WX_)?QZ&X\BB;*2!+ACQW%
M$RG<?[/U>$3M$TJ8(E39.XQH-3&&Q22.(F*,(&4Z'GTCN26EA40Z,H[Q%REO
MQJ/E>+3X.U+"GYT;T40(#O0G@DL.O[AA;/^Y$1*?&Z[Q>1PK_CQ!1MYR:DA,
M(\(I%]QRM+#2X:.H><1YR^SY=#SZ[F-R/0/).)G"=*L#2]!+S94F-&+P&`0W
M?"(TW)C^.1Z]N?KQ^\_OIO^^O+CZ&YG^=SRZ`&K_.O:+&G7Y_!<I@P]&[H-O
M?F,B&IB\VB%/^M'N4I8";XB5)1U-J)*,3&?CT5NP+].43._ABU^WY6:;Y!6I
M"E(M4Z!_M\W*=)WFU884"WOO*IUMRZS*T@UY-ZOP+C6<GY$/#\D\FY$?\RHM
M\Z3*BCQ9G<'E;$)F:5EE"WRC6B85R2JR3#9`/-G`I.M52F[*8IO/-_C9ZW25
MI;^G;N:P"@#;&65J!5@M._D9N+<5'QA;IRF(FJQ67MP]%2R*DBRR59;?D"(G
M'XMR37KZ5Q>/3)N&2<,F(HJH<^BW`W\GYCO*8-(8KPW)I'3JX"3)Y]94\^WJ
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M)N7UOL$=Y<OOD?(],O73>`2T)Y!S2`;_`WFA:'.Y&H^N!E".4(,HIYM\JYS!
M'5Q`DL5K#](3J8S+/D#QU"^ICU4^L'2"-AR\BG2T=2NJ&Z_B]8+YM4PWV1R1
M'U>*]\LL79"+/R!!J#)8PK\L%ADL_<-*+"&!]5SUE3B`M%J?YHFA9!56(2UC
MGZMJR*9K9XD@@)T^OWR[N"1?/I)WT^F7R\\7OPXO'X]?<25IJ/<Q3$!UD+IJ
M1KWF.*5QHSK.:MW]\_.7;^3=SS^33Q>?R?FO9/K#Q=4%^0H5P,7GZ=!9&I1/
MGB$(!Q.UV9.*F./GS*6P:3);DEO(>2!ON%\6&Y<>)=6V3$ER>YLF):9(J^*>
M8&X"6=*LR#=55FTK2)<QJF!2D6'RZ9%D\*Q)1\)7!3)NLF(1Q764-ZL%LO,M
M><A3\JF`3!BSH*K<IO;^*KE?;%<DJ:JBS-.'S<!8!&NS9_,UTV(.R.*_@]XE
M'>:]R?*A<P_YU\C#S*YYE6J+/EYG8(MD5ITY-X41EC;)JLC3,W*?08(+-EV1
MV^(>'!@3W<WVVCDGYOUH=E@`=FZ=V0IIF:WM,TBI!_=5%6LOC(Y56\'&-0J@
M3^;)&MB_724SYYJ;*DU<AI_D#RZF0*A9<IO,;!U[AG4+1J5]#@+@8Z"1SVW5
MAV_.5MNY50U,N"TVU;!R2=D*]IK>(*7:52!V8KP"A:I+I'2Q2&=V^=[5@.T'
M/*[[AC>NCAK>VFR#&U[G4DVA>6:M"$Q!,9[:NFUC;6Y=-OUCF5UCY6FKO:IP
MDPN\(O-BMG6EO"M5\7WKJ("Z.<IMJSMX#2G5]!XU/9#8Q1^S99+?I*^@`LF]
M"B+9UDM2UM'ZOEBOL\W&QEJ]8*`U%@_..^<HR"(KURZ.5VX-VB39_-6069F&
MZ5=%,LV;[[PJ,L?\KY$'XG#'V'&300@9LQ:9$8[``;.RA5X$K&?@>IT\U(OP
MZ@'\'%^T'9O:TX?W5.Y[B2S2NN4>Q\C]'+C"KL_O65E!CH#.6BR&;XTHJEXQ
MH6VH#]^+M2VWVOAM9T3(B)_>BPWUZ+"?=YVFN6_3U8VY1;&")!3]R26K&]\1
M&]QQK'_7;4?5""XC54-<NS`[X'9LS!-,B+-\GLU@-!_>D:1ZS1Y;0WU?G_!=
MH`N>H`U0ME3;U^TF"B/,X,LX@79.`"#!":)K@H"'.(%U3(@EBX,3-/930Q,4
M[@Z%)DCT\M`$$:LP!1X+$YS`8D&#$VC,PQ.BF`;%I$;'029IK%50U51KR,)"
M$Y06X4](S65P@M`TJ"C*%:!T:`)3+#S!5HK!"9$.FIM&D0E.,%%8TW$D@XK6
MG`;U#!(&190\"CX7,JPB(;0,A357+,@?DR;LBE*&O2#2W>_?U5-J5Z0[F\0-
MH`&&8T>\1C3Z=!M4-@N8I*ZNQ'V7N"XDIG9G#Y:D]T5>X:+UI-=,'_6:*7:5
M@:QVO6:S<^EZS:T,'-(_"4Z^=J:"T<J-&,61?>R&RUV!\1X7$I+)E_6?*-(3
MS4Z&P=8/)I]7OI7S>+TX]*T#2Q$+-"%/(:U:TD_6=:]2@'%N7KB_8=73M2G>
MSE<\\E;CVGBSV:$SEIWPV&[^.9/TQ883AC:&>S/-JM432QVD'I+;OANPU4G$
M`6`[K-5.CB/F->J5NZ]&.^&Q1OUSJMF+-:HA/_4:-0IR?_BDK8\^0%KV6/Z#
M'PK([]X-*/<TXJ)+N>VQ%71K[(LXD,&1`QFA(P\R]7`/9/`>1J?HB*+NU!B<
M)5+/;N,QWZU[;A?OX"8>4`8,E9%PP`J)5'/9;.*=PCBDAB(V)VV#>5TS].<>
MZ%/W.#NCT-(&REW$N]L.^T81K-T%@SSL!=M@=C_[:YGEL^PV63V%WU.8!)3S
M!K![(FKG;(OO'#UA"'?4:X:3K%PGN:\JSXNDG`_*H,!W=7,V0V/D^9,`K#YM
M@L<HH+Z=547YI$6%H8[?QE!_Z;>5THT%`;"H4J;Q3N:5XP]PP$KOSG"$(`%"
MI88$^%=#`F10'A+<<!\2X!Y&EGPNSPHMV+'-,X/)P"':G5$K0*?<YS2"ZN:\
M#&@L;M&FW?`YC#,"ZG@@RFN<87%SN8<SO3D&G*%QS3%7;?-`4=\\Z.#VKC4=
M(HQZ.<((&3CT9V/#YNSTQ<1E=,#&QQ#O##R$\YT3"A([31Z:HWK/Q`'6QRQ/
M`)L`FCKV[4_A`[N=K>E@:6L!2JL:1??QL64'(>K=;%9L<]ONW$&O9V'"UM@O
MM[$&IPR:X1CB(0QJS#`$!G$I:PS"T:H>:8]!]7`/@^Q]C#KYXGJ$FT"/]0C2
MW8D#LPMLD_%(V68\0K88]/TJS7-R,2&?T_G]HX[_LT#$L7;D6ON$1S67NT#4
MFV^`3EXW]""JA'7AVIQ^'RW$\EUK1$2CEQ8&^*K18<"PM#%07T@<T2AH[F.(
M=Z(1E#2[]N;&V?N-7_@'EZ1N470&-!*W`?U"XH@6034=0SR$%EY-@Z`%,[Z(
MP5&-%E%3Q-3#?;2(HMYHP0-*/X)T=WT4$\Z:)!*SUS;)I2U87&:S)2:P/TW(
M>8IY[1'U$28JG$4>+DQSN0<7?1GGJ./F(!W%QF;-.;6+(G(>YOJN-61?Q!!1
M.*@M[;YQ%C+Y,<2#B%';_&C$.$F2Z$`*@,1[(T9(3<<0#R)&K:9A$$-0CQB"
MUHC!!/>(40_W$`/O]40,%H=+G$.DNQ$#E@[E2QP:\W:;FG/=(L8/25D^D/],
MR&6Q2?.;I*R.@`PY0>*^U!&\N=R%C-Z<<XX;8IYSVD`=5S72'>#YKK5C3\#`
MOQ`)Q[2@O<,L:/%CB(<`PYO\>,`X11)QH$6)Q/L"1E!-QQ`/`897TR"`0:&P
M7-<[H*(&#!HK#QCU<`\P\%Y?P#BP07*(=*@%RZ(F["+#VA-8ANVD&`6HI2+G
M$W*U3&ZSLCBR!<LBM9MBN,M=O.C-.,`9-?Y`<D15VZ5$4[L,(\CT76O'OH#!
M#I0-EG;?,#NTS7*(>!`P:I,?#1BG2$+CP`E\C&DDWALP#FV8'"(>!(Q:3<,`
M!M,>,)CV@,%,`QANN`\8<*\G8-BR/`08!TAW`P8\E,T?`LAV=P!,O9-A7%7I
M[3+-,;O_EI1Y>D0OE6&W@@KC$PS:7.X!1E_&.5#CS<'P>.?\(8^-/VX;8OJN
MM6-/P*#J0-5@:?<-LY#%CR$>`@QO\N,!XQ1).#T0T^B$/0$CJ*9CB(<`PZNI
M)V`X#S?NG!%]SL$5QG:'F2)*?(.&L\>'[L)'T=XRU7VT!PA<_#(>C4?_!X7[
MQ1X-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*-C4@,"!O8FH-"CP\#0HO0V]N
M=&5N=',@6R`V-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*
M+U!A<F5N="`V."`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B
M8S$Q(#<X(#`@4@T*+T9A8F,Q,B`W.2`P(%(-"B]&86)C,3,@.#`@,"!2#0HO
M1F%B8S$T(#@Q(#`@4@T*+T9A8F,V(#<S(#`@4@T*+T9A8F,W(#<T(#`@4@T*
M/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-
M"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C8V
M(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@.38W
M#0H^/@T*<W1R96%M#0IXG+57VV[;.!!]%Z!_X-,BN]A5.;SSL6F\W2R*[4U`
M4Z`OCJLX6KAR8KMHT:_O#"7;B2--8+M!@)@6#P]G#H]GJ-.+/+O-,UFX:(6D
MOS0*A37MO\F7/(,T`T(Y`2X]4<)#+&)4000IA;8@%E6>?1!-XO+&$I$-@3[$
M8IIGUWEV]0=1T=^=![(P1N,&A=%6XX>.2MV?C\;2?-2>YD-PNI]0"><Q<L!P
M0!N=`KI*V>%,V,QHO0WUM,RS9W^/+R>>$BL1G21(=.ND00F0$D2):9]\4D;^
M+LK_\VR$2]_^`G9WAUWL3XW+]0"U-E[$8!)U5(4*`9$_2%$I)<;S#7<\_^]L
M="'*UV)T\<_YZ7GY_M<FIT1TYNF4VY`?(!P?MH]/&/:&_'[8N*V&&#7.(W-B
MW2Y/5D>`M-8E``P"\-@)8(8`!CU!`-4/4-$JQ0)"U#S`1W`LP`4?6(`-EF?`
M)#0+T$%;%J""X@$0@$]3>L\&"=%;5FH(WDH6X+WFMW!>119@/;!"@7$>6(!V
MB@<HZST/D(X];@`9>("4O-11&E;IH($5VBM>!*<E.V\MKY$U+G*_:^,4&Y^V
MD?>B-:P-T*OL>I#,#_*V@ZPKC^FI>&@R@$W)@X<=U,94\V0!%K^7D]2'(AY[
MZD/E^')6B?F5>#%O5E6S6MZKC"W-NY=$^8WJ[[\446&)UN-'V^`V7V=Y]OYN
M#A%$Q./YTCH%1[-NI&F49M/H^FZZ],Q'H?V>31=78@%>]UQ'"6+//1E]OZXO
MZ]5N*WEDHT=ZJ_+#3>H(9K=E%@_.H<4&J=::=NK>4[*=WA&UF_;HDWU5I:6=
MJG^A;12-T4$G9]5RLJAO5O6\V<W_L=T8`=)21MICJ.V0MNV1A=2;!VF'],'B
M%V58NTYC8VI=9PO8?Q/&<2$$UG&',KLM\P-54.U$RZC-V::3!5T#8)-KT$'*
MT9@*S^N;ND'W4.EYN:BJYK):3$6Y&']=U-,_Q9OB>7%`/(RQ6`6/H;:,A'0R
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M86T-"@T*96YD;V)J#0H-"C8W(#`@;V)J#0H\/`T*+U1Y<&4@+T]U=&QI;F5S
M#0H^/@T*96YD;V)J#0H-"C8X(#`@;V)J#0H\/`T*+T-O=6YT(#,T#0HO2VED
M<R!;(#<R(#`@4@T*,2`P(%(-"C,@,"!2#0HU(#`@4@T*-R`P(%(-"CD@,"!2
M#0HQ,2`P(%(-"C$S(#`@4@T*,34@,"!2#0HQ-R`P(%(-"C$Y(#`@4@T*,C$@
M,"!2#0HR,R`P(%(-"C(U(#`@4@T*,C<@,"!2#0HR.2`P(%(-"C,Q(#`@4@T*
M,S,@,"!2#0HS-2`P(%(-"C,W(#`@4@T*,SD@,"!2#0HT,2`P(%(-"C0S(#`@
M4@T*-#4@,"!2#0HT-R`P(%(-"C0Y(#`@4@T*-3$@,"!2#0HU,R`P(%(-"C4U
M(#`@4@T*-3<@,"!2#0HU.2`P(%(-"C8Q(#`@4@T*-C,@,"!2#0HV-2`P(%(@
M70T*+U1Y<&4@+U!A9V5S#0H^/@T*96YD;V)J#0H-"GAR968-"C`@-CD-"C`P
M,#`P,#`P,#`@-C4U,S4@9@T*,#`P,#`Q-3,X,2`P,#`P,"!N#0HP,#`P,#$U
M-C8U(#`P,#`P(&X-"C`P,#`P,3<Y,#8@,#`P,#`@;@T*,#`P,#`Q.#$Y,"`P
M,#`P,"!N#0HP,#`P,#(P-S<Y(#`P,#`P(&X-"C`P,#`P,C$P-C,@,#`P,#`@
M;@T*,#`P,#`R,C<Q,2`P,#`P,"!N#0HP,#`P,#(R.3DU(#`P,#`P(&X-"C`P
M,#`P,C<U.#,@,#`P,#`@;@T*,#`P,#`R-S@V."`P,#`P,"!N#0HP,#`P,#,R
M,S4U(#`P,#`P(&X-"C`P,#`P,S(V-#$@,#`P,#`@;@T*,#`P,#`S-C`V,2`P
M,#`P,"!N#0HP,#`P,#,V,S0W(#`P,#`P(&X-"C`P,#`P,SDX,#@@,#`P,#`@
M;@T*,#`P,#`T,#`Y-"`P,#`P,"!N#0HP,#`P,#0S-3DV(#`P,#`P(&X-"C`P
M,#`P-#,X.#(@,#`P,#`@;@T*,#`P,#`T-S@X."`P,#`P,"!N#0HP,#`P,#0X
M,3<T(#`P,#`P(&X-"C`P,#`P-3$W,SD@,#`P,#`@;@T*,#`P,#`U,C`R-2`P
M,#`P,"!N#0HP,#`P,#4U-S(R(#`P,#`P(&X-"C`P,#`P-38P,#@@,#`P,#`@
M;@T*,#`P,#`U.3(W,"`P,#`P,"!N#0HP,#`P,#4Y-34V(#`P,#`P(&X-"C`P
M,#`P-C,U,#<@,#`P,#`@;@T*,#`P,#`V,S<Y,R`P,#`P,"!N#0HP,#`P,#8W
M,C,X(#`P,#`P(&X-"C`P,#`P-C<U,C0@,#`P,#`@;@T*,#`P,#`W,3(U-2`P
M,#`P,"!N#0HP,#`P,#<Q-30Q(#`P,#`P(&X-"C`P,#`P-S4R-C,@,#`P,#`@
M;@T*,#`P,#`W-34T.2`P,#`P,"!N#0HP,#`P,#<X-S0T(#`P,#`P(&X-"C`P
M,#`P-SDP,S`@,#`P,#`@;@T*,#`P,#`X,C<V-R`P,#`P,"!N#0HP,#`P,#@S
M,#4S(#`P,#`P(&X-"C`P,#`P.#8X-S@@,#`P,#`@;@T*,#`P,#`X-S$V-"`P
M,#`P,"!N#0HP,#`P,#@Y-S$P(#`P,#`P(&X-"C`P,#`P.#DY.38@,#`P,#`@
M;@T*,#`P,#`Y,C<V-2`P,#`P,"!N#0HP,#`P,#DS,#4Q(#`P,#`P(&X-"C`P
M,#`Q,#$S,C,@,#`P,#`@;@T*,#`P,#$P,38P.2`P,#`P,"!N#0HP,#`P,3`T
M,S@Q(#`P,#`P(&X-"C`P,#`Q,#0V-C<@,#`P,#`@;@T*,#`P,#$P-3DX.2`P
M,#`P,"!N#0HP,#`P,3`V,C<U(#`P,#`P(&X-"C`P,#`Q,#DV,C<@,#`P,#`@
M;@T*,#`P,#$P.3DQ,R`P,#`P,"!N#0HP,#`P,3$S,S<P(#`P,#`P(&X-"C`P
M,#`Q,3,V-38@,#`P,#`@;@T*,#`P,#$Q-C,W.2`P,#`P,"!N#0HP,#`P,3$V
M-C8U(#`P,#`P(&X-"C`P,#`Q,3@Q,C8@,#`P,#`@;@T*,#`P,#$Q.#0Q,B`P
M,#`P,"!N#0HP,#`P,3(R,#$U(#`P,#`P(&X-"C`P,#`Q,C(S,#$@,#`P,#`@
M;@T*,#`P,#$R-34X-"`P,#`P,"!N#0HP,#`P,3(U.#<P(#`P,#`P(&X-"C`P
M,#`Q,C<X-C4@,#`P,#`@;@T*,#`P,#$R.#$U,2`P,#`P,"!N#0HP,#`P,3,Q
M,S@R(#`P,#`P(&X-"C`P,#`Q,S$V-C@@,#`P,#`@;@T*,#`P,#$S,C<R,2`P
M,#`P,"!N#0HP,#`P,3,R-S8V(#`P,#`P(&X-"G1R86EL97(-"CP\#0HO4VEZ
A92`V.0T*/CX-"G-T87)T>')E9@T*,3@T#0HE)45/1@T*
`
end
</PDF>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
